<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="You Peng" />

<meta name="date" content="2022-03-07" />

<title>Homework 3</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/font-sfnt;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<style type="text/css">.hljs-literal {
color: #990073;
}
.hljs-number {
color: #099;
}
.hljs-comment {
color: #998;
font-style: italic;
}
.hljs-keyword {
color: #900;
font-weight: bold;
}
.hljs-string {
color: #d14;
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>








<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div id="header">



<h1 class="title toc-ignore">Homework 3</h1>
<h4 class="author">You Peng</h4>
<h4 class="date">2022-03-07</h4>

</div>


<pre><code>## 
## Attaching package: &#39;dplyr&#39;</code></pre>
<pre><code>## The following objects are masked from &#39;package:stats&#39;:
## 
##     filter, lag</code></pre>
<pre><code>## The following objects are masked from &#39;package:base&#39;:
## 
##     intersect, setdiff, setequal, union</code></pre>
<pre><code>## Loading required package: RColorBrewer</code></pre>
<div id="apis" class="section level2">
<h2>APIs</h2>
<div id="using-the-ncbi-api-look-for-papers-that-show-up-under-the-term-sars-cov-2-vaccine.-look-for-the-data-in-the-pubmed-database-and-then-retrieve-the-details-of-the-paper-as-shown-in-the-lab.-how-many-papers-were-you-able-to-find" class="section level4">
<h4>Using the NCBI API, look for papers that show up under the term
“sars-cov-2 vaccine.” Look for the data in the pubmed database, and then
retrieve the details of the paper as shown in the lab. How many papers
were you able to find?</h4>
<p>Counts from the website extraction is 18,440.</p>
<pre><code>## [1] &quot;18,566&quot;</code></pre>
<p>Counts from the API query is 18336, which is 4 less than the result
from website extraction.</p>
<pre><code>## [1] &quot;18438&quot;</code></pre>
</div>
<div id="using-the-list-of-pubmed-ids-you-retrieved-download-the-details-of-each-paper-using-the-query-parameter-rettype-abstract.-if-you-get-more-than-250-ids-just-keep-the-first-250." class="section level4">
<h4>Using the list of pubmed ids you retrieved, download the details of
each paper using the query parameter rettype = abstract. If you get more
than 250 ids, just keep the first 250.</h4>
<p>We will first obtain the ids of papers:</p>
<pre class="r"><code># Turn the result into a character vector
ids &lt;- as.character(ids)

# Find all the ids 
ids &lt;- stringr::str_extract_all(ids, &quot;&lt;Id&gt;[1-9]+&lt;/Id&gt;&quot;)[[1]]

# Remove all the leading and trailing &lt;Id&gt; &lt;/Id&gt;. Make use of &quot;|&quot;
ids &lt;- stringr::str_remove_all(ids, &quot;&lt;Id&gt;|&lt;/Id&gt;&quot;)
ids &lt;- ids[1:250]</code></pre>
<p>We will then use these ids to get our papers:</p>
<pre class="r"><code>publications &lt;- GET(
  url   = &quot;https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi&quot;,
  query = list(
    db = &quot;pubmed&quot;,
    id = paste(ids, collapse=&quot;,&quot;),
    retmax = 250,
    rettype = &quot;abstract&quot;

  )
)

# Turning the output into character vector
publications &lt;- httr::content(publications)
publications_txt &lt;- as.character(publications)</code></pre>
<p>The details of first 250 papers are stored in publications_txt.</p>
</div>
<div id="create-a-dataset" class="section level4">
<h4>Create a dataset</h4>
<p>We want to build a dataset which includes: 1. Pubmed ID number, 2.
Title of the paper, 3. Name of the journal where it was published, 4.
Publication date, and 5. Abstract of the paper (if any)</p>
<p>First separate our papers and store them in a list,</p>
<p>then extract the abstracts of papers:</p>
<pre class="r"><code>abstracts &lt;- stringr::str_extract(pub_char_list, &quot;&lt;Abstract&gt;(\\n|.)+&lt;/Abstract&gt;&quot;)
abstracts &lt;- str_remove_all(abstracts, &quot;&lt;/?[[:alpha:]]+&gt;&quot;)
abstracts &lt;- str_replace_all(abstracts, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(abstracts))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##   227    23</code></pre>
<p>Then the titles of papers:</p>
<pre class="r"><code>titles &lt;- stringr::str_extract(pub_char_list, &quot;&lt;ArticleTitle&gt;(\\n|.)+&lt;/ArticleTitle&gt;&quot;)
titles &lt;- str_remove_all(titles, &quot;&lt;/?[[:alnum:]]+&gt;&quot;)
titles &lt;- str_replace_all(titles, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(titles))</code></pre>
<pre><code>## 
## FALSE 
##   250</code></pre>
<p>Then names of the journals where each paper was published:</p>
<pre class="r"><code>journals &lt;- stringr::str_extract(pub_char_list, &quot;&lt;Title&gt;(\\n|.)+&lt;/Title&gt;&quot;)
journals &lt;- str_remove_all(journals, &quot;&lt;/?[[:alnum:]]+&gt;&quot;)
journals &lt;- str_replace_all(journals, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(journals))</code></pre>
<pre><code>## 
## FALSE 
##   250</code></pre>
<p>Then Publication dates:</p>
<pre class="r"><code>dates &lt;- stringr::str_extract(pub_char_list, &quot;&lt;PubDate&gt;(\\n|.)+&lt;/PubDate&gt;&quot;)
dates &lt;- str_remove_all(dates, &quot;&lt;/?[[:alnum:]]+&gt;&quot;)
dates &lt;- str_replace_all(dates, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(dates))</code></pre>
<pre><code>## 
## FALSE 
##   250</code></pre>
<p>Finally, put everything together into a single
<code>data.frame</code> and use <code>knitr::kable</code> to print the
results</p>
<table>
<colgroup>
<col width="0%" />
<col width="2%" />
<col width="41%" />
<col width="0%" />
<col width="55%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">PubMedId</th>
<th align="left">Title</th>
<th align="left">Journals</th>
<th align="left">Date</th>
<th align="left">Abstract</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">35254412</td>
<td align="left">Hypersensitivity Reactions to COVID-19
Vaccines-Identify High-Risk Children and Vaccinate the Rest.</td>
<td align="left">JAMA pediatrics</td>
<td align="left">2022 Mar 07</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35254219</td>
<td align="left">Adverse Events of Special Interest Following the Use of
BNT162b2 in Adolescents: A Population-Based Retrospective Cohort
Study.</td>
<td align="left">Emerging microbes &amp; infections</td>
<td align="left">2022 Mar 07</td>
<td align="left">Accruing evidence suggests an increased risk of
myocarditis in adolescents from messenger RNA COVID-19 vaccines.
However, other potential adverse events remain under-researched. We
conducted a retrospective cohort study of adolescents aged 12-18 with a
territory-wide electronic healthcare database of the Hong Kong
population linked with population-based vaccination records and
supplemented with age- and sex-specific population numbers. Two age- and
sex-matched retrospective cohorts were formed to observe 28 days
following the first and second doses of BNT162b2 and estimate the age-
and sex-adjusted incidence rate ratios between the vaccinated and
unvaccinated. Thirty AESIs adapted from the World Health Organization’s
Global Advisory Committee on Vaccine Safety were examined. Eventually,
the first-dose cohort comprised 274,881 adolescents (50.25% received the
first dose) and the second-dose cohort 237,964 (50.29% received the
second dose). Ninety-four (34.2 per 100,000 persons) adolescents in the
first-dose cohort and 130 (54.6 per 100,000 persons) in the second-dose
cohort experienced =1 AESIs. There were no statistically significant
differences in the risk of any AESI associated with BNT162b2 except
myocarditis [first-dose cohort: incidence rate ratio (IRR) = 9.15, 95%
confidence interval (CI) 1.14-73.16; second-dose cohort: IRR = 29.61,
95% CI 4.04-217.07] and sleeping disturbances/disorders after the second
dose (IRR = 2.06, 95% CI 1.01-4.24). Sensitivity analysis showed that,
with myocarditis excluded as AESIs, no significantly elevated risk of
AESIs as a composite outcome associated with vaccination was observed (P
= 0.195). To conclude, the overall absolute risk of AESIs was low with
no evidence of an increased risk of AESIs except myocarditis and
sleeping disturbances/disorders.</td>
</tr>
<tr class="odd">
<td align="left">35254213</td>
<td align="left">VITT with inactivated SARS-CoV-2 vaccine - index
case.</td>
<td align="left">Human vaccines &amp; immunotherapeutics</td>
<td align="left">2022 Mar 07</td>
<td align="left">We report a case of vaccine-induced immune thrombotic
thrombocytopenia (VITT) in a 73-year-old gentleman who presented with
pulmonary embolism and thrombocytopenia, two weeks after receiving
inactivated COVID-19 vaccine. He responded well to nonheparin
anticoagulation with complete resolution of symptoms and platelet
count.</td>
</tr>
<tr class="even">
<td align="left">35254166</td>
<td align="left">Comparative 6-Month Wild-Type and Delta-Variant
Antibody Levels and Surrogate Neutralization for Adults Vaccinated with
BNT162b2 versus mRNA-1273.</td>
<td align="left">Microbiology spectrum</td>
<td align="left">2022 Mar 07</td>
<td align="left">While mRNA vaccines are highly efficacious against
short-term COVID-19, long-term immunogenicity is less clear. We compared
humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months
after the first vaccine dose, examining the wild-type strain and
multiple Delta-variant lineages. Using samples from a prospective
observational cohort study of adult paramedics, we included
COVID-19-negative participants who received two BNT162b2 or mRNA-1273
vaccines, and provided a blood sample 170 to 190 days post first vaccine
dose. We compared wild-type spike IgG concentrations using the
Mann-Whitney U test. We also compared secondary outcomes of: receptor
binding domain (RBD) wild-type antibody concentrations, and inhibition
of angiotensin-converting enzyme 2 (ACE-2) binding to spike proteins
from the wild-type strain and five Delta-variant lineages. We included
571 adults: 475 BNT162b2 (83%) and 96 mRNA-1273 (17%) vaccinees, with a
mean age of 39 (SD = 10) and 43 (SD = 10) years, respectively. Spike IgG
antibody concentrations were significantly higher (P &lt; 0.0001) for
those who received mRNA-1273 (GM 601 BAU/mL [GSD 2.05]) versus BNT162b2
(GM 375 BAU/mL [GSD 2.33) vaccines. Results of RBD antibody comparisons
(P &lt; 0.0001), and inhibition of ACE-2 binding to the wild-type strain
and all tested Delta lineages (all P &lt; 0.0001), were consistent.
Adults who received two doses of mRNA-1273 vaccines demonstrated
improved wild-type and Delta variant-specific humoral immunity outcomes
at 6 months compared with those who received two doses of the BNT162b2
vaccine. IMPORTANCE The BNT162b2 and mRNA-1273 mRNA SARS-CoV-2 vaccines
have demonstrated high efficacy for preventing short-term COVID-19.
However, comparative long-term effectiveness is unclear, especially
pertaining to the Delta variant. We tested virus-specific antibody
responses 6 months after the first vaccine dose and compared individuals
who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. We found
that individuals who received the mRNA-1273 vaccine demonstrated
superior serological markers at 6 months in comparison with those who
received the BNT162b2 vaccine.</td>
</tr>
<tr class="odd">
<td align="left">35254122</td>
<td align="left">Correlation Analysis between Gut Microbiota Alterations
and the Cytokine Response in Patients with Coronavirus Disease during
Hospitalization.</td>
<td align="left">Microbiology spectrum</td>
<td align="left">2022 Mar 07</td>
<td align="left">The role of the intestinal microbiota in coronavirus
disease 2019 (COVID-19) is being elucidated. Here, we analyzed the
temporal changes in microbiota composition and the correlation between
inflammation biomarkers/cytokines and microbiota in hospitalized
COVID-19 patients. We obtained stool specimens, blood samples, and
patient records from 22 hospitalized COVID-19 patients and performed 16S
rRNA metagenomic analysis of stool samples over the course of disease
onset compared to 40 healthy individual stool samples. We analyzed the
correlation between the changes in the gut microbiota and plasma
proinflammatory cytokine levels. Immediately after admission,
differences in the gut microbiota were observed between COVID-19
patients and healthy subjects, mainly including enrichment of the
classes Bacilli and Coriobacteriia and decrease in abundance of the
class Clostridia. The bacterial profile continued to change throughout
the hospitalization, with a decrease in short-chain fatty acid-producing
bacteria including Faecalibacterium and an increase in the facultatively
anaerobic bacteria Escherichia-Shigella. A consistent increase in
Eggerthella belonging to the class Coriobacteriia was observed. The
abundance of the class Clostridia was inversely correlated with
interferon-&lt;U+03B3&gt; level and that of the phylum Actinobacteria,
which was enriched in COVID-19, and was positively correlated with
gp130/sIL-6Rb levels. Dysbiosis was continued even after 21 days from
onset. The intestines tended to be an aerobic environment in
hospitalized COVID-19 patients. Because the composition of the gut
microbiota correlates with the levels of proinflammatory cytokines, this
finding emphasizes the need to understand how pathology is related to
the temporal changes in the specific gut microbiota observed in COVID-19
patients. IMPORTANCE There is growing evidence that the commensal
microbiota of the gastrointestinal and respiratory tracts regulates
local and systemic inflammation (gut-lung axis). COVID-19 is primarily a
respiratory disease, but the involvement of microbiota changes in the
pathogenesis of this disease remains unclear. The composition of the gut
microbiota of patients with COVID-19 changed over time during
hospitalization, and the intestines tended to be an aerobic environment
in hospitalized COVID-19 patients. These changes in gut microbiota may
induce increased intestinal permeability, called leaky gut, allowing
bacteria and toxins to enter the circulatory system and further
aggravate the systemic inflammatory response. Since gut microbiota
composition correlates with levels of proinflammatory cytokines, this
finding highlights the need to understand how pathology relates to the
gut environment, including the temporal changes in specific gut
microbiota observed in COVID-19 patients.</td>
</tr>
<tr class="even">
<td align="left">35253789</td>
<td align="left">Dynamic Monitoring of Seroconversion using a
Multianalyte Immunobead Assay for Covid-19.</td>
<td align="left">Journal of visualized experiments : JoVE</td>
<td align="left">2022 Feb 16</td>
<td align="left">Multiplex technologies for interrogating multiple
biomarkers in concert have existed for several decades; however, methods
to evaluate multiple epitopes on the same analyte remain limited. This
report describes the development and optimization of a multiplexed
immunobead assay for serological testing of common immunoglobulin
isotypes (e.g., IgA, IgM, and IgG) associated with an immune response to
SARS-CoV-2 infection or vaccination. Assays were accomplished using a
flow-based, multiplex fluorescent reader with dual-channel capability.
Optimizations focused on analyte capture time, detection antibody
concentration, and detection antibody incubation time. Analytical assay
performance characteristics (e.g., assay range (including lower and
upper limits of quantitation); and intra- and inter-assay precision)
were established for either IgG/IgM or IgA/IgM serotype combination in
tandem using the ‘dual channel’ mode. Analyte capture times of 30 min
for IgG, 60 min for IgM, and 120 min for IgA were suitable for most
applications, providing a balance of assay performance and throughput.
Optimal detection antibody incubations at 4 µg/mL for 30 min was
observed and are recommended for general applications, given the overall
excellent precision (percent coefficient of variance (%CV) = 20%) and
sensitivity values observed. The dynamic range for the IgG isotype
spanned several orders of magnitude for each assay (Spike S1,
Nucleocapsid, and Membrane glycoproteins), which supports robust titer
evaluations at a 1:500 dilution factor for clinical applications.
Finally, the optimized protocol was applied to monitoring Spike S1
seroconversion for subjects (n = 4) that completed a SARS-CoV-2 vaccine
regimen. Within this cohort, Spike S1 IgG levels were observed to reach
maximum titers at 14 days following second dose administration, at a
much higher (~40-fold) signal intensity than either IgM or IgA isotypes.
Interestingly, we observed highly variable Spike S1 IgG titer decay
rates that were largely subject-dependent were observed, which will be
the topic of future studies.</td>
</tr>
<tr class="odd">
<td align="left">35253346</td>
<td align="left">Coronavirus disease 2019 and vaccination in patients
with Shwachman-Diamond syndrome.</td>
<td align="left">Pediatric blood &amp; cancer</td>
<td align="left">2022 Mar 06</td>
<td align="left">Because they can experience neutropenia due to bone
marrow failure, patients with Shwachman-Diamond syndrome (SDS) carry
increased risk for serious infections compared with the general
population; however, there has been a paucity of data on the incidence
and severity of coronavirus disease 2019 (COVID-19) in patients with
SDS. We compiled results from a survey distributed to participants in
the SDS Registry in May-June 2021. In this report, we describe the
characteristics and outcomes of patients with SDS who had COVID-19.
Patients reported a short clinical course without significant
complications or cytopenias. Additionally, COVID-19 vaccines were well
tolerated with minor side effects. © 2022 Wiley Periodicals LLC.</td>
</tr>
<tr class="even">
<td align="left">35253229</td>
<td align="left">Augmented Neutralization of SARS-CoV-2 Omicron Variant
by Boost Vaccination and Monoclonal Antibodies.</td>
<td align="left">European journal of immunology</td>
<td align="left">2022 Mar 06</td>
<td align="left">Effective vaccines and monoclonal antibodies have been
developed against coronavirus disease 2019 (COVID-19) caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the
appearance of virus variants with higher transmissibility and
pathogenicity is a major concern because of their potential to escape
vaccines and clinically approved SARS-CoV-2- antibodies. Here, we use
flow cytometry-based binding and pseudotyped SARS-CoV-2 neutralization
assays to determine the efficacy of boost immunization and therapeutic
antibodies to neutralize the dominant Omicron variant. We provide
compelling evidence that the third vaccination with BNT162b2 increases
the amount of neutralizing serum antibodies against Delta and Omicron
variants, albeit to a lower degree when compared to the parental Wuhan
strain. Therefore, a third vaccination is warranted to increase titers
of protective serum antibodies, especially in the case of the Omicron
variant. We also found that most clinically approved and otherwise
potent therapeutic antibodies against the Delta variant failed to
recognize and neutralize the Omicron variant. In contrast, some
antibodies under pre-clinical development potently neutralized the
Omicron variant. Our studies also support using a flow cytometry-based
antibody binding assay to rapidly monitor therapeutic candidates and
serum titers against emerging SARS-CoV-2 variants. This article is
protected by copyright. All rights reserved. This article is protected
by copyright. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35252935</td>
<td align="left">A highly immunogenic live-attenuated vaccine candidate
prevents SARS-CoV-2 infection and transmission in hamsters.</td>
<td align="left">Innovation (New York, N.Y.)</td>
<td align="left">2022 Mar 02</td>
<td align="left">The highly pathogenic and readily transmissible
SARS-CoV-2 has caused a global coronavirus pandemic, urgently requiring
effective countermeasures against its rapid expansion. All available
vaccine platforms are being utilized to generate safe and effective
COVID-19 vaccines. Here, we generated a live-attenuated candidate
vaccine strain by serial passaging of a SARS-CoV-2 clinical isolate in
Vero cells. Deep sequencing revealed the dynamic adaptation of
SARS-CoV-2 in Vero cells, resulting in a stable clone with a deletion of
seven amino acids (N679SPRRAR685) at the S1/S2 junction of the S protein
(named VAS5). VAS5 showed significant attenuation of replication in
multiple human cell lines, human airway epithelium organoids, and hACE2
mice. Viral fitness competition assays demonstrated that VAS5 showed
specific tropism to Vero cells but decreased fitness in human cells
compared to the parental virus. More importantly, a single intranasal
injection of VAS5 elicited a high level of neutralizing antibodies and
prevented SARS-CoV-2 infection in mice as well as close contact
transmission in golden Syrian hamsters. Structural and biochemical
analysis revealed a stable and locked prefusion conformation of the S
trimer of VAS5, which most resembles SARS-CoV-2-3Q-2P, an advanced
vaccine immunogen (NVAX-CoV2373). Further systematic antigenic profiling
and immunogenicity validation confirmed that the VAS5 S trimer presents
an enhanced antigenic mimic of the wild-type S trimer. Our results not
only provide a potent live-attenuated vaccine candidate against COVID-19
but also clarify the molecular and structural basis for the highly
attenuated and super immunogenic phenotype of VAS5. © 2022.</td>
</tr>
<tr class="even">
<td align="left">35252837</td>
<td align="left">COVID-19 susceptibility and vaccination coverage for
measles, rubella and mumps in students and healthcare workers in Trieste
hospitals (NE Italy).</td>
<td align="left">Vaccine: X</td>
<td align="left">2022 Apr</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">Measles,
mumps, and rubella (MMR) vaccines have been suggested as preventive
measures to protect subjects from the worst sequelae of COVID-19
infection because neutralizing antibodies can cross-react with other
viruses. <AbstractText Label="Aim" NlmCategory="UNASSIGNED">To verify
COVID-19 infection in MMR vaccinated and non-vaccinated healthcare
workers and medical students in Trieste Hospitals.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">Nurse aids
resulted in significantly more infections than structured physicians (OR
1.80; 95% CI 1.14-2.80) while students resulted in less infections (OR,
0.66; 95% CI 0.43-1.01). The presence of an MMR vaccination was
inversely associated with COVID-19 (OR, 0.77; 95% CI 0.61-0.96) but only
in univariate analysis. In the multivariable logistic regression
analysis, MMR vaccination lost statistical significance (OR, 0.86; 95%CI
0.62-1.20).On 13 HCWs hospitalized for COVID-19, 11 resulted not
vaccinated for MMR.
<AbstractText Label="Discussion" NlmCategory="UNASSIGNED">Our study
found a mild, non-significant reduction in SARS-CoV-2 infections in
workers vaccinated with MMR. © 2022 The Authors. Published by Elsevier
Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35252469</td>
<td align="left">Tacrolimus-resistant SARS-CoV-2-specific T-cell
products to prevent and treat severe COVID-19 in immunosuppressed
patients.</td>
<td align="left">Molecular therapy. Methods &amp; clinical
development</td>
<td align="left">2022 Feb 26</td>
<td align="left">Solid organ transplant (SOT) recipients receive
therapeutic immunosuppression that compromises their immune response to
infections and vaccines. For this reason, SOT patients have a high risk
of developing severe COVID-19 and an increased risk of death from
SARS-CoV-2 infection. Moreover, the efficiency of immunotherapies and
vaccines is reduced due to the constant immunosuppression in this
patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific
T-cells made resistant to a common immunosuppressant, Tacrolimus, for
optimized performance in the immunosuppressed patient. Using a
ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated
Tacrolimus-resistant SARS-CoV-2-specific T-cell products from
convalescent donors and demonstrate their specificity and function
through characterizations at the single cell level, including flow
cytometry, scRNA-CITE and TCR sequencing analyses. Based on the
promising results, we aim for clinical validation of this approach in
transplant recipients. Additionally, we propose a combinatory approach
with Tacrolimus, to prevent an overshooting immune response manifested
as bystander T-cell activation in the setting of severe COVID-19
immunopathology, and Tacrolimus-resistant SARS-CoV-2-specific T-cell
products, allowing for efficient clearance of viral infection. Our
strategy has the potential to prevent severe COVID-19 courses in SOT or
autoimmunity settings and to prevent immunopathology whilst providing
viral clearance in severe non-transplant COVID-19 cases. © 2022.</td>
</tr>
<tr class="even">
<td align="left">35252231</td>
<td align="left">Randomized, Double Blind, Placebo Controlled, Clinical
Trial to Study Ashwagandha Administration in Participants Vaccinated
Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19
Vaccine-A Study Protocol.</td>
<td align="left">Frontiers in medicine</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Vaccines
have emerged as the most effective tool in the fight against COVID-19.
Governments all over the world have rolled out the COVID-19 vaccine
program for their populations. Oxford-AstraZeneca COVID-19 vaccine
(COVISHIELD™) is widely used in India. A large number of Indian people
have been consuming various traditional medicines in the hope of better
protection against COVID-19 infection. Several studies have reported
immunological benefits of Withania somnifera (Ashwagandha) and its
potential as a vaccine adjuvant. We propose to study the safety,
immunogenicity and clinical protection offered by a 6-month regimen of
Ashwagandha in participants who volunteer to be vaccinated against
COVID-19 (COVISHIELDTM) in the ongoing national program of vaccination.
<AbstractText Label="Methods and Analysis" NlmCategory="UNASSIGNED">We
designed a prospective, randomized, double-blind, parallel-group,
placebo-controlled, two-arm, exploratory study on healthy volunteers
receiving the COVISHIELDTM vaccine. The administration of Ashwagandha
will begin within 7 days of the first or second dose of COVISHIELDTM.
Primary outcome measure is immunogenicity as measured by SARS-CoV-2
spike (S1) and RBD-specific IgG antibody titres. Secondary outcome
measures are safety, protective immune response and quality of life
measures. All adverse events will be monitored at each time throughout
the study. Participants will be tracked on a daily basis with a
user-friendly mobile phone application. Following power calculation 600
participants will be recruited per arm to demonstrate superiority by a
margin of 7% with 80% power. Study duration is 28 weeks with interim
analysis at the end of 12 weeks.
<AbstractText Label="Ethics and Dissemination" NlmCategory="UNASSIGNED">Ethics
approval was obtained through the Central and Institutional Ethics
Committees. Participant recruitment commenced in December 2021. Results
will be presented in conferences and published in preprints followed by
peer-reviewed medical journals.
<AbstractText Label="Clinical Trial Registration" NlmCategory="UNASSIGNED">[www.ClinicalTrials.gov],
identifier [CTRI/2021/06/034496]. Copyright © 2022 Chopra,
Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav,
Srikanth and Patwardhan.</td>
</tr>
<tr class="odd">
<td align="left">35251817</td>
<td align="left">Seasonal and 2009 Pandemic H1N1 Vaccine Acceptance as a
Predictor for COVID-19 Vaccine Acceptance.</td>
<td align="left">Cureus</td>
<td align="left">2022 Jan</td>
<td align="left">The emergence of COVID-19 also began an unprecedented
production and distribution of several novel COVID-19 vaccines to combat
the pandemic. Unfortunately, with the history of vaccine hesitancy in
the United States and abroad, concern remains regarding the ability to
vaccinate enough of the population to achieve herd immunity. In this
study, 101 adults were surveyed about their vaccine experience in the
waiting room of their visit to a Med-Peds clinic in Albany County, NY,
to gauge interest in the upcoming rollout of COVID-19 vaccines.
Questions included their opinions on seasonal influenza vaccines, the
2009 H1N1 vaccine, and the COVID-19 vaccine. The results of our survey
are consistent with previous studies where gaps in acceptance were
notable in black populations, lower education, and individuals with
public health insurance. Furthermore, 92.9% of respondents who denied
getting the 2009 H1N1 pandemic vaccine also did not plan to receive the
COVID-19 vaccine (p&lt;0.05), therefore a strong correlation was found
between receipt of the previous 2009 H1N1 pandemic vaccine and the
COVID-19 vaccine acceptance. The qualitative results of our study
revealed that COVID-19 precautions deterred people from receiving the
seasonal influenza vaccine, and a lack of information on the COVID-19
vaccine caused hesitancy to receive the vaccine on behalf of patients.
Copyright © 2022, Nair et al.</td>
</tr>
<tr class="even">
<td align="left">35251812</td>
<td align="left">COVID-19 Vaccine-Related Myocarditis: A Descriptive
Study of 40 Case Reports.</td>
<td align="left">Cureus</td>
<td align="left">2022 Jan</td>
<td align="left">After the surging rise in the Coronavirus disease 2019
(COVID-19) pandemic, the Food and Drug Administration (FDA) approved
emergency approval of vaccinations to prevent life-threatening
complications of COVID-19 infection. These vaccines are BNT162b2,
mRNA-1273. Later, the FDA also approved JNJ-78436735. COVID-19
vaccination does not have major side effects, but there are some
concerning adverse events reported right after vaccination. Myocarditis
is one of them. Based on our analysis of 40 case reports, we are
presenting the epidemiology and clinical picture of myocarditis related
to the COVID-19 vaccine. Based on our analysis, we found that the
majority of cases were seen in males with 90% predominance, and these
cases were seen in the age group of 29.13 years old (mean, SD of 14.39
years). In 65% of cases, patients took the BNT162b2 vaccine; 30% of
cases were reported with the mRNA-1273 vaccine; and 5% of cases with
JNJ-78436735. Of all the cases, 80% of them are reported after the
second dose of the vaccine with either Moderna or Pfizer. The
characteristics of COVID-19 vaccine-related myocarditis were analyzed in
this study. We identified several findings, ranging from age, gender,
type of vaccination, presentation of symptoms, and diagnosis modality.
This depicts the picture of COVID-19 vaccine-related myocarditis and
what physicians should expect when dealing with the disease. Our
analysis showed that more cases were reported after receiving the
BNT162b2 vaccine compared to mRNA-1273 and JNJ-78436735 vaccines.
Further research needs to be conducted to analyze the underlying cause
of this association. Copyright © 2022, Chen et al.</td>
</tr>
<tr class="odd">
<td align="left">35251795</td>
<td align="left">Comorbidities and Vaccination Status of COVID-19
All-Cause Mortality at a Tertiary Care Center of Western India.</td>
<td align="left">Cureus</td>
<td align="left">2022 Jan</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">COVID-19
vaccines have been found to be efficacious for preventing severe
disease, yet breakthrough infections and deaths have occurred in a small
proportion of vaccinated individuals. This study aimed to describe the
vaccination status and comorbidities of COVID-19 all-cause deaths.
<AbstractText Label="METHODS" NlmCategory="METHODS">This descriptive
observational study was conducted at a tertiary care center in western
India. A total of 310, RT-PCR positive COVID-19 deaths, aged 45 years
and above irrespective of the cause of death (all-cause mortality), were
included in the study. Death after breakthrough infection was defined as
death in patient with disease onset after 14 days of the second dose of
vaccine. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Diabetes
was the most common comorbidity found in 17.1% of the deaths, followed
by hypertension. Cardiovascular disease and renal disease were other
common comorbidities seen in 8.7% and 4.83% deaths respectively. Other
less common comorbidities include neurological disorders, HIV,
autoimmune disorders. Out of these 310 deaths, 21.4% of patients
developed disease within 14 days of the first dose. Death after true
breakthrough infection (after 14 days of both doses) was seen in only
two patients (0.6%). One of these two patients was aged 60 years and had
diabetes, while the other was aged 72 years and had a history of
smoking.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Diabetes and
hypertension were the most common comorbidities, indicating a higher
risk of mortality among comorbid patients. Only a small proportion of
deaths (0.6%) occurred after breakthrough infection beyond 14 days of
two doses. COVID-19 vaccines have shown promising efficacy against
severe disease, thus high vaccination coverage needs to be achieved to
prevent morbidity and mortality. Copyright © 2022, Verma et al.</td>
</tr>
<tr class="even">
<td align="left">35251762</td>
<td align="left">Pixel-based analysis of pulmonary changes on CT lung
images due to COVID-19 pneumonia.</td>
<td align="left">Journal of clinical imaging science</td>
<td align="left">2022</td>
<td align="left">Objectives: Computed tomography (CT) plays a
complementary role in the diagnosis of the pneumonia-burden of COVID-19
disease. However, the low contrast of areas of inflammation on CT
images, areas of infection are difficult to identify. The purpose of
this study is to develop a post-image-processing method for quantitative
analysis of COVID-19 pneumonia-related changes in CT attenuation values
using a pixel-based analysis rather than more commonly used clustered
focal pneumonia volumes. The COVID-19 pneumonia burden is determined by
experienced radiologists in the clinic. Previous AI software was
developed for the measurement of COVID-19 lesions based on the
extraction of local pneumonia features. In this respect, changes in the
pixel levels beyond the clusters may be overlooked by deep learning
algorithms. The proposed technique focuses on the quantitative
measurement of COVID-19 related pneumonia over the entire lung in
pixel-by-pixel fashion rather than only clustered focal pneumonia
volumes. Material and Methods: Fifty COVID-19 and 50 age-matched
negative control patients were analyzed using the proposed technique and
commercially available artificial intelligence (AI) software. The
%pneumonia was calculated using the relative volume of parenchymal
pixels within an empirically defined CT density range, excluding
pulmonary airways, vessels, and fissures. One-way ANOVA analysis was
used to investigate the statistical difference between lobar and whole
lung %pneumonia in the negative control and COVID-19 cohorts. Results:
The threshold of high-and-low CT attenuation values related to pneumonia
caused by COVID-19 were found to be between &lt;U+208B&gt;642.4 HU and
143 HU. The %pneumonia of the whole lung, left upper, and lower lobes
were 8.1 ± 4.4%, 6.1 ± 4.5, and 11.3 ± 7.3% for the COVID-19 cohort,
respectively, and statistically different (P &lt; 0.01). Additionally,
the pixel-based methods correlate well with existing AI methods and are
approximately four times more sensitive to pneumonia particularly at the
upper lobes compared with commercial software in COVID-19 patients (P
&lt; 0.01). Conclusion: Pixel-by-pixel analysis can accurately assess
pneumonia in COVID-19 patients with CT. Pixel-based techniques produce
more sensitive results than AI techniques. Using the proposed novel
technique, %pneumonia could be quantitatively calculated not only in the
clusters but also in the whole lung with an improved sensitivity by a
factor of four compared to AI-based analysis. More significantly,
pixel-by-pixel analysis was more sensitive to the upper lobe pneumonia,
while AI-based analysis overlooked the upper lung pneumonia region. In
the future, this technique can be used to investigate the efficiency of
vaccines and drugs and post COVID-19 effects. © 2022 Published by
Scientific Scholar on behalf of CosmoDerma.</td>
</tr>
<tr class="odd">
<td align="left">35251658</td>
<td align="left">Presumed oculomotor nerve palsy following COVID-19
vaccination.</td>
<td align="left">SAGE open medical case reports</td>
<td align="left">2022</td>
<td align="left">We herein report the case of an 84-year-old female who
presented to the outpatient clinic one day following her first dose of
the Pfizer-BioNTech COVID-19 vaccine with mydriasis, ptosis, and a “down
and out” gaze. She was subsequently diagnosed with oculomotor nerve
palsy, and treated with corticosteroids and valacyclovir for a total of
7 days, with no clear improvement. On subsequent visits, ophthalmic
examination improved steadily and showed complete resolution after 8
weeks. This article aims to report this unusual incidence that occurred
following vaccination with the Pfizer-BioNTech COVID-19 vaccine. It is
important for physicians to identify and report abnormal occurrences
which may potentially be related to the COVID-19 vaccines, in order to
reach a complete understanding of their possible side effects. © The
Author(s) 2022.</td>
</tr>
<tr class="even">
<td align="left">35251522</td>
<td align="left">MALDI-TOF mass spectrometry of saliva samples as a
prognostic tool for COVID-19.</td>
<td align="left">Journal of oral microbiology</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">The
SARS-CoV-2 infections are still imposing a great public health challenge
despite the recent developments in vaccines and therapy. Searching for
diagnostic and prognostic methods that are fast, low-cost and accurate
are essential for disease control and patient recovery. The MALDI-TOF
mass spectrometry technique is rapid, low cost and accurate when
compared to other MS methods, thus its use is already reported in the
literature for various applications, including microorganism
identification, diagnosis and prognosis of diseases.
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">Here we developed
a prognostic method for COVID-19 using the proteomic profile of saliva
samples submitted to MALDI-TOF and machine learning algorithms to train
models for COVID-19 severity assessment.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">We achieved an
accuracy of 88.5%, specificity of 85% and sensitivity of 91.5% for
classification between mild/moderate and severe conditions. When we
tested the model performance in an independent dataset, we achieved an
accuracy, sensitivity and specificity of 67.18, 52.17 and 75.60%
respectively.
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Saliva is
already reported to have high inter-sample variation; however, our
results demonstrates that this approach has the potential to be a
prognostic method for COVID-19. Additionally, the technology used is
already available in several clinics, facilitating the implementation of
the method. Further investigation using a larger dataset is necessary to
consolidate the technique. © 2022 The Author(s). Published by Informa UK
Limited, trading as Taylor &amp; Francis Group.</td>
</tr>
<tr class="odd">
<td align="left">35249775</td>
<td align="left">Social media use and vaccine hesitancy in the European
Union.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Mar 03</td>
<td align="left">Vaccine hesitancy can hinder the successful roll-out of
vaccines. This paper examines COVID-19 vaccine hesitancy in the European
Union, drawing from a large-scale cross-national survey covering all 27
EU Member States, carried out between February and March 2021 (n =
29,755). We study the determinants of vaccine hesitancy, focusing on the
role of social media use. In multivariate regression models, we find
statistically significant (p &lt; 0.05) impacts on vaccine hesitancy of
heavy use of social media and using social media as a main source of
news. However, the effect of social media and the drivers of vaccine
hesitancy vary depending on the reason for hesitancy. Most notably,
hesitancy due to health concerns is mainly driven by physical health
status and less by social media use, while views that COVID-19 risks are
exaggerated (or that COVID-19 does not exist) are more common among men,
people in good health, and those using social media as their main source
of news. Copyright © 2022 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35249774</td>
<td align="left">How do COVID-19 vaccine mandates affect attitudes
toward the vaccine and participation in mandate-affected activities?
Evidence from the United States.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Mar 02</td>
<td align="left">The spread of COVID-19 has prompted many governments,
schools, and companies to institute vaccine mandates. Proponents suggest
that mandates will enhance public health and increase vaccination rates.
Critics suggest that evidence of mandates’ effectiveness is unclear and
warn that mandates risk increasing societal inequalities if unvaccinated
minority groups opt out of educational, commercial, and social
activities where mandates are required. We conduct an original survey
experiment on a nationally representative sample of 1,245 Americans to
examine the efficacy and effect of COVID-19 mandates. Our findings
suggest that mandates are unlikely to change vaccination behavior
overall. Further, they may increase the likelihood that sizable
percentages of the population opt out of activities where vaccines are
mandated. We conclude that mandates that do go into effect should be
accompanied by persuasive communications targeted to specific
information needs and identities. Copyright © 2022 Elsevier Ltd. All
rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35249675</td>
<td align="left">Modifying SARS-CoV-2 vaccine schedule in Spain: When
numbers matters.</td>
<td align="left">Enfermedades infecciosas y microbiologia clinica
(English ed.)</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35249568</td>
<td align="left">Variations in COVID-19 vaccination uptake among people
in receipt of psychotropic drugs: cross-sectional analysis of a national
population-based prospective cohort.</td>
<td align="left">The British journal of psychiatry : the journal of
mental science</td>
<td align="left">2022 Mar 07</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronavirus
disease 2019 (COVID-19) has disproportionately affected people with
mental health conditions.
<AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We investigated the
association between receiving psychotropic drugs, as an indicator of
mental health conditions, and COVID-19 vaccine uptake.
<AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a
cross-sectional analysis of a prospective cohort of the Northern Ireland
adult population using national linked primary care registration,
vaccination, secondary care and pharmacy dispensing data. Univariable
and multivariable logistic regression analyses investigated the
association between anxiolytic, antidepressant, antipsychotic, and
hypnotic use and COVID-19 vaccination status, accounting for age,
gender, deprivation and comorbidities. Receiving any COVID-19 vaccine
was the primary outcome.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1 433 814
individuals, of whom 1 166 917 received a COVID-19 vaccination.
Psychotropic medications were dispensed to 267 049 people. In
univariable analysis, people who received any psychotropic medication
had greater odds of receiving COVID-19 vaccination: odds ratio (OR) =
1.42 (95% CI 1.41-1.44). However, after adjustment, psychotropic
medication use was associated with reduced odds of vaccination (ORadj =
0.90, 95% CI 0.89-0.91). People who received anxiolytics (ORadj = 0.63,
95% CI 0.61-0.65), antipsychotics (ORadj = 0.75, 95% CI 0.73-0.78) and
hypnotics (ORadj = 0.90, 95% CI 0.87-0.93) had reduced odds of being
vaccinated. Antidepressant use was not associated with vaccination
(ORadj = 1.02, 95% CI 1.00-1.03).
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found
significantly lower odds of vaccination in people who were receiving
treatment with anxiolytic and antipsychotic medications. There is an
urgent need for evidence-based, tailored vaccine support for people with
mental health conditions.</td>
</tr>
<tr class="odd">
<td align="left">35249484</td>
<td align="left">The Immune Response to SARS-CoV-2: Mechanisms, Aging,
Sequelae and Vaccines.</td>
<td align="left">Mini reviews in medicinal chemistry</td>
<td align="left">2022 Mar 04</td>
<td align="left">This review seeks to clarify the factors involved in
the various immune responses to SARS-CoV-2 infection and the mechanisms
that influence the development of COVID-19 with severe evolution. The
innate immune response that evolves against SARS-CoV-2 in a complex way
is highlighted, integrating multiple pathways by coronaviruses to evade
it, in addition to characterizing the adaptive immune response, which
can lead to an effective immune response or can contribute to
immunopathological imbalance. In turn, host-dependent biomarkers such as
age, gender, ABO blood group, and risk factors that contribute to the
critical and varied progress of COVID-19 immunopathogenesis were
analyzed. Finally, the potential vaccine candidates are presented,
capable of generating immune protection with humoral and/or cellular
neutralizing responses, in favor of blocking and destroying both the new
human coronavirus and its variants, which cause the current pandemic.
Copyright© Bentham Science Publishers; For any queries, please email at
<a href="mailto:epub@benthamscience.net" class="email">epub@benthamscience.net</a>.</td>
</tr>
<tr class="even">
<td align="left">35249377</td>
<td align="left">Immunity to SARS-CoV-2: What Do We Know and Should We
Be Testing for It?</td>
<td align="left">Journal of clinical microbiology</td>
<td align="left">2022 Mar 07</td>
<td align="left">Preexisting immunity to Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2) was nonexistent in humans, which
coupled with high transmission rates of certain SARS-CoV-2 variants and
limited vaccine uptake or availability, has collectively resulted in an
ongoing global pandemic. The identification and establishment of one or
multiple correlates of protection (CoP) against infectious pathogens is
challenging, but beneficial from both the patient care and public health
perspectives. Multiple studies have shown that neutralizing antibodies,
whether generated following SARS-CoV-2 infection, vaccination, or a
combination of both (i.e., hybrid immunity), as well as adaptive
cellular immune responses, serve as CoPs for COVID-19. However, the
diverse number and type of serologic assays, alongside the lack of
cross-assay standardization and emergence of new SARS-CoV-2 variants
with immune evasive characteristics, have collectively posed challenges
to determining a robust CoP ‘threshold’ and for the routine utilization
of these assays to document ‘immunity,’ as is commonly done for other
vaccine preventable diseases. Here, we discuss what CoPs are, review our
current understanding of infection-induced, vaccine-elicited and hybrid
immunity to COVID-19 and summarize the current and potential future
utility of SARS-CoV-2 serologic testing.</td>
</tr>
<tr class="odd">
<td align="left">35249272</td>
<td align="left">Covid-19 Vaccine Effectiveness against the Omicron
(B.1.1.529) Variant.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A
rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome
coronavirus 2 in highly vaccinated populations has aroused concerns
about the effectiveness of current vaccines.
<AbstractText Label="METHODS" NlmCategory="METHODS">We used a
test-negative case-control design to estimate vaccine effectiveness
against symptomatic disease caused by the omicron and delta (B.1.617.2)
variants in England. Vaccine effectiveness was calculated after primary
immunization with two doses of BNT162b2 (Pfizer-BioNTech), ChAdOx1
nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a
booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Between November 27,
2021, and January 12, 2022, a total of 886,774 eligible persons infected
with the omicron variant, 204,154 eligible persons infected with the
delta variant, and 1,572,621 eligible test-negative controls were
identified. At all time points investigated and for all combinations of
primary course and booster vaccines, vaccine effectiveness against
symptomatic disease was higher for the delta variant than for the
omicron variant. No effect against the omicron variant was noted from 20
weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness
after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9
to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25
or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine
effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks
after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to
41.1) at 10 or more weeks. Among BNT162b2 primary course recipients,
vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to
4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7
to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1
nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to
4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7
to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273
booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6)
at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to
66.1) at 5 to 9 weeks.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Primary
immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine
provided limited protection against symptomatic disease caused by the
omicron variant. A BNT162b2 or mRNA-1273 booster after either the
ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased
protection, but that protection waned over time. (Funded by the U.K.
Health Security Agency.). Copyright © 2022 Massachusetts Medical
Society.</td>
</tr>
<tr class="even">
<td align="left">35249187</td>
<td align="left">On the Frontline-A bibliometric Study on
Sustainability, Development, Coronaviruses, and COVID-19.</td>
<td align="left">Environmental science and pollution research
international</td>
<td align="left">2022 Mar 06</td>
<td align="left">The COVID-19 pandemic has placed the world’s population
in a state of unprecedented public health and global health
vulnerability. Risks to public and global health have escalated due to
COVID-19 contamination. This has raised the statistics of inequity and
environmental concerns. A possible outlook entails reducing the pandemic
consequences by prioritizing development, biodiversity, and
adaptability, offering buffer solutions. It contains vital methods for
studying, comprehending, and unraveling events-examining early responses
to COVID-19, sustainability, and development, relating them with overall
Coronaviruses reaction. This study maps out environmental,
socioeconomic, and medical/technological issues using as statistical
techniques multiple correspondence analysis and validated cluster
analysis. The findings encourage rapid, long-term development policy
involvement to address the pandemic. The resulting crises have
highlighted the necessity for the revival of health justice policies
anchored in distinctive public health ethical patterns in response to
them. As a general rule, resilience and preparedness will be targeted at
developing and vulnerable nations and are prone to include access to
vaccines, public health care, and health investment. Our findings show
the relevance of innovating on sustainable development routes and
yardsticks. Sustainable global health requires crucial measures in
prevention, preparation, and response. Long-term policy recommendations
are needed to address pandemics and their interrelated crises and foster
sustained growth and socioecological protection. © 2022. The
Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35248745</td>
<td align="left">Assessment of BIV1-CovIran inactivated vaccine-elicited
neutralizing antibody against the emerging SARS-CoV-2 variants of
concern.</td>
<td align="left">Clinical microbiology and infection : the official
publication of the European Society of Clinical Microbiology and
Infectious Diseases</td>
<td align="left">2022 Mar 03</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">BIV1-CovIran
vaccine is highly effective against COVID-19. The neutralizing potency
of all SARS-CoV-2 vaccines seems to be decreased against the variants of
concern (VOCs). We assessed the sensitivity of the Alpha (B.1.1.7), Beta
(B.1.351) and Delta (B.1.617.2) variants to neutralizing antibodies
(NAbs) present in sera from individuals who had received BIV1-CovIran
candidate vaccine compared with an original Wuhan-related strain.
<AbstractText Label="METHODS" NlmCategory="METHODS">The ability of
vaccine serum to neutralize the variants was measured using the
conventional virus neutralization test (cVNT). Correlation of spike (S)
protein antibody and anti-receptor binding domain (RBD) with
neutralizing activity was investigated.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Results of the
current study demonstrated 29/32 (90.6%; 95%CI: 75.0-98.0) of the
vaccinees developed NAbs against a Wuhan-related strain. It is
noteworthy that 28/32 (87.50 %, 87.50 %) and 24/32 (75 %) of the
recipients were able to produce NAbs versus Alpha, Beta and Delta
variants, respectively. Serum virus-neutralizing titers for different
SARS-CoV-2 strains were weakly correlated with anti-RBD antibodies
(Spearman r = 36-42, p values &lt; 0.05), but not S-binding antibodies
(p values &gt; 0.05).
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although
there was a reduction in neutralization titers against the variants of
Alpha, Beta and Delta than Wuhan strain, the BIV1-CovIran still
exhibited potent neutralizing activity against the SARS-CoV-2 variants
of concern. Copyright © 2022 European Society of Clinical Microbiology
and Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35248659</td>
<td align="left">Role of Genomics in combating COVID-19 pandemic.</td>
<td align="left">Gene</td>
<td align="left">2022 Mar 03</td>
<td align="left">The coronavirus disease 2019 (COVID-19) quickly swept
over the world, becoming one of the most devastating outbreaks in human
history. Being the first pandemic in the post-genomic era, advancements
in genomics contributed significantly to scientific understanding and
public health response to COVID-19. Genomic technologies have been
employed by researchers all over the world to better understand the
biology of SARS-CoV-2 and its origin, genomic diversity, and evolution.
Worldwide genomic resources have greatly aided in the investigation of
the COVID-19 pandemic. The pandemic has ushered in a new era of genomic
surveillance, wherein scientists are tracking the changes of the
SARS-CoV-2 genome in real-time at the international and national levels.
Availability of genomic and proteomic information enables the rapid
development of molecular diagnostics and therapeutics. The advent of
high-throughput sequencing and genome editing technologies led to the
development of modern vaccines. We briefly discuss the impact of
genomics in the ongoing COVID-19 pandemic in this review. Copyright ©
2022. Published by Elsevier B.V.</td>
</tr>
<tr class="odd">
<td align="left">35248424</td>
<td align="left">Monitoring COVID-19 vaccine use in Italian long term
care centers: The GeroCovid VAX study.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 22</td>
<td align="left">The COVID-19 pandemic has changed routine care practice
for older persons, especially in those with frailty living in long term
care (LTC) facilities. Due to the high mortality rates of Nursing home
(NH) residents during the first wave of the COVID-19 pandemic, priority
for COVID-19 vaccinations was given to this vulnerable population.
However, the safety and efficacy of such vaccines in older frail elders
remains questionable due to the fact that initial randomized clinical
trials (RCTs) for such vaccines did not include this population. This
type of discrimination in patient participation in RCTs continues and
has been recognized in the literature. Nevertheless, in the context of a
worldwide emergency, COVID-19 vaccination in older persons living in LTC
facilities may provide a solid basis to protect against negative
outcomes, such as COVID-19 infection and death. In this report, we
present the protocol of the GeroCovid Vax study, an Italian study that
began in February 2021 which is aimed at investigating the safety and
efficacy of the anti-SARS-CoV-2 vaccinations in older persons living in
LTCs. This protocol specially aims to continuously and closely monitor
events related to- and following- the anti-SARS-CoV-2 vaccination in
elderly living in LTC facilities. In this report, we will provide
information related to the study protocol and describe baseline
characteristics of the sample. Copyright © 2022 Elsevier Ltd. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35248422</td>
<td align="left">WHO guidance on COVID-19 vaccine trial designs in the
context of authorized COVID-19 vaccines and expanding global access:
Ethical considerations.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 28</td>
<td align="left">While the degree of COVID-19 vaccine accessibility and
uptake varies at both national and global levels, increasing vaccination
coverage raises questions regarding the standard of prevention that
ought to apply to different settings where COVID-19 vaccine trials are
hosted. A WHO Expert Group has developed guidance on the ethical
implications of conducting placebo-controlled trials in the context of
expanding global COVID-19 vaccine coverage. The guidance also considers
alternative trial designs to placebo controlled trials in the context of
prototype vaccines, modified vaccines, and next generation vaccines.
Copyright © 2022. Published by Elsevier Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35248142</td>
<td align="left">Manifesto of the pediatricians of Emilia-Romagna
region, Italy, in favor of vaccination against COVID in children 5-11
years old.</td>
<td align="left">Italian journal of pediatrics</td>
<td align="left">2022 Mar 05</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Following
the authorization by the regulatory authorities of vaccination against
COVID for children aged between 5 and 11, in Emilia-Romagna Region,
Italy, the pediatricians of the Italian Society of Pediatrics (SIP), the
Italian Society of Neonatology (SIN), the Cultural Association of
Pediatrics, the Italian Federation of Pediatricians (FIMP) and the
Italian Union of Family Pediatricians (SIMPeF), who work in the hospital
and in the territorial setting, have made a univocal and convinced
appeal in favor of vaccination also in this age group.
<AbstractText Label="MAIN FINDINGS" NlmCategory="RESULTS">In order to
contribute to a conscious choice, on the part of parents, based on
exhaustive and correct information, a 24-point manifesto was developed.
The manifesto showed that vaccines against COVID are the most effective
and safest tool we have to counter the spread of SARS-CoV-2 and
vaccination against COVID is a right of children just as it is for
adults. Children between 5 and 11 years are not protected from the virus
and a large part of the newly infected is this age. Although SARS-CoV-2
infection is certainly more benign in children, in some cases it can
cause a serious pathology and long COVID. The stress caused by the
pandemic, the prolonged closure of schools and the interruption of
sports and recreational activities have had a devastating effect on the
mental health of children and on the development of their personality.
Vaccinating children against COVID serves to protect them from severe
forms of disease and long COVID, allowing them to attend school
face-to-face and lead a normal social life. The safety of vaccinatin is
very high and vaccines against COVID have no influence on fertility nor
can they cause developmental or growth side effects.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The
manifesto highlighted that the vaccine against COVID for children aged
between 5 and 11 is effective and safe and represents an extraordinary
gift for safeguarding health of the younger ones. The invitation,
therefore, to parents is to have their children vaccinated against COVID
as early as possible. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35248116</td>
<td align="left">COVAX, vaccine donations and the politics of global
vaccine inequity.</td>
<td align="left">Globalization and health</td>
<td align="left">2022 Mar 05</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In
2021, donor countries, the pharmaceutical industry, and the COVAX
initiative promoted vaccine donation or “dose-sharing” as a main
solution to the inequitable global distribution of Covid-19 vaccines.
COVAX positioned itself as a global vaccine-sharing hub that promised to
share doses “equitably, effectively and transparently,” according to
rational criteria overseen by independent scientists. This article
provides a critical analysis of the principles and practice of
“dose-sharing,” showing how it reveals the politics at play within
COVAX. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Donated doses
were an important source of COVAX’s vaccine supply in 2021, accounting
for 60% of the doses the initiative delivered (543 million out of 910
million). However, donations could not compensate fully for COVAX’s
persistent procurement struggles: it delivered less than half of the two
billion doses it originally projected for 2021, a fraction of the 9.25
billion doses that were administered globally in 2021. Donor countries
and vaccine manufacturers systematically broke COVAX’s principles for
maximizing the impact of dose-sharing, delivering doses late, in smaller
quantities than promised, and in ad hoc ways that made roll-out in
recipient countries difficult. Some donors even earmarked doses for
specific recipients, complicating and potentially undermining COVAX’s
equitable allocation mechanism.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVAX’s
pivot from global vaccine procurement mechanism to dose-sharing hub can
be seen as a “win-win-win” solution for COVAX itself (who could claim
success by having access to more doses), for donor countries (who could
rebrand themselves as charitable donors rather than “vaccine hoarders”),
and for the pharmaceutical industry (maintaining the status quo on
intellectual property rights and protecting their commercial interests).
Although dose-sharing helped COVAX’s vaccine delivery, its impact was
undermined by donors’ and industry’s pursuit of national security,
diplomatic and commercial interests, which COVAX largely accommodated.
The lack of transparency and accountability mechanisms within COVAX’s
overly complex governance structure as a global public-private
partnership enabled these practices. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35247355</td>
<td align="left">DNA aptamer selection for SARS-CoV-2 spike glycoprotein
detection.</td>
<td align="left">Analytical biochemistry</td>
<td align="left">2022 Mar 02</td>
<td align="left">The rapid spread of SARS-CoV-2 infection throughout the
world led to a global public health and economic crisis triggering an
urgent need for the development of low-cost vaccines, therapies and
high-throughput detection assays. In this work, we used a combination of
Ideal-Filter Capillary Electrophoresis SELEX (IFCE-SELEX), Next
Generation Sequencing (NGS) and binding assays to isolate and validate
single-stranded DNA aptamers that can specifically recognize the
SARS-CoV-2 Spike glycoprotein. Two selected non-competing DNA aptamers,
C7 and C9 were successfully used as sensitive and specific biological
recognition elements for the development of electrochemical and
fluorescent aptasensors for the SARS-CoV-2 Spike glycoprotein with
detection limits of 0.07 fM and 41.87 nM, respectively. Copyright ©
2022. Published by Elsevier Inc.</td>
</tr>
<tr class="even">
<td align="left">35247269</td>
<td align="left">Neutralizing antibody responses 300 days after
SARS-CoV-2 infection and induction of high antibody titers after
vaccination.</td>
<td align="left">European journal of immunology</td>
<td align="left">2022 Mar 05</td>
<td align="left">Neutralizing antibodies against SARS-CoV-2 are
important to protect against infection and/or disease. Using an assay to
detect antibodies directed against the receptor binding domain (RBD) of
SARS-CoV-2 Spike, we identified individuals with SARS-CoV-2 infection
after an outbreak at a local health institution. All but one COVID-19
patient developed detectable anti-RBD antibodies and 77% had virus
neutralizing antibody titers of &gt;1:25. Antibody levels declined
slightly over time. However, we still detected virus neutralizing
antibody titers in 64% of the COVID-19 patients at &gt;300 days after
infection, demonstrating durability of neutralizing antibody levels
after infection. Importantly, full COVID-19 vaccination of these
individuals resulted in higher antibody titers compared to fully
vaccinated individuals in the absence of prior infection. These data
demonstrate long-lived antibody-mediated immunity after SARS-CoV-2
infection, and a clear benefit of two vaccine doses for recovered
individuals. This article is protected by copyright. All rights
reserved. This article is protected by copyright. All rights
reserved.</td>
</tr>
<tr class="odd">
<td align="left">35246846</td>
<td align="left">Current Evidence on Efficacy of COVID-19 Booster Dose
Vaccination Against the Omicron Variant. A Systematic Review.</td>
<td align="left">Journal of medical virology</td>
<td align="left">2022 Mar 04</td>
<td align="left">Coronavirus disease -2019 (COVID-19) is an ongoing
pandemic that affected around 27 million confirmed cases of COVID-19,
including more than 5 million deaths. However, on 24th November 2021,
the world health organization (WHO) announced a new SARS-CoV-2 variant
designated as the B.1.1.529 a variant of concern (VOC) and the variant
has been named as “Omicron”. Available preliminary evidence suggests
that, as compared to previous VOCs, it has an increased risk of
infectivity. Studies have shown that protection from various vaccines
effectiveness against hospitalization and death from severe COVID-19
disease is decreasing slowly after a two-dose schedule of COVID-19
vaccines. In response to experiencing a new COVID-19 variant and ongoing
resurgence of cases importance of COVID-19 vaccine booster dose and
durability of the effect of the third dose of vaccine against Covid-19
Omicron variant is controversial yet. Hence here we have done a
systematic search in Pub Med, Google Scholar and MedRXiv database, from
inception to January 2022 using the MeSH terms and keywords “Corona
Virus Disease-2019 OR COVID-19 AND Omicron AND COVID-19 Booster
Vaccine”. We have identified a total of 21 published studies. We have
reviewed all the eligible available studies on the effectiveness of the
COVID-19 vaccine booster shots against the Omicron variant. This article
is protected by copyright. All rights reserved. This article is
protected by copyright. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35246689</td>
<td align="left">Granulomatosis with Polyangiitis Following
Pfizer-BioNTech COVID-19 Vaccination.</td>
<td align="left">Modern rheumatology case reports</td>
<td align="left">2022 Mar 04</td>
<td align="left">We report the first case of proteinase 3 (PR3)-
antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with
polyangiitis (GPA) with predominant ears, nose, and throat (ENT)
manifestations following COVID-19 vaccination. A 63-year-old woman
presented with aural fullness three days after vaccination. She
presented with progressive rhinosinusitis and otitis media leading to
profound hearing loss within three weeks. Clinical imaging revealed
soft-tissue shadows in the paranasal sinuses with multiple pulmonary
nodules, and histopathology was consistent with a diagnosis of GPA. It
is crucial to be wary of the possibility of GPA in patients who received
COVID-19 vaccines due to its rapid disease progression. © Japan College
of Rheumatology 2022. Published by Oxford University Press. All rights
reserved. For permissions, please e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">35246682</td>
<td align="left">Systemic Lupus Erythematosus and Antiphospholipid
Syndrome After COVID-19 Vaccination. A Case Report.</td>
<td align="left">Modern rheumatology case reports</td>
<td align="left">2022 Mar 04</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">COVID-19
vaccines have some adverse effects, mostly mild. However, by presenting
an immunological challenge to the individual, they could infrequently
trigger immune-mediated diseases.
<AbstractText Label="CASE REPORT" NlmCategory="METHODS">We report the
case of a 42-year-old woman, with no previous medical history, who
received the first dose of vaccine against COVID-19 and developed
inflammatory arthralgias, associated with sudden onset dyspnea and
hypoxemia. Pulmonary thromboembolism was documented and the diagnosis of
systemic lupus erythematosus (SLE) and secondary antiphospholipid
syndrome (APS) was suspected. Autoantibodies were measured confirming
this suspicion. After a few days, she presented a massive pericardial
effusion with cardiac tamponade that required surgical management. She
received treatment with hydroxychloroquine, corticosteroids and
anticoagulation with improvement of all symptoms.
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There is
controversy regarding the potential of COVID-19 vaccines to induce
autoimmunity. Studies addressing the safety of using these vaccines have
reported the occurrence of mild local and systemic reactions, most
frequently in young adults. So far there are few reports of patients who
have developed autoimmune or autoinflammatory diseases after getting
vaccinated with any of the COVID-19 vaccines. To the best of our
knowledge, to date this is one of the first cases of new-onset SLE and
secondary APS after COVID-19 vaccination. © Japan College of
Rheumatology 2022. Published by Oxford University Press. All rights
reserved. For permissions, please e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">35246578</td>
<td align="left">Immunogenicity of ChAdOx1 nCoV-19 vaccine after a
two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and
kidney transplant recipients.</td>
<td align="left">Scientific reports</td>
<td align="left">2022 Mar 04</td>
<td align="left">Vaccination with inactivated SARS-CoV-2 virus produces
suboptimal immune responses among kidney transplant (KT), peritoneal
dialyzed (PD), and hemodialyzed (HD) patients. Participants were
vaccinated with two-dose inactivated SARS-CoV-2 vaccine (V2) and a third
dose of ChAdOx1 nCoV-19 vaccine (V3) at 1-2 months after V2. We enrolled
106 participants: 31 KT, 28 PD, and 31 HD patients and 16 controls.
Among KT, PD, and HD groups, median (IQR) of anti-receptor binding
domain antibody levels were 1.0 (0.4-26.8), 1092.5 (606.9-1927.2), and
1740.9 (1106-3762.3) BAU/mL, and percent neutralization was 0.9 (0-9.9),
98.8 (95.9-99.5), and 99.4 (98.8-99.7), respectively, at two weeks after
V3. Both parameters were significantly increased from V2 across all
groups (p &lt; 0.05). Seroconversion and neutralization positivity rates
in PD, HD, and control groups were 100% but were impaired in KT patients
(39% and 16%, respectively). S1-specific T-cell counts were increased in
PD and HD groups (p &lt; 0.05) but not in KT patients. The positive
S1-specific T-cell responder rate was &gt; 90% in PD, HD, and control
groups, which was higher than that in KT recipients (74%, p &lt; 0.05).
The heterologous inactivated virus/ChAdOx1 nCoV-19 vaccination strategy
elicited greater immunogenicity among dialysis patients; however,
inadequate responses remained among KT recipients (TCTR20210226002). ©
2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35246536</td>
<td align="left">The indirect effect of mRNA-based COVID-19 vaccination
on healthcare workers’ unvaccinated household members.</td>
<td align="left">Nature communications</td>
<td align="left">2022 Mar 04</td>
<td align="left">Mass vaccination is effective in reducing SARS-CoV-2
infections among vaccinated individuals. However, it remains unclear how
effectively COVID-19 vaccines prevent people from spreading the virus to
their close contacts. Using nationwide administrative datasets on
SARS-CoV-2 infections, vaccination records, demographics, and unique
household IDs, we conducted an observational cohort study to estimate
the direct and indirect effectiveness of mRNA-based COVID-19 vaccines in
reducing infections among vaccinated healthcare workers and their
unvaccinated household members. Our estimates for adults imply indirect
effectiveness of 39.1% (95% CI: -7.1% to 65.3%) two weeks and 39.0% (95%
CI: 18.9% to 54.0%) eight weeks after the second dose. We find that the
indirect effect of mRNA-based COVID-19 vaccines within households is
smaller for unvaccinated children than for adults and statistically
insignificant. Here, we show that mRNA-based COVID-19 vaccines are
associated with a reduction in SARS-CoV-2 infections not only among
vaccinated individuals but also among unvaccinated adult household
members in a real-world setting. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35246429</td>
<td align="left">Nephrotic syndrome with minimal change disease after
the Pfizer-BioNTech COVID-19 vaccine: two cases.</td>
<td align="left">BMJ case reports</td>
<td align="left">2022 Mar 04</td>
<td align="left">We present two cases of nephrotic syndrome with minimal
change disease after the Pfizer-BioNTech COVID-19 vaccine. We discuss
the initial presentation, investigation and management of these patients
along with a discussion around the current evidence base for
vaccine-induced nephrotic syndrome. © BMJ Publishing Group Limited 2022.
No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">35246221</td>
<td align="left">Mild disease course of SARS-CoV-2 infections and mild
side effects of vaccination in Pompe disease: a cohort description.</td>
<td align="left">Orphanet journal of rare diseases</td>
<td align="left">2022 Mar 04</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients
with Glycogen Storage Disease type II (GSDII), an inheritable metabolic
myopathy also known as Pompe disease, are considered to be at risk for
severe COVID-19 due to a reduced respiratory function and a tendency to
be overweight. However, so far little is known about the course of
SARS-CoV-2 infection and side effects of COVID-19 vaccinations in
patients with GSDII.
<AbstractText Label="METHODS" NlmCategory="METHODS">169 Dutch Pompe
patients are followed at the Erasmus MC Rotterdam. During the COVID-19
pandemic patients were requested to directly inform their physicians
about SARS-CoV-2 infection. Infected patients were interviewed regularly
by telephone until their symptoms subsided. Furthermore, all patients
eligible for vaccination on 16-7-2021 (= 17 years, n = 122) were asked
to complete a questionnaire.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">To date, fifteen
patients (8.9% of our cohort) reported a SARS-CoV-2 infection (classic
infantile Pompe disease n = 5, late onset n = 10). No patients were
admitted to hospital or needed intensivation of ventilatory support. All
patients made a recovery within 19 days. 41.8% of patients filled in our
questionnaire regarding vaccination, of whom 98% were vaccinated.
Besides one case of perimyocarditis, only mild side effects were
reported.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall,
patients with Pompe disease showed mild symptoms from infection with
SARS-CoV-2. All patients made a full recovery. Side effects after
vaccination were mostly mild. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35245864</td>
<td align="left">Survival and risk of COVID-19 after SARS-COV-2
vaccination in a series of 2391 cancer patients.</td>
<td align="left">European journal of cancer (Oxford, England :
1990)</td>
<td align="left">2022 Feb 10</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients
with cancer are at high risk of severe or lethal COVID-19. The impact of
SARS-COV-2 vaccination on the risk of developing COVID-19 was
investigated in an exhaustive series of patients from a comprehensive
cancer center. <AbstractText Label="METHODS" NlmCategory="METHODS">This
is a study of the exhaustive population of 2391 cancer patients who were
prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics,
documented SARS-COV-2 infection with RT-PCR, and survival were
collected. The primary endpoint was the rate of COVID-19 after
vaccination. Secondary endpoints included risk factors to develop
COVID-19 after vaccination, with a comparison with the cohort of
vaccinated health care workers (HCW), and risk factors for death.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">From January to
September 2021, among 2391 patients with cancer under active treatment
in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and
139 (6%) received 1, 2, and 3 doses, respectively. Ninety five patients
received a single dose of vaccine after a previous COVID-19. Two
thousand two hundred eighty five health care workers (HCW) received one
(N = 17, 0.7%), 2-3 (N = 2026, 88.7%) vaccine doses and one dose after
COVID-19 (N = 242, 10.6%). With a median follow-up of 142 and 199 days
for patients and HCW, respectively. Thirty nine (1.6%) patients and 35
(1.5%) HCW developed COVID-19 after vaccination. Six of 39 cancer
patients and no HCW died because ofCOVID-19 within 50 days after
diagnosis. Independent risk factors for COVID-19 in vaccinated patients
were age, single dose of vaccine without previous COVID-19 and anti-CD20
treatment in the last three months. Independent risk factors for death
included metastatic disease, gender, cancer type, but also documented
COVID-19 before vaccination.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients
receiving two or more doses of COVID-19 vaccine have reduced risk of
COVID-19. The risk of death of vaccinated cancer patients presenting
COVID-19 remains high. COVID-19 before vaccination is associated with an
increased overall risk of death. Copyright © 2022 Elsevier Ltd. All
rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35245755</td>
<td align="left">Applying an extended protection motivation theory to
predict Covid-19 vaccination intentions and uptake in 50-64 year olds in
the UK.</td>
<td align="left">Social science &amp; medicine (1982)</td>
<td align="left">2022 Feb 24</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To
examine the correlates of Covid-19 vaccination intentions and subsequent
uptake as outlined in an extended version of protection motivation
theory (PMT). <AbstractText Label="DESIGN" NlmCategory="METHODS">A
two-wave online survey conducted at the start of the vaccination rollout
to 50-64 year olds in the UK and three months later.
<AbstractText Label="MEASURES" NlmCategory="METHODS">Unvaccinated UK
adults (N = 438) aged 50-64 completed baseline measures from PMT
(perceived vulnerability, perceived severity, maladaptive response
rewards, response efficacy, self-efficacy, response costs, intention) as
well as measures of injunctive and descriptive norms, demographics,
Covid-19 experiences, and past influenza vaccine uptake. Self-reported
uptake of a Covid-19 vaccination was assessed three months later (n =
420). <AbstractText Label="RESULTS" NlmCategory="RESULTS">The extended
PMT explained 59% of the variance in Covid-19 vaccination intentions,
after controlling for demographics, Covid-19 experiences, and past
influenza vaccine uptake. All extended PMT variables, with the exception
of perceived severity and descriptive norms, were significant
independent predictors of intention. In line with national figures, 94%
of the sample reported having received a Covid-19 vaccination at
follow-up with intention found to be the key predictor of uptake.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Interventions
to increase Covid-19 vaccination uptake need to increase intentions to
be vaccinated by emphasizing the benefits of vaccination (e.g., in terms
of reducing risk) and likely approval from others while also addressing
the concerns (e.g., safety issues) and common misperceptions (e.g.,
natural immunity versus vaccines) that people might have about Covid-19
vaccines. Future research is needed in countries, and on groups, with
lower uptake rates. Copyright © 2022 Elsevier Ltd. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35245422</td>
<td align="left">A comparative analysis on the safety and efficacy of
Covaxin versus other vaccines against COVID-19: a review.</td>
<td align="left">Zeitschrift fur Naturforschung. C, Journal of
biosciences Z Naturforsch C J Biosci A comparative analysis on the
safety and efficacy of Covaxin versus other vaccines against COVID-19: a
review. <ELocationID EIdType="doi" ValidYN="Y">10.1515/znc-2021-0301
Since the identification of the genomic sequence of SARS-CoV-2, an
unprecedented effort is being made until this date for the development
of a safe and effective vaccine by pharma companies and laboratories
worldwide. To attain herd immunity and quite possibly recover from this
pandemic, which has claimed the life of about 4.23 million people, an
exceptional effort has been made by the scientific community for the
development of a vaccine. Various vaccines have been developed based on
different platforms and each of them seems to possess its own merits and
demerits based on its safety, immunogenicity, the durability of
immunity, dosing schedule, technological platform, and ease of
manufacture and transport. Based on these parameters this review aims to
critically assess the efficacy of Covaxin and compare it with other
vaccines in the WHO EUL list and perform a comparative analysis of
COVID-19 vaccines which are in phase 3 and phase 4 of clinical trials.
This will help us determine where COVAXIN stands against other vaccines
and vaccine candidates based on these parameters which will ultimately
help us determine the best vaccine that could potentially eradicate the
COVID-19 pandemic. © 2022 Walter de Gruyter GmbH, Berlin/Boston.
<AuthorList CompleteYN="Y"> <Author ValidYN="Y"> Talukder Abhijita A
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-5849-390X" class="uri">https://orcid.org/0000-0001-5849-390X</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. <Author ValidYN="Y"> Kalita Chayanika C
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-5090-1286" class="uri">https://orcid.org/0000-0001-5090-1286</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. <Author ValidYN="Y"> Neog Nayanika N
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0003-0673-8674" class="uri">https://orcid.org/0000-0003-0673-8674</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. <Author ValidYN="Y"> Goswami Chayanika C
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0003-3554-9186" class="uri">https://orcid.org/0000-0003-3554-9186</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. <Author ValidYN="Y"> Sarma Mrinal Kashyap MK
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-7471-2703" class="uri">https://orcid.org/0000-0001-7471-2703</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. <Author ValidYN="Y"> Hazarika Iswar I
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-8091-1741" class="uri">https://orcid.org/0000-0001-8091-1741</a> Department of
Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science,
Guwahati 781017, India. eng <PublicationType UI="D016428">Journal
Article <PublicationType UI="D016454">Review
<ArticleDate DateType="Electronic"> 2022 03 02 Germany Z Naturforsch C J
Biosci 8912155 0341-0382 IM <KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">COVAXIN <Keyword MajorTopicYN="N">SARS-CoV-2
<Keyword MajorTopicYN="N">WHO EUL list <Keyword MajorTopicYN="N">herd
immunity <Keyword MajorTopicYN="N">vaccine
<PubMedPubDate PubStatus="received"> 2021 11 26
<PubMedPubDate PubStatus="accepted"> 2022 02 04
<PubMedPubDate PubStatus="entrez"> 2022 3 4 17 12
<PubMedPubDate PubStatus="pubmed"> 2022 3 5 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 5 6 0 aheadofprint
<ArticleId IdType="pubmed">35245422
<ArticleId IdType="pii">znc-2021-0301
<ArticleId IdType="doi">10.1515/znc-2021-0301 References</td>
<td align="left">2022 Mar 02</td>
<td align="left">Since the identification of the genomic sequence of
SARS-CoV-2, an unprecedented effort is being made until this date for
the development of a safe and effective vaccine by pharma companies and
laboratories worldwide. To attain herd immunity and quite possibly
recover from this pandemic, which has claimed the life of about 4.23
million people, an exceptional effort has been made by the scientific
community for the development of a vaccine. Various vaccines have been
developed based on different platforms and each of them seems to possess
its own merits and demerits based on its safety, immunogenicity, the
durability of immunity, dosing schedule, technological platform, and
ease of manufacture and transport. Based on these parameters this review
aims to critically assess the efficacy of Covaxin and compare it with
other vaccines in the WHO EUL list and perform a comparative analysis of
COVID-19 vaccines which are in phase 3 and phase 4 of clinical trials.
This will help us determine where COVAXIN stands against other vaccines
and vaccine candidates based on these parameters which will ultimately
help us determine the best vaccine that could potentially eradicate the
COVID-19 pandemic. © 2022 Walter de Gruyter GmbH, Berlin/Boston.</td>
</tr>
<tr class="odd">
<td align="left">35244753</td>
<td align="left">Best practice approaches to outpatient management of
people living with Parkinson’s disease during the COVID-19
pandemic.</td>
<td align="left">Journal of neural transmission (Vienna, Austria :
1996)</td>
<td align="left">2022 Mar 04</td>
<td align="left">The prevalence of Parkinson’s disease (PD) is rising,
rendering it one of the most common neurodegenerative diseases.
Treatment and monitoring of patients require regular specialized in- and
outpatient care. Patients with PD are more likely to have a complicated
disease course if they become infected with severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2). Regular in-hospital
appointments place these patients at risk of exposure to SARS-CoV-2 due
to travel and contact with other patients and staff. However, guidelines
for the management of outpatients with PD during times of increased risk
of infection are currently lacking. These are urgently needed to conduct
risk-benefit evaluations to recommend the best medical treatment. This
article discusses best practice approaches based on the current
literature, as suggested by the multidisciplinary Network of University
Medicine (NUM) in Germany. These include measures such as mask-wearing,
hand hygiene, social distancing measures, and appropriate testing
strategies in outpatient settings, which can minimize the risk of
exposure. Furthermore, the urgency of appointments should be considered.
Visits of low urgency may be conducted by general practitioners or via
telemedicine consultations, whereas in-person presentation is required
in case of moderate and high urgency visits. Classification of urgency
should be carried out by skilled medical staff, and telemedicine
(telephone or video consultations) may be a useful tool in this
situation. The currently approved vaccines against SARS-CoV-2 are safe
and effective for patients with PD and play a key role in minimizing
infection risk for patients with PD. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35244289</td>
<td align="left">Improved immunologic response to COVID-19 vaccine with
prolonged dosing interval in hemodialysis patients.</td>
<td align="left">Scandinavian journal of immunology</td>
<td align="left">2022 Mar 04</td>
<td align="left">Vaccination against 2019 coronavirus disease (COVID-19)
can reduce disease incidence and severity. Dialysis patients demonstrate
a delayed immunologic response to vaccines. We determined factors
affecting the immunologic response to COVID-19 vaccines in hemodialysis
patients. All patients within a Swedish hemodialysis network, vaccinated
with two doses of COVID-19 vaccine 2-8 weeks before inclusion, were
eligible for this cross-sectional study. Severe adult respiratory
syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody levels were
determined by EliA SARS-CoV-2-Sp1 IgG test (Thermo Fisher Scientific,
Phadia AB) and related to clinical and demographic parameters.
Eighty-nine patients were included. Patients were vaccinated with two
doses of Comirnaty (BNT162b2, 73%) or Spikevax (mRNA-1273, 23,6%). Three
patients received combinations of different vaccines. Response rate
(antibody titres &gt; 7 U/mL) was 89.9%, while 39.3% developed high
antibody titres (&gt; 204 U/mL), 47 (43-50) days after the second dose.
A previous COVID-19 infection associated with higher antibody titres
(median (25th - 75th percentile) 1,558.5 (814.5-3,763.8) U/mL vs. 87
(26-268) U/mL, p=0.002), while time between vaccine doses did not differ
between groups (p=0.7). Increasing SARS-CoV-2 antibody titres were
independently associated with increasing time between vaccine doses (B
0.241, P=0.02), decreasing serum calcium levels (B -0.233, P=0.007), and
previous COVID-19 (B 1.078, P&lt;0.001). In conclusion, a longer
interval between COVID-19 mRNA vaccine doses, lower calcium, and a
previous COVID-19 infection were independently associated with a
stronger immunologic vaccination response in hemodialysis patients.
While the response rate was good, only a minority developed high
antibody titres, 47 (43-50) days after the second vaccine dose. This
article is protected by copyright. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35244237</td>
<td align="left">Implication of in silico studies in the search for
novel inhibitors against SARS-CoV-2.</td>
<td align="left">Archiv der Pharmazie Arch Pharm (Weinheim) Implication
of in silico studies in the search for novel inhibitors against
SARS-CoV-2. e2100360
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ardp.202100360 Corona
Virus Disease-19 (COVID-19) is a pandemic disease mainly caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It had
spread from Wuhan, China, in late 2019 and spread over 222 countries and
territories all over the world. Earlier, at the very beginning of
COVID-19 infection, there were no approved medicines or vaccines for
combating this disease, which adversely affected a lot of individuals
worldwide. Although frequent mutation leads to the generation of more
deadly variants of SARS-CoV-2, researchers have developed several highly
effective vaccines that were approved for emergency use by the World
Health Organization (WHO), such as mRNA-1273 by Moderna, BNT162b2 by
Pfizer/BioNTech, Ad26.COV2.S by Janssen, AZD1222 by Oxford/AstraZeneca,
Covishield by the Serum Institute of India, BBIBP-CorV by Sinopharm,
coronaVac by Sinovac, and Covaxin by Bharat Biotech, and the first US
Food and Drug Administration-approved antiviral drug Veklury
(remdesivir) for the treatment of COVID-19. Several waves of COVID-19
have already occurred worldwide, and good-quality vaccines and medicines
should be available for ongoing as well as upcoming waves of the
pandemic. Therefore, in silico studies have become an excellent tool for
identifying possible ligands that could lead to the development of safer
medicines or vaccines. Various phytoconstituents from plants and herbs
with antiviral properties are studied further to obtain inhibitors of
SARS-CoV-2. In silico screening of various molecular databases like
PubChem, ZINC, Asinex Biol-Design Library, and so on has been performed
extensively for finding effective ligands against targets. Herein, in
silico studies carried out by various researchers are summarized so that
one can easily find the best molecule for further in vitro and in vivo
studies. © 2022 Deutsche Pharmazeutische Gesellschaft.
<AuthorList CompleteYN="Y"> <Author ValidYN="Y"> Ali Farak F Girijananda
Chowdhury Institute of Pharmaceutical Science, Tezpur, Sonitpur, Assam,
India. <Author ValidYN="Y"> Alom Shahnaz S Girijananda Chowdhury
Institute of Pharmaceutical Science, Tezpur, Sonitpur, Assam, India.
<Author ValidYN="Y"> Shakya Anshul A Department of Pharmaceutical
Sciences, Dibrugarh University, Dibrugarh, Assam, India.
<Author ValidYN="Y"> Ghosh Surajit K SK Department of Pharmaceutical
Sciences, Dibrugarh University, Dibrugarh, Assam, India.
<Author ValidYN="Y"> Singh Udaya P UP <Identifier Source="ORCID"><a href="https://orcid.org/0000-0003-0865-0502" class="uri">https://orcid.org/0000-0003-0865-0502</a> Drug Design &amp;
Discovery Laboratory, Department of Pharmaceutical Sciences, Sam
Higginbottom University of Agriculture, Technology &amp; Sciences,
Allahabad, Uttar Pradesh, India. <Author ValidYN="Y"> Bhat Hans R HR
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0002-9643-4916" class="uri">https://orcid.org/0000-0002-9643-4916</a> Department of
Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India.
eng <GrantList CompleteYN="Y"> (8-21/FDC/RPS (NER)/POLICY-1/2020-21) All
India Council for Technical Education <Country></Country>
<PublicationType UI="D016428">Journal Article
<PublicationType UI="D016454">Review <ArticleDate DateType="Electronic">
2022 03 04 Germany Arch Pharm (Weinheim) 0330167 0365-6233 IM
<KeywordList Owner="NOTNLM"> <Keyword MajorTopicYN="N">COVID-19
<Keyword MajorTopicYN="N">SARS-CoV-2 <Keyword MajorTopicYN="N">antiviral
phytoconstituents <Keyword MajorTopicYN="N">in silico screening
<Keyword MajorTopicYN="N">molecular docking
<PubMedPubDate PubStatus="revised"> 2022 01 11
<PubMedPubDate PubStatus="received"> 2021 09 15
<PubMedPubDate PubStatus="accepted"> 2022 01 14
<PubMedPubDate PubStatus="entrez"> 2022 3 4 8 51
<PubMedPubDate PubStatus="pubmed"> 2022 3 5 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 5 6 0 aheadofprint
<ArticleId IdType="pubmed">35244237
<ArticleId IdType="doi">10.1002/ardp.202100360 REFERENCES</td>
<td align="left">2022 Mar 04</td>
<td align="left">Corona Virus Disease-19 (COVID-19) is a pandemic
disease mainly caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). It had spread from Wuhan, China, in late 2019 and spread
over 222 countries and territories all over the world. Earlier, at the
very beginning of COVID-19 infection, there were no approved medicines
or vaccines for combating this disease, which adversely affected a lot
of individuals worldwide. Although frequent mutation leads to the
generation of more deadly variants of SARS-CoV-2, researchers have
developed several highly effective vaccines that were approved for
emergency use by the World Health Organization (WHO), such as mRNA-1273
by Moderna, BNT162b2 by Pfizer/BioNTech, Ad26.COV2.S by Janssen, AZD1222
by Oxford/AstraZeneca, Covishield by the Serum Institute of India,
BBIBP-CorV by Sinopharm, coronaVac by Sinovac, and Covaxin by Bharat
Biotech, and the first US Food and Drug Administration-approved
antiviral drug Veklury (remdesivir) for the treatment of COVID-19.
Several waves of COVID-19 have already occurred worldwide, and
good-quality vaccines and medicines should be available for ongoing as
well as upcoming waves of the pandemic. Therefore, in silico studies
have become an excellent tool for identifying possible ligands that
could lead to the development of safer medicines or vaccines. Various
phytoconstituents from plants and herbs with antiviral properties are
studied further to obtain inhibitors of SARS-CoV-2. In silico screening
of various molecular databases like PubChem, ZINC, Asinex Biol-Design
Library, and so on has been performed extensively for finding effective
ligands against targets. Herein, in silico studies carried out by
various researchers are summarized so that one can easily find the best
molecule for further in vitro and in vivo studies. © 2022 Deutsche
Pharmazeutische Gesellschaft.</td>
</tr>
<tr class="even">
<td align="left">35244174</td>
<td align="left">Perspective on COVID-19 vaccination in patients with
immune-mediated kidney diseases: consensus statements from ERA-IWG and
EUVAS.</td>
<td align="left">Nephrology, dialysis, transplantation : official
publication of the European Dialysis and Transplant Association -
European Renal Association</td>
<td align="left">2022 Mar 04</td>
<td align="left">Patients with immune-mediated kidney diseases are at
increased risk of severe COVID-19. The international rollout of COVID-19
vaccines has provided varying degrees of protection and enabled the
understanding of vaccine efficacy and safety. The immune response to
COVID-19 vaccines is lower in most patients with immune-mediated kidney
diseases; either related to immunosuppression or to co-morbidities and
complications caused by the underlying disease. Humoral vaccine
response, measured by the presence of antibodies, is impaired or absent
in patients receiving rituximab, mycophenolate mofetil (MMF), higher
doses of glucocorticoids and likely other immunosuppressants, such as
cyclophosphamide. Timing between the use of these agents and
administration of vaccines associate with the level of immune response:
with rituximab, vaccine response can only be expected once B cells start
to recover and patients with transient discontinuation of MMF mount a
humoral response more frequently. The emergence of new COVID-19 variants
and waning of vaccine induced immunity highlight the value of booster
dose and need to develop mutant proof vaccines. COVID-19 vaccines are
safe, exhibiting a very low risk of de novo or relapsing immune-mediated
kidney disease. Population-based studies will determine whether this is
causal or co-incidental. Such cases respond to standard management,
including the use of immunosuppression. The IWG and EUVAS recommend that
patients with immune-mediated kidney diseases follow national guidance
on vaccination. Booster doses based on antibody measurements could be
considered. © The Author(s) 2022. Published by Oxford University Press
on behalf of the ERA.</td>
</tr>
<tr class="odd">
<td align="left">35244157</td>
<td align="left">Varicella zoster virus reactivation following COVID-19
vaccination: a report of 3 cases.</td>
<td align="left">Family practice</td>
<td align="left">2022 Mar 04</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
advent of vaccination against COVID-19 brought great expectations for
the control of the pandemic. As novel vaccines, much of the associated
side effects were unknown. Currently, an increasing number of reports
from side effects of COVID-19 vaccines have been published, namely on
cutaneous reactions. These are of utmost importance to increase our
knowledge about possible undesirable effects and its prevention.
<AbstractText Label="METHODS" NlmCategory="METHODS">We describe a series
of 3 cases who presented with varicella zoster virus (VZV) reactivation
following the first dose of 3 different COVID-19 vaccines.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Three patients
sought their Family Doctor after developing typical lesions of VZV
reactivation, following a period of 3-13 days after COVID-19
vaccination. None was under immunosuppressive therapy. The 3 patients
recovered in a few weeks and the subsequent doses of the vaccines were
administered, without recurrence of the symptoms.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These cases
highlight the possibility of VZV reactivation after the first dose of
COVID-19 vaccines. Family Doctors should be aware of this event and play
an important role informing and reassuring local communities for this
possible vaccine reaction. © The Author(s) 2022. Published by Oxford
University Press. All rights reserved. For permissions, please e-mail:
<a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">35244125</td>
<td align="left">A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly
boosts robust immunity against SARS-CoV-2 and variants of concern.</td>
<td align="left">Chemical communications (Cambridge, England)</td>
<td align="left">2022 Mar 04</td>
<td align="left">Adjuvants are important components in vaccines to
increase the immunogenicity of proteins and induce optimal immunity. In
this study, we designed a novel ternary adjuvant system Alum + c-GAMP +
poly(I:C) with STING agonist 3,3’-c-GAMP (c-GAMP) and TLR3 agonist
poly(I:C) co-adsorbed on the conventional adjuvant aluminum gel (Alum),
and further constructed an S1 protein vaccine. Two doses of vaccination
with the ternary adjuvant vaccine were sufficient to induce a balanced
Th1/Th2 immune response and robust humoral and cellular immunity.
Additionally, the ternary adjuvant group had effective neutralizing
activity against live virus SARS-CoV-2 and pseudovirus of all variants
of concern (alpha, beta, gamma, delta and omicron). These results
indicate that the ternary adjuvants have a significant synergistic
effect and can rapidly trigger potent immune responses; the combination
of the ternary adjuvant system with S1 protein is a promising COVID-19
vaccine candidate.</td>
</tr>
<tr class="odd">
<td align="left">35243732</td>
<td align="left">COVID-19 Severity and SARS-Cov-2 Vaccine Safety in
Pemphigus Patients.</td>
<td align="left">Dermatologic therapy</td>
<td align="left">2022 Mar 04</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There
are safety concerns in the treatment of pemphigus patients with
immunosuppressants, particularly Rituximab (RTX), in times of the
COVID-19 pandemic. In the beginning, the reports were more pessimistic.
However, few reports have recently pointed to manageable courses in this
patient group. Therefore, we investigated the disease characteristics
and demographic features of pemphigus patients in the period of the
COVID-19 pandemic.
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to
investigate the impact of immunosuppressants on the course of COVID-19
in pemphigus patients. Also, we tried to find out the rate of flares due
to COVID-19 and SARS-Cov-2 vaccines.
<AbstractText Label="METHOD" NlmCategory="METHODS">This multicenter
study included 247 patients with pemphigus from three tertiary
dermatology clinics with the specialized outpatient clinic for
autoimmune blistering diseases. Patients were asked standardized
questions in person or via telephone calls. Also, demographic data were
collected from patients’ files.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">244 of 247 patients
took the survey between August and September 2021. The data of 3
patients were obtained from the National Health System. We collected the
data of all pemphigus patients who visited the clinics at least once in
the past three years. Among 51 patients having COVID-19, 40 had a
non-serious disease, whereas 11 required hospitalization. One patient
died because of COVID-19 infection.
<AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">The number of
patients is limited, and data depends mainly on patients’ statements.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RTX treatment
does not require additional safety cautions than other
immunosuppressives. This article is protected by copyright. All rights
reserved. This article is protected by copyright. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35243679</td>
<td align="left">Three cases of drug-induced hypersensitivity syndrome
associated with mRNA-based coronavirus disease 2019 vaccines.</td>
<td align="left">The Journal of dermatology J Dermatol Three cases of
drug-induced hypersensitivity syndrome associated with mRNA-based
coronavirus disease 2019 vaccines.
<ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.16347
Drug-induced hypersensitivity syndrome (DiHS) is a severe drug eruption
that can induce reactivation of herpesviruses such as human herpesvirus
6, resulting in symptom flare-up and organ damage. DiHS is known as drug
reaction with eosinophilia and systemic symptoms (DRESS) in Europe. We
report three cases of DiHS that could have been triggered by mRNA-based
coronavirus disease 2019 (COVID-19) vaccines. In these three patients,
symptoms of DiHS developed 2-6 days after the first dose of an
mRNA-based COVID-19 vaccine. Although there have been no reports of
DiHS/DRESS induced by mRNA-based COVID-19 vaccines in domestic and
international journals despite the progress in vaccination worldwide, we
speculate that mRNA-based COVID-19 vaccines might have triggered the
development of DiHS/DRESS in our patients. In the current coronavirus
epidemic, it might be important to assess mRNA-based COVID-19
vaccination status and date of vaccination when evaluating a patient
with DiHS/DRESS. © 2022 Japanese Dermatological Association.
<AuthorList CompleteYN="Y"> <Author ValidYN="Y"> Korekawa Ayumi A
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0002-4534-8313" class="uri">https://orcid.org/0000-0002-4534-8313</a> Department of
Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki,
Japan. <Author ValidYN="Y"> Nakajima Koji K
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0003-0652-9338" class="uri">https://orcid.org/0000-0003-0652-9338</a> Department of
Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki,
Japan. <Author ValidYN="Y"> Fukushi Karen K Department of Dermatology,
Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
<Author ValidYN="Y"> Nakano Hajime H Department of Dermatology, Hirosaki
University Graduate School of Medicine, Hirosaki, Japan.
<Author ValidYN="Y"> Sawamura Daisuke D Department of Dermatology,
Hirosaki University Graduate School of Medicine, Hirosaki, Japan. eng
<PublicationType UI="D016428">Journal Article
<ArticleDate DateType="Electronic"> 2022 03 03 England J Dermatol
7600545 0385-2407 IM <KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">coronavirus disease 2019
<Keyword MajorTopicYN="N">drug-induced hypersensitivity syndrome
<Keyword MajorTopicYN="N">human herpesvirus 6
<Keyword MajorTopicYN="N">mRNA <Keyword MajorTopicYN="N">vaccine
<PubMedPubDate PubStatus="revised"> 2022 02 10
<PubMedPubDate PubStatus="received"> 2021 10 21
<PubMedPubDate PubStatus="accepted"> 2022 02 19
<PubMedPubDate PubStatus="entrez"> 2022 3 4 5 46
<PubMedPubDate PubStatus="pubmed"> 2022 3 5 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 5 6 0 aheadofprint
<ArticleId IdType="pubmed">35243679
<ArticleId IdType="doi">10.1111/1346-8138.16347 REFERENCES</td>
<td align="left">2022 Mar 03</td>
<td align="left">Drug-induced hypersensitivity syndrome (DiHS) is a
severe drug eruption that can induce reactivation of herpesviruses such
as human herpesvirus 6, resulting in symptom flare-up and organ damage.
DiHS is known as drug reaction with eosinophilia and systemic symptoms
(DRESS) in Europe. We report three cases of DiHS that could have been
triggered by mRNA-based coronavirus disease 2019 (COVID-19) vaccines. In
these three patients, symptoms of DiHS developed 2-6 days after the
first dose of an mRNA-based COVID-19 vaccine. Although there have been
no reports of DiHS/DRESS induced by mRNA-based COVID-19 vaccines in
domestic and international journals despite the progress in vaccination
worldwide, we speculate that mRNA-based COVID-19 vaccines might have
triggered the development of DiHS/DRESS in our patients. In the current
coronavirus epidemic, it might be important to assess mRNA-based
COVID-19 vaccination status and date of vaccination when evaluating a
patient with DiHS/DRESS. © 2022 Japanese Dermatological
Association.</td>
</tr>
<tr class="odd">
<td align="left">35242782</td>
<td align="left">Comparative Genomics and Characterization of SARS-CoV-2
P.1 (Gamma) Variant of Concern From Amazonas, Brazil.</td>
<td align="left">Frontiers in medicine</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">P.1
lineage (Gamma) was first described in the State of Amazonas, northern
Brazil, in the end of 2020, and has emerged as a very important variant
of concern (VOC) of SARS-CoV-2 worldwide. P.1 has been linked to
increased infectivity, higher mortality, and immune evasion, leading to
reinfections and potentially reduced efficacy of vaccines and
neutralizing antibodies.
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">The samples of
276 patients from the State of Amazonas were sent to a central referral
laboratory for sequencing by gold standard techniques, through Illumina
MiSeq platform. Both global and regional phylogenetic analyses of the
successfully sequenced genomes were conducted through maximum likelihood
method. Multiple alignments were obtained including previously obtained
unique human SARS-CoV-2 sequences. The evolutionary histories of spike
and non-structural proteins from ORF1a of northern genomes were
described and their molecular evolution was analyzed for detection of
positive (FUBAR, FEL, and MEME) and negative (FEL and SLAC) selective
pressures. To further evaluate the possible pathways of evolution
leading to the emergence of P.1, we performed specific analysis for
copy-choice recombination events. A global phylogenomic analysis with
subsampled P.1 and B.1.1.28 genomes was applied to evaluate the
relationship among samples.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">Forty-four
samples from the State of Amazonas were successfully sequenced and
confirmed as P.1 (Gamma) lineage. In addition to previously described
P.1 characteristic mutations, we find evidence of continuous
diversification of SARS-CoV-2, as rare and previously unseen P.1
mutations were detected in spike and non-structural protein from ORF1a.
No evidence of recombination was found. Several sites were demonstrated
to be under positive and negative selection, with various mutations
identified mostly in P.1 lineage. According to the Pango assignment,
phylogenomic analyses indicate all samples as belonging to the P.1
lineage. <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">P.1
has shown continuous evolution after its emergence. The lack of clear
evidence for recombination and the positive selection demonstrated for
several sites suggest that this lineage emergence resulted mainly from
strong evolutionary forces and progressive accumulation of a favorable
signature set of mutations. Copyright © 2022 Zimerman, Ferrareze,
Cadegiani, Wambier, Fonseca, de Souza, Goren, Rotta, Ren and
Thompson.</td>
</tr>
<tr class="even">
<td align="left">35241699</td>
<td align="left">Dynamical regulations on mobility and vaccinations for
controlling COVID-19 spread.</td>
<td align="left">Scientific reports</td>
<td align="left">2022 03 03</td>
<td align="left">Using a system of time-dynamical equations, we
investigate how daily mobility indices, such as the homestay percentage
above the pre-COVID normal ([Formula: see text]; or H-forcing), and the
vaccinated percentage ([Formula: see text]; or V-forcing) impact the net
reproductive rate (R0) of COVID-19 in ten island nations as a prototype,
and then, extending it to 124 countries worldwide. Our H- and V-forcing
model of R0 can explain the new trends in 106 countries. The disease
transmission can be controlled by forcing down [Formula: see text] with
an enforcement of continuous [Formula: see text] in [Formula: see text]
of countries with [Formula: see text] vaccinated plus recovered,
[Formula: see text]. The required critical [Formula: see text] decreases
with increasing [Formula: see text], dropping it down to [Formula: see
text] with [Formula: see text], and further down to [Formula: see text]
with [Formula: see text]. However, the regulations on [Formula: see
text] are context-dependent and country-specific. Our model gives
insights into forecasting and controlling the disease’s transmission
behaviour when the effectiveness of the vaccines is a concern due to new
variants, and/or there are delays in vaccination rollout programs. ©
2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35241679</td>
<td align="left">Clinical validation of a multiplex PCR-based detection
assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A
and B.</td>
<td align="left">Scientific reports</td>
<td align="left">2022 03 03</td>
<td align="left">The COVID-19 pandemic has resulted in significant
diversion of human and material resources to COVID-19 diagnostics, to
the extent that influenza viruses and co-infection in COVID-19 patients
remains undocumented and pose serious public-health consequences. We
optimized and validated a highly sensitive RT-PCR based multiplex-assay
for the detection of SARS-CoV-2, influenza A and B viruses in a
single-test. This study evaluated clinical specimens (n = 1411), 1019
saliva and 392 nasopharyngeal swab (NPS), tested using two-assays:
FDA-EUA approved SARS-CoV-2 assay that targets N and ORF1ab gene, and
the PKamp-RT-PCR based assay that targets SARS-CoV-2, influenza viruses
A and B. Of the 1019 saliva samples, 17.0% (174/1019) tested positive
for SARS-CoV-2 using either assay. The detection rate for SARS-CoV-2 was
higher with the multiplex assay compared to SARS-specific assay [91.9%
(160/174) vs. 87.9% (153/174)], respectively. Of the 392 NPS samples,
10.4% (41/392) tested positive for SARS-CoV-2 using either assay. The
detection rate for SARS-CoV-2 was higher with the multiplex assay
compared to SARS-specific assay [97.5% (40/41) vs. 92.1% (39/41)],
respectively. This study presents clinical validation of a multiplex-PCR
assay for testing SARS-CoV-2, influenza A and B viruses, using NPS and
saliva samples, and demonstrates the feasibility of implementing the
assay without disrupting the existing laboratory workflow. © 2022. The
Author(s).</td>
</tr>
<tr class="even">
<td align="left">35241645</td>
<td align="left">Immunogenicity and protective efficacy of a recombinant
protein subunit vaccine and an inactivated vaccine against SARS-CoV-2
variants in non-human primates.</td>
<td align="left">Signal transduction and targeted therapy</td>
<td align="left">2022 03 03</td>
<td align="left">Emerging SARS-CoV-2 variants and the gradually
decreasing neutralizing antibodies over time post vaccination have led
to an increase in incidents of breakthrough infection across the world.
To investigate the potential protective effect of the recombinant
protein subunit COVID-19 vaccine targeting receptor-binding domain (RBD)
(PS-RBD) and whole inactivated virus particle vaccine (IV) against the
variant strains, in this study, rhesus macaques were immunized with
PS-RBD or IV vaccine, followed by a Beta variant (B.1.351) challenge.
Although neutralizing activity against the Beta variant was reduced
compared with that against the prototype, the decreased viral load in
both upper and lower respiratory tracts, milder pathological changes,
and downregulated inflammatory cytokine levels in lung tissues after
challenge demonstrated that PS-RBD and IV still provided effective
protection against the Beta variant in the macaque model. Furthermore,
PS-RBD-induced macaque sera possessed general binding and neutralizing
activity to Alpha, Beta, Delta, and Omicron variants in our study,
though the neutralizing antibody (NAb) titers declined by varying
degrees, demonstrating potential protection of PS-RBD against current
circulating variants of concern (VOCs). Interestingly, although the IV
vaccine-induced extremely low neutralizing antibody titers against the
Beta variant, it still showed reduction for viral load and significantly
alleviated pathological change. Other correlates of vaccine-induced
protection (CoP) like antibody-dependent cellular cytotoxicity (ADCC)
and immune memory were both confirmed to be existing in IV vaccinated
group and possibly be involved in the protective mechanism. © 2022. The
Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35241569</td>
<td align="left">Axillary Lymph Node Swelling Mimicking Breast Cancer
Metastasis After COVID-19 Vaccination: A Japanese Case Report and
Literature Review.</td>
<td align="left">In vivo (Athens, Greece)</td>
<td align="left">2022 Mar-Apr</td>
<td align="left"><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">COVID-19
started to spread as a pandemic in December 2019 and COVID-19
vaccination has been initiated worldwide. The efficacy of vaccination
has been scientifically proven, but it might cause axillary lymph node
swelling. To diagnose patients with axillary lymph node swelling caused
by COVID-19 vaccination, we herein reviewed existing literature on this
symptom. <AbstractText Label="CASE REPORT" NlmCategory="METHODS">We
report the case of a 70-year-old woman with a breast tumour. She had
undergone cecum cancer surgery and regular computed tomography (CT).
During breast tumour follow-up, she received scheduled CT that indicated
severe axillary lymph node swelling mimicking breast cancer metastasis.
We performed aspiration biopsy cytology of that lymph node, and
determined this was not cancer metastasis but an effect of the COVID-19
vaccine. We confirmed this diagnosis at one month after computed
tomography showed that the lymph node swelling had improved.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Axillary
lymph node swelling can occur after COVID-19 vaccination. Therefore, it
is important to consider the effect of the COVID-19 vaccination on
axillary lymph node swelling when diagnosing breast tumours. Copyright ©
2022, International Institute of Anticancer Research (Dr. George J.
Delinasios), All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35241495</td>
<td align="left">Spontaneous tumor regression following COVID-19
vaccination.</td>
<td align="left">Journal for immunotherapy of cancer</td>
<td align="left">2022 03</td>
<td align="left">Vaccination against COVID-19 is critical for
immuno-compromised individuals, including patients with cancer. Systemic
reactogenicity, a manifestation of the innate immune response to
vaccines, occurs in up to 69% of patients following vaccination with
RNA-based COVID-19 vaccines. Tumor regression can occur following an
intense immune-inflammatory response and novel strategies to treat
cancer rely on manipulating the host immune system. Here, we report
spontaneous regression of metastatic salivary gland myoepithelial
carcinoma in a patient who experienced grade 3 systemic reactogenicity,
following vaccination with the mRNA-1273 COVID-19 vaccine. Histological
and immunophenotypic inspection of the postvaccination lung biopsy
specimens showed a massive inflammatory infiltrate with scant embedded
tumor clusters (&lt;5%). Highly multiplexed imaging mass cytometry
showed that the postvaccination lung metastasis samples had remarkable
immune cell infiltration, including CD4+ T cells, CD8+ T cells, natural
killer cells, B cells, and dendritic cells, which contrasted with very
low levels of these cells in the prevaccination primary tumor and lung
metastasis samples. CT scans obtained 3, 6, and 9 months after the
second vaccine dose demonstrated persistent tumor shrinkage (50%, 67%,
and 73% reduction, respectively), suggesting that vaccination stimulated
anticancer immunity. Insight: This case suggests that the mRNA-1273
COVID-19 vaccine stimulated anticancer immunity and tumor regression. ©
Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC.
No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">35241474</td>
<td align="left">Dietary supplements to reduce symptom severity and
duration in people with SARS-CoV-2: study protocol for a randomised,
double-blind, placebo controlled clinical trial.</td>
<td align="left">BMJ open</td>
<td align="left">2022 03 03</td>
<td align="left"><AbstractText Label="INTRODUCTION">COVID-19 has caused
morbidity, hospitalisations and deaths worldwide. Despite four approved
vaccines for COVID-19 in Canada, there is still a need for effective
treatments, especially for people in the community. Vaccine efficacy is
not 100% and long-term efficacy is still unknown. Furthermore, there are
challenges to herd immunity including vaccine hesitancy and underlying
conditions preventing vaccination. We aim to explore if the nutrients
vitamin C, vitamin D, vitamin K2 and zinc are an effective treatment
option for outpatients diagnosed with COVID-19. The primary outcome is
the difference in participant-reported overall health; secondary
outcomes include the effect on health status, symptom severity and
duration, frequency and length of hospitalisations and mortality.
<AbstractText Label="METHODS AND ANALYSIS">This study is a two-arm,
parallel-group, double-blind, placebo-controlled, phase III randomised
controlled trial. 200 patients will be recruited remotely from COVID-19
test centres in Ottawa, Canada associated with The Ottawa Hospital.
Overall health will be measured using the EuroQol Visual Assessment
Scale; health status will be measured using the EuroQol 5-dimension
5-level questionnaire; symptom severity and duration will be measured
using an independently developed questionnaire; analyses will use an
area under the curve approach and compare mean scores using unadjusted t
tests. Study data will be recorded on electronic case report forms using
the Research Electronic Data Capture platform. An independent data
safety and monitoring board will perform ongoing review of the study for
feasibility and safety.
<AbstractText Label="ETHICS AND DISSEMINATION">This study has received
ethical approval from the research ethics boards of the Canadian College
of Naturopathic Medicine and the Ottawa Health Sciences Network, as well
as regulatory approval from the Therapeutic Products Directorate and
Natural and Non-Prescription Health Products Directorate of Health
Canada. Results will be published in a peer-reviewed scientific journal
with open access.
<AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04780061. © Author(s)
(or their employer(s)) 2022. Re-use permitted under CC BY-NC. No
commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">35241215</td>
<td align="left">Risk of severe COVID-19 from the Delta and Omicron
variants in relation to vaccination status, sex, age and comorbidities -
surveillance results from southern Sweden, July 2021 to January
2022.</td>
<td align="left">Euro surveillance : bulletin Europeen sur les maladies
transmissibles = European communicable disease bulletin</td>
<td align="left">2022 03</td>
<td align="left">We compared the risk of severe COVID-19 during two
periods 2021 and 2022 when Delta and Omicron, respectively, were the
dominating virus variants in Scania county, Sweden. We adjusted for
differences in sex, age, comorbidities, prior infection and vaccination.
Risk of severe disease from Omicron was markedly lower among vaccinated
cases. It was also lower among the unvaccinated but remained high (&gt;
5%) for older people and middle-aged men with two or more comorbidities.
Efforts to increase vaccination uptake should continue.</td>
</tr>
<tr class="odd">
<td align="left">35239863</td>
<td align="left">Generation of neutralizing antibodies against Omicron,
Gamma and Delta SARS-CoV-2 variants following CoronaVac
vaccination.</td>
<td align="left">Revista do Instituto de Medicina Tropical de Sao
Paulo</td>
<td align="left">2022</td>
<td align="left">Vaccination is a fundamental tool to prevent SARS-CoV-2
infection and to limit the COVID-19 pandemic. The emergence of
SARS-CoV-2 variants with multiple mutations has raised serious concerns
about the ability of neutralizing antibody responses elicited by prior
vaccination to effectively combat these variants. The neutralizing
capacity against the Gamma, Delta and Omicron variants of sera from
individuals immunized with the CoronaVac vaccine remains incompletely
determined. The present study evaluated 41 health care workers at the
Faculdade de Medicina of the Universidade de Sao Paulo, in Sao Paulo,
Brazil, naive to previous SARS- CoV-2 infection, who were vaccinated
with two doses of the CoronaVac SARS-CoV-2 vaccine 28 days apart.
Neutralizing antibody levels against the Gamma, Delta, and Omicron
variants were measured at 32 and 186 days after the second vaccination.
We also measured neutralizing antibodies against Omicron in 34 of these
individuals following a subsequent booster immunization with the Pfizer
vaccine. Quantification of neutralizing antibodies was performed using
the Cytopathic Effect-based Virus Neutralization test. Neutralization
antibody activity against the Gamma, Delta and Omicron variants was
observed in 78.0%, 65.9% and 58.5% of serum samples, respectively,
obtained at a mean of 32 days after the second immunization. This
decreased to 17.1%, 24.4% and 2.4% of sera having activity against
Delta, Gamma and Omicron, respectively, at 186 days post-vaccination.
The median neutralizing antibody titers at 32 days were 1:40, 1:20 and
1:20 against Gamma, Delta and Omicron, respectively, and decreased to an
undetectable median level against all variants at the later time. A
booster immunization with the Pfizer vaccine elicited neutralizing
antibodies against Omicron in 85% of subjects tested 60 days after
vaccination. We conclude that two doses of the CoronaVac vaccine results
in limited protection of short duration against the Gamma, Delta and
Omicron SARS-CoV-2 variants. A booster dose with the Pfizer vaccine
induced antibody neutralizing activity against Omicron in most patients
which was measurable 60 days after the booster.</td>
</tr>
<tr class="even">
<td align="left">35239711</td>
<td align="left">Willingness to take COVID-19 vaccination in low-income
countries: Evidence from Ethiopia.</td>
<td align="left">PloS one</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="BACKGROUND">In low-income
countries, vaccination campaigns are lagging, and evidence on vaccine
acceptance, a crucial public health planning input, remains scant. This
is the first study that reports willingness to take COVID-19 vaccines
and its socio-demographic correlates in Ethiopia, Africa’s second most
populous country. <AbstractText Label="METHODS">The analysis is based on
a nationally representative survey data of 2,317 households conducted in
the informal economy in November 2020. It employs two logistic
regression models where the two outcome variables are (i) a household
head’s willingness to take a COVID-19 vaccine or not, and (ii) if yes if
they would also hypothetically pay (an unspecified amount) for it or
not. Predictors include age, gender, education, marital status, income
category, health insurance coverage, sickness due to COVID-19, chronic
illness, trust in government, prior participation in voluntary
activities, urban residence. <AbstractText Label="RESULTS">Willingness
to take the vaccine was high (88%) and significantly associated with
COVID-19 cases in the family, trust in government and pro-social
behavior. All other predictors such as gender, education, income, health
insurance, chronic illness, urban residence did not significantly
predict vaccine willingness at the 5% level. Among those willing to take
the vaccine, 33% also answered that they would hypothetically pay (an
unspecified amount) for it, an answer that is significantly associated
with trust in government, health insurance coverage and income.
<AbstractText Label="CONCLUSION">The results highlight both
opportunities and challenges. There is little evidence of vaccine
hesitancy in Ethiopia among household heads operating in the informal
economy. The role played by trust in government and pro-social behavior
in motivating this outcome suggests that policy makers need to consider
these factors in the planning of COVID-19 vaccine campaigns in order to
foster vaccine uptake. At the same time, as the willingness to
hypothetically pay for a COVID-19 vaccine seems to be small,
fairly-priced vaccines along with financial support are also needed to
ensure further uptake of COVID-19 vaccines.</td>
</tr>
<tr class="odd">
<td align="left">35239636</td>
<td align="left">Disparities in COVID-19 Vaccination Coverage Between
Urban and Rural Counties - United States, December 14, 2020-January 31,
2022.</td>
<td align="left">MMWR. Morbidity and mortality weekly report</td>
<td align="left">2022 Mar 04</td>
<td align="left">Higher COVID-19 incidence and mortality rates in rural
than in urban areas are well documented (1). These disparities persisted
during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges
during late 2021 and early 2022 (1,2). Rural populations tend to be
older (aged =65 years) and uninsured and are more likely to have
underlying medical conditions and live farther from facilities that
provide tertiary medical care, placing them at higher risk for adverse
COVID-19 outcomes (2). To better understand COVID-19 vaccination
disparities between urban and rural populations, CDC analyzed
county-level vaccine administration data among persons aged =5 years who
received their first dose of either the BNT162b2 (Pfizer-BioNTech) or
mRNA-1273 (Moderna) COVID-19 vaccine or a single dose of the
Ad.26.COV2.S (Janssen [Johnson &amp; Johnson]) COVID-19 vaccine during
December 14, 2020-January 31, 2022, in 50 states and the District of
Columbia (DC). COVID-19 vaccination coverage with =1 doses in rural
areas (58.5%) was lower than that in urban counties (75.4%) overall,
with similar patterns across age groups and sex. Coverage with =1 doses
varied among states: 46 states had higher coverage in urban than in
rural counties, one had higher coverage in rural than in urban counties.
Three states and DC had no rural counties; thus, urban-rural differences
could not be assessed. COVID-19 vaccine primary series completion was
higher in urban than in rural counties. However, receipt of booster or
additional doses among primary series recipients was similarly low
between urban and rural counties. Compared with estimates from a
previous study of vaccine coverage among adults aged =18 years during
December 14, 2020-April 10, 2021, these urban-rural disparities among
those now eligible for vaccination (aged =5 years) have increased more
than twofold through January 2022, despite increased availability and
access to COVID-19 vaccines. Addressing barriers to vaccination in rural
areas is critical to achieving vaccine equity, reducing disparities, and
decreasing COVID-19-related illness and death in the United States
(2).</td>
</tr>
<tr class="even">
<td align="left">35239587</td>
<td align="left">Reshaping the Future: An Innovative Academic-Practice
Collaboration for COVID-19 Vaccinations and Testing.</td>
<td align="left">Nursing administration quarterly</td>
<td align="left">2022 Apr-Jun 01</td>
<td align="left">The coronavirus disease-2019 (COVID-19) pandemic posed
unprecedented challenges for health care organizations, schools of
nursing, and surrounding communities. Health care organizations
encountered rapidly changing guidelines and shortages in the health care
workforce and critical medical supplies. Schools of nursing were
responding to abrupt suspensions of clinical placements, uncertainties
about the transmission of the novel virus, and shortages of personal
protective equipment. Despite these challenges, health care
organizations and schools of nursing were laser-focused on the need to
ensure a competent nursing workforce and timely pandemic response
efforts. Thus, an innovative academic-practice collaboration between
Yale New Haven Hospital and Quinnipiac University School of Nursing was
developed to meet community vaccination and testing needs. The
partnership was designed to provide undergraduate student nurses with
valuable community health clinical hours during the spring 2021 semester
while meeting the hospital’s needs for supporting the COVID-19 vaccine
clinics and testing sites. The positive outcomes of the collaboration
and specific lessons learned are discussed. Copyright © 2022 Wolters
Kluwer Health, Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35239462</td>
<td align="left">COVID-19 vaccine uptake and effectiveness in adults
aged 50 years and older in Wales UK: a 1.2m population data-linkage
cohort approach.</td>
<td align="left">Human vaccines &amp; immunotherapeutics</td>
<td align="left">2022 Mar 03</td>
<td align="left">Vaccination programs against COVID-19 vary globally
with estimates of vaccine effectiveness (VE) affected by vaccine type,
schedule, strain, outcome, and recipient characteristics. This study
assessed VE of BNT162b2 and ChAdOx1 vaccines against PCR positive
SARS-CoV-2 infection, hospital admission, and death among adults aged 50
years and older in Wales, UK during the period 7 December 2020 to 18
July 2021, when Alpha, followed by Delta, were the predominant variants.
We used individual-level linked routinely collected data within the
Secure Anonymized Information Linkage (SAIL) Databank. Data were
available for 1,262,689 adults aged 50 years and over; coverage of one
dose of any COVID-19 vaccine in this population was 92.6%, with coverage
of two doses 90.4%. VE against PCR positive infection at 28-days or more
post first dose of any COVID-19 vaccine was 16.0% (95%CI 9.6-22.0), and
42.0% (95%CI 36.5-47.1) seven or more days after a second dose. VE
against hospital admission was higher at 72.9% (95%CI 63.6-79.8) 28 days
or more post vaccination with one dose of any vaccine type, and 84.9%
(95%CI 78.2-89.5) at 7 or more days post two doses. VE for one dose
against death was estimated to be 80.9% (95%CI 72.1-86.9). VE against
PCR positive infection and hospital admission was higher for BNT162b2
compared to ChAdOx1. In conclusion, vaccine uptake has been high among
adults in Wales and VE estimates are encouraging, with two doses
providing considerable protection against severe outcomes. Continued
roll-out of the vaccination programme within Wales, and globally, is
crucial in our fight against COVID-19.</td>
</tr>
<tr class="even">
<td align="left">35239452</td>
<td align="left">Detection of anti-NMDA receptor antibodies following
BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with
multiple sclerosis presenting with manifestations of an acute
relapse.</td>
<td align="left">Human vaccines &amp; immunotherapeutics</td>
<td align="left">2022 Mar 03</td>
<td align="left">Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
is a relatively unknown autoimmune entity. Scant reports of
post-infection/vaccination anti-NMDAR encephalitis exist. We, hereby,
reviewed the relevant cases and added to the literature a possible case
of anti-NMDAR encephalitis following COVID-19 vaccination with
BBIBP-CorV (Sinopharm). A 50-year-old Persian woman with previously
known rituximab-treated MS presented complaining of worsening
neurological symptoms all gradually starting and worsening after
receiving the second dose of BBVIP-CorV 2 weeks before. Notable findings
in her physical examination included ataxic gait and Babinski sign.
Considering an acute MS relapse, corticosteroid pulse therapy was
initiated, and she was referred for MRI, which revealed multiple new
plaques. Her serum sample interestingly tested positive for anti-NMDAR
antibodies. CSF analysis was unfortunately not performed. She responded
well to the corticosteroid pulse therapy and showed substantial
resolution of the symptoms. Considering its relatively low cost of
workup and the benefits of correct early diagnosis, clinicians are
advised to consider autoimmune encephalitis encountering patients with
progressive neurological symptoms after the administration of vaccines,
including the ones for COVID-19 which are currently being used
extensively.</td>
</tr>
<tr class="odd">
<td align="left">35238565</td>
<td align="left">Current Status and Future Perspectives on MRNA Drug
Manufacturing.</td>
<td align="left">Molecular pharmaceutics</td>
<td align="left">2022 Mar 03</td>
<td align="left">The coronavirus disease of 2019 (COVID-19) pandemic
launched an unprecedented global effort to rapidly develop vaccines to
stem the spread of the novel severe acute respiratory syndrome
coronavirus (SARS-CoV-2). Messenger ribonucleic acid (mRNA) vaccines
were developed quickly by companies that were actively developing mRNA
therapeutics and vaccines for other indications, leading to two mRNA
vaccines being not only the first SARS-CoV-2 vaccines to be approved for
emergency use but also the first mRNA drugs to gain emergency use
authorization and to eventually gain full approval. This was possible
partly because mRNA sequences can be altered to encode nearly any
protein without significantly altering its chemical properties, allowing
the drug substance to be a modular component of the drug product. Lipid
nanoparticle (LNP) technology required to protect the ribonucleic acid
(RNA) and mediate delivery into the cytoplasm of cells is likewise
modular, as are technologies and infrastructure required to encapsulate
the RNA into the LNP. This enabled the rapid adaptation of the
technology to a new target. Upon the coattails of the clinical success
of mRNA vaccines, this modularity will pave the way for future RNA
medicines for cancer, gene therapy, and RNA engineered cell therapies.
In this review, trends in the publication records and clinical trial
registrations are tallied to show the sharp intensification in
preclinical and clinical research for RNA medicines. Demand for the
manufacturing of both the RNA drug substance (DS) and the LNP drug
product (DP) has already been strained, causing shortages of the
vaccine, and the rise in development and translation of other mRNA drugs
in the coming years will exacerbate this strain. To estimate demand for
DP manufacturing, the dosing requirements for the preclinical and
clinical studies of the two approved mRNA vaccines were examined. To
understand the current state of mRNA-LNP production, current methods and
technologies are reviewed, as are current and announced global
capacities for commercial manufacturing. Finally, a vision is
rationalized for how emerging technologies such as self-amplifying mRNA,
microfluidic production, and trends toward integrated and distributed
manufacturing will shape the future of RNA manufacturing and unlock the
potential for an RNA medicine revolution.</td>
</tr>
<tr class="even">
<td align="left">35238384</td>
<td align="left">Myocarditis post SARS-CoV-2 vaccination: a systematic
review.</td>
<td align="left">QJM : monthly journal of the Association of
Physicians</td>
<td align="left">2022 Mar 03</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Variable
clinical criteria taken by medical professionals across the world for
myocarditis following COVID-19 vaccination along with wide variation in
treatment necessitates understanding and reviewing the same.
<AbstractText Label="OBJECTIVES AND METHODS" NlmCategory="OBJECTIVE">A
systematic review was conducted to elucidate the clinical findings,
laboratory parameters, treatment and outcomes of individuals with
Myocarditis after COVID-19 vaccination after registering with PROSPERO.
Electronic databases including MEDLINE, EMBASE, PubMed, LitCovid,
Scopus, ScienceDirect, Cochrane Library, Google Scholar, Web of Science
were searched. <AbstractText Label="RESULTS" NlmCategory="RESULTS">A
total of 85 articles encompassing 2184 patients were analysed. It was a
predominantly male (73.4%) and young population (Mean age 25.5 ± 14.2
years) with most having taken an mRNA-based vaccines (99.4%). The mean
duration from vaccination to symptom onset was 4.01 ± 6.99 days. Chest
pain (90.1%), dyspnoea (25.7%) and fever (11.9%) were the most common
symptoms. Only 2.3% had comorbidities. CRP was elevated in 83.3% and
cardiac troponin in 97.6% patients. An abnormal ECG was reported in
979/1313 (74.6%) patients with ST-segment elevation being most common
(34.9%). Echocardiographic data was available for 1243 patients (56.9%)
of whom 288 (23.2%) had reduced left ventricular ejection fraction.
NSAIDS (76.5%), steroids (14.1%) followed by colchicine (7.3%) were used
for treatment. Only 6 patients died among 1317 of whom data was
available.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Myocarditis
following COVID-19 vaccination is often mild, seen more commonly in
young healthy males and is followed by rapid recovery with conservative
treatment. The emergence of this adverse event calls for harmonizing
case definitions and definite treatment guidelines which require wider
research. © The Author(s) 2022. Published by Oxford University Press on
behalf of the Association of Physicians. All rights reserved. For
Permissions, please email: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">35238361</td>
<td align="left">Typhoid in India: An Age-old Problem With an Existing
Solution.</td>
<td align="left">The Journal of infectious diseases</td>
<td align="left">2021 Nov 23</td>
<td align="left">Enteric fever continues to impact millions of people
who lack adequate access to clean water and sanitation. The typhoid and
paratyphoid fever burden in South Asia is broadly acknowledged, but
current estimates of incidence, severity, and cost of illness from India
are lacking. This supplement addresses this gap in our knowledge,
presenting findings from two years of surveillance, conducted at
multiple sites between October 2017 and February 2020, in the
Surveillance for Enteric Fever in India (SEFI) network. Results provide
contemporaneous evidence of high disease burden and cost of illness-the
latter borne largely by patients in the absence of universal healthcare
coverage in India. Against a backdrop of immediate priorities in the
COVID-19 pandemic, these data are a reminder that typhoid, though often
forgotten, remains a public health problem in India. Typhoid conjugate
vaccines, produced by multiple Indian manufacturers, and recommended for
use in high burden settings, ensure that the tools to tackle typhoid are
an immediately available solution to this public health problem. © The
Author(s) 2021. Published by Oxford University Press for the Infectious
Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">35238329</td>
<td align="left">Impact of BNT162b2 vaccination and isolation on
SARS-CoV-2 transmission in Israeli households: an observational
study.</td>
<td align="left">American journal of epidemiology</td>
<td align="left">2022 Mar 03</td>
<td align="left">Several studies have characterized the effectiveness of
vaccines against SARS-CoV-2 infections. However, estimates of their
impact on transmissibility remain limited. Here, we evaluated the impact
of isolation and vaccination (7 days after the 2nd dose) on SARS-CoV-2
transmission within Israeli households. From December 2020 to April
2021, confirmed cases were identified among healthcare workers of the
Sheba Medical Centre and their family members. Recruited households were
followed up with repeated PCR for at least ten days after case
confirmation. Data were analyzed using a data augmentation Bayesian
framework. 210 households with 215 index cases were enrolled. 269 out of
667 (40%) susceptible household contacts developed a SARS-CoV-2
infection. Of those, 170 (63%) developed symptoms. Compared with
unvaccinated and unisolated adult/teenager contacts, vaccination reduced
the risk of infection among unisolated adult/teenager contacts above 12
(RR=0.21, 95% CrI credible interval 0.08-0.44) and isolation reduced the
risk of infection among unvaccinated adult/teenager (RR=0.12, 95% CrI
0.06-0.21) and child contacts (RR=0.17, 95% CrI 0.08-0.32). Infectivity
was reduced in vaccinated cases (RR=0.25, 95% CrI 0.06-0.77). Within
households, vaccination reduces both the risk of infection and of
transmission if infected. When contacts were unvaccinated, isolation
also led to important reductions in the risk of transmission. © The
Author(s) 2022. Published by Oxford University Press on behalf of the
Johns Hopkins Bloomberg School of Public Health.</td>
</tr>
<tr class="odd">
<td align="left">35238274</td>
<td align="left">An instrument to measure psychosocial determinants of
health care professionals’ vaccination behavior: Validation of the
Pro-VC-Be questionnaire.</td>
<td align="left">Expert review of vaccines</td>
<td align="left">2022 Mar 03</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The
lack of validated instruments assessing vaccine hesitancy/confidence
among health care professionals (HCPs) for themselves, and their
patients led us to develop and validate the Pro-VC-Be instrument to
measure vaccine confidence and other psychosocial determinants of HCPs’
vaccination behavior among diverse HCPs in different countries.
<AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Cross-sectional
survey in October-November 2020 among 1,249 GPs in France, 432 GPs in
French-speaking parts of Belgium, and 1,055 nurses in Quebec (Canada),
all participating in general population immunization. Exploratory and
confirmatory factor analyses evaluated the instrument’s construct
validity. We used HCPs’ self-reported vaccine recommendations to
patients, general immunization activity, self-vaccination, and future
COVID-19 vaccine acceptance to test criterion validity.
<AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The final results
indicated a 6-factor structure with good fit: vaccine confidence
(combining complacency, perceived vaccine risks, perceived benefit-risk
balance, perceived collective responsibility), trust in authorities,
perceived constraints, proactive efficacy (combining commitment to
vaccination and self-efficacy), reluctant trust, and openness to
patients. The instrument showed good convergent and criterion validity
and adequate discriminant validity.
<AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study
found that the Pro-VC-Be is a valid instrument for measuring
psychosocial determinants of HCPs’ vaccination behaviors in different
settings. Its validation is currently underway in Europe among various
HCPs in different languages.</td>
</tr>
<tr class="even">
<td align="left">35238263</td>
<td align="left">Trends in adolescent COVID-19 vaccination receipt and
parental intent to vaccinate their adolescent children, United States,
July to October, 2021.</td>
<td align="left">Annals of medicine</td>
<td align="left">2022 12</td>
<td align="left"><AbstractText Label="INTRODUCTION">There was a
five-fold increase in COVID-19 hospitalization case counts among
children and adolescents between June and October 2021. However, polls
suggest that adolescent COVID-19 vaccination coverage has plateaued in
the United States. <AbstractText Label="METHODS">Using the Census
Bureau’s Household Pulse Survey, we assessed trends in COVID-19
vaccination among adolescents ages 12-17 years, parents’ intention to
vaccinate their adolescent children, and their reasons for not intending
to vaccinate their children from July to October 2021 using a large,
nationally representative survey of U.S. households (n = 59,424). Trends
in COVID-19 adolescent vaccination coverage, nationally and by
sociodemographic characteristics, factors associated with adolescent
vaccination status and parental intent to vaccinate their adolescent
children, as well as changes in reasons for non-vaccination were
examined using regression models. <AbstractText Label="RESULTS">Receipt
of =1 dose of a COVID-19 vaccine among adolescents ages 12-17 years
increased five percentage points, from 56% (July) to 61% (October), with
significant increases across most sociodemographic variables. However,
there were no significant changes in parental intention to vaccinate
their adolescent children during the same time period. Approximately
one-quarter of parents were unsure about or reluctant to vaccinate their
children, which remained consistent from July to October. Among those
who had not vaccinated their children, lack of trust in the government
and vaccines, and the belief that the COVID-19 vaccine is not needed or
effective, was higher in October compared to July.
<AbstractText Label="CONCLUSIONS">Parental intention to vaccinate their
children has remained relatively stable throughout the late summer and
early fall of 2021. Encouraging paediatricians to discuss the importance
and safety of COVID-19 vaccines, addressing concerns and misinformation,
as well as recommending and offering vaccines are important for
increasing parental confidence in vaccines as well as vaccination uptake
among adolescents.KEY MESSAGEReceipt of =1 dose of a COVID-19 vaccine
among adolescents ages 12-17 years increased five percentage points,
from 56% (July) to 61% (October), with significant increases across most
sociodemographic variables.Approximately one quarter of parents were
unsure about or reluctant to vaccinate their children, which remained
consistent from July to October.Encouraging paediatricians to discuss
the importance and safety of COVID-19 vaccines, addressing concerns and
misinformation, as well as recommending and offering vaccines is
important for increasing parental confidence in vaccines as well as
vaccination uptake among adolescents.</td>
</tr>
<tr class="odd">
<td align="left">35238119</td>
<td align="left">An Extremely Rare Mucocutaneous Adverse Reaction
Following COVID-19 Vaccination: Toxic Epidermal Necrolysis.</td>
<td align="left">Dermatologic therapy</td>
<td align="left">2022 Mar 02</td>
<td align="left">Stevens-Johnson syndrome (SJS)/ toxic epidermal
necrolysis (TEN), is a type of delayed hypersensitivity reaction that
requires urgent medical intervention. In the COVID-19 era, COVID-19
vaccines are currently being widely administered and mucocutaneous
adverse reactions following vaccination have been reported; however,
severe cutaneous adverse reactions associated with COVID-19 vaccines
including SJS/TEN, are extremely rare. Herein, we describe a case of
COVID-19 vaccination induced TEN which developed one day after receiving
the first dose of Sinopharm COVID-19 vaccine with favorable clinical
outcome. This article is protected by copyright. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35237749</td>
<td align="left">A master autoantigen-ome links alternative splicing,
female predilection, and COVID-19 to autoimmune diseases.</td>
<td align="left">Journal of translational autoimmunity</td>
<td align="left">2022</td>
<td align="left">Chronic and debilitating autoimmune sequelae pose a
grave concern for the post-COVID-19 pandemic era. Based on our discovery
that the glycosaminoglycan dermatan sulfate (DS) displays peculiar
affinity to apoptotic cells and autoantigens (autoAgs) and that
DS-autoAg complexes cooperatively stimulate autoreactive B1 cell
responses, we compiled a database of 751 candidate autoAgs from six
human cell types. At least 657 of these have been found to be affected
by SARS-CoV-2 infection based on currently available multi-omic COVID
data, and at least 400 are confirmed targets of autoantibodies in a wide
array of autoimmune diseases and cancer. The autoantigen-ome is
significantly associated with various processes in viral infections,
such as translation, protein processing, and vesicle transport.
Interestingly, the coding genes of autoAgs predominantly contain
multiple exons with many possible alternative splicing variants, short
transcripts, and short UTR lengths. These observations and the finding
that numerous autoAgs involved in RNA-splicing showed altered expression
in viral infections suggest that viruses exploit alternative splicing to
reprogram host cell machinery to ensure viral replication and survival.
While each cell type gives rise to a unique pool of autoAgs, 39 common
autoAgs associated with cell stress and apoptosis were identified from
all six cell types, with several being known markers of systemic
autoimmune diseases. In particular, the common autoAg UBA1 that
catalyzes the first step in ubiquitination is encoded by an X-chromosome
escape gene. Given its essential function in apoptotic cell clearance
and that X-inactivation escape tends to increase with aging, UBA1
dysfunction can therefore predispose aging women to autoimmune
disorders. In summary, we propose a model of how viral infections lead
to extensive molecular alterations and host cell death, autoimmune
responses facilitated by autoAg-DS complexes, and ultimately autoimmune
diseases. Overall, this master autoantigen-ome provides a molecular
guide for investigating the myriad of autoimmune sequalae to COVID-19
and clues to the rare adverse effects of the currently available mRNA
and viral vector-based COVID vaccines. © 2022 Published by Elsevier
B.V.</td>
</tr>
<tr class="odd">
<td align="left">35237634</td>
<td align="left">Case Report: Myocarditis After COVID-19 Vaccination -
Case Series and Literature Review.</td>
<td align="left">Frontiers in medicine</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">The
ongoing COVID-19 pandemic demands a series of measures and, above all,
the vaccination of a substantial proportion of the population. Acute
myocarditis is a rare complication of the widely used mRNA-based
vaccines.
<AbstractText Label="Case Presentation" NlmCategory="UNASSIGNED">We
present a case series of four patients (three men and one woman, 16 to
47 years old) with acute pericarditis/myocarditis 3 to 17 days after
mRNA vaccination. They presented with chest pain, fever, and flu-like
symptoms. Diagnosis was made based on the synopsis of clinical
presentation, elevated levels of troponin T and NT-proBNP, impaired
systolic function on echocardiography, and findings in non-invasive
tissue characterization by cardiovascular magnetic resonance imaging.
Two patients also underwent endomyocardial biopsies. As none of the
patients showed signs of cardiogenic shock, they were discharged from
ward care only a few days after their initial presentations.
<AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Our data are
consistent with other case reports of myocarditis early after mRNA
vaccination and demonstrate the need for multimodal diagnostics. In view
of its rarity and mild course, the risk-benefit ratio of vaccination
remains positive compared to potential SARS-CoV-2 infection. Copyright ©
2022 Nunn, Kersten, Tadic, Wolf, Gonska, Hüll, Dietenberger, Rottbauer
and Buckert.</td>
</tr>
<tr class="even">
<td align="left">35237629</td>
<td align="left">Case Report: Rowell Syndrome-Like Flare of Cutaneous
Lupus Erythematosus Following COVID-19 Infection.</td>
<td align="left">Frontiers in medicine</td>
<td align="left">2022</td>
<td align="left">The current COVID-19 pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an important
impact on dermatology practice, posing diagnostic and therapeutic
challenges especially in patients with inflammatory and autoimmune skin
disorders. Disease-specific and nonspecific cutaneous manifestations
have been increasingly reported in the spectrum of COVID-19 but the
influence of the infection on pre-existing dermatologic diseases has not
been clearly defined. There has been a debate in the literature as to
whether patients suffering from autoimmune dermatoses, including
cutaneous lupus erythematosus (CLE), are at increased risk of SARS-CoV-2
infection, as well as if they experience worsening of their lupus
erythematosus (LE)-related clinical symptoms. This article reports on a
case of Rowell syndrome occurring after COVID-19 in a 67-year old woman
with pre-existing chronic CLE manifesting with few discoid lesions on
the face, scalp, and upper chest, successfully controlled with topical
corticosteroids and photoprotection. Erythema multiforme (EM)-like
eruption developed approximately two weeks after the SARS-CoV-2
infection, the latter being confirmed by positive nasopharyngeal swab
and successfully treated with systemic antibiotics and antiaggregants.
Diffuse hair loss and patches of cicatricial alopecia were also present
upon scalp examination. Laboratory workup, including routine tests,
histologic, immunofluorescent, and serologic investigations, was
supportive to the diagnosis. Administration of topical and systemic
corticosteroids along with peroral hydroxychloroquine resulted in the
progressive improvement of the cutaneous lesions. Rowell syndrome is a
rare entity in the spectrum of LE, characterized by EM-like lesions,
photosensitivity, and positive antinuclear and anti-Ro antibodies, that
is currently considered to be a variant of subacute CLE (SCLE). Several
cases of SCLE have been described in association with medications,
including anti-SARS-CoV-2 vaccines but only a few reports incriminate
the infection itself as a potential exacerbating factor. Based on the
clinical course of the disease, we suggest that the observed Rowell
syndrome-like flare of CLE was related to the COVID-19 infection in this
patient. Copyright © 2022 Drenovska, Shahid, Mateeva and Vassileva.</td>
</tr>
<tr class="odd">
<td align="left">35237261</td>
<td align="left">SARS-CoV-2 Immunization Orchestrates the Amplification
of IFN&lt;U+03B3&gt;-Producing T Cell and NK Cell Persistence.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2022</td>
<td align="left">A successful vaccination would represent the most
efficient means to control the pandemic of Coronavirus Disease-19
(COVID-19) that led to millions of deaths worldwide. Novel mRNA-based
vaccines confer protective immunity against SARS-CoV-2, but whether
immunity is immediately effective and how long it will remain in
recipients are uncertain. We sought to assess the effectiveness of a
two-dose regimen since the boosts are often delayed concerning the
recommended intervals. <AbstractText Label="Methods">A longitudinal
cohort of healthcare workers (HCW, N = 46; 30.4% men; 69.6% women; mean
age 36.05 ± 2.2 years) with no SARS-CoV-2 infection as documented by
negative polymerase chain reaction was immunophenotyped in PBMC once a
week for 4 weeks from the prime immunization (Pfizer mRNA BNT162b2) and
had received 2 doses, to study the kinetic response.
<AbstractText Label="Results">We identified three risk groups to develop
SARS-CoV-2 infection IgG+-based (late responders, R-; early responders,
R+; pauci responders, PR). In all receipts, amplification of B cells and
NK cells, including IL4-producing B cells and IL4-producing CD8+ T
cells, is early stimulated by the vaccine. After the boost, we observed
a growing increase of NK cells but a resistance of T cells,
IFN&lt;U+03B3&gt;-producing CD4+T cells, and IFN&lt;U+03B3&gt;-producing
NK cells. Also, hematologic parameters decline until the boost. The
positive association of IFN&lt;U+03B3&gt;-producing NK with
IFN&lt;U+03B3&gt;-producing CD4+T cells by the multiple mixed-effect
model, adjusted for confounders (p = 0.036) as well as the correlation
matrix (r = 0.6, p &lt; 0.01), suggests a relationship between these two
subsets of lymphocytes. <AbstractText Label="Conclusions">These findings
introduce several concerns about policy delay in vaccination: based on
immunological protection, B cells and the persistent increase of NK
cells during 2 doses of the mRNA-based vaccine could provide further
immune protection against the virus, while CD8+ T cells increased
slightly only in the R+ and PR groups. Copyright © 2022 La Sala,
Gandini, Bruno, Allevi, Gallazzi, Senesi, Palano, Meregalli, Longhi,
Sommese, Luzi and Trabucchi.</td>
</tr>
<tr class="even">
<td align="left">35236859</td>
<td align="left">Dataset of ultralow temperature refrigeration for COVID
19 vaccine distribution solution.</td>
<td align="left">Scientific data</td>
<td align="left">2022 03 02</td>
<td align="left">Most COVID-19 vaccines require temperature control for
transportation and storage. Two types of vaccine have been developed by
manufacturers (Pfizer and Moderna). Both vaccines are based on mRNA and
lipid nanoparticles requiring low temperature storage. The Pfizer
vaccine requires ultra-low temperature storage (-80 °C to -60 °C), while
the Moderna vaccine requires -30 °C storage. However, the last stage of
distribution is quite challenging, especially for rural or suburban
areas, where local towns, pharmacy chains and hospitals may not have the
infrastructure required to store the vaccine at the required
temperature. In addition, there is limited data available to address
ancillary challenges of the distribution framework for both
transportation and storage stages, including safety concerns due to
human exposure to large amounts of CO2 from dry-ice sublimation, issues
due to the pressure increase caused by dry-ice sublimation, and the
potential issue caused by non-uniform cryogenic temperatures. As such,
there is a need for test dataset to assist the development of a quick,
effective, secure, and safe solution to mitigate the challenges faced by
vaccine distribution logistics. © 2022. This is a U.S. government work
and not under copyright protection in the U.S.; foreign copyright
protection may apply.</td>
</tr>
<tr class="odd">
<td align="left">35236844</td>
<td align="left">Acute kidney rejection after anti-SARS-CoV-2
virus-vectored vaccine-case report.</td>
<td align="left">NPJ vaccines</td>
<td align="left">2022 Mar 02</td>
<td align="left">COVID-19 infection remains a threat to the health
systems of many countries. Potential success in the fight against the
COVID-19 pandemic is the vaccination of high-risk groups, including
patients with end-stage kidney disease (ESKD) and after solid organ
transplantation (SOT). Immunosuppression in kidney transplant recipients
can also reduce the immunogenicity of SARS-CoV-2 vaccines (varied by
vaccine platform), available data suggest that they are efficacious in
approximately 50-70%, compared to non-transplant situations. In this
paper, we present a newly developed acute humoral and cellular rejection
with acute allograft failure and need of hemodialysis 14 days after
administration of the adenovirus vectored SARS-CoV-2 vaccine
(AstraZeneca; CHADOx1, AZD1222). This occurred in a patient who
previously had an asymptomatic COVID-19 infection. Case reports of acute
allograft rejection after vaccination against SARS-CoV-2 can help
stratify risk groups of patients who develop hyperimmune reactions.
However, it is also possible that those with a previous mild primary
COVID-19 infection may also develop acute allograft rejections upon
COVID-19 re-infection. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35236842</td>
<td align="left">Use of analgesics/antipyretics in the management of
symptoms associated with COVID-19 vaccination.</td>
<td align="left">NPJ vaccines</td>
<td align="left">2022 Mar 02</td>
<td align="left">COVID-19 vaccines are effective and important to
control the ongoing pandemic, but vaccine reactogenicity may contribute
to poor uptake. Analgesics or antipyretic medications are often used to
alleviate vaccine side effects, but their effect on immunogenicity
remains uncertain. Few studies have assessed the effect of
analgesics/antipyretics on vaccine immunogenicity and reactogenicity.
Some studies revealed changes in certain immune response parameters
post-vaccination when analgesics/antipyretics were used either
prophylactically or therapeutically. Still, there is no evidence that
these changes impact vaccine efficacy. Specific data on the impact of
analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines
are limited. However, available data from clinical trials of licensed
vaccines, along with recommendations from public health bodies around
the world, should provide reassurance to both healthcare professionals
and vaccine recipients that short-term use of analgesics/antipyretics at
non-prescription doses is unlikely to affect vaccine-induced immunity. ©
2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35236838</td>
<td align="left">Pandemic-response adenoviral vector and RNA vaccine
manufacturing.</td>
<td align="left">NPJ vaccines</td>
<td align="left">2022 Mar 02</td>
<td align="left">Rapid global COVID-19 pandemic response by mass
vaccination is currently limited by the rate of vaccine manufacturing.
This study presents a techno-economic feasibility assessment and
comparison of three vaccine production platform technologies deployed
during the COVID-19 pandemic: (1) adenovirus-vectored (AVV) vaccines,
(2) messenger RNA (mRNA) vaccines, and (3) the newer self-amplifying RNA
(saRNA) vaccines. Besides assessing the baseline performance of the
production process, impact of key design and operational uncertainties
on the productivity and cost performance of these vaccine platforms is
quantified using variance-based global sensitivity analysis. Cost and
resource requirement projections are computed for manufacturing
multi-billion vaccine doses for covering the current global demand
shortage and for providing annual booster immunisations. The model-based
assessment provides key insights to policymakers and vaccine
manufacturers for risk analysis, asset utilisation, directions for
future technology improvements and future epidemic/pandemic
preparedness, given the disease-agnostic nature of these vaccine
production platforms. © 2022. The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35236716</td>
<td align="left">SARS-CoV-2 Vaccine Mandates for Patients on the Kidney
Transplant Waitlist.</td>
<td align="left">Clinical journal of the American Society of Nephrology
: CJASN</td>
<td align="left">2022 Mar 02</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35236664</td>
<td align="left">Efficacy of covid-19 vaccines in immunocompromised
patients: systematic review and meta-analysis.</td>
<td align="left">BMJ (Clinical research ed.)</td>
<td align="left">2022 03 02</td>
<td align="left"><AbstractText Label="OBJECTIVE">To compare the efficacy
of covid-19 vaccines between immunocompromised and immunocompetent
people. <AbstractText Label="DESIGN">Systematic review and
meta-analysis. <AbstractText Label="DATA SOURCES">PubMed, Embase,
Central Register of Controlled Trials, COVID-19 Open Research Dataset
Challenge (CORD-19), and WHO covid-19 databases for studies published
between 1 December 2020 and 5 November 2021. ClinicalTrials.gov and the
WHO International Clinical Trials Registry Platform were searched in
November 2021 to identify registered but as yet unpublished or ongoing
studies. <AbstractText Label="STUDY SELECTION">Prospective observational
studies comparing the efficacy of covid-19 vaccination in
immunocompromised and immunocompetent participants.
<AbstractText Label="METHODS">A frequentist random effects meta-analysis
was used to separately pool relative and absolute risks of
seroconversion after the first and second doses of a covid-19 vaccine.
Systematic review without meta-analysis of SARS-CoV-2 antibody titre
levels was performed after first, second, and third vaccine doses and
the seroconversion rate after a third dose. Risk of bias and certainty
of evidence were assessed. <AbstractText Label="RESULTS">82 studies were
included in the meta-analysis. Of these studies, 77 (94%) used mRNA
vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole
virus vaccines. 63 studies were assessed to be at low risk of bias and
19 at moderate risk of bias. After one vaccine dose, seroconversion was
about half as likely in patients with haematological cancers (risk ratio
0.40, 95% confidence interval 0.32 to 0.50, I2=80%; absolute risk 0.29,
95% confidence interval 0.20 to 0.40, I2=89%), immune mediated
inflammatory disorders (0.53, 0.39 to 0.71, I2=89%; 0.29, 0.11 to 0.58,
I2=97%), and solid cancers (0.55, 0.46 to 0.65, I2=78%; 0.44, 0.36 to
0.53, I2=84%) compared with immunocompetent controls, whereas organ
transplant recipients were 16 times less likely to seroconvert (0.06,
0.04 to 0.09, I2=0%; 0.06, 0.04 to 0.08, I2=0%). After a second dose,
seroconversion remained least likely in transplant recipients (0.39,
0.32 to 0.46, I2=92%; 0.35, 0.26 to 0.46), with only a third achieving
seroconversion. Seroconversion was increasingly likely in patients with
haematological cancers (0.63, 0.57 to 0.69, I2=88%; 0.62, 0.54 to 0.70,
I2=90%), immune mediated inflammatory disorders (0.75, 0.69 to 0.82,
I2=92%; 0.77, 0.66 to 0.85, I2=93%), and solid cancers (0.90, 0.88 to
0.93, I2=51%; 0.89, 0.86 to 0.91, I2=49%). Seroconversion was similar
between people with HIV and immunocompetent controls (1.00, 0.98 to
1.01, I2=0%; 0.97, 0.83 to 1.00, I2=89%). Systematic review of 11
studies showed that a third dose of a covid-19 mRNA vaccine was
associated with seroconversion among vaccine non-responders with solid
cancers, haematological cancers, and immune mediated inflammatory
disorders, although response was variable in transplant recipients and
inadequately studied in people with HIV and those receiving non-mRNA
vaccines. <AbstractText Label="CONCLUSION">Seroconversion rates after
covid-19 vaccination were significantly lower in immunocompromised
patients, especially organ transplant recipients. A second dose was
associated with consistently improved seroconversion across all patient
groups, albeit at a lower magnitude for organ transplant recipients.
Targeted interventions for immunocompromised patients, including a third
(booster) dose, should be performed.
<AbstractText Label="SYSTEMATIC REVIEW REGISTRATION">PROSPERO
CRD42021272088. © Author(s) (or their employer(s)) 2019. Re-use
permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">35236393</td>
<td align="left">Management of COVID-19 vaccines cold chain logistics: a
scoping review.</td>
<td align="left">Journal of pharmaceutical policy and practice</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Successful
mass vaccination programmes are public health achievements of the
contemporary world. While pharmaceutical companies are actively
developing new vaccines, and demonstrating results of effectiveness and
safety profiles, concerns on COVID-19 vaccine management are
under-reported. We aimed to synthesise the evidence for efficient cold
chain management of COVID vaccines.
<AbstractText Label="METHODS" NlmCategory="METHODS">The scoping review’s
conduct and reporting were based on the PRISMA-ScR 2018 checklist. We
searched from April 2020 to January 2022 for publications in PubMed
(LitCovid), Scopus and ScienceDirect. All review stages were
pilot-tested to calibrate 2 reviewers. Articles on cold chain logistics
and management were included, while publications solely describing COVID
vaccines, their development and clinical aspects of the vaccine, were
excluded. To capture relevant data, charting was conducted by one
reviewer and verified by another. Results were analysed thematically and
summarised descriptively in a table and in-text.
<AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="CONCLUSIONS">We
assessed 6984 potentially relevant citations. We included 14
publications originating from USA (n = 6), India (n = 2), Finland,
Spain, Bangladesh, Netherlands, Switzerland and Ethiopia. They were
reported as reviews (4), policy or guidance documents (3), experimental
studies (2), case reports (2), expert commentary (1), phenomenological
study (1), and decision-making trial and evaluation laboratory trial
(1). The findings were presented in three themes: (i) regulatory
requirements for cold-chain logistics, (ii) packaging and storage, and
(iii) transportation and distribution. A conceptual framework emerged
linking regulatory requirements, optimal logistics operation and
formulation stability as the key to efficient cold chain management.
Recommendations were made for improving formulation stability,
end-product storage conditions, and incorporating monitoring
technologies.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19
vaccines require special end-to-end supply cold chain requirements, from
manufacture, and transportation to warehouses and healthcare facilities.
To sustain production, minimise wastage, and for vaccines to reach
target populations, an efficient and resilient vaccine supply chain
which is assisted by temperature monitoring technologies is imperative.
© 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35236319</td>
<td align="left">Longitudinal changes in COVID-19 vaccination intent
among South African adults: evidence from the NIDS-CRAM panel survey,
February to May 2021.</td>
<td align="left">BMC public health</td>
<td align="left">2022 03 02</td>
<td align="left"><AbstractText Label="BACKGROUND">COVID-19 vaccine
hesitancy has threatened the ability of many countries worldwide to
contain the pandemic. Given the severe impact of the pandemic in South
Africa and disruptions to the roll-out of the vaccine in early 2021,
slower-than-expected uptake is a pressing public health challenge in the
country. We examined longitudinal changes in COVID-19 vaccination intent
among South African adults, as well as determinants of intent to receive
a vaccine. <AbstractText Label="METHODS">We used longitudinal data from
Wave 4 (February/March 2021) and Wave 5 (April/May 2021) of the National
Income Dynamics Study: Coronavirus Rapid Mobile Survey (NIDS-CRAM), a
national and broadly representative panel survey of adults in South
Africa. We conducted cross-sectional analyses on aggregate and
between-group variation in vaccination intent, examined individual-level
changes between waves, and modeled demographic predictors of intent.
<AbstractText Label="RESULTS">We analysed data for 5629 (Wave 4; 48%
male, mean age 41.5 years) and 5862 (Wave 5; 48% male, mean age 41.6
years) respondents. Willingness to get a COVID-19 vaccine significantly
increased from 70.8% (95% CI: 68.5-73.1) in Wave 4 to 76.1% (95% CI:
74.2-77.8) in Wave 5. Individual-level analyses indicated that only 6.6%
of respondents remained strongly hesitant between survey waves. Although
respondents aged 18-24 years were 8.5 percentage points more likely to
report hesitancy, hesitant respondents in this group were 5.6 percentage
points more likely to change their minds by Wave 5. Concerns about
rushed testing and safety of the vaccines were frequent and
strongly-held reasons for hesitancy.
<AbstractText Label="CONCLUSIONS">Willingness to receive a COVID-19
vaccine has increased among adults in South Africa, and those who were
entrenched in their reluctance make up a small proportion of the
country’s population. Younger adults, those in formal housing, and those
who trusted COVID-19 information on social media were more likely to be
hesitant. Given that stated vaccination intent may not translate into
behaviour, our finding that three-quarters of the population were
willing to accept the vaccine may reflect an upper bound. Vaccination
promotion campaigns should continue to frame vaccine acceptance as the
norm and tailor strategies to different demographic groups. © 2022. The
Author(s).</td>
</tr>
<tr class="even">
<td align="left">35235975</td>
<td align="left">[Attitudes Towards COVID-19 Vaccination Compared to
Influenza Vaccination Among Hospital Staff].</td>
<td align="left">Psychotherapie, Psychosomatik, medizinische
Psychologie</td>
<td align="left">2022 Mar 02</td>
<td align="left">This cross-sectional study compared hospital staff who
had received influenza or COVID-19 vaccination or who had refused
COVID-19 vaccination in terms of attitudes towards each vaccination,
uptake of influenza vaccination and reasons for refusing COVID-19
vaccination. COVID-19 vaccine refusers rated the risk of infection for
themselves and in general and the effectiveness of the vaccination
lowest and the vaccination risk highest compared to the other two
groups. They also reported the lowest past uptake of influenza
vaccination. Perceived pressure to vaccinate proved to be a relevant
barrier. Future vaccination campaigns should maintain a balance between
information on vaccines, the need for vaccination, and voluntary uptake.
Thieme. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35235852</td>
<td align="left">Generational differences in beliefs about COVID-19
vaccines.</td>
<td align="left">Preventive medicine</td>
<td align="left">2022 Feb 27</td>
<td align="left">Vaccine uptake variation across demographic groups
remains a public health barrier to overcome the coronavirus pandemic
despite substantial evidence demonstrating the effectiveness of COVID-19
vaccines against severe illness and death. Generational cohorts differ
in their experience with historical and public health events, which may
contribute to variation in beliefs about COVID-19 vaccines. Nationally
representative longitudinal data (December 20, 2020 to July 23, 2021)
from the Understanding America Study (UAS) COVID-19 tracking survey (N =
7279) and multilevel logistic regression were used to investigate
whether generational cohorts differ in COVID-19 vaccine beliefs.
Regression models adjusted for wave, socioeconomic and demographic
characteristics, political affiliation, and trusted source of
information about COVID-19. Birth-year cutoffs define the generational
cohorts: Silent (1945 and earlier), Boomer (1946-1964), Gen X
(1965-1980), Millennial (1981-1996), and Gen Z (1997-2012). Compared to
Boomers, Silents had a lower likelihood of believing that COVID-19
vaccines have many known harmful side effects (OR = 0.52, 95%CI =
0.35-0.74) and that they may lead to illness and death (OR = 0.53, 95%CI
= 0.37-0.77). Compared to Boomers, Silents had a higher likelihood of
believing that the vaccines provide important benefits to society (OR =
2.27, 95%CI = 1.34-3.86) and that they are useful and effective (OR =
1.97, 95%CI = 1.17-3.30). Results for Gen Z are similar to those
reported for Silents. Beliefs about COVID-19 vaccines markedly differ
across generations. This is consistent with the idea of generational
imprinting-the idea that some beliefs may be resistant to change through
adulthood. Policy strategies other than vaccine education may be needed
to overcome this pandemic and future public health challenges. Copyright
© 2022 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35235738</td>
<td align="left">The Future of SARS-CoV-2 Vaccination. Reply.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2022 03 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35235737</td>
<td align="left">The Future of SARS-CoV-2 Vaccination.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2022 03 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35235734</td>
<td align="left">Audio Interview: Using Our Covid-19 Experience to
Develop Vaccines More Quickly.</td>
<td align="left">The New England journal of medicine</td>
<td align="left">2022 Mar 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35235677</td>
<td align="left">Enablers and barriers towards ensuring routine
immunization services during the COVID-19 pandemic: findings from a
qualitative study across five different states in India.</td>
<td align="left">Transactions of the Royal Society of Tropical Medicine
and Hygiene</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
coronavirus disease 2019 (COVID-19) pandemic has led to disruption in
delivering routine healthcare services including routine immunization
(RI) worldwide. Understanding the enablers and barriers for RI services
during a pandemic is critically important to develop context-appropriate
strategies to ensure uninterrupted routine services.
<AbstractText Label="METHODS" NlmCategory="METHODS">A community-based,
cross-sectional descriptive study was conducted in five different states
of India, nested within an ongoing multicentric study on RI. Telephone
in-depth interviews among 56 health workers were carried out and the
data were analyzed using a content analysis method.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">During the COVID-19
pandemic, healthcare providers encountered many challenges at the health
system, community and individual level when rendering RI services.
Challenges like the limited availability of personal protective
equipment and vaccines, deployment for COVID-19 duty at system level,
the difficulty in mobilizing people in the community, fear among people
at community level, mobility restrictions and limited family support, as
well as the stress and stigma at individual level, were barriers to
providing RI services. By contrast, the issuing of identification cards
to health staff, engaging community volunteers, the support given to
health workers by their families and training on COVID-19, were factors
that enabled health workers to maintain RI services during the pandemic.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">When
addressing the COVID-19-related public health emergency, we should not
lose sight of the importance of services like RI. © Crown copyright
2022.</td>
</tr>
<tr class="even">
<td align="left">35235663</td>
<td align="left">SARS-CoV-2 mRNA Vaccination and Graves’ Disease: a
report of 12 cases and review of the literature.</td>
<td align="left">The Journal of clinical endocrinology and
metabolism</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Thyroid
autoimmunity has been reported to be associated with SARS-CoV-2 and the
SARS-CoV-2 vaccination recently. We report a series of patients who
presented with new onset or relapse of Graves’ disease related
hyperthyroidism shortly after receiving the SARS-CoV-2 mRNA vaccine at a
single tertiary institution in Singapore.
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We
describe 12 patients who developed hyperthyroidism within a relatively
short interval (median onset of 17 (range: 5 - 63) days) after receiving
the SARS-CoV-2 mRNA vaccine. The majority were females (11/12) with
median age of 35.5 (range: 22-74) years. Six patients had new onset
hyperthyroidism, while the other six had relapse of previously
well-controlled Graves’ disease. TSH Receptor antibody concentrations
ranged from 2.4-32 IU/L. Majority of the patients were able to go for
the second dose of the vaccine without any further exacerbations.
Literature review revealed 21 other similar cases reported from across
the world.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our case
series provide insight into the characteristics of individuals in whom
Graves’ disease was triggered by the SARS-CoV-2 vaccination. Clinicians
need to be vigilant of precipitation or exacerbation of autoimmune
thyroid disorders in predisposed individuals after exposure to the
SARS-CoV-2 vaccination. Further epidemiological and mechanistic studies
are required to elucidate the possible associations between the
SARS-CoV-2 vaccines and the development of thyroid autoimmunity. © The
Author(s) 2022. Published by Oxford University Press on behalf of the
Endocrine Society. All rights reserved. For permissions, please e-mail:
<a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">35235179</td>
<td align="left">Insights into the immune responses of SARS-CoV-2 in
relation to COVID-19 vaccines.</td>
<td align="left">Journal of microbiology (Seoul, Korea)</td>
<td align="left">2022 Mar</td>
<td align="left">The three types of approved coronavirus disease 2019
(COVID-19) vaccines that have been emergency-use listed (EUL) by the
World Health Organization are mRNA vaccines, adenovirus-vectored
vaccines, and inactivated vaccines. Canonical vaccine developments
usually take years or decades to be completed to commercialization;
however, the EUL vaccines being used in the current situation comprise
several COVID-19 vaccine candidates applied in studies and clinical
settings across the world. The extraordinary circumstances of the
COVID-19 pandemic have necessitated the emergency authorization of these
EUL vaccines, which have been rapidly developed. Although the benefits
of the EUL vaccines outweigh their adverse effects, there have been
reports of rare but fatal cases directly associated with COVID-19
vaccinations. Thus, a reassessment of the immunological rationale
underlying EUL vaccines in relation to COVID-19 caused by SARSCOV-2
virus infection is now required. In this review, we discuss the
manifestations of COVID-19, immunologically projected effects of EUL
vaccines, reported immune responses, informed issues related to COVID-19
vaccination, and the potential strategies for future vaccine use against
antigenic variants. © 2022. The Microbiological Society of Korea.</td>
</tr>
<tr class="even">
<td align="left">35235177</td>
<td align="left">Transmissibility and pathogenicity of SARS-CoV-2
variants in animal models.</td>
<td align="left">Journal of microbiology (Seoul, Korea)</td>
<td align="left">2022 Mar</td>
<td align="left">As of February 2022, SARS-CoV-2 is still one of the
most serious public health threats due to its high mortality rate and
rapid spread of novel variants. Since the first outbreak in 2019,
general understanding of SARS-CoV-2 has been improved through basic and
clinical studies; however, knowledge gaps still exist in our
understanding of the emerging novel SARSCoV-2 variants, which impacts
the corresponding development of vaccines and therapeutics. Especially,
accumulation of mutations in SARS-CoV-2 and rapid spread in populations
with previous immunity has resulted in selection of variants that evade
the host immune response. This phenomenon threatens to render current
SARS-CoV-2 vaccines ineffective for controlling the pandemic. Proper
animal models are essential for detailed investigations into the viral
etiology, transmission and pathogenesis mechanisms, as well as
evaluation of the efficacy of vaccine candidates against recent
SARS-CoV-2 variants. Further, the choice of animal model for each
research topic is important for researchers to gain better knowledge of
recent SARS-CoV-2 variants. Here, we review the advantages and
limitations of each animal model, including mice, hamsters, ferrets, and
non-human primates, to elucidate variant SARS-CoV-2 etiology and
transmission and to evaluate therapeutic and vaccine efficacy. © 2022.
The Microbiological Society of Korea.</td>
</tr>
<tr class="odd">
<td align="left">35235159</td>
<td align="left">Current advances and challenges in COVID-19 vaccine
development: from conventional vaccines to next-generation vaccine
platforms.</td>
<td align="left">Molecular biology reports</td>
<td align="left">2022 Mar 02</td>
<td align="left">The world is grappling with an unprecedented public
health crisis COVID-19 pandemic caused by the novel coronavirus
SARS-CoV-2. Due to the high transmission/mortality rates and
socioeconomic impacts of the COVID-19, its control is crucial. In the
absence of specific treatment, vaccines represent the most efficient way
to control and stop the pandemic. Many companies around the world are
currently making efforts to develop the vaccine to combat COVID-19. This
review outlines key strategies for generating SARS-CoV-2 vaccine
candidates, along with the mechanism of action, advantages, and
potential limitations of each vaccine. The use of nanomaterials and
nanotechnology for COVID-19 vaccines development will also be discussed.
© 2022. The Author(s), under exclusive licence to Springer Nature
B.V.</td>
</tr>
<tr class="even">
<td align="left">35234868</td>
<td align="left">Antibody response in immunocompromised patients after
the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: A
randomised controlled trial.</td>
<td align="left">Clinical infectious diseases : an official publication
of the Infectious Diseases Society of America</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">BNT162b2
by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used
vaccines to prevent SARS-CoV-2 infections. Head-to-head comparison of
the efficacy of these vaccines in immunocompromised patients is lacking.
<AbstractText Label="METHODS" NlmCategory="METHODS">Parallel, two-arm
(allocation 1:1), open-label, non-inferiority randomised clinical trial
nested into the Swiss HIV Cohort Study and the Swiss Transplant Cohort
Study. Patients living with HIV (PLWH) or solid organ transplant
recipients (SOTR; i.e. lung and kidney) from these cohorts were
randomised to mRNA-1273 or BNT162b2. The primary endpoint was antibody
response to SARS-CoV-2 spike (S1) protein receptor binding domain
(Elecsys Anti-SARS-CoV-2 immunoassay, Roche; cut-off =0.8 units/ml) 8
weeks after second vaccination. In addition, antibody response was
measured with the Antibody CORonavirus Assay 2 (ABCORA 2).
<AbstractText Label="RESULTS" NlmCategory="RESULTS">430 patients were
randomised and 412 were included in the intention-to-treat analysis (341
PLWH and 71 SOTR). The percentage of patients showing an immune response
was 92.1% (95% confidence interval [CI] 88.4-95.8%; 186/202) for
mRNA-1273 and 94.3% (95% CI 91.2-97.4; 198/210) for BNT162b2
(difference: 2.2%; 95% CI -7.1 to 2.7), fulfilling non-inferiority of
mRNA-1273. With the ABCORA 2 test 89.1% had an immune response to
mRNA-1273 (95% CI 84.8-93.4%; 180/202) and 89.5% to BNT162b2 (95% CI
85.4-93.7%; 188/210). Based on the Elecsys test, all PLWH had an
antibody response (100.0%; 341/341), while for SOTR only 60.6% (95% CI
49.2-71.9%; 43/71) had titres above the cut-off.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In
immunocompromised patients the antibody response of mRNA-1273 was
non-inferior to BNT162b2. PLWH had in general an antibody response,
while a high proportion of SOTR had no antibody response. © The
Author(s) 2022. Published by Oxford University Press for the Infectious
Diseases Society of America.</td>
</tr>
<tr class="odd">
<td align="left">35234625</td>
<td align="left">Immunogenicity of a recombinant VSV-Vectored SARS-CoV
vaccine induced robust immunity in rhesus monkeys after single-dose
immunization.</td>
<td align="left">Virologica Sinica</td>
<td align="left">2022 Jan 12</td>
<td align="left">Severe acute respiratory syndrome (SARS) is a highly
contagious zoonotic disease caused by SARS coronavirus (SARS-CoV). Since
its outbreak in Guangdong Province of China in 2002, SARS has caused
8096 infections and 774 deaths by December 31st, 2003. Although there
have been no more SARS cases reported in human populations since 2004,
the recent emergence of a novel coronavirus disease (COVID-19) indicates
the potential of the recurrence of SARS and other coronavirus disease
among humans. Thus, developing a rapid response SARS vaccine to provide
protection for human populations is still needed. Spike (S) protein of
SARS-CoV can induce neutralizing antibodies, which is a pivotal
immunogenic antigen for vaccine development. Here we constructed a
recombinant chimeric vesicular stomatitis virus (VSV)
VSV&lt;U+0394&gt;G-SARS, in which the glycoprotein (G) gene is replaced
with the SARS-CoV S gene. VSV&lt;U+0394&gt;G-SARS maintains the
bullet-like shape of the native VSV, with the heterogeneous S protein
incorporated into its surface instead of G protein. The results of
safety trials revealed that VSV&lt;U+0394&gt;G-SARS is safe and
effective in mice at a dose of 1 &lt;U+200B&gt;× &lt;U+200B&gt;106
TCID50. More importantly, only a single-dose immunization of 2
&lt;U+200B&gt;× &lt;U+200B&gt;107 TCID50 can provide high-level
neutralizing antibodies and robust T cell responses to non-human primate
animal models. Thus, our data indicate that VSV&lt;U+0394&gt;G-SARS can
be used as a rapid response vaccine candidate. Our study on the
recombinant VSV-vectored SARS-CoV vaccines can accumulate experience and
provide a foundation for the new coronavirus disease in the future.
Copyright © 2022 The Authors. Publishing services by Elsevier B.V. All
rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35234297</td>
<td align="left">COVID-19 in pregnancy-what study designs can we use to
assess the risk of congenital anomalies in relation to COVID-19 disease,
treatment and vaccination?</td>
<td align="left">Paediatric and perinatal epidemiology Paediatr Perinat
Epidemiol COVID-19 in pregnancy-what study designs can we use to assess
the risk of congenital anomalies in relation to COVID-19 disease,
treatment and vaccination?
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ppe.12840
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19
pandemic has accelerated pregnancy outcome research, but little
attention has been given specifically to the risk of congenital
anomalies (CA) and first trimester exposures.
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We reviewed the
main data sources and study designs used internationally, particularly
in Europe, for CA research, and their strengths and limitations for
investigating COVID-19 disease, medications and vaccines.
<AbstractText Label="POPULATION" NlmCategory="METHODS">We classify
research designs based on four data sources: a) spontaneous adverse
event reporting, where study subjects are positive for both exposure and
outcome, b) pregnancy exposure registries, where study subjects are
positive for exposure, c) congenital anomaly registries, where study
subjects are positive for outcome and d) population healthcare data
where the entire population of births is included, irrespective of
exposure and outcome.
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Each data
source allows different study designs, including case series, exposed
pregnancy cohorts (with external comparator), ecological studies,
case-control studies and population cohort studies (with internal
comparator). <AbstractText Label="METHODS" NlmCategory="METHODS">The
quality of data sources for CA studies is reviewed in relation to
criteria including diagnostic accuracy of CA data, size of study
population, inclusion of terminations of pregnancy for foetal anomaly,
inclusion of first trimester COVID-19-related exposures and use of an
internal comparator group. Multinational collaboration models are
reviewed. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Pregnancy
exposure registries have been the main design for COVID-19 pregnancy
studies, but lack detail regarding first trimester exposures relevant to
CA, or a suitable comparator group. CA registries present opportunities
for improving diagnostic accuracy in COVID-19 research, especially when
linked to other data sources. Availability of inpatient hospital
medication use in population healthcare data is limited. More use of
ongoing mother-baby linkage systems would improve research efficiency.
Multinational collaboration delivers statistical power.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Challenges
and opportunities exist to improve research on CA in relation to the
COVID-19 pandemic and future pandemics. © 2022 The Authors. Paediatric
and Perinatal Epidemiology published by John Wiley &amp; Sons
Ltd. <AuthorList CompleteYN="Y"> <Author ValidYN="Y"> Dolk Helen H
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-6639-5904" class="uri">https://orcid.org/0000-0001-6639-5904</a> Ulster University,
United Kingdom. <Author ValidYN="Y"> Damase-Michel Christine C
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0001-5018-0108" class="uri">https://orcid.org/0000-0001-5018-0108</a> INSERM, Centre
Hospitalier Universitaire de Toulouse, France. <Author ValidYN="Y">
Morris Joan K JK <Identifier Source="ORCID"><a href="https://orcid.org/0000-0002-7164-612X" class="uri">https://orcid.org/0000-0002-7164-612X</a> St George’s
University of London, United Kingdom. <Author ValidYN="Y"> Loane Maria M
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0002-1206-3637" class="uri">https://orcid.org/0000-0002-1206-3637</a> Ulster University,
United Kingdom. eng <GrantList CompleteYN="Y"> MR/T039132/1 MRC
<Country></Country> EU H2020 733001 MRC <Country></Country>
<PublicationType UI="D016428">Journal Article
<ArticleDate DateType="Electronic"> 2022 03 02 England Paediatr Perinat
Epidemiol 8709766 0269-5022 IM <KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N"> COVID-19 <Keyword MajorTopicYN="N">congenital
anomalies <Keyword MajorTopicYN="N">healthcare databases
<Keyword MajorTopicYN="N">pregnancy cohorts
<Keyword MajorTopicYN="N">registries <Keyword MajorTopicYN="N">study
design <PubMedPubDate PubStatus="revised"> 2021 10 07
<PubMedPubDate PubStatus="received"> 2021 07 16
<PubMedPubDate PubStatus="accepted"> 2021 11 08
<PubMedPubDate PubStatus="entrez"> 2022 3 2 8 42
<PubMedPubDate PubStatus="pubmed"> 2022 3 3 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 3 6 0 aheadofprint
<ArticleId IdType="pubmed">35234297
<ArticleId IdType="doi">10.1111/ppe.12840 REFERENCES</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
COVID-19 pandemic has accelerated pregnancy outcome research, but little
attention has been given specifically to the risk of congenital
anomalies (CA) and first trimester exposures.
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We reviewed the
main data sources and study designs used internationally, particularly
in Europe, for CA research, and their strengths and limitations for
investigating COVID-19 disease, medications and vaccines.
<AbstractText Label="POPULATION" NlmCategory="METHODS">We classify
research designs based on four data sources: a) spontaneous adverse
event reporting, where study subjects are positive for both exposure and
outcome, b) pregnancy exposure registries, where study subjects are
positive for exposure, c) congenital anomaly registries, where study
subjects are positive for outcome and d) population healthcare data
where the entire population of births is included, irrespective of
exposure and outcome.
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Each data
source allows different study designs, including case series, exposed
pregnancy cohorts (with external comparator), ecological studies,
case-control studies and population cohort studies (with internal
comparator). <AbstractText Label="METHODS" NlmCategory="METHODS">The
quality of data sources for CA studies is reviewed in relation to
criteria including diagnostic accuracy of CA data, size of study
population, inclusion of terminations of pregnancy for foetal anomaly,
inclusion of first trimester COVID-19-related exposures and use of an
internal comparator group. Multinational collaboration models are
reviewed. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Pregnancy
exposure registries have been the main design for COVID-19 pregnancy
studies, but lack detail regarding first trimester exposures relevant to
CA, or a suitable comparator group. CA registries present opportunities
for improving diagnostic accuracy in COVID-19 research, especially when
linked to other data sources. Availability of inpatient hospital
medication use in population healthcare data is limited. More use of
ongoing mother-baby linkage systems would improve research efficiency.
Multinational collaboration delivers statistical power.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Challenges
and opportunities exist to improve research on CA in relation to the
COVID-19 pandemic and future pandemics. © 2022 The Authors. Paediatric
and Perinatal Epidemiology published by John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35234272</td>
<td align="left">Correlation of SARS-CoV-2 to cancer: Carcinogenic or
anticancer? (Review).</td>
<td align="left">International journal of oncology</td>
<td align="left">2022 Apr</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is highly infectious and pathogenic. Among patients with
severe SARS-CoV-2-caused by corona virus disease 2019 (COVID-19), those
complicated with malignant tumor are vulnerable to COVID-19 due to
compromised immune function caused by tumor depletion, malnutrition and
anti-tumor treatment. Cancer is closely related to the risk of severe
illness and mortality in patients with COVID-19. SARS-CoV-2 could
promote tumor progression and stimulate metabolism switching in tumor
cells to initiate tumor metabolic modes with higher productivity
efficiency, such as glycolysis, for facilitating the massive replication
of SARS-CoV-2. However, it has been shown that infection with SARS-CoV-2
leads to a delay in tumor progression of patients with natural killer
cell (NK cell) lymphoma and Hodgkin’s lymphoma, while SARS-CoV-2
elicited anti-tumor immune response may exert a potential oncolytic role
in lymphoma patients. The present review briefly summarized potential
carcinogenicity and oncolytic characteristics of SARS-CoV-2 as well as
strategies to protect patients with cancer during the COVID-19
pandemic.</td>
</tr>
<tr class="even">
<td align="left">35234199</td>
<td align="left">FDG PET/MRI of Acute Myocarditis After mRNA COVID-19
Vaccination.</td>
<td align="left">Clinical nuclear medicine</td>
<td align="left">2022 Feb 28</td>
<td align="left"><AbstractText Label="ABSTRACT" NlmCategory="UNASSIGNED">A
22-year-old man visited the emergency department with chest pain. He had
received a second dose of the coronavirus disease 2019 (COVID-19) mRNA
(Moderna) vaccine 5 days prior. 18F-FDG PET/MR revealed a focal FDG
uptake and late gadolinium enhancement on the basal posterolateral wall
of the left ventricle. Myocarditis after a COVID-19 vaccination has been
reported predominantly after the second dose of mRNA vaccines in young
men. This was a case of acute focal myocarditis after a COVID-19 mRNA
vaccination, which was well-visualized by FDG PET/MRI. Copyright © 2022
Wolters Kluwer Health, Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35233819</td>
<td align="left">Neurological Events Reported after COVID-19 Vaccines:
An Analysis of VAERS.</td>
<td align="left">Annals of neurology</td>
<td align="left">2022 Mar 02</td>
<td align="left"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To
identify the rates of neurological events following administration of
mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the
U.S.. <AbstractText Label="METHODS" NlmCategory="METHODS">We utilized
publicly available data from the U.S. Vaccine Adverse Event Reporting
System (VAERS) collected between January 1, 2021-June 14, 2021. All free
text symptoms that were reported within 42 days of vaccine
administration were manually reviewed and grouped into 36 individual
neurological diagnostic categories. Post-vaccination neurological event
rates were compared between vaccine types and to age-matched baseline
incidence rates in the U.S. and rates of neurological events following
COVID. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of
306,907,697 COVID vaccine doses administered during the study timeframe,
314,610 (0.1%) people reported any adverse event and 105,214 (0.03%)
reported neurological adverse events in a median of 1 day (IQR0-3) from
inoculation. Guillain-Barre Syndrome (GBS), and cerebral venous
thrombosis (CVT) occurred in fewer than 1 per 1,000,000 doses.
Significantly more neurological adverse events were reported following
Janssen (Ad26.COV2.S) vaccination compared to either Pfizer-BioNtech
(BNT162b2) or Moderna (mRNA-1273; 0.15% versus 0.03% versus 0.03% of
doses, respectively,P&lt;0.0001). The observed-to-expected ratios for
GBS, CVT and seizure following Janssen vaccination were =1.5-fold higher
than background rates. However, the rate of neurological events after
acute SARS-CoV-2 infection was up to 617-fold higher than after COVID
vaccination.
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Reports
of serious neurological events following COVID vaccination are rare.
GBS, CVT and seizure may occur at higher than background rates following
Janssen vaccination. Despite this, rates of neurological complications
following acute SARS-CoV-2 infection are up to 617-fold higher than
after COVID vaccination. This article is protected by copyright. All
rights reserved. This article is protected by copyright. All rights
reserved.</td>
</tr>
<tr class="even">
<td align="left">35233581</td>
<td align="left">Influenza vaccination reveals and partly reverses sex
dimorphic immune imprints associated with prior mild COVID-19.</td>
<td align="left">medRxiv : the preprint server for health sciences</td>
<td align="left">2022 Feb 22</td>
<td align="left">Viral infections can have profound and durable
functional impacts on the immune system. There is an urgent need to
characterize the long-term immune effects of SARS-CoV-2 infection given
the persistence of symptoms in some individuals and the continued threat
of novel variants including the recent rapid acceleration in infections.
As the majority of COVID-19 patients experienced mild disease, here we
use systems immunology approaches to comparatively assess the
post-infection immune status (mean: 151 [5 th - 95 th percentile: 58 -
235] days after diagnosis) and subsequent innate and adaptive responses
to seasonal influenza vaccination (as an “immune challenge”) in 33
previously healthy individuals after recovery from mild,
non-hospitalized COVID-19, as compared to 40 age- and sex-matched
healthy controls with no history of COVID-19. Sex-specific, temporally
stable shifts in signatures of metabolism, T-cell activation, and innate
immune/inflammatory processes suggest that mild COVID-19 can establish
new post-infection immunological set-points. COVID-19-recovered males
had an increase in CD71 hi B-cells (including influenza-specific
subsets) before vaccination and more robust innate, influenza-specific
plasmablast, and antibody responses after vaccination compared to
healthy males. Intriguingly, by day 1 post-vaccination in
COVID-19-recovered subjects, the expression of numerous innate
defense/immune receptor genes (e.g., Toll-like receptors) in monocytes
increased and moved away from their post-COVID-19 repressed state toward
the pre-vaccination baseline of healthy controls, and these changes
tended to persist to day 28 in females, hinting that the acute
inflammatory responses induced by vaccination could partly reset the
immune states established by prior mild COVID-19. Our study reveals
sex-dimorphic immune imprints and in vivo functional impacts of mild
COVID-19 in humans, suggesting that prior COVID-19 could change future
responses to vaccination and in turn, vaccines could help reset the
immune system after COVID-19, both in an antigen-agnostic manner.</td>
</tr>
<tr class="odd">
<td align="left">35233565</td>
<td align="left">Characterization and antiviral susceptibility of
SARS-CoV-2 Omicron/BA.2.</td>
<td align="left">Research square</td>
<td align="left">2022 Feb 24</td>
<td align="left">The recent emergence of SARS-CoV-2 Omicron variants
possessing large numbers of mutations has raised concerns of decreased
effectiveness of current vaccines, therapeutic monoclonal antibodies,
and antiviral drugs for COVID-19 against these variants1,2. While the
original Omicron lineage, BA.1, has become dominant in many countries,
BA.2 has been detected in at least 67 countries and has become dominant
in the Philippines, India, and Denmark. Here, we evaluated the
replicative ability and pathogenicity of an authentic infectious BA.2
isolate in immunocompetent and human ACE2 (hACE2)-expressing mice and
hamsters. In contrast to recent data with chimeric, recombinant
SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an
ancestral WK-521 backbone3, we observed similar infectivity and
pathogenicity in mice and hamsters between BA.2 and BA.1, and less
pathogenicity compared to early SARS-CoV-2 strains. We also observed a
marked and significant reduction in the neutralizing activity of plasma
from COVID-19 convalescent individuals and vaccine recipients against
BA.2 compared to ancestral and Delta variant strains. In addition, we
found that some therapeutic monoclonal antibodies (REGN10987/REGN10933,
COV2-2196/COV2-2130, and S309) and antiviral drugs (molnupiravir,
nirmatrelvir, and S-217622) can restrict viral infection in the
respiratory organs of hamsters infected with BA.2. These findings
suggest that the replication and pathogenicity of BA.2 is comparable to
that of BA.1 in rodents and that several therapeutic monoclonal
antibodies and antiviral compounds are effective against Omicron/BA.2
variants.</td>
</tr>
<tr class="even">
<td align="left">35233545</td>
<td align="left">Neutralizing-antibody-independent SARS-CoV-2 control
correlated with intranasal-vaccine-induced CD8+ T cell responses.</td>
<td align="left">Cell reports. Medicine</td>
<td align="left">2022 02 15</td>
<td align="left">Effective vaccines are essential for the control of the
coronavirus disease 2019 (COVID-19) pandemic. Currently developed
vaccines inducing severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs)
are effective, but the appearance of NAb-resistant S variant viruses is
of great concern. A vaccine inducing S-independent or NAb-independent
SARS-CoV-2 control may contribute to containment of these variants.
Here, we investigate the efficacy of an intranasal vaccine expressing
viral non-S antigens against intranasal SARS-CoV-2 challenge in
cynomolgus macaques. Seven vaccinated macaques exhibit significantly
reduced viral load in nasopharyngeal swabs on day 2 post-challenge
compared with nine unvaccinated controls. The viral control in the
absence of SARS-CoV-2-specific NAbs is significantly correlated with
vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our
results indicate that CD8+ T cell induction by intranasal vaccination
can result in NAb-independent control of SARS-CoV-2 infection,
highlighting a potential of vaccine-induced CD8+ T cell responses to
contribute to COVID-19 containment. © 2022 The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35233475</td>
<td align="left">Optimizing COVID-19 vaccination programs during vaccine
shortages: A review of mathematical models.</td>
<td align="left">Infectious Disease Modelling</td>
<td align="left">2022 Feb 25</td>
<td align="left">During the ongoing COVID-19 pandemic, vaccine shortages
occur due to various types of constraints, including interruptions in
production/supply, higher-than-expected demands, and a lack of resources
such as healthcare capacity to administer vaccines. Scientifically
informed epidemic models have been utilized as pivotal tools to optimize
the immunization programs subject to vaccine shortages. The current
paper reviews modelling methods to optimize the allocation strategies of
vaccines with differential efficacies by using various model-based
outcome measures. The models reviewed in this study are expected to be
adopted and extended to make contributions on policy development for
disease control under the vaccine shortage scenario. © 2022 The
Authors.</td>
</tr>
<tr class="even">
<td align="left">35233279</td>
<td align="left">Pharmacists’ Readiness to Receive, Recommend and
Administer COVID-19 Vaccines in an African Country: An Online
Multiple-Practice Settings Survey in Nigeria.</td>
<td align="left">Malawi medical journal : the journal of Medical
Association of Malawi</td>
<td align="left">2021 09</td>
<td align="left"><AbstractText Label="Background">Without a cure,
vaccination is the most reliable means of combating COVID-19 pandemic,
since non-pharmacological measures could not prevent its spread, as
evidenced in the emergence of a second wave. This study assessed the
readiness of pharmacists to receive, recommend and administer COVID-19
vaccines to clients in Nigeria. <AbstractText Label="Methods">This was a
cross-sectional study in which responses were collected from pharmacists
in Nigeria through Google Form link. A 21-item questionnaire was
developed and validated for the study. The link was shared on the
WhatsApp groups of eligible respondents. The response was downloaded
into Microsoft Excel (2019) and cleared of errors. This was uploaded
into KwikTables (Beta Version 2021) for data analysis. Descriptive
statistics such as frequencies and percentages were used to describe the
data. Chi-squared test was used to determine the relationship between
all the responses and the practice areas of the pharmacists.
<AbstractText Label="Results">A total of 509 pharmacists responded to
the study, but 507 indicated their areas of practice. The highest
response of 247(48.7%) was obtained from hospital pharmacists, then
community pharmacists; 157(31.0%). Hospital and community pharmacists
accounted for 96 and 66 of the 191(37.7%) pharmacists that would
probably accept the vaccine (p=0.126). The Pfizer-bioNTech vaccine was
the preferred brand for 275(54.2%) respondents. Healthcare
Professionals&gt;Elderly&gt;General Populace&gt;Children was the order
of roll-out recommended by 317(62.5%).
Adverse-effect-following-immunization was the concern of 330(65.1%)
pharmacists. Age was a factor in their likelihood of recommending the
COVID-19 vaccine to clients (p=0.001).
<AbstractText Label="Conclusion">This study established that most
pharmacists are willing to accept to be vaccinated against COVID-19,
recommend and administer it to other citizens. They were impressed by
the effectiveness and cost of some of the vaccines, but were concerned
about their possible adverse effects. The pharmacists would want the
authorities to consider strategies that will make the vaccines
accessible to all citizens. © 2021 The College of Medicine and the
Medical Association of Malawi.</td>
</tr>
<tr class="odd">
<td align="left">35233264</td>
<td align="left">[Peripheral facial palsy following COVID-19
vaccination: a case report].</td>
<td align="left">The Pan African medical journal</td>
<td align="left">2021</td>
<td align="left">We conducted a clinical study of a patient with no
particular medical history and without a personal or family history
presenting with right facial asymmetry occurred two days after COVID-19
vaccination (recombinant vaccine). Full clinical examination, laboratory
assessments and magnetic resonance imaging (MRI) were normal, suggesting
the diagnosis of post-vaccine peripheral facial palsy (COVID-19). The
diagnosis of peripheral facial palsy following COVID-19 vaccination with
complete recovery was retained. Copyright: Smail Kharoubi et al.</td>
</tr>
<tr class="even">
<td align="left">35233113</td>
<td align="left">Overview of preparedness and response to COVID-19 in
Ghana.</td>
<td align="left">Ghana medical journal</td>
<td align="left">2021 Jun</td>
<td align="left">The Coronavirus disease 2019 (COVID-19) outbreak in
Ghana is part of an ongoing pandemic caused by the Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The first two cases of
COVID-19 were confirmed in Ghana on 12th March 2020. COVID-19 was
consequently declared a Public Health Emergency of National Concern,
triggering several response actions, including enhanced surveillance,
case detection, case management and contact tracing, closure of borders,
suspension of international flights, ban on social gatherings and
closure of schools. Preparedness and response plans were activated for
implementation at the national, regional, district and community levels.
Ghana’s Strategic approaches were to limit and stop the importation of
cases; detect and contain cases early; expand infrastructure, logistics
and capacity to provide quality healthcare for the sick; minimise
disruption to social and economic life and increase the domestic
capacity of all sectors to deal with existing and future shocks. The
health sector strategic frame focused on testing, treatment, and
tracking. As of 31st December 2020, a total of 535,168 cases, including
335 deaths (CFR: 0.61%), have been confirmed with 53,928 recoveries and
905 active cases. All the regions have reported cases, with Greater
Accra reporting the highest number. The response actions in Ghana have
seen high-level political commitment, appropriate and timely decisions,
and a careful balance of public health interventions with economic and
socio-cultural dynamics. Efforts are ongoing to intensify
non-pharmaceutical interventions, sustain the gains made so far and
introduce COVID-19 vaccines to reduce the public health burden of the
disease in Ghana.
<AbstractText Label="Funding" NlmCategory="UNASSIGNED">None declared.
Copyright © The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35232873</td>
<td align="left">BAME community hesitancy in the UK for COVID-19
vaccine: suggested solutions.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35232861</td>
<td align="left">Fake COVID-19 vaccination in India: an emerging
dilemma?</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35232853</td>
<td align="left">Mix and match COVID-19 vaccines: potential benefit and
perspective from India.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35232848</td>
<td align="left">Multisystem inflammatory syndrome after SARS-CoV-2
vaccination (MIS-V), to interpret with caution.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35232847</td>
<td align="left">Prioritising COVID-19 vaccination: an unprecedented
conundrum.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35232844</td>
<td align="left">Some reflections on vaccine research ethics during
COVID-19 pandemic.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35232842</td>
<td align="left">Survival of the wealthiest? Wait in line for COVID-19
vaccination.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35232839</td>
<td align="left">Upcoming SARS-CoV-2 vaccine: expectations and
reality.</td>
<td align="left">Postgraduate medical journal</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35232787</td>
<td align="left">Characteristics associated with COVID-19 vaccine uptake
among adults aged 50 years and above in England (8 December 2020-17 May
2021): a population-level observational study.</td>
<td align="left">BMJ open</td>
<td align="left">2022 03 01</td>
<td align="left"><AbstractText Label="OBJECTIVE">To determine
characteristics associated with COVID-19 vaccine coverage among
individuals aged 50 years and above in England since the beginning of
the programme. <AbstractText Label="DESIGN">Observational
cross-sectional study assessed by logistic regression and mean
prevalence margins. <AbstractText Label="SETTING">COVID-19 vaccinations
delivered in England from 8 December 2020 to 17 May 2021.
<AbstractText Label="PARTICIPANTS">30 624 257/61 967 781 (49.4%) and 17
360 045/61 967 781 (28.1%) individuals in England were recorded as
vaccinated in the National Immunisation Management System with a first
dose and a second dose of a COVID-19 vaccine, respectively.
<AbstractText Label="INTERVENTIONS">Vaccination status with COVID-19
vaccinations. <AbstractText Label="MAIN OUTCOME MEASURES">Proportion,
adjusted ORs and mean prevalence margins for individuals not vaccinated
with dose 1 among those aged 50-69 years and dose 1 and 2 among those
aged 70 years and above. <AbstractText Label="RESULTS">Of individuals
aged 50 years and above, black/African/Caribbean ethnic group was the
least likely of all ethnic groups to be vaccinated with dose 1 of the
COVID-19 vaccine. However, of those aged 70 years and above, the odds of
not having dose 2 was 5.53 (95% CI 5.42 to 5.63) and 5.36 (95% CI 5.29
to 5.43) greater among Pakistani and black/African/Caribbean compared
with white British ethnicity, respectively. The odds of not receiving
dose 2 was 1.18 (95% CI 1.16 to 1.20) higher among individuals who lived
in a care home compared with those who did not. This was the opposite to
that observed for dose 1, where the odds of being unvaccinated was
significantly higher among those not living in a care home (0.89 (95% CI
0.87 to 0.91)). <AbstractText Label="CONCLUSIONS">We found that there
are characteristics associated with low COVID-19 vaccine coverage.
Inequalities, such as ethnicity are a major contributor to suboptimal
coverage and tailored interventions are required to improve coverage and
protect the population from SARS-CoV-2. © Author(s) (or their
employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial
re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">35232629</td>
<td align="left">A gaps-and-needs analysis of vaccine R&amp;D in Europe:
Recommendations to improve the research infrastructure.</td>
<td align="left">Biologicals : journal of the International Association
of Biological Standardization</td>
<td align="left">2022 Feb 26</td>
<td align="left">The COVID-19 pandemic has brought into sharp focus the
importance of strategies supporting vaccine development. During the
pandemic, TRANSVAC, the European vaccine-research-infrastructure
initiative, undertook an in-depth consultation of stakeholders to
identify how best to position and sustain a European vaccine R&amp;D
infrastructure. The consultation included an online survey incorporating
a gaps-and-needs analysis, follow-up interviews and focus-group
meetings. Between October 2020 and June 2021, 53 organisations completed
the online survey, including 24 research institutes and universities,
and 9 pharmaceutical companies; 24 organisations participated in
interviews, and 14 in focus-group meetings. The arising recommendations
covered all aspects of the vaccine-development value chain: from
preclinical development to financing and business development; and
covered prophylactic and therapeutic vaccines, for both human and
veterinary indications. Overall, the recommendations supported the
expansion and elaboration of services including training programmes, and
improved or more extensive access to expertise, technologies,
partnerships, curated databases, and-data analysis tools. Funding and
financing featured as critical elements requiring support throughout the
vaccine-development programmes, notably for academics and small
companies, and for vaccine programmes that address medical and
veterinary needs without a great potential for commercial gain.
Centralizing the access to these research infrastructures via a single
on-line portal was considered advantageous. Copyright © 2022 The
Authors. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35232595</td>
<td align="left">The scourge of vaccine falsification.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 26</td>
<td align="left">Fake vaccines trafficking is a recent but growing
phenomenon, which represents a severe threat to public health. During
the Covid-19 pandemic, anti-Covid vaccines have been a prime target for
traffickers, but all types of vaccines are falsified by profit-hungry
criminals. The consequences of falsification on global health are
serious: decline in vaccination coverage, loss of control of epidemics
which will claim yet more victims, and resurgence of diseases that were
under control. Fake vaccines also fuel the mistrust of populations
towards science and authorities. In order to tackle this scourge, a
general and coordinated mobilization of all actors concerned is urgently
needed: health professionals, political decision-makers, police and
customs forces, judges and prosecutors, without forgetting the crucial
awareness-raising of public opinion. Copyright © 2022 Elsevier Ltd. All
rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35232455</td>
<td align="left">Development of a theory-informed questionnaire to
assess the acceptability of healthcare interventions.</td>
<td align="left">BMC health services research</td>
<td align="left">2022 Mar 01</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
theoretical framework of acceptability (TFA) was developed in response
to recommendations that acceptability should be assessed in the design,
evaluation and implementation phases of healthcare interventions. The
TFA consists of seven component constructs (affective attitude, burden,
ethicality, intervention coherence, opportunity costs, perceived
effectiveness, and self-efficacy) that can help to identify
characteristics of interventions that may be improved. The aim of this
study was to develop a generic TFA questionnaire that can be adapted to
assess acceptability of any healthcare intervention.
<AbstractText Label="METHODS" NlmCategory="METHODS">Two
intervention-specific acceptability questionnaires based on the TFA were
developed using a 5-step pre-validation method for developing
patient-reported outcome instruments: 1) item generation; 2) item
de-duplication; 3) item reduction and creation; 4) assessment of
discriminant content validity against a pre-specified framework (TFA);
5) feedback from key stakeholders. Next, a generic TFA-based
questionnaire was developed and applied to assess prospective and
retrospective acceptability of the COVID-19 vaccine. A think-aloud
method was employed with two samples: 10 participants who self-reported
intention to have the COVID-19 vaccine, and 10 participants who
self-reported receiving a first dose of the vaccine.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">1) The item pool
contained 138 items, identified from primary papers included in an
overview of reviews. 2) There were no duplicate items. 3) 107 items were
discarded; 35 new items were created to maximise coverage of the seven
TFA constructs. 4) 33 items met criteria for discriminant content
validity and were reduced to two intervention-specific acceptability
questionnaires, each with eight items. 5) Feedback from key stakeholders
resulted in refinement of item wording, which was then adapted to
develop a generic TFA-based questionnaire. For prospective and
retrospective versions of the questionnaire, no participants identified
problems with understanding and answering items reflecting four TFA
constructs: affective attitude, burden, perceived effectiveness,
opportunity costs. Some participants encountered problems with items
reflecting three constructs: ethicality, intervention coherence,
self-efficacy.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A generic
questionnaire for assessing intervention acceptability from the
perspectives of intervention recipients was developed using methods for
creating participant-reported outcome measures, informed by theory,
previous research, and stakeholder input. The questionnaire provides
researchers with an adaptable tool to measure acceptability across a
range of healthcare interventions. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35232337</td>
<td align="left">COVID-19 Effects on Geriatric Populationand Failures of
Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China;
Safety and Efficacy of Vaccinesin the Prevention &amp; Treatment of
COVID-19.</td>
<td align="left">Current medicinal chemistry</td>
<td align="left">2022 Mar 01</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mortality
of theolder adult population suffering from COVID-19 has been increasing
at an alarming rate, and people older than 76 years of age reported 18%
mortality. Mainly, the EU and USA exhibited a greater fatality rate due
to lack of selective immunization and anti-SARS Co-V-2 therapeutics.
Very limited reports are available to delineate the impact of COVID-19
on thegeriatric population and thefailures of aminoquinoline therapy.
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed a
substantial literature review in the PubMed/Medline databases to extract
the information pertaining to the COVID-19 impact on the geriatric
population and recent failures of aminoquinoline therapy in COVID-19
patients of EU, China, USA and the requirement of vaccination.
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Both parental
strains and mutant variants of SARS Co-V-2 can induce severe respiratory
complications, multiorgan failure, and clotting abnormalities in older
adults due to low immunocompetence. Aminoquinoline derivatives, such as
chloroquine (CQ) and hydroxychloroquine (HCQ), are preferred primarily
for COVID-19 treatment, but several controversies are being reported for
its usage worldwide. In this review, we have provided theeffects of
COVID-19 on the geriatric population of EU and an overview on the
mechanism of action of aminoquinolines. Furthermore, CQ, and HCQ are not
thepreferred choice of drugs if the COVID-19 patients already have
existing co-morbid conditions viz., diabetes mellitus and hypertension.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A new advent
of COVID-19 vaccines, such as nucleic acid-based (DNA/mRNA) vaccines,
protein subunit vaccines, viral vector vaccines, and inactivated
vaccines, have been developed for treating SARS-CoV-2 infection after
the failure of aminoquinoline therapy in EU, China, and USA patients.
However, some of the vaccines yet to be examined against mutant strains
of SARS CoV-2 originated in UK, Nigeria, South Africa, Brazil, and
India. Copyright© Bentham Science Publishers; For any queries, please
email at <a href="mailto:epub@benthamscience.net" class="email">epub@benthamscience.net</a>.</td>
</tr>
<tr class="even">
<td align="left">35231633</td>
<td align="left">Africa is going to develop their own health
capabilities for future challenges - Correspondence.</td>
<td align="left">International journal of surgery (London, England)</td>
<td align="left">2022 Feb 26</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35231463</td>
<td align="left">A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine
improves serum neutralization against the delta variant in kidney
transplant recipients.</td>
<td align="left">Kidney international</td>
<td align="left">2022 Feb 26</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35231141</td>
<td align="left">Studying the Key Intermediate of RNA Autohydrolysis by
Cryogenic Gas-Phase Infrared Spectroscopy.</td>
<td align="left">Angewandte Chemie (International ed. in English)</td>
<td align="left">2022 Mar 01</td>
<td align="left">Over the course of the COVID-19 pandemic, mRNA-based
vaccines have gained tremendous importance. The development and analysis
of modified RNA molecules benefit from advanced mass spectrometry and
require sufficient understanding of fragmentation processes. Analogous
to the degradation of RNA in solution by autohydrolysis, backbone
cleavage of RNA strands was equally observed in the gas phase; however,
the fragmentation mechanism remained elusive. In this work,
autohydrolysis-like intermediates were generated from isolated RNA
dinucleotides in the gas phase and investigated using cryogenic infrared
spectroscopy in helium nanodroplets. Data from both experiment and
density functional theory provide evidence for the formation of a
five-membered cyclic phosphate intermediate and rule out linear or
six-membered structures. Furthermore, the experiments show that another
prominent condensed-phase reaction of RNA nucleotides can be induced in
the gas phase: the tautomerization of cytosine. Both observed reactions
are therefore highly universal and intrinsic properties of the
investigated molecules. © 2022 Wiley-VCH GmbH.</td>
</tr>
<tr class="odd">
<td align="left">35229541</td>
<td align="left">The impact of anxiety level on decision to seek medical
care of non-COVID cardiac patients during the pandemic
outbreak-single-center experience in Israel.</td>
<td align="left">Reviews in cardiovascular medicine</td>
<td align="left">2022 02 08</td>
<td align="left"><AbstractText Label="BACKGROUND">Coronavirus disease
2019 (COVID-19) has significantly the delivery of healthcare all around
the world. In part, an abnormal and unexplained high non-COVID-related
cardiovascular mortality rate was reported during the outbreak. We
assess the correlation between anxiety level and decision to seek
medical care (DSMC) during the COVID-19 pandemic.
<AbstractText Label="MATERIALS AND METHODS">We recruited patients with
cardiovascular complaints admitted to the emergency department in a
single institute in Israel between February and September 2020. Anxiety
level was measured using available questionnaires. DSMC was assessed
with a newly designed questionnaire (DM-19).
<AbstractText Label="RESULTS">Two-hundreds seventy patients were
included in the study. The mean age was 52.6 ± 14.9 (females represent
36.2%). 23.6% of the patients had at least moderate cardiovascular risk.
High anxiety levels were (HAL) reported in nearly half of the patients
(57.1% and 49.8% for General Anxiety Disorder Assessment [GAD-7] and
Beck Anxiety Inventory [BAI], respectively). It was more prevalent in
old, married, and unemployed patients (significant p-value for all in
both questionnaires). Age was an independent factor (&lt;U+03C7&gt;2 =
6.33, p &lt; 0.001, odds-ratio: 4.8) and had a positive correlation on
anxiety level (r = 0.81, p &lt; 0.001 and r = 0.62, p &lt; 0.001, for
GAD-7 and BAI, respectively). The DM-19 revealed a strong and positive
correlation of seeking medical care with anxiety level (R2 linear =
0.44, r = 0.70, p &lt; 0.001 and R2 linear = 0.30, r = 0.58, p &lt;
0.001 for GAD-7 and BAI, respectively) and results in deferring medical
care for several days than patient with low anxiety level (p = 0.02).
<AbstractText Label="CONCLUSIONS">We observed an abnormal prevalence of
a high level of anxiety among non-COVID patients with cardiovascular
complaints, which affected the patient’s likelihood to seek medical care
and resulted in an unreasonable postponement of medical treatment. Our
results may explain cardiovascular mortality trends during the outbreak
and should be considered in health crisis management. Future studies
will involve multi-institutional efforts to address reproducibility of
our findings across geographic regions in the state of the global
impact. Additionally, it is imperative to understand the effects of the
coronavirus vaccine on patient consideration to seek medical care. ©
2022 The Author(s). Published by IMR Press.</td>
</tr>
<tr class="even">
<td align="left">35229416</td>
<td align="left">COVID-19 vaccine-induced immunity: Head-to-head
comparison of mRNA (BNT162b2) versus inactivated (CoronaVac)
vaccines.</td>
<td align="left">Respirology (Carlton, Vic.) Respirology COVID-19
vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2)
versus inactivated (CoronaVac) vaccines.
<ELocationID EIdType="doi" ValidYN="Y">10.1111/resp.14236
<AuthorList CompleteYN="Y"> <Author ValidYN="Y"> M Kagina Benjamin B
<Identifier Source="ORCID"><a href="https://orcid.org/0000-0003-4943-9762" class="uri">https://orcid.org/0000-0003-4943-9762</a> Vaccines for
Africa Initiative (VACFA), Institute of Infectious Disease and Molecular
Medicine &amp; School of Public Health &amp; Family Medicine, Faculty of
Health Sciences, University of Cape Town, Cape Town, South Africa.
<Author ValidYN="Y"> Dochez Carine C Network for Education and Support
in Immunisation (NESI), Department of Family Medicine and Population
Health, Faculty of Medicine and Health Sciences, University of Antwerp,
Antwerp, Belgium. eng <PublicationType UI="D016421">Editorial
<ArticleDate DateType="Electronic"> 2022 02 28 Australia Respirology
9616368 1323-7799 IM <KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">inactivated <Keyword MajorTopicYN="N">mRNA
<Keyword MajorTopicYN="N">vaccine-induced immunity
<PubMedPubDate PubStatus="received"> 2022 02 17
<PubMedPubDate PubStatus="accepted"> 2022 02 18
<PubMedPubDate PubStatus="entrez"> 2022 3 1 6 1
<PubMedPubDate PubStatus="pubmed"> 2022 3 2 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 2 6 0 aheadofprint
<ArticleId IdType="pubmed">35229416
<ArticleId IdType="doi">10.1111/resp.14236 REFERENCES</td>
<td align="left">2022 Feb 28</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35229414</td>
<td align="left">COVID-19 vaccine acceptability among health care
workers in Ethiopia: Do we practice what we preach?</td>
<td align="left">Tropical medicine &amp; international health : TM &amp;
IH</td>
<td align="left">2022 Mar 01</td>
<td align="left"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We
assessed health care workers (HCWs) COVID-19 vaccine acceptability in
Ethiopia. <AbstractText Label="METHODS" NlmCategory="METHODS">We carried
out a cross sectional survey from February to April 2021 in HCWs from
five teaching hospitals. HCWs were selected using convenient sampling
and data were collected through a survey link. Descriptive analysis and
mixed-effect logistic regression was performed. A total of 1,314 HCWs
participated in the study.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that 25.5%
(n=332) of the HCWs would not accept a COVID-19 vaccine and 20.2%
(n=264) were not willing to recommend COVID-19 vaccination to others.
Factors associated with vaccine non-acceptance were female sex (AOR=1.8;
95% CI: 1.3-2.5), the perception that vaccines are unsafe (AOR=15.0; 95%
CI: 8.7-25.9), not considering COVID-19 as health risk (AOR=4.4; 95% CI:
2.0-9.5) and being unconcerned about contracting COVID-19 at work
(AOR=3.5; 95% CI: 1.5-8.4). Physicians were more willing to accept
vaccination than other HCWs. Higher vaccine acceptability was also noted
with increasing age. Participants most often indicated safety concerns
as the determining factor on their decision to get vaccinated or not.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, a
quarter of HCWs would not accept a COVID-19 vaccine. Communications and
trainings should address vaccine safety concerns. Additionally, emphasis
should be given to showing current and future impact of COVID-19 on the
personal, public and country level unless control efforts are improved.
Interventions aimed to increase vaccine uptake should focus their
efforts on younger and non-physician HCWs. This article is protected by
copyright. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35229357</td>
<td align="left">Knowledge, attitude and practice survey towards
COVID-19 vaccination: A mediation analysis.</td>
<td align="left">The International journal of health planning and
management Int J Health Plann Manage Knowledge, attitude and practice
survey towards COVID-19 vaccination: A mediation analysis.
<ELocationID EIdType="doi" ValidYN="Y">10.1002/hpm.3449
<AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">The
COVID-19 pandemic has significantly impacted human lives across the
world. In a country like India, with the second highest population in
the world, impact of COVID-19 has been diverse and multidimensional.
Under such circumstances, vaccination against COVID-19 infection is
claimed to be one of the major solutions to contain the pandemic.
Understanding of Knowledge, Attitude and Practice (KAP) measures are
essential prerequisites to design suitable intervention programs. This
paper examines the different KAP factors in Indians towards their
decision of vaccine uptake.
<AbstractText Label="METHOD" NlmCategory="METHODS">An online
questionnaire was administered to Indian respondents. (Pilot study: n =
100, Main study: n = 221) to assess their existing knowledge on COVID-19
infections and vaccination, attitude and intentions towards COVID-19
vaccines and their decision towards COVID-19 vaccine uptake.
<AbstractText Label="RESULT" NlmCategory="RESULTS">The findings
highlighted that existing knowledge on COVID-19 infections and
vaccination directly impacted their attitude and intention towards
vaccination. The attitude and intention towards COVID-19 vaccines
directly impacted their practice of undergoing COVID-19 vaccination.
Further, there was a statistically significant and considerably large
indirect effect of existing knowledge on COVID-19 infections and
vaccination on the practice of undergoing COVID-19 vaccination through
attitude and intention towards the vaccine. There was no direct effect
of Knowledge (existing knowledge on COVID-19 infections and vaccination)
on Practice (decision to undergo COVID-19 vaccination). Therefore,
Attitude and intention towards COVID-19 vaccine is the primary mediator
between Knowledge (existing knowledge on COVID-19 infections and
vaccination) and Practice (decision to undergo COVID-19 vaccination).
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Participants
decision towards COVID-19 vaccination decisions are strongly related to
their attitude and intentions that confirms the strong role of attitude
towards success of COVID-19 vaccination programme. Therefore,
‘person-centric’ attitude based positive intervention strategies that
links their prior knowledge on COVID-19 infections and vaccination must
be designed for greater vaccine acceptance amongst Indians. © 2022 John
Wiley &amp; Sons Ltd. <AuthorList CompleteYN="Y"> <Author ValidYN="Y">
Sengupta Mitali M <Identifier Source="ORCID"><a href="https://orcid.org/0000-0002-2865-4394" class="uri">https://orcid.org/0000-0002-2865-4394</a> University of
Engineering &amp; Management, Kolkata, India. <Author ValidYN="Y"> Dutta
Smita S University of Engineering &amp; Management, Kolkata, India.
<Author ValidYN="Y"> Roy Arijit A Cradle Fertility Centre, Kolkata,
Chikitsa Medicare Centre Pvt Ltd, Kolkata, India. <Author ValidYN="Y">
Chakrabarti Satyajit S University of Engineering &amp; Management,
Kolkata, India. <Author ValidYN="Y"> Mukhopadhyay Indraneel I Institute
of Engineering &amp; Management, Kolkata, India. eng
<PublicationType UI="D016428">Journal Article
<ArticleDate DateType="Electronic"> 2022 02 28 England Int J Health
Plann Manage 8605825 0749-6753 <KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">COVID-19 <Keyword MajorTopicYN="N">India
<Keyword MajorTopicYN="N">attitude <Keyword MajorTopicYN="N">knowledge
<Keyword MajorTopicYN="N">practice <Keyword MajorTopicYN="N">vaccination
<PubMedPubDate PubStatus="revised"> 2022 01 25
<PubMedPubDate PubStatus="received"> 2021 07 14
<PubMedPubDate PubStatus="accepted"> 2022 02 15
<PubMedPubDate PubStatus="entrez"> 2022 3 1 6 0
<PubMedPubDate PubStatus="pubmed"> 2022 3 2 6 0
<PubMedPubDate PubStatus="medline"> 2022 3 2 6 0 aheadofprint
<ArticleId IdType="pubmed">35229357
<ArticleId IdType="doi">10.1002/hpm.3449 REFERENCES</td>
<td align="left">2022 Feb 28</td>
<td align="left"><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">The
COVID-19 pandemic has significantly impacted human lives across the
world. In a country like India, with the second highest population in
the world, impact of COVID-19 has been diverse and multidimensional.
Under such circumstances, vaccination against COVID-19 infection is
claimed to be one of the major solutions to contain the pandemic.
Understanding of Knowledge, Attitude and Practice (KAP) measures are
essential prerequisites to design suitable intervention programs. This
paper examines the different KAP factors in Indians towards their
decision of vaccine uptake.
<AbstractText Label="METHOD" NlmCategory="METHODS">An online
questionnaire was administered to Indian respondents. (Pilot study: n =
100, Main study: n = 221) to assess their existing knowledge on COVID-19
infections and vaccination, attitude and intentions towards COVID-19
vaccines and their decision towards COVID-19 vaccine uptake.
<AbstractText Label="RESULT" NlmCategory="RESULTS">The findings
highlighted that existing knowledge on COVID-19 infections and
vaccination directly impacted their attitude and intention towards
vaccination. The attitude and intention towards COVID-19 vaccines
directly impacted their practice of undergoing COVID-19 vaccination.
Further, there was a statistically significant and considerably large
indirect effect of existing knowledge on COVID-19 infections and
vaccination on the practice of undergoing COVID-19 vaccination through
attitude and intention towards the vaccine. There was no direct effect
of Knowledge (existing knowledge on COVID-19 infections and vaccination)
on Practice (decision to undergo COVID-19 vaccination). Therefore,
Attitude and intention towards COVID-19 vaccine is the primary mediator
between Knowledge (existing knowledge on COVID-19 infections and
vaccination) and Practice (decision to undergo COVID-19 vaccination).
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Participants
decision towards COVID-19 vaccination decisions are strongly related to
their attitude and intentions that confirms the strong role of attitude
towards success of COVID-19 vaccination programme. Therefore,
‘person-centric’ attitude based positive intervention strategies that
links their prior knowledge on COVID-19 infections and vaccination must
be designed for greater vaccine acceptance amongst Indians. © 2022 John
Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35229324</td>
<td align="left">Characterization of the significant decline in humoral
immune response six months post-SARS-CoV-2 mRNA vaccination: A
systematic review.</td>
<td align="left">Journal of medical virology</td>
<td align="left">2022 Feb 28</td>
<td align="left">Accumulating evidence shows a progressive decline in
the efficacy of coronavirus disease 2019 (SARS-CoV-2) mRNA vaccines such
as Pfizer-BioNTech (mRNA BNT161b2) and Moderna (mRNA-1273) in preventing
breakthrough infections due to diminishing humoral immunity over time.
Thus, this review characterizes the kinetics of anti-SARS-CoV-2 (Severe
Acute Respiratory Syndrome Coronavirus 2) antibodies after the second
dose of a primary cycle of COVID-19 mRNA vaccination. A systematic
search of literature was performed and a total of 18 articles (N=15,980
participants) were identified and reviewed. The percent difference of
means of reported antibody titers were then calculated to determine the
decline in humoral response after the peak levels post-vaccination.
Findings revealed that the peak humoral response was reached at 21-28
days after the second dose, after which serum levels progressively
diminished at 4-6 months post-vaccination. Additionally, results showed
that regardless of age, sex, serostatus and presence of comorbidities,
longitudinal data reporting antibody measurement exhibited a decline of
both anti-receptor binding domain (RBD) IgG and anti-spike IgG, ranging
from 94-95% at 90-180 days and 55-85% at 140-160 days, respectively,
after the peak antibody response. This suggests that the rate of
antibody decline may be independent of patient-related factors and peak
antibody titers but mainly a function of time and antibody
class/molecular target. Hence, this study highlights the necessity of
more efficient vaccination strategies to provide booster administration
in attenuating the effects of waning immunity, especially in the
appearance of new variants of concerns (VoCs). This article is protected
by copyright. All rights reserved. This article is protected by
copyright. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35229317</td>
<td align="left">Development and optimisation of a high-throughput
screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of
5676 phase 1 passed structures.</td>
<td align="left">Journal of medical virology</td>
<td align="left">2022 Feb 28</td>
<td align="left">Although vaccines are currently used to control the
coronavirus disease 2019 (COVID-19) pandemic, treatment options are
urgently needed for those who cannot be vaccinated and for future
outbreaks involving new severe acute respiratory syndrome coronavirus
virus 2 (SARS-CoV-2) strains or coronaviruses not covered by current
vaccines. Thus far, few existing antivirals are known to be effective
against SARS-CoV-2 and clinically successful against COVID-19. As part
of an immediate response to the COVID-19 pandemic, a high-throughput,
high content imaging-based SARS-CoV-2 infection assay was developed in
VeroE6-eGFP cells and was used to screen a library of 5676 compounds
that passed phase 1 clinical trials. Eight drugs (nelfinavir, RG-12915,
itraconazole, chloroquine, hydroxychloroquine, sematilide, remdesivir,
and doxorubicin) were identified as inhibitors of in vitro
anti-SARS-CoV-2 activity in VeroE6-eGFP and/or Caco-2 cell lines.
However, apart from remdesivir, toxicity and pharmacokinetic data did
not support further clinical development of these compounds for COVID-19
treatment. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35228973</td>
<td align="left">The Diagnosis of Common Variable Immunodeficiency After
Multisystem Dysfunction.</td>
<td align="left">Cureus</td>
<td align="left">2022 Jan</td>
<td align="left">Common variable immunodeficiency (CVID) is a primary
immunodeficiency caused by the lack of B cell differentiation into
plasma cells, thereby leading to decreased serum immunoglobulins.
Patients with this condition are predisposed to recurrent infections and
are more likely to develop certain cancers and autoimmune diseases. We
report the case of a 53-year-old female suffering from recurrent
pulmonary infections and a history of non-Hodgkin lymphoma (NHL) who had
a poor response to the measles, mumps, and rubella (MMR) and varicella
vaccines as a child, and was infected with coronavirus disease 2019
(COVID-19) twice in 2020. Testing of her antibody titers in order to
determine suitability for Streptococcus pneumoniae (S. pneumoniae)
vaccination found an overall decrease in major immunoglobulin classes
(IgG, IgM, and IgA) and B cells with normal morphology. The diagnosis of
CVID was made, and prompt treatment with intravenous immunoglobulins
(IVIG) brought her IgG levels up from 282 to 680 mg/dL within three
months. This case highlights the importance for providers to keep
immunological dysfunction on their differentials for patients with
atypical presentations involving multiple organ systems. Copyright ©
2022, Rasul et al.</td>
</tr>
<tr class="even">
<td align="left">35228965</td>
<td align="left">A Case of Giant Cell Arteritis Presenting After
COVID-19 Vaccination: Is It Just a Coincidence?</td>
<td align="left">Cureus</td>
<td align="left">2022 Jan</td>
<td align="left">Giant cell arteritis (GCA) is a large vessel vasculitis
with variable presentations, including fevers, myalgias, headache, and
jaw claudication. A particularly concerning symptom is transient vision
loss, which may become irreversible without prompt recognition and
treatment. The pathogenesis of GCA is incompletely understood, but it
seems that the innate and adaptive immune systems play a key role in
vessel inflammation, remodeling, and occlusion. We present a case of a
79-year-old male who developed GCA two days after he received his second
dose of a COVID-19 mRNA vaccine. He presented with headaches, fever, and
myalgias. Lab workup revealed elevated inflammatory markers, with
C-reactive protein (CRP) 272 mg/L (&lt;8.1 mg/L) and erythrocyte
sedimentation rate (ESR) 97 mm/hr (0-20mm/hr). Imaging of the head, with
CT and MRI, was unremarkable. His headache persisted despite supportive
treatment, and he developed new, transient blurred vision, which
increased suspicion for GCA. He underwent bilateral temporal artery
biopsies, which were consistent with GCA. His symptoms resolved quickly
with oral prednisone 60mg daily, and his inflammatory markers returned
to normal within a month. A review of the literature revealed several
case reports of giant cell arteritis following influenza vaccination.
However, no large-scale studies have demonstrated a causal relationship
between GCA and immunization. Our case demonstrates the first instance
of GCA following a COVID-19 mRNA vaccine. We propose that the
upregulated immune response to the vaccine acted as a trigger for GCA in
this patient with predisposing factors. While causation cannot be
determined based on one case alone, our case demonstrates an opportunity
for further research into the relationship between vasculitis and
immunizations. Despite this isolated case, the proven benefits of
COVID-19 mRNA vaccines significantly outweigh any theoretical risk of
immune dysregulation following administration. Copyright © 2022, Greb et
al.</td>
</tr>
<tr class="odd">
<td align="left">35228886</td>
<td align="left">COVID-19 vaccine-induced Radiation Recall Dermatitis:
Report of a case.</td>
<td align="left">Clinical case reports</td>
<td align="left">2022 Feb</td>
<td align="left">Radiation Recall Dermatitis (RRD) is an inflammatory
process in the site of irradiation, induced by physical and medical
agents. Few cases of RRD in the skin and lung have been reported after
COVID-19 vaccination. Here, we report radiation recall dermatitis after
both doses of inactivated SARS-CoV-2 vaccine (Sinopharm, China). © 2022
The Authors. Clinical Case Reports published by John Wiley &amp; Sons
Ltd.</td>
</tr>
<tr class="even">
<td align="left">35228869</td>
<td align="left">Post-COVID-19 vaccine medium-vessel vasculitis and
acute anterior uveitis, causation vs temporal relation; case report and
literature review.</td>
<td align="left">Annals of medicine and surgery (2012)</td>
<td align="left">2022 Feb 24</td>
<td align="left"><AbstractText Label="Introduction" NlmCategory="UNASSIGNED">and
importance: Multiple immunologic phenomena were reported following the
administration of COVID-19 vaccines. However, the important point is
that their possible association with medium-vessel vasculitis involving
the celiac trunk and its branches with acute anterior uveitis in the
same patient has not been reported before.
<AbstractText Label="Case presentation" NlmCategory="UNASSIGNED">In this
manuscript, we are reporting a case of a middle-aged gentleman who
developed vasculitis involving the celiac trunk and its branches, and
acute anterior uveitis one week and three weeks after the second dose of
Pfizer BioNTech COVID-19 vaccine, respectively. The patient showed
significant clinical and radiographic improvement after receiving
corticosteroids and azathioprine.
<AbstractText Label="Clinical discussion" NlmCategory="UNASSIGNED">Previously
reported cases of vasculitis following COVID-19 vaccines included both
renal-limited and more generalized vasculitis with some being positive
and others negative for ANCA (anti-neutrophil cytoplasmic antibodies).
Nevertheless, it is worth mentioning that most cases responded to
immunosuppressive treatment. Post-COVID-19 vaccine uveitis was reported
in patients with different age spans including both anterior and
posterior uveitis, with remission being achieved after the use of
corticosteroids.
<AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Multiple
cases of vasculitis and acute anterior uveitis were reported following
COVID-19 vaccines; however, it is important to mention that more
research is needed to establish an association between the COVID-19
vaccine and both vasculitis and acute anterior uveitis. In our opinion,
the benefits of the COIVID-19 vaccine largely outweigh the expected
risks. © 2022 The Authors. Published by Elsevier Ltd on behalf of IJS
Publishing Group Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35228772</td>
<td align="left">An epidemiology-based model for the operational
allocation of COVID-19 vaccines: A case study of Thailand.</td>
<td align="left">Computers &amp; industrial engineering</td>
<td align="left">2022 May</td>
<td align="left">This paper addresses a framework for the operational
allocation and administration of COVID-19 vaccines in Thailand, based on
both COVID-19 transmission dynamics and other vital operational
restrictions that might affect the effectiveness of vaccination
strategies in the early stage of vaccine rollout. In this framework, the
SIQRV model is first developed and later combined with the COVID-19
Vaccine Allocation Problem (CVAP) to determine the optimal
allocation/administration strategies that minimize total weighted strain
on the whole healthcare system. According to Thailand’s second pandemic
wave data (17th January 2021, to 15th February 2021), we find that the
epicenter-based strategy is surprisingly the worst allocation strategy,
due largely to the negligence of provincial demographics, vaccine
efficacy, and overall transmission dynamics that lead to higher number
of infectious individuals. We also find that early vaccination seems to
significantly contribute to the reduction in the number of infectious
individuals, whose effects tend to increase with more vaccine supply.
With these insights, healthcare policy-makers should therefore focus not
only on the procurement of COVID-19 vaccines at strategic levels but
also on the allocation and administration of such vaccines at
operational levels for the best of their limited vaccine supply. © 2022
Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35228696</td>
<td align="left">An engineered bispecific human monoclonal antibody
against SARS-CoV-2.</td>
<td align="left">Nature immunology</td>
<td align="left">2022 Feb 28</td>
<td align="left">The global severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic requires effective therapies against
coronavirus disease 2019 (COVID-19), and neutralizing antibodies are a
promising therapy. A noncompeting pair of human neutralizing antibodies
(B38 and H4) blocking SARS-CoV-2 binding to its receptor, ACE2, have
been described previously. Here, we develop bsAb15, a bispecific
monoclonal antibody (bsAb) based on B38 and H4. bsAb15 has greater
neutralizing efficiency than these parental antibodies, results in less
selective pressure and retains neutralizing ability to most SARS-CoV-2
variants of concern (with more potent neutralizing activity against the
Delta variant). We also selected for escape mutants of the two parental
mAbs, a mAb cocktail and bsAb15, demonstrating that bsAb15 can
efficiently neutralize all single-mAb escape mutants. Furthermore,
prophylactic and therapeutic application of bsAb15 reduced the viral
titer in infected nonhuman primates and human ACE2 transgenic mice.
Therefore, this bsAb is a feasible and effective strategy to treat and
prevent severe COVID-19. © 2022. The Author(s), under exclusive licence
to Springer Nature America, Inc.</td>
</tr>
<tr class="odd">
<td align="left">35228558</td>
<td align="left">Development and validation of a population-based risk
stratification model for severe COVID-19 in the general population.</td>
<td align="left">Scientific reports</td>
<td align="left">2022 02 28</td>
<td align="left">The shortage of recently approved vaccines against the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
highlighted the need for evidence-based tools to prioritize healthcare
resources for people at higher risk of severe coronavirus disease
(COVID-19). Although age has been identified as the most important risk
factor (particularly for mortality), the contribution of underlying
comorbidities is often assessed using a pre-defined list of chronic
conditions. Furthermore, the count of individual risk factors has
limited applicability to population-based “stratify-and-shield”
strategies. We aimed to develop and validate a COVID-19 risk
stratification system that allows allocating individuals of the general
population into four mutually-exclusive risk categories based on
multivariate models for severe COVID-19, a composite of hospital
admission, transfer to intensive care unit (ICU), and mortality among
the general population. The model was developed using clinical,
hospital, and epidemiological data from all individuals among the entire
population of Catalonia (North-East Spain; 7.5 million people) who
experienced a COVID-19 event (i.e., hospitalization, ICU admission, or
death due to COVID-19) between March 1 and September 15, 2020, and
validated using an independent dataset of 218,329 individuals with
COVID-19 confirmed by reverse transcription-polymerase chain reaction
(RT-PCR), who were infected after developing the model. No exclusion
criteria were defined. The final model included age, sex, a summary
measure of the comorbidity burden, the socioeconomic status, and the
presence of specific diagnoses potentially associated with severe
COVID-19. The validation showed high discrimination capacity, with an
area under the curve of the receiving operating characteristics of 0.85
(95% CI 0.85-0.85) for hospital admissions, 0.86 (0.86-0.97) for ICU
transfers, and 0.96 (0.96-0.96) for deaths. Our results provide
clinicians and policymakers with an evidence-based tool for prioritizing
COVID-19 healthcare resources in other population groups aside from
those with higher exposure to SARS-CoV-2 and frontline workers. © 2022.
The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35228535</td>
<td align="left">Humoral immune responses to COVID-19 vaccination in
people living with HIV receiving suppressive antiretroviral
therapy.</td>
<td align="left">NPJ vaccines</td>
<td align="left">2022 Feb 28</td>
<td align="left">Humoral responses to COVID-19 vaccines in people living
with HIV (PLWH) remain incompletely characterized. We measured
circulating antibodies against the SARS-CoV-2 spike protein
receptor-binding domain (RBD), ACE2 displacement and viral
neutralization activities one month following the first and second
COVID-19 vaccine doses, and again 3 months following the second dose, in
100 adult PLWH and 152 controls. All PLWH were receiving suppressive
antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR
525-935) cells/mm3, though nadir CD4+ T-cell counts ranged as low as
&lt;10 cells/mm3. After adjustment for sociodemographic, health and
vaccine-related variables, HIV infection was associated with lower
anti-RBD antibody concentrations and ACE2 displacement activity after
one vaccine dose. Following two doses however, HIV was not significantly
associated with the magnitude of any humoral response after
multivariable adjustment. Rather, older age, a higher burden of chronic
health conditions, and dual ChAdOx1 vaccination were associated with
lower responses after two vaccine doses. No significant correlation was
observed between recent or nadir CD4+ T-cell counts and responses to two
vaccine doses in PLWH. These results indicate that PLWH with
well-controlled viral loads and CD4+ T-cell counts in a healthy range
generally mount strong initial humoral responses to dual COVID-19
vaccination. Factors including age, co-morbidities, vaccine brand,
response durability and the rise of new SARS-CoV-2 variants will
influence when PLWH will benefit from additional doses. Further studies
of PLWH who are not receiving antiretroviral treatment or who have low
CD4+ T-cell counts are needed, as are longer-term assessments of
response durability. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35228445</td>
<td align="left">[Production of antiviral vaccines using a
silkworm-baculovirus expression system].</td>
<td align="left">Nihon yakurigaku zasshi. Folia pharmacologica
Japonica</td>
<td align="left">2022</td>
<td align="left">The outbreak of the new coronavirus (SARS-2) infection
(COVID-19) in Wuhan, China, has become a global outbreak and continues
to cause many deaths. Not only COVID-19, but the risk of pandemic
continues to increase due to global environmental changes and
globalization of human exchange and logistics. On the other hand, we are
inadequately prepared for such unknown emerging infectious diseases, and
dealing with viral infections has become one of the most important
issues facing humanity. Vaccine based disease prevention is considered
an ideal disease control strategy, especially for viral diseases for
which there is no or little cure. New nucleic acid vaccines (mRNA and
viral vector vaccines) are leading the way in the fight against
COVID-19, but even today, the mainstream of vaccines are inactivated
vaccines and live-attenuated vaccines. Subunit vaccines, in which some
specific viral proteins of the pathogen are produced as recombinant
proteins and used as vaccine antigens, have also been developed. On the
other hand, many antigens that are difficult to produce in large
quantities as recombinant proteins, such as the spike protein antigen of
COVID-19 (the same antigen is also targeted by nucleic acid vaccines),
have not yet been produced and developed. In this paper, we describe the
development of a recombinant protein vaccine based on the silkworm
insect factory, which has an advantage in the production of such
difficult-to-express vaccine antigens.</td>
</tr>
<tr class="even">
<td align="left">35228444</td>
<td align="left">[Development of COVID-19 drugs using human iPS cell
technology].</td>
<td align="left">Nihon yakurigaku zasshi. Folia pharmacologica
Japonica</td>
<td align="left">2022</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which results
in a rapid increase in the number of patients and deaths. In addition,
various mutant strains have emerged and to be considered to accelerate
the number of infected persons. To overcome this situation, effective
strategies against COVID-19 include the development of vaccines to
prevent SARS-CoV-2 infection and therapeutic agents that suppress the
severity after infection. The drug repositioning approach, which search
existing drugs that are effective against COVID-19, are expected to
develop anti-COVID-19 drugs. In addition, various methods using human
iPSC-derived differentiated cells has been developed to evaluate the
efficacy and safety of drugs, and are also used for searching for
therapeutic drugs for COVID-19. Here, we would like to describe the
recent research and future perspectives for COVID-19 therapeutic drugs
from the viewpoint of human iPS cell technology.</td>
</tr>
<tr class="odd">
<td align="left">35228441</td>
<td align="left">[Drug screening for COVID-19 using supercomputer
“Fugaku”].</td>
<td align="left">Nihon yakurigaku zasshi. Folia pharmacologica
Japonica</td>
<td align="left">2022</td>
<td align="left">The expansion of COVID-19 in the world has not ended
yet, and the situation in Japan is still unpredictable. Under these
circumstances, the development of SARS-CoV-2 treatments such as vaccines
and medicines is still underway. We have been conducting research on the
drug screening for SARS-CoV-2 using the supercomputer “Fugaku”.
Specifically, we searched for and identified therapeutic drug candidates
that showed high affinity to the target protein (main protease) related
to the multiplication of SARS-CoV-2 from among about 2,000 existing
drugs by performing molecular dynamics calculations using Fugaku. This
is the first attempt in the world to screen drugs on a scale of several
thousand using molecular dynamics calculations, and it is a case where
we were able to take on the challenge because Fugaku is ranked No. 1 in
the world. In this chapter, we will show the impact of the supercomputer
“Fugaku” on drug discovery using our search for therapeutic agents for
SARS-CoV-2 as an example.</td>
</tr>
<tr class="even">
<td align="left">35227871</td>
<td align="left">Immunogenicity and reactogenicity of homologous
mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients
receiving maintenance dialysis.</td>
<td align="left">Clinical immunology (Orlando, Fla.)</td>
<td align="left">2022 Feb 25</td>
<td align="left">Patients receiving maintenance dialysis (MD) are
vulnerable to COVID-19-related morbidity and mortality. Currently, data
on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in
this population are scarce. We conducted a prospective single-center
study exploring the specific cellular (interferon-&lt;U+03B3&gt; and
interleukin-2 ELISpot assays) and humoral immune responses (dot plot
array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks
and 6 weeks following a single dose or a complete homologous dual dose
SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of
COVID-19). Our results show that MD patients exhibit a high
seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA)
tend to wane rapidly after full immunization. Only 51.7% of the patients
developed T cell immune response. High anti-spike IgG antibodies may
predict a better cellular immunity. While patients with prior COVID-19
showed the best response after one, SARS-CoV-2-naïve patients may
benefit from a third vaccine injection. Copyright © 2022 Elsevier
Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35227552</td>
<td align="left">Early safety and tolerability profile of the BNT162b2
COVID-19 vaccine in myasthenia gravis.</td>
<td align="left">Neuromuscular disorders : NMD</td>
<td align="left">2022 Feb 05</td>
<td align="left">Although the COVID-19 vaccines are currently
recommended for people with myasthenia gravis (MG), there is no data
regarding the safety of the vaccines in this population. In order to
investigate the real-life safety data of the BNT162b2 COVID-19 vaccine
in people with MG, an anonymous survey was distributed to 142 MG
patients. Fifty-six MG patients completed the questionnaire. The median
age was 53 years (range 23-83 years); 35 (62.5%) were males, and 25
(44.6%) had associated comorbidities. Thirty-seven participants (66.1%)
were treated with immunotherapies. Fifty-five participants (98.2% of the
responders) received the BNT162b2 COVID-19 vaccine. Of these, 32 (58.2%)
were &lt; 55 years old, and 23 (41.8%) were &gt; 55 years old. Adverse
events were more common in patients younger than 55 years old (46.9% Vs.
17.4%; p = 0.0428). Eight participants (14.5%) reported worsening
neurological symptoms following the vaccination. Three of those who
reported worsening of neurological symptoms (37.5%) required additional
treatment. Most events occurred within the first few days after
vaccination and resolved within a few weeks. This survey indicates an
overall favorable safety and tolerability profile of the BNT162b2
vaccine in people with MG. Additional prospective, large-scale studies
are warranted to confirm these findings. Copyright © 2022 Elsevier B.V.
All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35227521</td>
<td align="left">Establishment of the first Chinese national standard
for protein subunit SARS-CoV-2 vaccine.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 14</td>
<td align="left">A reference standard is needed for quality control of
protein subunit SARS-CoV-2 vaccines to meet urgent domestic needs. The
Chinese National Institutes for Food and Drug Control (NIFDC) launched a
project to establish the first reference material for the protein
subunit SARS-CoV-2 vaccine to be used for calibration of antigen
testing. The potency and stability of the national candidate standard
(CS) were determined by collaborative calibration, and accelerated and
freeze-thaw degradation studies. Moreover, a suitability study of the CS
was performed. Eight laboratories in mainland China were asked to detect
antigen content of CS using a common validated enzyme-linked
immunosorbent assay (ELISA) kit established by NIFDC and in-house kits
in the collaborative study. Six laboratories returned valid results,
which established that the antigen content of the CS was 876,938 YU/mL,
with good agreement across laboratories. In the suitability study, the
CS exhibited excellent parallelism and a linear relationship with four
samples produced by different expression systems and target proteins. In
addition, good stability in the accelerated and freeze-thaw degradation
study was observed. In conclusion, the CS was approved by the Biological
Product Reference Standards Sub-Committee of the National Drug Reference
Standards Committee as the first Chinese national standard for
determining antigen content of protein subunit SARS-CoV-2 vaccines, with
an assigned antigen content of 877,000 U/mL (Lot. 300050-202101). This
standard will contribute to a standardized assessment of protein subunit
SARS-CoV-2 vaccine in China and may provide experience for developing
reference materials for antigen content detection of SARS-CoV-2 vaccine
in other countries. Copyright © 2022 The Author(s). Published by
Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35227416</td>
<td align="left">Vaccine efficacy against severe COVID-19 in relation to
delta variant (B.1.617.2) and time since second dose in patients in
Scotland (REACT-SCOT): a case-control study.</td>
<td align="left">The Lancet. Respiratory medicine</td>
<td align="left">2022 Feb 25</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reports
have suggested that the efficacy of vaccines against COVID-19 might have
fallen since the delta (B.1.617.2) SARS-CoV-2 variant replaced the alpha
(B.1.1.7) variant as the predominant variant. We aimed to investigate,
for the two main classes of vaccine, whether efficacy against severe
COVID-19 has decreased since delta became the predominant variant and
whether the efficacy of two doses of vaccine against severe COVID-19
wanes with time since second dose.
<AbstractText Label="METHODS" NlmCategory="METHODS">In the REACT-SCOT
case-control study, vaccine efficacy was estimated using a matched
case-control design that includes all diagnosed cases of COVID-19 in
Scotland up to Sept 8, 2021. For every incident case of COVID-19 in the
Scottish population, ten controls matched for age rounded to the nearest
year, sex, and primary care practice, and alive on the day of
presentation of the case that they were matched to were selected using
the Community Health Index database. To minimise ascertainment bias we
prespecified the primary outcome measure to assess vaccine efficacy as
severe COVID-19, defined as diagnosed patients with entry to critical
care within 21 days of first positive test, death within 28 days of
first positive test, or any death for which COVID-19 was coded as
underlying cause. Although the data extracted for this study included
cases presenting up to Sept 22, 2021, the analyses reported here are
restricted to cases and controls presenting from Dec 1, 2020, to Sept 8,
2021, ensuring follow-up for at least 14 days after presentation date to
allow classification of hospitalisation and (for most cases) severity
based on entry to critical care or fatal outcome.
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">During the study
period, a total of 5645 severe cases of COVID-19 were recorded; these
were matched to 50 096 controls. Of the severe cases, 4495 (80%) were
not vaccinated, and of the controls, 36 879 (74%) were not vaccinated.
Of the severe cases of COVID-19 who had been vaccinated, 389 had
received an mRNA vaccine and 759 had received the ChAdOx1 vaccine. The
efficacy of vaccination against severe COVID-19 decreased in May, 2021,
coinciding with the replacement of the alpha SARS-CoV-2 variant by the
delta variant in Scotland, but this decrease was reversed over the
following month. In the most recent time window centred on July 29,
2021, the efficacy of two doses was 91% (95% CI 87-94) for the ChAdOx1
vaccine and 92% (88-95) for mRNA (Pfizer or Moderna) vaccines. The
efficacy of the ChAdOx1 vaccine against severe COVID-19 declined with
time since second dose to 69% (95% CI 52-80) at 20 weeks from second
dose. The efficacy of mRNA vaccines declined in the first ten weeks from
second dose but more slowly thereafter to 93% (88-96) at 20 weeks from
second dose.
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our
results are reassuring with respect to concerns that vaccine efficacy
against severe COVID-19 might have fallen since the delta variant became
predominant, or that efficacy of mRNA vaccines wanes within the first
5-6 months after second dose. However, the efficacy of the ChAdOx1
vaccine against severe COVID-19 wanes substantially by 20 weeks from
second dose. Efficacy of mRNA vaccines after 20 weeks and against newer
variants remains to be established. Our findings support the case for
additional protective measures for those at risk of severe disease,
including, but not limited to, booster doses, at times when transmission
rates are high or expected to rise.
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">None. Copyright ©
2022 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35227415</td>
<td align="left">Comparative vaccine effectiveness against severe
COVID-19 over time in US hospital administrative data: a case-control
study.</td>
<td align="left">The Lancet. Respiratory medicine</td>
<td align="left">2022 Feb 25</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Research
suggests the protection offered by COVID-19 vaccines might wane over
time, prompting consideration of booster vaccinations. Data on which
vaccines offer the most robust protection over time, and which patients
are most vulnerable to attenuating protection, could help inform
potential booster programmes. In this study, we used comprehensive
hospitalisation data to estimate vaccine effectiveness over time.
<AbstractText Label="METHODS" NlmCategory="METHODS">In this case-control
study, we used data from a large US health-care system to estimate
vaccine effectiveness against severe SARS-CoV-2 infection and examined
variation based on time since vaccination, vaccine type, and patients’
demographic and clinical characteristics. We compared trends in
attenuation of protection across vaccines and used a multivariable model
to identify key factors associated with risk for severe breakthrough
infection. Patients were considered to have severe COVID-19 if they were
admitted to the hospital, had a final coded diagnosis of COVID-19
(according to International Classification of Diseases Tenth Revision
code U07.1) or a positive nucleic acid amplification test for
symptomatic SARS-CoV-2 during their hospitalisation, and were treated
with remdesivir or dexamethasone during hospitalisation.
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between April 1,
2021, and Oct 26, 2021, we observed 9667 admissions for severe COVID-19
(ie, cases). Overall, 1293 (13·4%) of 9667 cases were fully vaccinated
at the time of admission, compared with 22 308 (57·7%) of 38 668
controls, who were admitted to hospital for other reasons. The median
time between vaccination and hospital admission among cases was 162 days
(IQR 118-198). Overall vaccine effectiveness declined mostly over the
course of the summer, from 94·5% (95% CI 91·4-96·5) in April, 2021
(pre-delta), to 84·0% (81·6-86·1) by October, 2021. Notably, vaccine
effectiveness declined over time, from 94·0% (95% CI 92·8-95·0) at days
50-100 after vaccination to 80·4% (77·8-82·7) by days 200-250 after
vaccination. After 250 days, vaccine effectiveness declines were even
more notable. Among those who received the BNT162b2 (Pfizer-BioNTech)
vaccine, vaccine effectiveness fell from an initial peak of 94·9%
(93·2-96·2) to 74·1% (69·6-77·9) by days 200-250 after vaccination.
Protection from the mRNA-1273 (Moderna) and Ad26.COV2 (Janssen) vaccines
declined less over time, although the latter offered lower overall
protection. Holding other factors constant, the risk of severe
breakthrough infection was most strongly associated with age older than
80 years (adjusted odds ratio 1·76, 95% CI 1·43-2·15), vaccine type
(Pfizer 1·39, 0·98-1·97; Janssen 14·53, 8·43-25·03; both relative to
Moderna), time since vaccination (1·05, 1·03-1·07; per week after week 8
when protection peaks, technically), and comorbidities including organ
transplantation (3·44, 95% CI 2·12-5·57), cancer (1·93, 1·60-2·33), and
immunodeficiency (1·49, 1·13-1·96).
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Vaccination
remains highly effective against hospitalisation, but vaccine
effectiveness declined after 200 days, particularly for older patients
or those with specific comorbidities. Additional protection (eg, a
booster vaccination) might be warranted for everyone, but especially for
these populations. In addition to promoting general vaccine uptake,
clinicians and policy makers should consider prioritising booster
vaccinations in those most at risk of severe COVID-19.
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">None. Copyright ©
2022 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35227348</td>
<td align="left">COVID-19 vaccine hesitancy in South Africa: A complex
social phenomenon.</td>
<td align="left">South African medical journal = Suid-Afrikaanse
tydskrif vir geneeskunde</td>
<td align="left">2021 06 07</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35227332</td>
<td align="left">Factors associated with survival of Iranian patients
with COVID-19: comparison of Cox regression and mixture cure model.</td>
<td align="left">Tropical diseases, travel medicine and vaccines</td>
<td align="left">2022 Mar 01</td>
<td align="left"><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">SARS-CoV-2
is almost the most problematic virus of this century. It has caused
extensive damage to various economic, social, and health aspects
worldwide. Nowadays, coronavirus disease 2019 (COVID-19) is the most
dangerous threat to human survival. Therefore, this study aimed to
investigate factors associated with the survival of Iranian patients
with SARS-CoV-2.
<AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective
hospital-based cohort study was conducted on 870 COVID-19 patients with
blood oxygen levels of less than 93%. Cox regression and mixture cure
model were used and compared to analyze the patients’ survival. It is
worth noting that no similar study has been previously conducted using
mixture cure regression to model the survival of Iranian patients with
COVID-19. <AbstractText Label="RESULT" NlmCategory="RESULTS">The cure
rate and median survival time were respectively 81.5% and 20 days. Cox
regression identified that respiratory distress, history of heart
disease and hypertension, and older age were shown to increase the
hazard. The Incidence and Latency parts of the mixture cure model
respectively revealed that respiratory distress, history of
hypertension, diabetes and cardiovascular diseases (CVDs), cough, fever,
and older age reduced the cure odds; also, respiratory distress, history
of hypertension, and CVDs, and older age increased the hazard.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings
of our study revealed that priority should be given to older patients
with a history of diabetes, hypertension, and CVDs in receiving
intensive care and immunization. Also, the lower cure odds for patients
with respiratory distress, fever, and cough favor early hospitalization
before the appearance of severe symptoms. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35227233</td>
<td align="left">Safety of SARS-CoV-2 vaccination during pregnancy-
obstetric outcomes from a large cohort study.</td>
<td align="left">BMC pregnancy and childbirth</td>
<td align="left">2022 Feb 28</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19
during pregnancy is associated with adverse outcomes for mother and
fetus. SARS-CoV-2 vaccination has significantly reduced the risk of
symptomatic disease. Several small studies have reported the safety of
SARS-CoV-2 vaccination during pregnancy, with no adverse effect on
obstetric outcomes.
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the
association between SARS-CoV-2 vaccination during pregnancy and maternal
and neonatal outcomes in a large cohort study. Furthermore, to evaluate
if timing of vaccination during pregnancy is related to adverse
outcomes. <AbstractText Label="METHODS" NlmCategory="METHODS">A
retrospective cohort study of women who delivered between December 2020
and July 2021 at a large tertiary medical center. Excluded were women
with multiple pregnancy, vaccination prior to pregnancy, COVID-19
infection during or before pregnancy, or unknown timing of vaccination.
Primary outcomes were the incidence of preterm labor and of small for
gestational age. Secondary outcomes were other maternal and neonatal
complications. A secondary analysis investigating the association
between time of vaccination and outcomes was also performed.
Multivariable logistic regression models were used to adjust for
potential confounders.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 5618
women who met the inclusion criteria: 2,305 (41%) women were vaccinated
and 3,313 (59%) were unvaccinated. There were no differences between
vaccinated and non-vaccinated patients with respect to primary outcomes.
The rate of preterm birth was 5.5% in the vaccinated group compared to
6.2% in the unvaccinated group (p = 0.31). Likewise, the rates of small
for gestational age were comparable between the two groups (6.2%
vs. 7.0% respectively, p = 0.2). In a secondary analysis focusing on
time of vaccination and its relationship with outcomes, patients
vaccinated in the second trimester (n = 964) and in the third trimester
(n = 1329) were independently compared to their unvaccinated
counterparts. Women who were vaccinated in the second trimester were
more likely to have a preterm birth (8.1% vs. 6.2%, p &lt; 0.001). This
association persisted after adjusting for potential confounders
(adjusted odds ratio 1.49, 95%CI 1.11, 2.01).
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SARS-CoV-2
vaccine appears to be safe during pregnancy with no increase in
incidence of preterm labor and small for gestational age compared to
unvaccinated women. However, in women vaccinated during the second
trimester there may be an increase in the rate of preterm birth. © 2022.
The Author(s).</td>
</tr>
<tr class="even">
<td align="left">35226841</td>
<td align="left">A Case Report of Prolonged Anaphylaxis after COVID-19
Vaccine.</td>
<td align="left">Clinical practice and cases in emergency medicine</td>
<td align="left">2022 Feb</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">As
the medical community and world have combatted the coronavirus disease
2019 (COVID-19) pandemic, a significant advance was the development of a
vaccine against the virus that has already claimed over 4.5 million
lives worldwide. Vaccines manufactured by Pfizer-BioNTech and Moderna
were the first two COVID-19 vaccines given emergency use authorization
by the United States Food and Drug Administration. Preliminary data
demonstrated not only the vaccines’ efficacy rates of greater than 95%
after a second dose, but also marked safety. Initial data showed only 21
cases of anaphylaxis of greater than 1.8 million doses administered. The
majority of those patients had a history of anaphylaxis and presented
within the first 15 minutes after administration of the vaccine.
<AbstractText Label="CASE REPORT" NlmCategory="METHODS">We describe a
patient who had an anaphylactic reaction to her second dose of the
Pfizer BioNTech severe acute respiratory syndrome coronavirus 2 (SARS
CoV-2) vaccine with no prior history of allergic reactions or
anaphylaxis. This reaction required multiple doses of epinephrine and a
four-day hospitalization. We review both the available reports of
anaphylaxis to the SAR CoV-2 vaccine and information on other prolonged
cases of anaphylaxis.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our case
report is unique in that the patient, despite no prior history of
anaphylaxis, had a prolonged course requiring a four-day
hospitalization. To our knowledge this is one of the first case reports
of prolonged anaphylaxis after the second dose of Pfizer BioNTech
COVID-19 vaccine in a patient with no history of prior anaphylaxis.</td>
</tr>
<tr class="odd">
<td align="left">35226687</td>
<td align="left">COVID-19 vaccination coverage in deprived populations
living in segregated colonies: A nationwide cross-sectional study in
Hungary.</td>
<td align="left">PloS one</td>
<td align="left">2022</td>
<td align="left">The segregated colonies (SCs) in Hungary are populated
mainly but not exclusively by Roma. Their health care use is restricted
in many respects. It has not been studied yet, whether fair COVID-19
vaccination coverage achieved in Hungary is accompanied with fair
effectiveness in SCs. Using census data, the vaccination coverage in SCs
and the complementary areas (CAs) in the same settlements of the country
was determined. To describe the settlement level differences, the
vaccination coverage (until June 30, 2021) in SCs were compared to those
in CAs by age, sex, and eligibility for exemption certificate
standardized measures. Aggregating settlement level data, the level of
geographic discrimination in Hungary was also determined. According to
nationwide aggregates, crude vaccination coverage was significantly
lower in SCs (40.05%, 95% CI 39.87%-40.23%) than in CAs (65.42%, 95% CI
65.37%-65.46%). The relative standardized vaccination coverage was 0.643
(95% CI 0.639-0.647) in SCs. A total of 437 of the 938 investigated
settlements showed significant local vaccination disparities. Hungarian
citizens living in SCs, mainly of Roma ethnicity, are a distinct
high-risk group. Special intervention adapted to SCs is needed to
mitigate inequality in vaccination coverage and further consequences of
the pandemic.</td>
</tr>
<tr class="even">
<td align="left">35226563</td>
<td align="left">Anterior Uveitis following COVID Vaccination: A Summary
of Cases from Global Reporting Systems.</td>
<td align="left">Ocular immunology and inflammation</td>
<td align="left">2022 Feb 28</td>
<td align="left"><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">COVID-19
vaccines are currently undergoing long-term safety monitoring, including
for ocular side effects. Uveitis following vaccination has been
described previously with other vaccines and warrants evaluation for
COVID-19 vaccines, especially given their widespread use.
<AbstractText Label="CASE REPORTS" NlmCategory="UNASSIGNED">We present
two cases of patients who developed anterior uveitis following the
Moderna COVID-19 vaccine, as reported to the National Registry for
Drug-Induced Ocular Side Effects. We also summarize reports of anterior
uveitis following COVID-19 vaccination as reported to the World Health
Organization global database of individual case safety reports.
<AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Based on the
temporal pattern of ocular inflammation following vaccine delivery in
these cases, an association may be present between uveitis and COVID-19
vaccination. Further investigation to explore this association is
warranted to guide patient care.</td>
</tr>
<tr class="odd">
<td align="left">35226425</td>
<td align="left">Kinetics of Neutralizing Antibody Responses Against
SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the
Pandemic.</td>
<td align="left">Journal of Korean medical science</td>
<td align="left">2022 Feb 28</td>
<td align="left">We investigated the kinetics of the neutralizing
antibody responses to the severe acute respiratory
syndrome-coronavirus-2 delta variant over the course of 1 year in 16
patients infected at the beginning of the pandemic. In patients with
severe disease, neutralizing responses to the delta variant were
detectable, albeit at lower levels than responses to the wild type.
Neutralizing responses to the delta variant were undetectable, however,
in asymptomatic persons. This finding implies that the vaccination
strategy for persons with past natural infection should depend on the
severity of the previous infection. © 2022 The Korean Academy of Medical
Sciences.</td>
</tr>
<tr class="even">
<td align="left">35226419</td>
<td align="left">A Case Report of Varicella Zoster Meningitis as
Co-Infection With Breakthrough COVID-19 in an Immunocompetent
Patient.</td>
<td align="left">Journal of Korean medical science</td>
<td align="left">2022 Feb 28</td>
<td align="left">There are several previous reports that infection or
reactivation of varicella zoster virus (VZV) can occur after coronavirus
disease 2019 (COVID-19), which is caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2). Herein, we report a rare case of
VZV meningitis in breakthrough COVID-19. An 18-years-old male visited
the emergency room, presenting with a headache and fever of up to 38.4°C
for 5 days. He received the second dose of BNT162b2 mRNA SARS-CoV-2
vaccine 7 weeks prior to symptom onset. The symptoms persisted with
headache, fever, and nausea. His cerebrospinal fluid (CSF) showed an
elevated opening pressure of 27 cm H2O, 6/µL red blood cells, 234/µL
white blood cells (polymorphonuclear leukocytes 3%, lymphocytes 83%, and
other 14%), 43.9 mg/dL protein, and 59 mg/dL glucose, and CSF polymerase
chain reaction (PCR) test was positive for VZV. Also, he was diagnosed
with COVID-19 by reverse transcriptase-PCR examining upper and lower
respiratory tract. We administered intravenous acyclovir for 12 days,
and he was discharged without any neurologic complication. © 2022 The
Korean Academy of Medical Sciences.</td>
</tr>
<tr class="odd">
<td align="left">35226358</td>
<td align="left">Humoral response to mRNA-based COVID-19 vaccine in
patients with myeloid malignancies.</td>
<td align="left">British journal of haematology</td>
<td align="left">2022 Feb 28</td>
<td align="left">COVID-19 vaccine response data for patients with
myeloid malignancy, who are at severe risk in case of infection, has not
emerged. In a study of 69 patients with myeloid malignancies, including
46 patients with acute myeloid leukemia (AML) and 23 patients with
myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titers
were measured at 3 months after the second mRNA-based vaccination.
Seroconversion rates for AML and MDS were 94.7% and 100%, without
significant difference from healthy controls (HC). Patients with MDS
showed a significantly lower antibody titer than that in HC or AML
patients. In AML patients, the antibody titers were comparable to those
in HC when treatment was completed, but lower in patients under
maintenance therapy. The response to COVID-19 vaccine appears to be
related to disease and treatment status. Patients with myeloid
malignancies may be more responsive than patients with lymphoid
malignancies to vaccines. This article is protected by copyright. All
rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35226134</td>
<td align="left">Non-clinical immunogenicity, biodistribution and
toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine
in rat and rhesus macaque.</td>
<td align="left">Archives of toxicology</td>
<td align="left">2022 Feb 28</td>
<td align="left">Coronavirus Disease 2019 (COVID-19) caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019
has rapidly expanded into a serious global pandemic. Due to the high
morbidity and mortality of COVID-19, there is an urgent need to develop
safe and effective vaccines. AdC68-19S is an investigational chimpanzee
adenovirus serotype 68 (AdC68) vector-based vaccine which encodes the
full-length spike protein of SARS-CoV-2. Here, we evaluated the
immunogenicity, biodistribution and safety profiles of the candidate
vaccine AdC68-19S in Sprague Dawley (SD) rat and rhesus macaque under
GLP conditions. To characterize the biodistribution profile of
AdC68-19S, SD rats were given a single intramuscular injection of
AdC68-19S 2 × 1011 VP/dose. Designated organs were collected on day 1,
day 2, day 4, day 8 and day 15. Genomic DNA was extracted from all
samples and was further quantified by real-time quantitative polymerase
chain reaction (qPCR). To characterize the toxicology and immunogenicity
profiles of AdC68-19S, the rats and rhesus macaques were injected
intramuscularly with AdC68-19S up to 2 × 1011vp/dose or 4 × 1011vp/dose
(2 and fourfold the proposed clinical dose of 1 × 1011vp/dose) on two or
three occasions with a 14-day interval period, respectively. In addition
to the conventional toxicological evaluation indexes, the
antigen-specific cellular and humoral responses were evaluated. We
proved that multiple intramuscular injections could elicit effective and
long-lasting neutralizing antibody responses and Th1 T cell responses.
AdC68-19S was mainly distributed in injection sites and no AdC68-19S
related toxicological reaction was observed. In conclusion, these
results have shown that AdC68-19S could induce an effective immune
response with a good safety profile, and is a promising candidate
vaccine against COVID-19. © 2022. The Author(s), under exclusive licence
to Springer-Verlag GmbH Germany, part of Springer Nature.</td>
</tr>
<tr class="odd">
<td align="left">35225866</td>
<td align="left">Antibodies against Platelet Factor 4 and Their
Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome,
to COVID-19, to VITT/TTS.</td>
<td align="left">Antibodies (Basel, Switzerland)</td>
<td align="left">2022 Jan 21</td>
<td align="left">Antibodies against platelet factor 4 (PF4), a protein
released from alpha-granules of activated platelets, may cause a number
of pathophysiological conditions. The most commonly known is
heparin-induced thrombocytopenia (HIT), which develops in a small
proportion of people treated with the anticoagulant drug heparin.
Notably, PF4 binds with high affinity to heparin, and in HIT, complexes
of PF4/H may, in a small proportion of susceptible patients, trigger the
development of anti-PF4 antibodies and subsequent platelet activation
and aggregation, ultimately leading to the development of pathological
thrombosis at sites of vessel occlusion. Of more modern interest,
antibodies against PF4 may also arise in patients with COVID-19
(Coronavirus Disease 2019) or in patients who have been vaccinated
against COVID-19, especially in recipients of adenovirus-based vaccines.
For this latter group of patients, the terms VITT (vaccine-induced
[immune] thrombotic thrombocytopenia) and TTS (thrombotic
thrombocytopenia syndrome) have been coined. Another category associated
with this pathophysiology comprises those in whom a precipitating event
is not clear; this category is referred to as ‘spontaneous HIT-like
syndrome’. Despite its name, it arises as an HIT-mimicking disorder but
without antecedent heparin exposure. In this narrative review, we
describe the development of antibodies against PF4, and associated
pathophysiology, in such conditions.</td>
</tr>
<tr class="even">
<td align="left">35225865</td>
<td align="left">Acute Demyelinating Encephalomyelitis Post-COVID-19
Vaccination: A Case Report and Literature Review.</td>
<td align="left">Diseases (Basel, Switzerland)</td>
<td align="left">2022 Feb 20</td>
<td align="left">New advancements in the medical community have rapidly
occurred with the development of medical information across the globe
during the COVID-19 pandemic. Several vaccine manufacturers were able to
obtain clearance to administer vaccines in selected age groups and for
those at high risk for COVID-19 complications. As vaccines became more
readily available, there was a significant effort supported by
scientific information to get people vaccinated to boost herd immunity.
Acute demyelinating encephalomyelitis (ADEM) is a rare autoimmune
disease, causing demyelination in the brain and spinal cord, presenting
as monophasic, acute-onset, and rapidly progressive multifocal
neurological deficits. A wide variety of precipitating factors can
trigger ADEM, and it has long been known to be a rare adverse event
following some types of vaccinations including rabies,
diphtheria-tetanus-polio, smallpox, measles, mumps, rubella, pertussis,
influenza, and hepatitis B vaccines. Recently, ADEM has also been
associated with COVID-19 infection and (very rarely) with COVID-19
vaccination. We have a 56-year-old female who was not known to have any
medical issues. She voluntarily received her first COVID-19 vaccination
(AstraZeneca) ten days after immunization; she developed weakness of the
lower limbs and slurred speech. She tested negative for COVID-19, and a
brain MRI showed T2-weighted white-matter hyperintense lesions
suggesting acute demyelinating encephalomyelitis. She was managed with
pulse-dose steroids, which resulted in a marked improvement in her
symptoms, and discharged in a stable condition. Physicians should be
aware of this neurological disorder and the management options for
better patient care and outcomes.</td>
</tr>
<tr class="odd">
<td align="left">35225218</td>
<td align="left">Skeletal muscles and Covid-19: a systematic review of
rhabdomyolysis and myositis in SARS-CoV-2 infection.</td>
<td align="left">Clinical and experimental rheumatology</td>
<td align="left">2022 Feb</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Myalgia
is a widely publicised feature of Covid-19, but severe muscle injury can
occur. This systematic review summarises relevant evidence for skeletal
muscle involvement in Covid-19.
<AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search
of OVID and Medline databases was conducted on 16/3/2021 and updated on
28/10/2021 to identify case reports or observational studies relating to
skeletal muscle manifestations of Covid-19 (PROSPERO: CRD42020198637).
Data from rhabdomyolysis case reports were combined and summary
descriptive statistics calculated. Data relating to other manifestations
were analysed for narrative review.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">1920 articles were
identified. From these, 61 case reports/series met inclusion criteria,
covering 86 rhabdomyolysis cases. Median age of rhabdomyolysis patients
was 50 years, (range 6-89). 49% had either hypertension, diabetes
mellitus or obesity. 77% were male. Symptoms included myalgia (74%),
fever (69%), cough (59%), dyspnoea (68%). Median peak CK was 15,783U/L.
28% required intravenous haemofiltration and 36% underwent mechanical
ventilation. 62% recovered to discharge and 30% died. Dyspnoea, elevated
CRP and need for intravenous haemofiltration increased risk of fatal
outcome. Additional articles relating to skeletal muscular pathologies
include 6 possible concomitant diagnoses or relapses of idiopathic
inflammatory myopathies and 10 reports of viral-induced muscle injuries
without rhabdomyolysis. Localised myositis and rhabdomyolysis with
SARS-CoV-2 vaccination have been reported.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rhabdomyolysis
is an infrequent but important complication of Covid-19. Increased
mortality was associated with a high CRP, renal replacement therapy and
dyspnoea. The idiopathic inflammatory myopathies (IIM) may have viral
environmental triggers. However, to date the limited number of case
reports do not confirm an association with Covid-19.</td>
</tr>
<tr class="even">
<td align="left">35225144</td>
<td align="left">Successful mRNA SARS-Cov-2 vaccine rechallenge after a
first episode of immune thrombocytopenic purpura.</td>
<td align="left">Platelets</td>
<td align="left">2022 Feb 28</td>
<td align="left">In 2021, the world experienced the most extensive
vaccination campaign to defeat COVID-19. Many cases of idiopathic
thrombocytopenia have been reported following injections of SARS-Cov-2
mRNA vaccine. We present the case of a 73-year-old woman with de novo
ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine)
who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine
(Pfizer vaccine) a few months later.</td>
</tr>
<tr class="odd">
<td align="left">35224612</td>
<td align="left">Graves’ disease after COVID-19 vaccination.</td>
<td align="left">Annals of the Academy of Medicine, Singapore</td>
<td align="left">2022 02</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35224524</td>
<td align="left">Real-world serological responses to extended-interval
and heterologous COVID-19 mRNA vaccination in frail, older people
(UNCoVER): an interim report from a prospective observational cohort
study.</td>
<td align="left">The Lancet. Healthy longevity</td>
<td align="left">2022 Feb 23</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">The
use of COVID-19 vaccines has been prioritised to protect the most
vulnerable-notably, older people. Because of fluctuations in vaccine
availability, strategies such as delayed second dose and heterologous
prime-boost have been used. However, the effectiveness of these
strategies in frail, older people are unknown. We aimed to assess the
antigenicity of mRNA-based COVID-19 vaccines in frail, older people in a
real-world setting, with a rationed interval dosing of 16 weeks between
the prime and boost doses.
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">This prospective
observational cohort study was done across 12 long-term care facilities
of the Montréal Centre-Sud - Integrated University Health and Social
Services Centre in Montréal, Québec, Canada. Under a rationing strategy
mandated by the provincial government, adults aged 65 years and older
residing in long-term care facilities in Québec, Canada, with or without
previously documented SARS-CoV-2 infection, were administered homologous
or heterologous mRNA vaccines, with an extended 16-week interval between
doses. All older residents in participating long-term care facilities
who received two vaccine doses were eligible for inclusion in this
study. Participants were enrolled from Dec 31, 2020, to Feb 16, 2021,
and data were collected up to June 9, 2021. Clinical data and blood
samples were serially collected from participants at the following
timepoints: at baseline, before the first dose; 4 weeks after the first
dose; 6-10 weeks after the first dose; 16 weeks after the first dose, up
to 2 days before administration of the second dose; and 4 weeks after
the second dose. Sera were tested for SARS-CoV-2-specific IgG antibodies
(to the trimeric spike protein, the receptor-binding domain [RBD] of the
spike protein, and the nucleocapsid protein) by automated
chemiluminescent ELISA. Two cohorts were used in this study: a discovery
cohort, for which blood samples were collected before administration of
the first vaccine dose and longitudinally thereafter; and a confirmatory
cohort, for which blood samples were only collected from 4 weeks after
the prime dose. Analyses were done in the discovery cohort, with
validation in the confirmatory cohort, when applicable.
<AbstractText Label="Findings" NlmCategory="UNASSIGNED">The total study
sample consisted of 185 participants. 65 participants received two doses
of mRNA-1273 (Spikevax; Moderna), 36 received two doses of BNT162b2
(Comirnaty; Pfizer-BioNTech), and 84 received mRNA-1273 followed by
BNT162b2. In the discovery cohort, after a significant increase in
anti-RBD and anti-spike IgG concentrations 4 weeks after the prime dose
(from 4·86 log binding antibody units [BAU]/mL to 8·53 log BAU/mL for
anti-RBD IgG and from 5·21 log BAU/mL to 8·05 log BAU/mL for anti-spike
IgG), there was a significant decline in anti-RBD and anti-spike IgG
concentrations until the boost dose (7·10 log BAU/mL for anti-RBD IgG
and 7·60 log BAU/mL for anti-spike IgG), followed by an increase 4 weeks
later for both vaccines (9·58 log BAU/mL for anti-RBD IgG and 9·23 log
BAU/mL for anti-spike IgG). SARS-CoV-2-naive individuals showed lower
antibody responses than previously infected individuals at all
timepoints tested up to 16 weeks after the prime dose, but achieved
similar antibody responses to previously infected participants by 4
weeks after the second dose. Individuals primed with the BNT162b2
vaccine showed a larger decrease in mean anti-RBD and anti-spike IgG
concentrations with a 16-week interval between doses (from 8·12 log
BAU/mL to 4·25 log BAU/mL for anti-RBD IgG responses and from 8·18 log
BAU/mL to 6·66 log BAU/mL for anti-spike IgG responses) than did those
who received the mRNA-1273 vaccine (two doses of mRNA-1273: from 8·06
log BAU/mL to 7·49 log BAU/mL for anti-RBD IgG responses and from 6·82
log BAU/mL to 7·56 log BAU/mL for anti-spike IgG responses; mRNA-1273
followed by BNT162b2: from 8·83 log BAU/mL to 7·95 log BAU/mL for
anti-RBD IgG responses and from 8·50 log BAU/mL to 7·97 log BAU/mL for
anti-spike IgG responses). No differences in antibody responses 4 weeks
after the second dose were noted between the two vaccines, in either
homologous or heterologous combinations.
<AbstractText Label="Interpretation" NlmCategory="UNASSIGNED">Interim
results of this ongoing longitudinal study show that among frail, older
people, previous SARS-CoV-2 infection and the type of mRNA vaccine
influenced antibody responses when used with a 16-week interval between
doses. In these cohorts of frail, older individuals with a similar age
and comorbidity distribution, we found that serological responses were
similar and clinically equivalent between the discovery and confirmatory
cohorts. Homologous and heterologous use of mRNA vaccines was not
associated with significant differences in antibody responses 4 weeks
following the second dose, supporting their interchangeability.
<AbstractText Label="Funding" NlmCategory="UNASSIGNED">Public Health
Agency of Canada, Vaccine Surveillance Reference Group; and the COVID-19
Immunity Task Force.
<AbstractText Label="Translation" NlmCategory="UNASSIGNED">For the
French translation of the abstract see Supplementary Materials section.
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY-NC-ND 4.0 license.</td>
</tr>
<tr class="odd">
<td align="left">35224473</td>
<td align="left">Safety, tolerability, and antibody response after
intradermal vaccination of PFE-BNT in adults who have completed
two-doses of Verocell (inactivated vaccine).</td>
<td align="left">Vaccine: X</td>
<td align="left">2022 Apr</td>
<td align="left"><AbstractText Label="Introduction" NlmCategory="UNASSIGNED">The
necessity for an equal distribution of the COVID-19 vaccination is
critical. Lower-middle and lower income countries may not be able to
manufacture their vaccines, nor may they be able to afford to buy them
for every inhabitant. Furthermore, the vaccination’s potency may wane
over time. A booster dosage is recommended. Despite this, certain areas
or groups of people are still waiting for their first vaccine dosage.
<AbstractText Label="Objectives" NlmCategory="UNASSIGNED">The purposes
of this study were to assess the safety and tolerability of patients who
received a fractionated intradermal administration (ID) of PFE-BNT as a
booster dose in a group of people who had previously finished full doses
of Verocell and to determine the antibody response after the injection.
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">An open-label
experiment was carried out. Participants were at least 18 years old.
Participants received 6 ug of PFE-BNT vaccination through intradermal
injection. The safety and adverse reactions were monitored at immediate
after injection, 30 min later, day 1, day 7, and day 30. Venous blood
tests for specific IgG concentration against SARS-CoV-2 spike S1 were
received prior to injection and day 30.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">42 participants
completed the study. The mean age was 48 (the range; 23-62). The average
duration after completing the 2nd dose of Verocell was 78.3 days (95%
CI; 73.9-82.8). There was no serious adverse event. Almost 50% of
participants reported minor adverse reactions on day 1 and roughly 30%
still reporting on day 7. Systemic reactions were found less than 5%.
The antibody level at day 30 was 16669.8 (95% CI; 3692.6-51238.9), which
was 40 times higher.
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">PFE-BNT at a
dose of 6 ug (1/5 of the typical dose) was shown to be safe and well
tolerated when given intradermally. The antibody reaction was very
strong. The ID administration could potentially save vaccine doses. ©
2022 The Authors.</td>
</tr>
<tr class="even">
<td align="left">35224447</td>
<td align="left">Axillary Adenopathy Secondary to SARS-CoV-2
Vaccination: a Case Report.</td>
<td align="left">SN comprehensive clinical medicine</td>
<td align="left">2022</td>
<td align="left">SARS-CoV-2 mRNA vaccines are safe and effective for the
prevention of COVID-19 infection, though local reactions are commonly
reported. Axillary lymphadenopathy has also been reported, which has the
potential of causing diagnostic confusion and unnecessary testing and
procedures. A 58-year-old female with untreated latent tuberculosis was
noted to have a pulmonary nodule on chest radiograph. Evaluation for
Mycobacterium tuberculosis was undertaken, and a FDG PET/CT was
performed to rule out malignancy. While the nodule demonstrated low
avidity, highly avid lymph nodes were noted in the left axillary region.
Further questioning elicited a recent history of mRNA-1273 (Moderna)
COVID-19 vaccination in her left deltoid muscle 3 weeks prior and a
sensation of axillary fullness. She was managed conservatively with
spontaneous resolution of her lymphadenopathy. Axillary lymphadenopathy
following mRNA vaccination has been reported and appears to be more
common with mRNA-1273 (Moderna) than BNT162b2 vaccine (Pfizer-BioNTech),
in those aged 18 to 64 as compared to age = 65, and following the second
vaccine dose compared to the first dose. Vaccination should be
considered in the differential diagnosis of axillary lymphadenopathy,
particularly ipsilateral to the vaccination site, to avoid unnecessary
testing, treatment, and patient anxiety.
<AbstractText Label="Supplementary Information" NlmCategory="UNASSIGNED">The
online version contains supplementary material available at
10.1007/s42399-022-01143-y. © The Author(s), under exclusive licence to
Springer Nature Switzerland AG 2022.</td>
</tr>
<tr class="odd">
<td align="left">35223726</td>
<td align="left">Impact of Refutational Two-Sided Messages on Attitudes
Toward Novel Vaccines Against Emerging Infectious Diseases During the
COVID-19 Pandemic.</td>
<td align="left">Frontiers in public health</td>
<td align="left">2022</td>
<td align="left">Two-sided messages that include two perspectives (i.e.,
risks and benefits) are more effective than one-sided messages that
convey only one perspective (usually only the benefits). Refutational
two-sided messages are effective for communicating risks regarding
vaccines. To examine the effectiveness of refutational two-sided
messages in risk communication regarding novel vaccines against emerging
infectious diseases, we conducted the randomized controlled study based
on a 3 × 3 × 2 mixed design (Intervention 1: vaccines against
subcutaneous influenza, “novel severe infectious disease,” or intranasal
influenza; intervention 2: one-sided, non-refutational two-sided, or
refutational two-sided messages; two questionnaires) using a Japanese
online panel. Participants completed questionnaires before and after
receiving an attack message (negative information). We evaluated the
impact of attack messages on the willingness to be vaccinated, and the
anticipated regret of inaction (ARI). Among 1,184 participants, there
was a significant difference in the willingness to be vaccinated among
the message groups (p &lt; 0.01). After receiving the attack message,
willingness to be vaccinated decreased in the one-sided message group
and increased in the non-refutational two-sided and refutational
two-sided message groups. Additionally, ARI in the refutational
two-sided message groups was significantly higher than in the one-sided
groups (p = 0.03). In conclusion, two-sided messages are more effective
than one-sided messages in terms of willingness to be vaccinated.
Furthermore, the high ARI in the refutational two-sided message group
indicated that refutational two-sided messages were more effective than
one-sided messages for communicating the risks of vaccines, especially
those against emerging infectious diseases. Copyright © 2022 Okuno,
Arai, Suzuki and Kikkawa.</td>
</tr>
<tr class="even">
<td align="left">35223675</td>
<td align="left">Alopecia areata after COVID-19 vaccination.</td>
<td align="left">Clinical and experimental vaccine research</td>
<td align="left">2022 Jan</td>
<td align="left">The coronavirus disease 2019 (COVID-19) vaccines are
authorized for use in numerous countries worldwide. Several cutaneous
findings are reported after severe acute respiratory syndrome
coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a
patient with a rapid onset of alopecia areata immediately after
receiving the second dose of the COVID-19 vaccine. Alopecia areata is a
common autoimmune disease leading to non-scarring hair loss. Among the
many cutaneous adverse effects reported after the anti-SARS-COV2
vaccination, no episodes of alopecia areata have been described to date.
In this paper, we report the first case of alopecia areata after
COVID-19 vaccination described in the literature with a revision of
cases of alopecia areata reported after other types of vaccination.
Although the significance of these skin reactions is not yet known,
further studies will certainly clarify whether the development of
alopecia areata or other forms of immune-mediated reactions could
represent a positive prognostic factor regarding immune protection from
SARS-CoV-2. © Korean Vaccine Society.</td>
</tr>
<tr class="odd">
<td align="left">35223674</td>
<td align="left">The risk of confusion between AstraZeneka COVID-19
vaccine side effects and signs of COVID-19 infection: a case
report.</td>
<td align="left">Clinical and experimental vaccine research</td>
<td align="left">2022 Jan</td>
<td align="left">Post-vaccination side effects of AstraZeneca (AZ)
coronavirus disease 2019 (COVID-19) vaccine are common. Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2) infection immediately
after the first dose of AZ COVID-19 vaccine has not been reported. In
this case, a 30-year-old female without a past medical history of
SARS-CoV2 infection presented to an outpatient clinic with
lightheadedness and weakness 2 hours after getting the first dose of the
AZ COVID-19 vaccine. Blood pressure (BP) was 80/60 mm Hg, and oxygen
saturation (SpO2) was 98%. After administering normal saline intravenous
fluid, the BP was 110/80 mm Hg. On the first day, fever (oral
temperature of 39&lt;U+2103&gt;), sweating, dry cough, sore throat, and
injection-site pain were presented. On the second day, diarrhea,
productive cough, and hypotension occurred in addition to fever (oral
temperature of 39.9&lt;U+2103&gt;). The fever did not stop and
productive cough, change in smell, and fatigue were reported. SpO2 was
96%. On the third day, no abnormality of the spiral lung computed
tomography and the positive reverse transcriptase-polymerase chain
reaction (RT-PCR) test were reported. Simultaneously, two out of three
members of the family became symptomatic on the second day and their
RT-PCR tests were positive. Dexamethasone ampule, Cefixime tablet,
Acetaminophen tablet, and Diphenhydramine syrup were prescribed. After a
week, fever subsided and SpO2 was 98%. After 3 weeks of self-quarantine
at home, her general condition improved. Despite the similarity between
SARS-CoV2 infection signs and symptoms and AZ COVID-19 vaccine side
effects, none of the approved vaccines contain the live virus that
causes disease. Therefore, any unusual post-vaccination signs and
symptoms should not be attributed to the vaccine itself and need to be
considered for further evaluations and early actions in order to prevent
the spread of the disease in society. © Korean Vaccine Society.</td>
</tr>
<tr class="even">
<td align="left">35223671</td>
<td align="left">Reactogenicity to COVID-19 vaccination in the United
States of America.</td>
<td align="left">Clinical and experimental vaccine research</td>
<td align="left">2022 Jan</td>
<td align="left"><AbstractText Label="Purpose" NlmCategory="UNASSIGNED">In
the United States, Pfizer-BioNTech, Moderna, and Janssen’s coronavirus
disease 2019 (COVID-19) vaccines have been granted Emergency Use
Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved
by the US Food and Drug Administration. The purpose of this study is to
analyze passive surveillance data on COVID-19 vaccine adverse reaction
in the United States.
<AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">We
analyzed passive surveillance data on COVID-19 vaccine adverse reactions
which were retrieved from the Vaccine Adverse Event Reporting System
database. Retrieved records on demographic information as well as the
top 10 common vaccine adverse events were extracted and assessed from
200 of the most recently reported cases for the study analysis.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">Local and
systemic adverse reactions were reported in the study. A significant
difference (p&lt;0.05) was recorded for the top 10 systemic reactions by
age category (0.041) and by gender (0.002). Analysis of the top five
systemic reactions, stratified by vaccine type yielded a significant
difference (p&lt;0.05) for chills (p=0.044), and when stratified by age
group and type of vaccination received, it yielded a significant
difference (p&lt;0.05) for fatigue (p=0.023). Overall, Pfizer had 182
persons (91.0%) reporting adverse events, Moderna with 13 (6.5%), and
Janssen with 5 (2.5%).
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Mild side
effects were reported following vaccination with the EUA COVID-19
vaccines in the United States. Thus, continuous monitoring and reporting
of all adverse events are recommended to ensure the safety of
vaccination. © Korean Vaccine Society.</td>
</tr>
<tr class="odd">
<td align="left">35223669</td>
<td align="left">Factors associated with side effects of COVID-19
vaccine in Indonesia.</td>
<td align="left">Clinical and experimental vaccine research</td>
<td align="left">2022 Jan</td>
<td align="left"><AbstractText Label="Purpose" NlmCategory="UNASSIGNED">As
coronavirus disease 2019 (COVID-19) continues to spread rapidly causing
approximately 186 million confirmed cases around the world, the urgency
to reach herd immunity through vaccination is increasing. However,
vaccine safety is a top priority to limit the occurrence of adverse
events. Henceforth, this study aims to recognize and perceive COVID-19
vaccine safety in Indonesia during the pandemic.
<AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">This
is a cross-sectional study and was conducted in Indonesia during the
COVID-19 pandemic using an online survey of demographic information and
a qualitative questionnaire. Responses were recorded and the association
between demographic characteristics from survey questions was tested
using chi-square with a risk estimate and 95% confidence interval.
<AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 311
participants from 33 out of 34 provinces in Indonesia participated in
this study. Recorded responses showed multiple side effects of the
COVID-19 vaccine both short- and long-term experienced by the
participants. Significant associations were found between demographic
factors and COVID-19 vaccine side effects such as female gender with
short-term puncture site (odds ratio [OR], 0.463; 95% confidence
interval [CI], 0.263-0.816) and short-term other reactions (OR, 0.463;
95% CI, 0.263-0.816), domicile outside Java island with long-term
puncture site (OR, 4.219; 95% CI, 1.401-12.701) and immune reactions
(OR, 3.375; 95% CI, 1.356-8.398), also between married marital status
and long-term vagal reaction (OR, 4.655; 95% CI, 1.321-16.409).
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Gender,
domicile and marital status factors were associated with COVID-19
vaccine side effects in Indonesian people. © Korean Vaccine
Society.</td>
</tr>
<tr class="even">
<td align="left">35223668</td>
<td align="left">COVID-19 vaccines development in Africa: a review of
current situation and existing challenges of vaccine production.</td>
<td align="left">Clinical and experimental vaccine research</td>
<td align="left">2022 Jan</td>
<td align="left">Following the development of the coronavirus disease
2019 (COVID-19) vaccines and the launching of vaccination, the World
Health Organization has reported that the African Continent is lagging
in the race to vaccinate its population against the deadly virus. The
Continent has received a limited number of vaccines, implying that
vaccine production needs to be scaled up in Africa. In this review, we
summarize the current situation concerning COVID-19 vaccine development
in Africa, progress made, challenges faced in vaccine development over
the years and potential strategies that will harness vaccine production
success. © Korean Vaccine Society.</td>
</tr>
<tr class="odd">
<td align="left">35223534</td>
<td align="left">Analyzing the Effect of Vaccination Over COVID Cases
and Deaths in Asian Countries Using Machine Learning Models.</td>
<td align="left">Frontiers in cellular and infection microbiology</td>
<td align="left">2021</td>
<td align="left">Coronavirus Disease 2019 (COVID-19) is spreading across
the world, and vaccinations are running parallel. Coronavirus has
mutated into a triple-mutated virus, rendering it deadlier than before.
It spreads quickly from person to person by contact and nasal or
pharyngeal droplets. The COVID-19 database ‘Our World in Data’ was
analyzed from February 24, 2020, to September 26, 2021, and predictions
on the COVID positives and their mortality rate were made. Factors such
as Vaccine data for the First and Second Dose vaccinated individuals and
COVID positives that influence the fluctuations in the COVID-19 death
ratio were investigated and linear regression analysis was performed.
Based on vaccination doses (partial or complete vaccinated), models are
created to estimate the number of patients who die from COVID infection.
The estimation of variance in the datasets was investigated using Karl
Pearson’s coefficient. For COVID-19 cases and vaccination doses, a
quartic polynomial regression model was also created. This predictor
model helps to predict the number of deaths due to COVID-19 and
determine the susceptibility to COVID-19 infection based on the number
of vaccine doses received. SVM was used to analyze the efficacy of
models generated. Copyright © 2022 Rustagi, Bajaj, Tanvi, Singh,
Aggarwal, AlAjmi, Hussain, Hassan, Singh and Singh.</td>
</tr>
<tr class="even">
<td align="left">35223427</td>
<td align="left">Intent to get vaccinated against COVID-19 pandemic and
its associated factors among adults with a chronic medical
condition.</td>
<td align="left">International journal of Africa nursing sciences</td>
<td align="left">2022</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">Vaccination
intent is defined as the willingness to get vaccinated against a
COVID-19 pandemic in a situation where the vaccine is available at no
cost. Nevertheless, even with the availability of COVID-19 vaccines,
some part of the public is not expected to get vaccinated, mainly due to
a phenomenon known as vaccine hesitancy or lack of intention.
Furthermore, there is little information available on the intention of
people with chronic medical conditions about the COVID-19 vaccines in
Ethiopia. <AbstractText Label="Objective" NlmCategory="UNASSIGNED">The
study aimed to assess the intent to get vaccinated against COVID-19 and
its associated factors among adults with a chronic medical condition.
<AbstractText Label="Method" NlmCategory="UNASSIGNED">An
institutional-based cross-sectional study was conducted from February 15
to March 15, 2021. Simple random sampling was employed to get
representative samples. Data were collected by using a structured
questionnaire through face to face interviews. The data were entered by
Epi Info version 7 and analyzed with SPSS version 20. The data were
analyzed by using binary logistic regression. Those variables with a
P-value of = 0.05 were considered significantly associated with the
outcome variable.
<AbstractText Label="Result" NlmCategory="UNASSIGNED">In this study, 423
study participants took part with a response rate of 100%. The mean age
of the study participants was 50.07 (SD ± 13.7) with a range of 18-85
years. The intention to get vaccinated against the COVID-19 pandemic was
63.8% [95% CI (58.6-68.2)]. In the multivariable analysis the variables,
retiring from the job was [AOR = 2.65, 95% CI (1.02-10.35)], having
health insurance coverage [AOR = 1.38, 95%CI (1.04-3.65)], being in the
high socio-demographic status [AOR = 1.67, 95%CI (1.01-2.78)], being
confident with the Country’s health care system [AOR = 2.00, 95%CI
(1.15-3.49)], and having good knowledge about COVID-19 [AOR = 6.59, 95%
CI (4.02-10.78)] were significant predictors of intent to get vaccinated
against COVID-19 pandemic compared.
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The intention
of getting vaccinated against the COVID-19 pandemic was relatively low.
There has to be a great effort by the health caregivers as well as the
government to increase vaccination intake, particularly for these
priority groups. © 2022 The Authors.</td>
</tr>
<tr class="odd">
<td align="left">35223425</td>
<td align="left">Interstitial lung disease after receiving the
mRNA-based COVID-19 vaccine tozinameran.</td>
<td align="left">Respiratory medicine case reports</td>
<td align="left">2022</td>
<td align="left">Tozinameran, a messenger ribonucleic acid (mRNA)-based
coronavirus disease 19 (COVID-19) vaccine, has a favorable safety
profile and is highly efficacious in preventing COVID-19. Adverse
reactions such as pain at the vaccination site, fever, malaise,
headache, rash, and anaphylaxis have been commonly reported for
mRNA-based COVID-19 vaccines. We report a case involving a 71-year-old
Japanese woman who developed interstitial lung disease (ILD) after
receiving an mRNA-based COVID-19 vaccine. We also review case reports of
COVID-19 mRNA vaccine-associated ILD. Dyspnea or hypoxia that develops
within 1-3 days after COVID-19 mRNA vaccination should be differentiated
from ILD. Further studies to elucidate mechanisms and risk factors of
rare adverse reactions such as ILD are warranted. © 2022 Published by
Elsevier Ltd.</td>
</tr>
<tr class="even">
<td align="left">35223113</td>
<td align="left">Widespread Arterial Thrombosis after ChAdOx1 nCov-19
Vaccination.</td>
<td align="left">Case reports in critical care</td>
<td align="left">2022</td>
<td align="left">Vaccine-induced thrombotic thrombocytopenia is an
uncommon complication of COVID-19 vaccines using adenovirus mRNA
carriers and has been associated with thrombosis of the cerebral venous
sinuses and portal system. We report a case of a 69-year-old woman
admitted to the intensive care unit due to stroke caused by thrombosis
of the right carotid artery 9 days after receiving the ChAdOx1 nCov-19
vaccine. Further investigations demonstrated multiple thrombi in the
arterial tree in the absence of any venous involvement. The clinical
course and the treatment are described and discussed. Copyright © 2022
Giorgio Berlot et al.</td>
</tr>
<tr class="odd">
<td align="left">35222357</td>
<td align="left">Impact on HIV-1 RNA Levels and Antibody Responses
Following SARS-CoV-2 Vaccination in HIV-Infected Individuals.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">This study aims to assess the immunological response
and impact on virological control of the mRNA vaccines for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with
HIV (PLWH). In this single-center observational study, all PLWH were
offered vaccination with mRNA1273 or BNT162b2. Both anti-N and
anti-S1-receptor binding domain (RBD) antibodies were measured together
with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2
(M2) and 6 (M6) months later. A total of 131 individuals (median age: 54
years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl
[IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0])
were included. All participants were positive for anti-RBD antibodies at
30 days, 60 days and 6 months after the first dose, with no statistical
difference between those with HIV-1 RNA below or &gt;20 copies/ml. HIV-1
RNA data were collected for 128 patients at baseline and 30 days after
the first dose; for 124 individuals, 30 days after the second dose; and
for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128
had detectable HIV-1 RNA (&gt;20 copies/ml) at M0, 13/128 (10.2%) at M1
(among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which
5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse
effects were reported. All participants elicited antibodies after two
doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels
over a 6-month period. Copyright © 2022 Portillo, Fedeli, Ustero Alonso,
Petignat, Mereles Costa, Sulstarova, Jaksic, Yerly and Calmy.</td>
</tr>
<tr class="even">
<td align="left">35222351</td>
<td align="left">AutoPlate: Rapid Dose-Response Curve Analysis for
Biological Assays.</td>
<td align="left">Frontiers in immunology</td>
<td align="left">2021</td>
<td align="left">The emergence of COVID-19 has emphasised that
biological assay data must be analysed quickly to develop safe,
effective and timely vaccines/therapeutics. For viruses such as
SARS-CoV-2, the primary way of measuring immune correlates of protection
is through assays such as the pseudotype microneutralisation (pMN)
assay, thanks to its safety and versatility. However, despite the
presence of existing tools for data analysis such as PRISM and R the
analysis of these assays remains cumbersome and time-consuming. We
introduce an open-source R Shiny web application and R library
(AutoPlate) to accelerate data analysis of dose-response curve
immunoassays. Using example data from influenza studies, we show that
AutoPlate improves on available analysis software in terms of ease of
use, flexibility and speed. AutoPlate (<a href="https://philpalmer.shinyapps.io/AutoPlate/" class="uri">https://philpalmer.shinyapps.io/AutoPlate/</a>) is a tool
for the use of laboratories and wider scientific community to accelerate
the analysis of biological assays in the development of viral vaccines
and therapeutics. Copyright © 2022 Palmer, Del Rosario, da Costa,
Carnell, Huang, Heeney, Temperton and Wells.</td>
</tr>
<tr class="odd">
<td align="left">35222312</td>
<td align="left">Cellular Responses to Membrane and Nucleocapsid Viral
Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in
Individuals With Either Past Infection or Cross-Reactivity.</td>
<td align="left">Frontiers in microbiology</td>
<td align="left">2021</td>
<td align="left">SARS-CoV-2 spike mRNA vaccines have shown remarkable
clinical efficacy in the general population, although the nature of
T-cell priming is not fully understood. We performed longitudinal
spike-, membrane-, and nucleocapsid-specific T-cell analysis in
individuals with past infection and infection-naïve individuals with
cross-reactivity. We found an additional enhancement of T-cell response
to the structural membrane (M) and nucleocapsid (N) SARS-CoV-2 proteins
after mRNA vaccine in these individuals. Thus, despite the
spike-specific response, we found that the first dose of the vaccine
boosted a significant CD8 cell response to M and N proteins, whereas no
cellular response to those proteins was found in infection-naïve
individuals without pre-existing cross-reactivity who were tested for
eventual asymptomatic infection. These findings highlight the additional
benefit of mRNA vaccines as broad boosters of cellular responses to
different viral epitopes in these individuals and suggest extended
protection to other viral variants. Copyright © 2022 Vallejo,
Martín-Hondarza, Gómez, Velasco, Vizcarra, Haemmerle and Casado.</td>
</tr>
<tr class="even">
<td align="left">35221837</td>
<td align="left">The COVID-19 vaccination acceptance/hesitancy rate and
its determinants among healthcare workers of 91 Countries: A multicenter
cross-sectional study.</td>
<td align="left">EXCLI journal</td>
<td align="left">2022</td>
<td align="left">The aim of this study was to investigate the COVID-19
vaccination acceptance rate and its determinants among healthcare
workers in a multicenter study. This was a cross-sectional multi-center
survey conducted from February 5 to April 29, 2021. The questionnaire
consisted of 26 items in 6 subscales. The English version of the
questionnaire was translated into seven languages and distributed
through Google Forms using snowball sampling; a colleague in each
country was responsible for the forward and backward translation, and
also the distribution of the questionnaire. A forward stepwise logistic
regression was utilized to explore the variables and questionnaire
factors tied to the intention to COVID-19 vaccination. 4630 participants
from 91 countries completed the questionnaire. According to the United
Nations Development Program 2020, 43.6 % of participants were from low
Human Development Index (HDI) regions, 48.3 % high and very high, and
8.1 % from medium. The overall vaccination hesitancy rate was 37 %.
Three out of six factors of the questionnaire were significantly related
to intention to the vaccination. While ‘Perceived benefits of the
COVID-19 vaccination’ (OR: 3.82, p-value&lt;0.001) and ‘Prosocial norms’
(OR: 5.18, p-value&lt;0.001) were associated with vaccination
acceptance, ‘The vaccine safety/cost concerns’ with OR: 3.52,
p-value&lt;0.001 was tied to vaccination hesitancy. Medical doctors and
pharmacists were more willing to take the vaccine in comparison to
others. Importantly, HDI with OR: 12.28, 95 % CI: 6.10-24.72 was a
strong positive determinant of COVID-19 vaccination acceptance. This
study highlighted the vaccination hesitancy rate of 37 % in our sample
among HCWs. Increasing awareness regarding vaccination benefits,
confronting the misinformation, and strengthening the prosocial norms
would be the primary domains for maximizing the vaccination coverage.
The study also showed that the HDI is strongly associated with the
vaccination acceptance/hesitancy, in a way that those living in low HDI
contexts are more hesitant to receive the vaccine. Copyright © 2022
Askarian et al.</td>
</tr>
<tr class="odd">
<td align="left">35221234</td>
<td align="left">Rural community pharmacists’ ability and interest in
administering COVID-19 vaccines in the Southern United States.</td>
<td align="left">Journal of the American Pharmacists Association :
JAPhA</td>
<td align="left">2022 Jan 19</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Community
pharmacists are often the most accessible health professional in rural
areas, which makes them well positioned to increase vaccine access in
their communities. This study sought to document rural pharmacists’
ability to and interest in administering coronavirus disease 2019
(COVID-19) vaccinations.
<AbstractText Label="METHODS" NlmCategory="METHODS">A sample of
community pharmacists participating in a rural community pharmacy
practice-based research network in the United States completed an online
survey that assessed (1) demographic characteristics, (2) previous
COVID-19 vaccine training, and (3) ability to administer COVID-19
vaccines. Data were collected between late December 2020 and
mid-February 2021. Descriptive statistics and correlations were
calculated. <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total
of 69 of 106 pharmacists completed the survey (response rate = 65%).
Approximately half of pharmacists were ready (52%) or actively taking
steps (39%) to provide COVID-19 vaccines in the next 6 months.
Pharmacies had a median of 2 staff members who were authorized to
administer COVID-19 vaccines. Almost half (46%) estimated they could
administer more than 30 vaccinations per day. Most pharmacies could
store vaccines at standard refrigeration (90%) and freezing (83%) levels
needed for thawed and premixed vaccines, respectively. Most pharmacists
planned to access COVID-19 vaccines through an agreement with a state or
local public health entity (48%) or by ordering through group purchasing
organizations (46%). Only 23% of pharmacists had received any COVID-19
vaccine training, and only 48% very much wanted to get the vaccine
themselves. Several variables, including pharmacy type and pharmacists’
vaccine attitudes and previous COVID-19 training, were significantly
associated (P &lt; 0.05) with the anticipated number of COVID-19
vaccines pharmacies could administer daily.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Even early in
the nation’s COVID-19 vaccine rollout, most rural pharmacies were
interested in and preparing to administer COVID-19 vaccines. Few rural
pharmacists had received COVID-19 training, and many expressed some
hesitancy to receive the vaccine themselves. The number of vaccines
pharmacists could administer varied with pharmacy and pharmacist
characteristics. Copyright © 2022 American Pharmacists Association®.
Published by Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35221122</td>
<td align="left">Promoting immunization equity in Latin America and the
Caribbean: Case studies, lessons learned, and their implication for
COVID-19 vaccine equity.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 14</td>
<td align="left">In 2020, the World Health Organization launched the
Immunization Agenda 2030: A Global Strategy to Leave No One Behind,
which prioritizes high equitable immunization coverage at the national
level and in all districts. Achieving high and homogenous immunization
coverage, which is all the more important within the current context of
the COVID-19 pandemic and vaccine rollout, requires the strengthening of
existing immunization activities and innovative approach to immunization
promotion. This research applied a descriptive case study methodology to
document the implementation of strategic multi-level alliances to
promote equitable immunization access and demand in Colombia, Guyana,
and Sucre, Bolivia. Data collection, carried out between September 2019
and March 2020, included documentary reviews, semi-structured
interviews, focus groups, and site visits accompanied by discussions
with relevant stakeholders. Case studies provide valuable examples of
people-centered, partnership-based, country-owned, and data-guided
approaches to promoting equitable immunization coverage, including
multi-level partnerships to build technical capacity for the
identification and measurement of social inequalities impacting
immunization in Colombia; intersectoral and community collaboration for
pro-equity emergency response to regional vaccine preventable disease
outbreaks in Guyana; and strategic alliances with the education sector
and civil society organizations for the introduction of the human
papilloma virus (HPV) vaccine in Sucre, Bolivia. Lessons learned
highlight avenues for improving the impact of multi-level,
equity-focused capacity building, particularly at the local level;
optimizing the use of data and resources, partnerships, and community
and stakeholder education and empowerment. While impact studies are
needed to better understand the quantitative contributions of such
strategic alliances, these case studies illustrate their practical
significance and reinforce the value of multi-level, intersectoral
collaboration for enhancing equitable immunization access and demand.
The experiences of Colombia, Guyana, and Sucre, Bolivia provide
evidence-based insight to support pro-equity immunization program
planning to ensure that no one is left behind and that everyone,
everywhere receives the benefits of vaccines, both routine and for
COVID-19. Copyright © 2022 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35219876</td>
<td align="left">Viroporins: structure, function, and their role in the
life cycle of SARS-CoV-2.</td>
<td align="left">The international journal of biochemistry &amp; cell
biology</td>
<td align="left">2022 Feb 24</td>
<td align="left">Viroporins are indispensable for viral replication. As
intracellular ion channels they disturb pH gradients of organelles and
allow Ca2+ flux across ER membranes. Viroporins interact with numerous
intracellular proteins and pathways and can trigger inflammatory
responses. Thus, they are relevant targets in the search for antiviral
drugs. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
underlies the world-wide pandemic of COVID-19, where an effective
therapy is still lacking despite impressive progress in the development
of vaccines and vaccination campaigns. Among the 29 proteins of
SARS-CoV-2, the E- and ORF3a proteins have been identified as viroporins
that contribute to the massive release of inflammatory cytokines
observed in COVID-19. Here, we describe structure and function of
viroporins and their role in inflammasome activation and cellular
processes during the virus replication cycle. Techniques to study
viroporin function are presented, with a focus on cellular and
electrophysiological assays. Contributions of SARS-CoV-2 viroporins to
the viral life cycle are discussed with respect to their structure,
channel function, binding partners, and their role in viral infection
and virus replication. Viroporin sequences of new variants of concern
(a-&lt;U+03BF&gt;) of SARS-CoV-2 are briefly reviewed as they harbour
changes in E and 3a proteins that may affect their function. Copyright ©
2022. Published by Elsevier Ltd.</td>
</tr>
<tr class="even">
<td align="left">35219385</td>
<td align="left">Waning effectiveness of COVID-19 vaccines.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2022 02 26</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35219376</td>
<td align="left">Variation in the COVID-19 infection-fatality ratio by
age, time, and geography during the pre-vaccine era: a systematic
analysis.</td>
<td align="left">Lancet (London, England)</td>
<td align="left">2022 Feb 24</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
infection-fatality ratio (IFR) is a metric that quantifies the
likelihood of an individual dying once infected with a pathogen.
Understanding the determinants of IFR variation for COVID-19, the
disease caused by the SARS-CoV-2 virus, has direct implications for
mitigation efforts with respect to clinical practice, non-pharmaceutical
interventions, and the prioritisation of risk groups for targeted
vaccine delivery. The IFR is also a crucial parameter in COVID-19
dynamic transmission models, providing a way to convert a population’s
mortality rate into an estimate of infections.
<AbstractText Label="METHODS" NlmCategory="METHODS">We estimated
age-specific and all-age IFR by matching seroprevalence surveys to total
COVID-19 mortality rates in a population. The term total COVID-19
mortality refers to an estimate of the total number of deaths directly
attributable to COVID-19. After applying exclusion criteria to 5131
seroprevalence surveys, the IFR analyses were informed by 2073 all-age
surveys and 718 age-specific surveys (3012 age-specific observations).
When seroprevalence was reported by age group, we split total COVID-19
mortality into corresponding age groups using a Bayesian hierarchical
model to characterise the non-linear age pattern of reported deaths for
a given location. To remove the impact of vaccines on the estimated IFR
age pattern, we excluded age-specific observations of seroprevalence and
deaths that occurred after vaccines were introduced in a location. We
estimated age-specific IFR with a non-linear meta-regression and used
the resulting age pattern to standardise all-age IFR observations to the
global age distribution. All IFR observations were adjusted for baseline
and waning antibody-test sensitivity. We then modelled age-standardised
IFR as a function of time, geography, and an ensemble of 100 of the
top-performing covariate sets. The covariates included seven clinical
predictors (eg, age-standardised obesity prevalence) and two measures of
health system performance. Final estimates for 190 countries and
territories, as well as subnational locations in 11 countries and
territories, were obtained by predicting age-standardised IFR
conditional on covariates and reversing the age standardisation.
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">We report IFR
estimates for April 15, 2020, to January 1, 2021, the period before the
introduction of vaccines and widespread evolution of variants. We found
substantial heterogeneity in the IFR by age, location, and time.
Age-specific IFR estimates form a J shape, with the lowest IFR occurring
at age 7 years (0·0023%, 95% uncertainty interval [UI] 0·0015-0·0039)
and increasing exponentially through ages 30 years (0·0573%,
0·0418-0·0870), 60 years (1·0035%, 0·7002-1·5727), and 90 years
(20·3292%, 14·6888-28·9754). The countries with the highest IFR on July
15, 2020, were Portugal (2·085%, 0·946-4·395), Monaco (1·778%,
1·265-2·915), Japan (1·750%, 1·302-2·690), Spain (1·710%, 0·991-2·718),
and Greece (1·637%, 1·155-2·678). All-age IFR varied by a factor of more
than 30 among 190 countries and territories. After age standardisation,
the countries with the highest IFR on July 15, 2020, were Peru (0·911%,
0·636-1·538), Portugal (0·850%, 0·386-1·793), Oman (0·762%,
0·381-1·399), Spain (0·751%, 0·435-1·193), and Mexico (0·717%,
0·426-1·404). Subnational locations with high IFRs also included
hotspots in the UK and southern and eastern states of the USA.
Sub-Saharan African countries and Asian countries generally had the
lowest all-age and age-standardised IFRs. Population age structure
accounted for 74% of logit-scale variation in IFRs estimated for 39
in-sample countries on July 15, 2020. A post-hoc analysis showed that
high rates of transmission in the care home population might account for
higher IFRs in some locations. Among all countries and territories, we
found that the median IFR decreased from 0·466% (interquartile range
0·223-0·840) to 0·314% (0·143-0·551) between April 15, 2020, and Jan 1,
2021.
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Estimating
the IFR for global populations helps to identify relative
vulnerabilities to COVID-19. Information about how IFR varies by age,
time, and location informs clinical practice and non-pharmaceutical
interventions like physical distancing measures, and underpins vaccine
risk stratification. IFR and mortality risk form a J shape with respect
to age, which previous research, such as that by Glynn and Moss in 2020,
has identified to be a common pattern among infectious diseases.
Understanding the experience of a population with COVID-19 mortality
requires consideration for local factors; IFRs varied by a factor of
more than 30 among 190 countries and territories in this analysis. In
particular, the presence of elevated age-standardised IFRs in countries
with well resourced health-care systems indicates that factors beyond
health-care capacity are important. Potential extenuating circumstances
include outbreaks among care home residents, variable burdens of severe
cases, and the population prevalence of comorbid conditions that
increase the severity of COVID-19 disease. During the pre-vaccine
period, the estimated 33% decrease in median IFR over 8 months suggests
that treatment for COVID-19 has improved over time. Estimating IFR for
the pre-vaccine era provides an important baseline for describing the
progression of COVID-19 mortality patterns.
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Bill &amp;
Melinda Gates Foundation, J Stanton, T Gillespie, and J and E Nordstrom.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY-NC-ND 4.0 license. Published by
Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35219127</td>
<td align="left">Assessing humoral immune response after two doses of an
inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.</td>
<td align="left">Public health</td>
<td align="left">2022 Jan 25</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">During
COVID-19 pandemic, the absence of immunity in the population left them
susceptible to infection with SARS-CoV-2; healthcare workers (HCWs)
being in the highest risk group. This study intends to assess and follow
up the humoral immunity in HCWs vaccinated with an inactive virus
vaccine (CoronaVac).
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">This is a
prospective observational study.
<AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1072 HCWs
were investigated for the presence of immunoglobulin G antibodies to the
receptor-binding domain of the S1 subunit of the spike protein of
SARS-CoV-2 after vaccination. Blood samples were obtained after 28 days
of the first dose, 21 days of the second dose, and 3 months after the
second dose. Detection of antispike antibodies was performed by the
chemiluminescent microparticle immunoassay method (SARS-CoV-2 IgG II
Quant, Abbott, Ireland). The results greater than or equal to the cutoff
value of 50.0 AU/mL were reported as positive.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Four weeks after the
first dose of vaccine, antispike antibodies were detected in 834/1072
(77.8%) of HCWs. Seropositivity was higher among females (84.6%) than
males (70.6% p &lt; 0.001) and was found to be highest in both women and
men between the ages of 18-34 years. Antispike antibodies were detected
in 1008 of 1012 (99.6%) after 21 days of the second dose and in 803 of
836 (96.1%) after 3 months of the second dose.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CoronaVac
was found to be highly immunogenic after two consecutive doses performed
28 days apart to HCWs; however, the immunogenicity declined
significantly (p &lt; 0.001) after 3 months following the second dose of
vaccine. Copyright © 2022 The Royal Society for Public Health. Published
by Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35218998</td>
<td align="left">B-cell aplasia is the most powerful predictive marker
for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in
recipients of allogeneic hematopoietic stem cell transplantation.</td>
<td align="left">Transplantation and cellular therapy</td>
<td align="left">2022 Feb 23</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little
is known on the immune response to SARS-CoV-2 vaccination in recipients
of allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
However, a few studies have reported that adequate protection could be
provided to this population.
<AbstractText Label="OBJECTIVE(S)" NlmCategory="OBJECTIVE">The purpose
of this study was to evaluate which factors can predict the efficacy of
SARS-CoV-2 vaccination in these specifically immunosuppressed patients.
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Specific anti
Spike (S) antibody responses were assessed in a cohort of 117 Allo-HSCT
recipients after two injections of BNT162b2 mRNA SARS-CoV-2 vaccine (V1
and V2). Factors considered liable to influence the antibody response
and analyzed in this series were the interval between Allo-HSCT and V1,
donor source, recipient and donor age, current
immunosuppressive/chemotherapy (I/C) treatment and levels of CD4+and
CD8+ T-cells, B-cells and NK-cells at the time of V1.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, the
S-antibody response rate, evaluated at a median of 35 days after V2, was
82.9% for the entire cohort, with 71 patients (61%) reaching the highest
titre. In univariate analysis, a lower pre-V1 median total lymphocyte
count, lower CD4+ T-cell and B-cell counts as well as ongoing I/C
treatment and a haploidentical donor were characteristic of non-humoral
responders. However, multiparameter analysis showed that B-cell aplasia
was the only factor predicting the absence of a specific immune response
(Odd Ratio 0.01, 95%CI [0.00 - 0.10], p &lt;10-3). Indeed, the rate of
humoral response was 9.1% in patients with B-cell aplasia, vs 95.9% in
patients with a B-cell count higher than 0 (p&lt;10-9).
<AbstractText Label="CONCLUSION(S)" NlmCategory="CONCLUSIONS">These
results advocate for the prescription of anti-SARS-CoV-2 vaccination in
Allo-HSCT recipients as early as peripheral B-cell levels can be
detected, suggesting also a need for a close monitoring of B-cell
reconstitution after Allo-HSCT. Copyright © 2022. Published by Elsevier
Inc.</td>
</tr>
<tr class="even">
<td align="left">35218966</td>
<td align="left">A global survey in the developmental landscape of
possible vaccination strategies for COVID-19.</td>
<td align="left">Clinical immunology (Orlando, Fla.)</td>
<td align="left">2022 Feb 23</td>
<td align="left">The development of COVID-19 vaccines was promptly
regulated to ensure the best possible approach. By January 2022, 75
candidates reached preclinical evaluation in various animal models, 114
vaccines were in clinical trials on humans, and 48 were in the final
testing stages. Vaccine platforms range from whole virus vaccines to
nucleic acid vaccines, which are the most promising in prompt
availability and safety. The USA and Europe have approved vaccines
developed by Pfizer-BioNTech (BNT162b2) and Moderna (mRNa1273). So far,
Pfizer-BioNTech, Moderna, Johnson &amp; Johnson, AstraZeneca-University
of Oxford, Sinopharm, Sinovac Biotech Gamaleya, Bharat Biotech, and
Novavax have documented effective vaccines. Even with technological
advances and a fast-paced development approach, many limitations and
problems need to be overcome before a large-scale production of new
vaccines can start. The Key is to ensure equal and fair distribution
globally through regulatory measures. Recent studies link Bacillus
Calmette-Guérin (BCG) vaccination programs and lower disease severity.
Copyright © 2021. Published by Elsevier Inc.</td>
</tr>
<tr class="odd">
<td align="left">35218512</td>
<td align="left">Hemophagocytic lymphohistiocytosis after SARS-CoV-2
vaccination.</td>
<td align="left">Infection</td>
<td align="left">2022 Feb 26</td>
<td align="left"><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The
coronavirus disease 2019 (COVID-19) pandemic has led to the approval of
novel vaccines with different mechanisms of action. Until now, more than
4.7 billion persons have been vaccinated around the world, and adverse
effects not observed in pre-authorization trials are being reported at
low frequency. <AbstractText Label="METHODS" NlmCategory="METHODS">We
report a case of severe hemophagocytic lymphohistiocytosis (HLH) after
SARS-CoV-2 immunization and performed a literature search for all
reported cases of COVID-19 vaccine-associated HLH.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A 24-year-old female
developed HLH after immunization with the mRNA COVID-19 vaccine
Comirnaty. Diagnosis was made according to HLH-2004 criteria; the HScore
was 259 (&gt; 99% HLH probability) with maximum ferritin of 138.244
µg/L. The patient was initially treated with intravenous immunoglobulins
(IVIGs) and dexamethasone without response. The addition of the human
interleukin 1 receptor antagonist Anakinra resulted in full recovery
within 6 weeks after vaccination. A literature search revealed 15
additional cases of HLH after SARS-CoV-2 vaccination, the majority after
immunization with Comirnaty (n = 7) or the viral vector vaccine
Vaxzevria (n = 6). Treatment modalities included corticosteroids (n =
13), Anakinra (n = 5), IVIGs (n = 5), and etoposide (n = 2). Eight
patients underwent combination treatment. Three of 16 patients died.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19
vaccines may occasionally trigger HLH, and Anakinra may be an
efficacious treatment option for this condition. © 2022. The
Author(s).</td>
</tr>
<tr class="even">
<td align="left">35218386</td>
<td align="left">Comparison of analytical sensitivity and efficiency for
SARS-CoV-2 primer sets by TaqMan-based and SYBR Green-based
RT-qPCR.</td>
<td align="left">Applied microbiology and biotechnology</td>
<td align="left">2022 Feb 26</td>
<td align="left">The pandemic of coronavirus disease 2019 (COVID-19)
continues to threaten public health. For developing countries where
vaccines are still in shortage, cheaper alternative molecular methods
for SARS-CoV-2 identification can be crucial to prevent the next wave.
Therefore, 14 primer sets recommended by the World Health Organization
(WHO) was evaluated on testing both clinical patient and environmental
samples with the gold standard diagnosis method, TaqMan-based RT-qPCR,
and a cheaper alternative method, SYBR Green-based RT-qPCR. Using
suitable primer sets, such as ORF1ab, 2019_nCoV_N1 and 2019_nCoV_N3, the
performance of the SYBR Green approach was comparable or better than the
TaqMan approach, even when considering the newly dominating or emerging
variants, including Delta, Eta, Kappa, Lambda, Mu, and Omicron. ORF1ab
and 2019_nCoV_N3 were the best combination for sensitive and reliable
SARS-CoV-2 molecular diagnostics due to their high sensitivity,
specificity, and broad accessibility. KEY POINTS: • With suitable primer
sets, the SYBR Green method performs better than the TaqMan one. • With
suitable primer sets, both methods should still detect the new variants
well. • ORF1ab and 2019_nCoV_N3 were the best combination for SARS-CoV-2
detection. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35217969</td>
<td align="left">Cerebral venous thrombosis without thrombocytopenia
after a single dose of COVID-19 (Ad26.COV2.S) vaccine injection: a case
report.</td>
<td align="left">Neurological sciences : official journal of the Italian
Neurological Society and of the Italian Society of Clinical
Neurophysiology</td>
<td align="left">2022 Feb 25</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The
coronavirus pandemic became the hard challenge for the modern global
health system. To date, vaccination is the best strategy against
Sars-Cov-2-related illness. About 3 billions of people received at least
one of the approved vaccines. The related adverse events were reported
during the various experimental phases, but newer and less common side
effects are emerging post-marketing. Vaccine-induced thrombocytopenia
with thrombosis (VITT) is one of these insidious adverse reactions and
it is considered responsible of venous thrombosis, in both the
splanchnic and the cerebral circulation. Although its mechanism has been
presumably established, resembling that observed in heparin-induced
thrombocytopenia, some venous thromboses seem not to recognize this
etiology and their pathogenesis remains unknown. Here we described a
case of cerebral venous thrombosis after administration of the
Ad26.COV2.S, presenting without thrombocytopenia, paving the way for
possible novel causes of this vaccine-induced pathological condition.
<AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A
45-year-old woman came to our observation for bilateral periorbital
headache associated with retro-orbital pain started 8 days after
administration of COVID vaccine Jannsen. Ophthalmologic exam showing a
bilateral papilledema raised the suspicion of intracranial hypertension.
Cerebral magnetic resonance imaging revealed signal alteration with
T1-positive contrast enhancement in the right temporal and insular lobes
suggestive of cerebral venous thrombosis. The absence of
thrombocytopenia and platelet factor 4 (PF-4) antibodies led the
clinicians to rule out VITT. The patient was treated successfully with
warfarin.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Venous
thrombosis occurring after COVID-19 vaccination represents an adverse
event of special interest. Patients with thrombosis and thrombocytopenia
appear to be affected by a general thrombophilic state, sustained by an
autoimmune mechanism, and show a higher mortality. Thrombosis without
thrombocytopenia’s pathogenesis has not yet been clarified, but
laboratory data and good response to vitamin K antagonists help
clinicians in the differential diagnosis with VITT. Future research will
allow us to discover other possible mechanisms and maybe identify a
subgroup of patients with a higher risk of developing this medical
complication. © 2022. Fondazione Società Italiana di Neurologia.</td>
</tr>
<tr class="even">
<td align="left">35217639</td>
<td align="left">Three doses of prototypic SARS-CoV-2 inactivated
vaccine induce cross-protection against its variants of concern.</td>
<td align="left">Signal transduction and targeted therapy</td>
<td align="left">2022 02 25</td>
<td align="left">Variants are globally emerging very quickly following
pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of
prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus
monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine,
followed by challenging with emerging SARS-CoV-2 variants of concern
(VOCs). These vaccinated animals produced neutralizing antibodies
against Alpha, Beta, Delta, and Omicron variants, although there were
certain declinations of geometric mean titer (GMT) as compared with
prototypic SARS-CoV-2. Of note, in vivo this prototypic vaccine not only
reduced the viral loads in nasal, throat and anal swabs, pulmonary
tissues, but also improved the pathological changes in the lung infected
by variants of Alpha, Beta, and Delta. In summary, the prototypic
SARS-CoV-2 inactivated vaccine in this study protected against VOCs to
certain extension, which is of great significance for prevention and
control of COVID-19. © 2022. The Author(s).</td>
</tr>
<tr class="odd">
<td align="left">35217543</td>
<td align="left">Factors influencing COVID-19 vaccination uptake among
community members in Hong Kong: a cross-sectional online survey.</td>
<td align="left">BMJ open</td>
<td align="left">2022 02 25</td>
<td align="left"><AbstractText Label="OBJECTIVE">Vaccination is
recognised as the most effective approach to contain the spread of the
COVID-19 pandemic in the long run. However, the global vaccination
uptake is still suboptimal. Although a considerable number of studies
have focused on factors influencing intention or acceptance of COVID-19
vaccination, few explore the factors that affect actual vaccination
uptake. This study aimed to explore the factors influencing COVID-19
vaccination uptake among the general public in a developed country.
<AbstractText Label="DESIGN">A cross-sectional online survey was
conducted between June and August 2021.
<AbstractText Label="SETTING AND PARTICIPANTS">Community members in Hong
Kong were recruited through convenient and snowball sampling to complete
an anonymous online survey. <AbstractText Label="OUTCOME MEASURES">The
outcomes of this study included participants’ sociodemographic
characteristics, vaccination status and perceived impact of COVID-19,
and their attitudes towards COVID-19. <AbstractText Label="RESULTS">A
total of 358 valid questionnaires were received. The results showed that
50.8% of the participants received two doses of the vaccine.
Multivariable logistic regression analysis suggested that the
participants’ vaccination uptake was associated with their jobs affected
by COVID-19, had an income source, perceived good/excellent physical
health status, perceived COVID-19 exposure, perceived good/excellent
knowledge of COVID-19, learnt about the vaccine from printed materials
and perceived that their family members were at risk of contracting
COVID-19. <AbstractText Label="CONCLUSIONS">This is one of the first few
cross-sectional studies that explored factors associated with the actual
vaccination uptake of the general public during the COVID-19 pandemic.
The results can provide insights for formulating strategies to increase
COVID-19 vaccination rates in developed countries. © Author(s) (or their
employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial
re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">35216872</td>
<td align="left">The Coronavirus pandemic - 2022: Viruses, variants
&amp; vaccines.</td>
<td align="left">Cytokine &amp; growth factor reviews</td>
<td align="left">2022 Feb</td>
<td align="left">Since the beginning of the COVID-19 pandemic in
2019-2020, Cytokine &amp; Growth Factor Reviews has published several
Special Issues focused on the biology, pathogenesis and therapeutic
options in the treatment of COVID-19 infection, including articles on
the involvement of the chemokine system in the cytokine storm in
COVID-19, intervention in the early stages of COVID-19 pneumonia, the
therapeutic value of corticosteroid treatment, early clinical
intervention with type 1 interferons, progress in vaccine development,
and organ specific complications of COVID-19. By 2022, multiple highly
efficacious vaccines are available and are being administered in
countries around the world, therapeutic options have been clinically
evaluated and approved, and SARS-CoV-2 has arguably become the most
thoroughly studied virus in history. But, with progress has also come
unanticipated problems - misinformation, anti-vaxxers, opposition to
protective masks, and politically motivated interference disguised as
knowledge. With this issue of CGFR, we continue to document the global
coronavirus pandemic and provide an update on the emergence of viral
variants, the global effort to administer vaccines and the impediments
to progress posed by misinformation and anti-vaccine sentiment.
Copyright © 2022. Published by Elsevier Ltd.</td>
</tr>
<tr class="odd">
<td align="left">35216853</td>
<td align="left">Encouraging COVID-19 vaccination via an evolutionary
theoretical approach: A randomized controlled study in Japan.</td>
<td align="left">Patient education and counseling</td>
<td align="left">2022 Feb 18</td>
<td align="left"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We
aimed to examine the effect of a message that target the fundamental
human motive of kin care on COVID-19 vaccination recommendations among
participants with young children, based on an evolutionary theoretical
approach.
<AbstractText Label="METHODS" NlmCategory="METHODS">Participants with
young children (n = 969) were randomly assigned either to a group that
received an intervention message that targeted the fundamental motive of
kin care, or that targeted the fundamental motive of disease avoidance,
or a control message. Intention to receive COVID-19 vaccination was
assessed both before and after reading the messages. A one-way ANOVA
with Tukey’s or Games-Howell test was conducted.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">An intervention
message targeting the fundamental motive of kin care and disease
avoidance significantly increased intention of vaccination versus a
control message (p &lt; 0.001, respectively).
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The
evolutionary theoretical approach that focuses on fundamental human
motives has the potential to extend the communication strategy for
COVID-19 vaccination recommendations.
<AbstractText Label="PRACTICE IMPLICATIONS" NlmCategory="CONCLUSIONS">Health
professionals should deliver messages that target the fundamental motive
of kin care as well as messages about the susceptibility and severity of
COVID-19 and vaccine efficacy (e.g., “Get vaccinated against COVID-19
for your child’s sake, because if you are infected, you will be unable
to care for your child.”). Copyright © 2022. Published by Elsevier
B.V.</td>
</tr>
<tr class="even">
<td align="left">35216841</td>
<td align="left">Couples and COVID-19 vaccination: Frequency and reasons
for discordance.</td>
<td align="left">Vaccine</td>
<td align="left">2022 Feb 18</td>
<td align="left">The purpose of this study was to determine the
frequency of concordance and discordance in the COVID-19 vaccination
status of intimate couples. Partners are well known to influence each
other’s health behaviors, but previous reports of couples’ COVID-19
vaccination status were not found. Among 1305 respondents to an on-line
survey who were living with their partners, couples’ COVID-19
vaccination status was 15.63% discordant and 84.37% concordant.
Different potentially modifiable reasons for being unvaccinated were
emphasized by unvaccinated participants with vaccinated partners and by
vaccinated participants with unvaccinated partners. This study provides
an estimate of the proportion of couples with discordant COVID-19
vaccine status. The development of tailored, scalable interventions
potentially involving the partner might increase the COVID-19 vaccine
concordance rate. Copyright © 2022 Elsevier Ltd. All rights
reserved.</td>
</tr>
<tr class="odd">
<td align="left">35216833</td>
<td align="left">The effect of coronavirus disease 2019 immunity on
frozen-thawed embryo transfer cycles outcome.</td>
<td align="left">Fertility and sterility</td>
<td align="left">2022 Jan 10</td>
<td align="left"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To
study the effect of patients’ immunization after coronavirus disease
2019 (COVID-19) infection or messenger ribonucleic acid (mRNA) severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine on
frozen-thawed embryo transfer (FET).
<AbstractText Label="DESIGN" NlmCategory="METHODS">Cohort retrospective
study. <AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary
university affiliated medical center.
<AbstractText Label="PATIENT(S)" NlmCategory="METHODS">All consecutive
patients undergoing FET cycles in our center. The study group (immune
group) consisted of patients treated during the COVID-19 pandemic
(between January 2021 and August 2021) who either recovered from
COVID-19 infection or received the mRNA SARS-CoV-2 vaccine. The control
groups consisted of patients treated during the COVID-19 pandemic
(between January 2021 and August 2021) but were not infected or did not
receive the mRNA SARS-CoV-2 vaccine (not-immune2021 group) and those
treated between January 2019 and August 2019 (before the pandemic)
(not-immune2019 group).
<AbstractText Label="INTERVENTION(S)" NlmCategory="METHODS">Frozen-thawed
embryo transfer cycles.
<AbstractText Label="MAIN OUTCOME MEASURE(S)" NlmCategory="METHODS">Ongoing
pregnancy rates and FET cycles’ characteristics. Data on patient age and
variables related to infertility treatment were collected from the
patient records.
<AbstractText Label="RESULT(S)" NlmCategory="RESULTS">During the study
periods, 428 patients underwent 672 FET cycles. The immune group
consisted of 141 patients who underwent 264 FET cycles (44 in
postinfection and 220 in postvaccination), whereas the not-immune2021
and not-immune2019 groups consisted of 93 and 194 patients undergoing
125 and 283 FET cycles, respectively. Patients’ characteristics and the
types of endometrial preparations were comparable between the study
groups. The implantation rate and clinical and ongoing pregnancy rates
per transfer were similar between the study groups (immune group,
postinfection and postvaccination; not-immune2021 group; not-immune2019
group).
<AbstractText Label="CONCLUSION(S)" NlmCategory="CONCLUSIONS">Coronavirus
disease 2019 infection or vaccination did not affect patients’
performance or implantation in their subsequent FET cycle. Copyright ©
2022 American Society for Reproductive Medicine. Published by Elsevier
Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">35216793</td>
<td align="left">Risk of disease relapse following COVID-19 vaccination
in patients with AQP4-IgG-positive NMOSD and MOGAD.</td>
<td align="left">Multiple sclerosis and related disorders</td>
<td align="left">2022 Feb</td>
<td align="left">Post-vaccination disease relapses have been reported in
patients with MOGAD and AQP4-IgG+NMOSD. In this retrospective
multicenter Italian study we assessed the frequency of relapses after
SARS-CoV-2 vaccination. We included 56 cases: MOGAD, 30; AQP4-IgG+NMOSD,
26. Vaccines received were BNT162b2-Pfizer-BioNTech in 42 patients and
mRNA-1273-Moderna in 14 patients. Six patients had a history of
SARS-CoV-2 infection; two of them experienced a post-infection disease
relapse (MOGAD). The frequency of relapses within one month of
SARS-CoV-2 vaccination was 4% (1/26) in the AQP4-IgG+NMOSD group and 0%
in the MOGAD group. In these patients the potential benefits of
vaccination overcome the risk of relapses. Copyright © 2021 Elsevier
B.V. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35216789</td>
<td align="left">Newly diagnosed neuromyelitis optica spectrum disorders
following vaccination: Case report and systematic review.</td>
<td align="left">Multiple sclerosis and related disorders</td>
<td align="left">2022 Feb</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The
pathogenesis of neuromyelitis optica spectrum disorder (NMOSD) has been
vigorously illustrated, but triggers of the disease remain unclear.
Viral infection and vaccination have been observed to precede certain
cases of NMOSD. Amidst the Coronavirus disease 2019 (COVID-19) pandemic,
mass vaccination takes place across the globe. We report two cases of
newly diagnosed NMOSD following COVID-19 vaccination and systematically
review previous reports.
<AbstractText Label="METHOD" NlmCategory="METHODS">Searching of Ovid
MEDLINE and EMBASE databases was done using predefined search terms
related to NMOSD and vaccination. Duplicates were removed. Newly
diagnosed NMOSD cases fulfilling the 2015 International Panel for NMO
Diagnosis criteria with symptoms presenting between 2-30 days after
vaccination were included. Data on age, sex, comorbidity, vaccine name,
type, and dose number, duration from vaccination to symptom onset,
clinical phenotype(s), MRI findings, CSF profiles, severity of attack,
initial and maintenance treatment, number of relapses after vaccination,
and clinical outcomes were extracted using a standardized table and
compared. <AbstractText Label="RESULT" NlmCategory="RESULTS">Ten cases
of postvaccination NMOSD were identified. Patients aged between 15-46
years old. Nine patients (90%) presented with transverse myelitis and 3
(30%) with optic neuritis. The mean duration from vaccination to
clinical onset was 8.2 days (median 9 days). Five patients (50%) tested
positive for aquaporin 4 (AQP4) antibody. One patient had a family
history of NMOSD. Three-fourths of AQP4-IgG seropositive patients with
myelopathy had short transverse myelitis. The reported vaccines included
CoronaVac, ChAdOx1 nCoV-19, yellow fever, quadrivalent influenza, H1N1
influenza, quadrivalent human papillomavirus, Japanese encephalitis,
rabies, and recombinant hepatitis B virus together with
tetanus-diphtheria-pertussis vaccines. All patients received high-dose
steroids for initial treatment and 2 received additional therapeutic
plasma exchange. Maintenance therapy was given in 4 patients. Five
patients (50%) experienced no subsequent relapses within the follow-up
period ranging between 3-34 months. Almost all patients returned to
baseline functional status.
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The temporal
relationship between vaccination and onset of symptoms suggests that
vaccine might be a trigger of NMOSD. Genetic predisposition could be a
risk factor for postvaccination NMOSD as there are evidences of family
history and presence of an associated HLA allele. The prevalence of
short-segment transverse myelitis seems to be higher than in typical
cases of NMOSD, but the natural history is otherwise similar. All
patients received acute treatment with high-dose corticosteroids, most
with excellent response. Long-term immunomodulation therapy should be
initiated for relapse prevention. Limitations of this study are lack of
some relevant data, precision of temporal relationship, and the small
number of reports.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Postvaccination
NMOSD is a rare condition that can occur with various types of vaccines.
The short temporal relationship between vaccination and onset of NMOSD
and the history of NMOSD in one patient’s sibling indicate that vaccine
might be a trigger for genetically predisposed individuals. Copyright ©
2021. Published by Elsevier B.V.</td>
</tr>
<tr class="even">
<td align="left">35216745</td>
<td align="left">Coronavirus disease 2019 messenger RNA vaccine skin
tests and serum histamine levels in allergic reactions.</td>
<td align="left">Annals of allergy, asthma &amp; immunology : official
publication of the American College of Allergy, Asthma, &amp;
Immunology</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">35216744</td>
<td align="left">Immune parameters during anaphylaxis to messenger RNA
coronavirus disease 2019 vaccines: Not the usual suspects?</td>
<td align="left">Annals of allergy, asthma &amp; immunology : official
publication of the American College of Allergy, Asthma, &amp;
Immunology</td>
<td align="left">2022 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35216673</td>
<td align="left">A blood atlas of COVID-19 defines hallmarks of disease
severity and specificity.</td>
<td align="left">Cell</td>
<td align="left">2022 Mar 03</td>
<td align="left">Treatment of severe COVID-19 is currently limited by
clinical heterogeneity and incomplete description of specific immune
biomarkers. We present here a comprehensive multi-omic blood atlas for
patients with varying COVID-19 severity in an integrated comparison with
influenza and sepsis patients versus healthy volunteers. We identify
immune signatures and correlates of host response. Hallmarks of disease
severity involved cells, their inflammatory mediators and networks,
including progenitor cells and specific myeloid and lymphocyte subsets,
features of the immune repertoire, acute phase response, metabolism, and
coagulation. Persisting immune activation involving AP-1/p38MAPK was a
specific feature of COVID-19. The plasma proteome enabled
sub-phenotyping into patient clusters, predictive of severity and
outcome. Systems-based integrative analyses including tensor and matrix
decomposition of all modalities revealed feature groupings linked with
severity and specificity compared to influenza and sepsis. Our approach
and blood atlas will support future drug development, clinical trial
design, and personalized medicine approaches for COVID-19. Copyright ©
2022 The Author. Published by Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">35216658</td>
<td align="left">Uptake of third doses of SARS-CoV-2 vaccines among
people with inflammatory bowel disease in Ontario, Canada.</td>
<td align="left">The lancet. Gastroenterology &amp; hepatology</td>
<td align="left">2022 Feb 22</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">35216358</td>
<td align="left">Kidney Injury in COVID-19: Epidemiology, Molecular
Mechanisms and Potential Therapeutic Targets.</td>
<td align="left">International journal of molecular sciences</td>
<td align="left">2022 Feb 17</td>
<td align="left">As of December 2021, SARS-CoV-2 had caused over 250
million infections and 5 million deaths worldwide. Furthermore, despite
the development of highly effective vaccines, novel variants of
SARS-CoV-2 continue to sustain the pandemic, and the search for
effective therapies for COVID-19 remains as urgent as ever. Though the
primary manifestation of COVID-19 is pneumonia, the disease can affect
multiple organs, including the kidneys, with acute kidney injury (AKI)
being among the most common extrapulmonary manifestations of severe
COVID-19. In this article, we start by reflecting on the epidemiology of
kidney disease in COVID-19, which overwhelmingly demonstrates that AKI
is common in COVID-19 and is strongly associated with poor outcomes. We
also present emerging data showing that COVID-19 may result in long-term
renal impairment and delve into the ongoing debate about whether AKI in
COVID-19 is mediated by direct viral injury. Next, we focus on the
molecular pathogenesis of SARS-CoV-2 infection by both reviewing
previously published data and presenting some novel data on the
mechanisms of cellular viral entry. Finally, we relate these molecular
mechanisms to a series of therapies currently under investigation and
propose additional novel therapeutic targets for COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">35216194</td>
<td align="left">Analysis of the Neutralizing Activity of Antibodies
Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations.</td>
<td align="left">International journal of molecular sciences</td>
<td align="left">2022 Feb 14</td>
<td align="left">SARS-CoV-2 infection elicits a polyclonal neutralizing
antibody (nAb) response that primarily targets the spike protein, but it
is still unclear which nAbs are immunodominant and what distinguishes
them from subdominant nAbs. This information would however be crucial to
predict the evolutionary trajectory of the virus and design future
vaccines. To shed light on this issue, we gathered 83 structures of nAbs
in complex with spike protein domains. We analyzed in silico the ability
of these nAbs to bind the full spike protein trimer in open and closed
conformations, and predicted the change in binding affinity of the most
frequently observed spike protein variants in the circulating strains.
This led us to define four nAb classes with distinct variant escape
fractions. By comparing these fractions with those measured from plasma
of infected patients, we showed that the class of nAbs that most
contributes to the immune response is able to bind the spike protein in
its closed conformation. Although this class of nAbs only partially
inhibits the spike protein binding to the host’s angiotensin converting
enzyme 2 (ACE2), it has been suggested to lock the closed pre-fusion
spike protein conformation and therefore prevent its transition to an
open state. Furthermore, comparison of our predictions with mRNA-1273
vaccinated patient plasma measurements suggests that spike proteins
contained in vaccines elicit a different nAb class than the one elicited
by natural SARS-CoV-2 infection and suggests the design of highly stable
closed-form spike proteins as next-generation vaccine immunogens.</td>
</tr>
<tr class="even">
<td align="left">35215994</td>
<td align="left">mRNA Vaccine Development for Emerging Animal and
Zoonotic Diseases.</td>
<td align="left">Viruses</td>
<td align="left">2022 02 15</td>
<td align="left">In the prevention and treatment of infectious diseases,
mRNA vaccines hold great promise because of their low risk of
insertional mutagenesis, high potency, accelerated development cycles,
and potential for low-cost manufacture. In past years, several mRNA
vaccines have entered clinical trials and have shown promise for
offering solutions to combat emerging and re-emerging infectious
diseases such as rabies, Zika, and influenza. Recently, the successful
application of mRNA vaccines against COVID-19 has further validated the
platform and opened the floodgates to mRNA vaccine’s potential in
infectious disease prevention, especially in the veterinary field. In
this review, we describe our current understanding of the mRNA vaccines
and the technologies used for mRNA vaccine development. We also provide
an overview of mRNA vaccines developed for animal infectious diseases
and discuss directions and challenges for the future applications of
this promising vaccine platform in the veterinary field.</td>
</tr>
<tr class="odd">
<td align="left">35215983</td>
<td align="left">In-Silico Analysis of Monoclonal Antibodies against
SARS-CoV-2 Omicron.</td>
<td align="left">Viruses</td>
<td align="left">2022 02 14</td>
<td align="left">Omicron was designated by the WHO as a VOC on 26
November 2021, only 4 days after its sequence was first submitted.
However, the impact of Omicron on current antibodies and vaccines
remains unknown and evaluations are still a few weeks away. We analysed
the mutations in the Omicron variant against epitopes. In our database,
132 epitopes of the 120 antibodies are classified into five groups,
namely NTD, RBD-1, RBD-2, RBD-3, and RBD-4. The Omicron mutations impact
all epitopes in NTD, RBD-1, RBD-2, and RBD-3, with no antibody epitopes
spared by these mutations. Only four out of 120 antibodies may confer
full resistance to mutations in the Omicron spike, since all antibodies
in these three groups contain one or more epitopes that are affected by
these mutations. Of all antibodies under EUA, the neutralisation
potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima,
Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened
to varying degrees. Our analysis suggests the impact of Omicron on
current therapeutic antibodies by the Omicron spike mutations may also
apply to current COVID-19 vaccines.</td>
</tr>
<tr class="even">
<td align="left">35215977</td>
<td align="left">In Silico Prediction and Selection of Target Sequences
in the SARS-CoV-2 RNA Genome for an Antiviral Attack.</td>
<td align="left">Viruses</td>
<td align="left">2022 02 14</td>
<td align="left">The SARS-CoV-2 pandemic has urged the development of
protective vaccines and the search for specific antiviral drugs. The
modern molecular biology tools provides alternative methods, such as
CRISPR-Cas and RNA interference, that can be adapted as antiviral
approaches, and contribute to this search. The unique CRISPR-Cas13d
system, with the small crRNA guide molecule, mediates a
sequence-specific attack on RNA, and can be developed as an
anti-coronavirus strategy. We analyzed the SARS-CoV-2 genome to localize
the hypothetically best crRNA-annealing sites of 23 nucleotides based on
our extensive expertise with sequence-specific antiviral strategies. We
considered target sites of which the sequence is well-conserved among
SARS-CoV-2 isolates. As we should prepare for a potential future
outbreak of related viruses, we screened for targets that are conserved
between SARS-CoV-2 and SARS-CoV. To further broaden the search, we
screened for targets that are conserved between SARS-CoV-2 and the more
distantly related MERS-CoV, as well as the four other human
coronaviruses (OC43, 229E, NL63, HKU1). Finally, we performed a search
for pan-corona target sequences that are conserved among all these
coronaviruses, including the new Omicron variant, that are able to
replicate in humans. This survey may contribute to the design of
effective, safe, and escape-proof antiviral strategies to prepare for
future pandemics.</td>
</tr>
<tr class="odd">
<td align="left">35215973</td>
<td align="left">Fighting Fire with Fire: Immunogenicity of Viral
Vectored Vaccines against COVID-19.</td>
<td align="left">Viruses</td>
<td align="left">2022 02 12</td>
<td align="left">The persistent expansion of the coronavirus disease
2019 (COVID-19) global pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) requires the rapid development of
safe and effective countermeasures to reduce transmission, morbidity,
and mortality. Several highly efficacious vaccines are actively being
deployed around the globe to expedite mass vaccination and control of
COVID-19. Notably, viral vectored vaccines (VVVs) are among the first to
be approved for global distribution and use. In this review, we examine
the humoral, cellular, and innate immune responses elicited by viral
vectors, and the immune correlates of protection against COVID-19 in
preclinical and clinical studies. We also discuss the durability and
breadth of immune response induced by VVVs and boosters. Finally, we
present challenges associated with VVVs and offer solutions for
overcoming certain limitations of current vaccine regimens.
Collectively, this review provides the rationale for expanding the
portfolio of VVVs against SARS-CoV-2.</td>
</tr>
<tr class="even">
<td align="left">35215962</td>
<td align="left">Antibody Response to SARS-CoV-2 Infection and
Vaccination in COVID-19-naïve and Experienced Individuals.</td>
<td align="left">Viruses</td>
<td align="left">2022 02 10</td>
<td align="left">Understanding the magnitude of responses to vaccination
during the ongoing SARS-CoV-2 pandemic is essential for ultimate
mitigation of the disease. Here, we describe a cohort of 102 subjects
(70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of
one of the mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273
(Moderna)). We document that a single exposure to antigen via infection
or vaccination induces a variable antibody response which is affected by
age, gender, race, and co-morbidities. In response to a second antigen
dose, both COVID-19-naïve and experienced subjects exhibited elevated
levels of anti-spike and SARS-CoV-2 neutralizing activity; however,
COVID-19-experienced individuals achieved higher antibody levels and
neutralization activity as a group. The COVID-19-experienced subjects
exhibited no significant increase in antibody or neutralization titer in
response to the second vaccine dose (i.e., third antigen exposure).
Finally, we found that COVID-19-naïve individuals who received the
Moderna vaccine exhibited a more robust boost response to the second
vaccine dose (p = 0.004) as compared to the response to Pfizer-BioNTech.
Ongoing studies with this cohort will continue to contribute to our
understanding of the range and durability of responses to SARS-CoV-2
mRNA vaccines.</td>
</tr>
<tr class="odd">
<td align="left">35215888</td>
<td align="left">Computational Analysis of Mutations in the
Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on
Antibody Binding.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 30</td>
<td align="left">Currently, SARS-CoV-2 causing coronavirus disease 2019
(COVID-19) is responsible for one of the most deleterious pandemics of
our time. The interaction between the ACE2 receptors at the surface of
human cells and the viral Spike (S) protein triggers the infection,
making the receptor-binding domain (RBD) of the SARS-CoV-2 S-protein a
focal target for the neutralizing antibodies (Abs). Despite the recent
progress in the development and deployment of vaccines, the emergence of
novel variants of SARS-CoV-2 insensitive to Abs produced in response to
the vaccine administration and/or monoclonal ones represent a potential
danger. Here, we analyzed the diversity of neutralizing Ab epitopes and
assessed the possible effects of single and multiple mutations in the
RBD of SARS-CoV-2 S-protein on its binding affinity to various
antibodies and the human ACE2 receptor using bioinformatics approaches.
The RBD-Ab complexes with experimentally resolved structures were
grouped into four clusters with distinct features at sequence and
structure level. The performed computational analysis indicates that
while single amino acid replacements in RBD may only cause partial
impairment of the Abs binding, moreover, limited to specific epitopes,
the variants of SARS-CoV-2 with multiple mutations, including some which
were already detected in the population, may potentially result in a
much broader antigenic escape. Further analysis of the existing RBD
variants pointed to the trade-off between ACE2 binding and antigenic
escape as a key limiting factor for the emergence of novel SAR-CoV-2
strains, as the naturally occurring mutations in RBD tend to reduce its
binding affinity to Abs but not to ACE2. The results provide guidelines
for further experimental studies aiming to identify high-risk RBD
mutations that allow for an antigenic escape.</td>
</tr>
<tr class="even">
<td align="left">35215848</td>
<td align="left">Rapid Biosensor of SARS-CoV-2 Using Specific Monoclonal
Antibodies Recognizing Conserved Nucleocapsid Protein Epitopes.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 27</td>
<td align="left">Coronavirus disease 2019 (COVID-19), the pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
is characterized by symptoms such as fever, fatigue, a sore throat,
diarrhea, and coughing. Although various new vaccines against COVID-19
have been developed, early diagnostics, isolation, and prevention remain
important due to virus mutations resulting in rapid and high disease
transmission. Amino acid substitutions in the major diagnostic target
antigens of SARS-CoV-2 may lower the sensitivity for the detection of
SARS-CoV-2. For this reason, we developed specific monoclonal antibodies
that bind to epitope peptides as antigens for the rapid detection of
SARS-CoV-2 NP. The binding affinity between antigenic peptides and
monoclonal antibodies was investigated, and a sandwich pair for capture
and detection was employed to develop a rapid biosensor for SARS-CoV-2
NP. The rapid biosensor, based on a monoclonal antibody pair binding to
conserved epitopes of SARS-CoV-2 NP, detected cultured virus samples of
SARS-CoV-2 (1.4 × 103 TCID50/reaction) and recombinant NP (1 ng/mL).
Laboratory confirmation of the rapid biosensor was performed with
clinical specimens (n = 16) from COVID-19 patients and other pathogens.
The rapid biosensor consisting of a monoclonal antibody pair (75E12 for
capture and the 54G6/54G10 combination for detection) binding to
conserved epitopes of SARS-CoV-2 NP could assist in the detection of
SARS-CoV-2 NP under the circumstance of spreading SARS-CoV-2
variants.</td>
</tr>
<tr class="odd">
<td align="left">35215822</td>
<td align="left">Coagulation System Activation for Targeting of
COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles,
and Hypercoagulability in COVID-19 Vaccines.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 24</td>
<td align="left">The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), also known as COVID-19, is currently developing into a
rapidly disseminating and an overwhelming worldwide pandemic. In severe
COVID-19 cases, hypercoagulability and inflammation are two crucial
complications responsible for poor prognosis and mortality. In addition,
coagulation system activation and inflammation overlap and produce
life-threatening complications, including coagulopathy and cytokine
storm, which are associated with overproduction of cytokines and
activation of the immune system; they might be a lead cause of organ
damage. However, patients with severe COVID-19 who received
anticoagulant therapy had lower mortality, especially with elevated
D-dimer or fibrin degradation products (FDP). In this regard, the
discovery of natural products with anticoagulant potential may help
mitigate the numerous side effects of the available synthetic drugs.
This review sheds light on blood coagulation and its impact on the
complication associated with COVID-19. Furthermore, the sources of
natural anticoagulants, the role of nanoparticle formulation in this
outbreak, and the prevalence of thrombosis with thrombocytopenia
syndrome (TTS) after COVID-19 vaccines are also reviewed. These combined
data provide many research ideas related to the possibility of using
these anticoagulant agents as a treatment to relieve acute symptoms of
COVID-19 infection.</td>
</tr>
<tr class="even">
<td align="left">35215786</td>
<td align="left">Herpes zoster: A Review of Clinical Manifestations and
Management.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 19</td>
<td align="left">The Varicella-zoster virus (VZV) or human herpes virus
3 is a neurotropic human alpha herpes virus responsible for
chickenpox/varicella and shingles/Herpes zoster (HZ). This review will
focus on HZ. Since HZ is secondary to varicella, its incidence increases
with age. In children and youngsters, HZ is rare and associated to
metabolic and neoplastic disorders. In adults, advanced age, distress,
other infections (such as AIDS or COVID-19), and immunosuppression are
the most common risk factors. HZ reactivation has recently been observed
after COVID-19 vaccination. The disease shows different clinical stages
of variable clinical manifestations. Some of the manifestations bear a
higher risk of complications. Among the possible complications,
postherpetic neuralgia, a chronic pain disease, is one of the most
frequent. HZ vasculitis is associated with morbidity and mortality.
Renal and gastrointestinal complications have been reported. The
cornerstone of treatment is early intervention with acyclovir or
brivudine. Second-line treatments are available. Pain management is
essential. For (secondary) prophylaxis, currently two HZV vaccines are
available for healthy older adults, a live attenuated VZV vaccine and a
recombinant adjuvanted VZV glycoprotein E subunit vaccine. The latter
allows vaccination also in severely immunosuppressed patients. This
review focuses on manifestations of HZ and its management. Although
several articles have been published on HZ, the literature continues to
evolve, especially in regard to patients with comorbidities and
immunocompromised patients. VZV reactivation has also emerged as an
important point of discussion during the COVID-19 pandemic, especially
after vaccination. The objective of this review is to discuss current
updates related to clinical presentations, complications, and management
of HZ.</td>
</tr>
<tr class="odd">
<td align="left">35215783</td>
<td align="left">Mucosal Vaccines, Sterilizing Immunity, and the Future
of SARS-CoV-2 Virulence.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 19</td>
<td align="left">Sterilizing immunity after vaccination is desirable to
prevent the spread of infection from vaccinees, which can be especially
dangerous in hospital settings while managing frail patients.
Sterilizing immunity requires neutralizing antibodies at the site of
infection, which for respiratory viruses such as SARS-CoV-2 implies the
occurrence of neutralizing IgA in mucosal secretions. Systemic
vaccination by intramuscular delivery induces no or low-titer
neutralizing IgA against vaccine antigens. Mucosal priming or boosting,
is needed to provide sterilizing immunity. On the other side of the
coin, sterilizing immunity, by zeroing interhuman transmission, could
confine SARS-CoV-2 in animal reservoirs, preventing spontaneous
attenuation of virulence in humans as presumably happened with the
endemic coronaviruses. We review here the pros and cons of each
vaccination strategy, the current mucosal SARS-CoV-2 vaccines under
development, and their implications for public health.</td>
</tr>
<tr class="even">
<td align="left">35215765</td>
<td align="left">Versatile SARS-CoV-2 Reverse-Genetics Systems for the
Study of Antiviral Resistance and Replication.</td>
<td align="left">Viruses</td>
<td align="left">2022 01 18</td>
<td align="left">The COVID-19 pandemic continues to threaten healthcare
systems worldwide due to the limited access to vaccines, suboptimal
treatment options, and the continuous emergence of new and more
transmissible SARS-CoV-2 variants. Reverse-genetics studies of viral
genes and mutations have proven highly valuable in advancing basic virus
research, leading to the development of therapeutics. We developed a
functional and highly versatile full-length SARS-CoV-2 infectious system
by cloning the sequence of a COVID-19 associated virus isolate (DK-AHH1)
into a bacterial artificial chromosome (BAC). Viruses recovered after
RNA-transfection of in vitro transcripts into Vero E6 cells showed
growth kinetics and remdesivir susceptibility similar to the DK-AHH1
virus isolate. Insertion of reporter genes, green fluorescent protein,
and nanoluciferase into the ORF7 genomic region led to high levels of
reporter activity, which facilitated high throughput treatment
experiments. We found that putative coronavirus remdesivir
resistance-associated substitutions F480L and V570L-and naturally found
polymorphisms A97V, P323L, and N491S, all in nsp12-did not decrease
SARS-CoV-2 susceptibility to remdesivir. A nanoluciferase reporter clone
with deletion of spike (S), envelope (E), and membrane (M) proteins
exhibited high levels of transient replication, was inhibited by
remdesivir, and therefore could function as an efficient non-infectious
subgenomic replicon system. The developed SARS-CoV-2 reverse-genetics
systems, including recombinants to modify infectious viruses and
non-infectious subgenomic replicons with autonomous genomic RNA
replication, will permit high-throughput cell culture studies-providing
fundamental understanding of basic biology of this coronavirus. We have
proven the utility of the systems in rapidly introducing mutations in
nsp12 and studying their effect on the efficacy of remdesivir, which is
used worldwide for the treatment of COVID-19. Our system provides a
platform to effectively test the antiviral activity of drugs and the
phenotype of SARS-CoV-2 mutants.</td>
</tr>
<tr class="odd">
<td align="left">35215217</td>
<td align="left">SARS-CoV-2 and Coronavirus Disease Mitigation:
Treatment Options, Vaccinations and Variants.</td>
<td align="left">Pathogens (Basel, Switzerland)</td>
<td align="left">2022 Feb 20</td>
<td align="left">COVID-19 is caused by a novel coronavirus (2019-nCoV),
which was declared as a pandemic after it emerged in China 2019. A vast
international effort has been conducted to prevent and treat COVID-19
due to its high transmissibility and severe morbidity and mortality
rates, particularly in individuals with chronic co-morbidities. In
addition, polymorphic variants increased the need for proper vaccination
to overcome the infectivity of new variants that are emerging across the
globe. Many treatment options have been proposed and more than 25
vaccines are in various stages of development; however, the infection
peaks are oscillating periodically, which raises a significant question
about the effectiveness of the prevention measures and the persistence
of this pandemic disease. In this review, we are exploring the most
recent knowledge and advances in the treatment and vaccination options
as well as the new emerging variants of 2019-nCoV and the possible
mitigation of one of the most aggressive pandemics in the last
centuries.</td>
</tr>
<tr class="even">
<td align="left">35214799</td>
<td align="left">SARS-CoV-2 mRNA Vaccination in People with Multiple
Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses
May Develop after the Preferred Third Shot.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 21</td>
<td align="left">Evidence suggests limited development of protective IgG
responses to mRNA-based vaccines in sphingosine-1-phosphate receptor
(S1PR)-modulator treated individuals with multiple sclerosis (MS). We
studied the extent of the humoral immune response after the preferred
third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS
(pwMS) and insufficient IgG responses after the standard immunization
scheme. Eight pwMS that were treated with fingolimod received a third
homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273
or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of
IgG antibodies against the receptor-binding domain of SARS-CoV-2 four
weeks later. An antibody titer of 100 AU/mL or more was considered
protective. After the third vaccination, we found clinically relevant
IgG titers in four out of eight individuals (50%). We conclude that the
humoral immune response may reach protective levels after the third
preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots
in S1PR-modulator treated pwMS ahead of schedule may be a strategy to
overcome insufficient humoral immune responses following the standard
vaccination scheme.</td>
</tr>
<tr class="odd">
<td align="left">35214797</td>
<td align="left">The Humoral Immune Response of the ChAdOx1 nCoV-19
Vaccine in Maintenance Dialysis Patients without Prior COVID-19
Infection.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 21</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic
kidney disease (CKD) patients tend to have a reduced immune response to
infection and vaccination. The efficacy of current available COVID-19
vaccines in CKD patients has not been widely evaluated.
<AbstractText Label="METHODS" NlmCategory="METHODS">In the present
study, three hundred and eight chronic dialysis patients received
ChAdOx1 nCoV-19 (Oxford-AstraZeneca, AZ). Blood tests using an antibody
against the receptor-binding domain (RBD) of the S1 subunit of the
SARS-CoV-2 spike protein had performed at four designed time points
before and after the first and second vaccine.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of
patients was 65.5 ± 12.38 years, and the male/female ratio was
61.4%:38.6% (189/119). Two weeks after the first vaccination, only
37.66% of patients had a positive antibody response (&gt;50 AU/mL).
However, 65.58% of the participants showed a delayed antibody response
ten weeks after the first vaccine. Four weeks after the second vaccine,
94.16% of participants had positive antibody levels. Age was the most
significant factor associated with antibody response. Flow cytometry
analysis revealed that immune-naïve patients had significantly lower
early active B cells and proliferative B cells than the age- and
sex-matched immune responders.
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite a
delayed response, 94.16% of chronic dialysis patients achieved a
positive antibody response after two doses of the AZ vaccine. Age is the
most significant factor associated with antibody response.</td>
</tr>
<tr class="even">
<td align="left">35214795</td>
<td align="left">Association of SARS-CoV-2 Vaccinations with SARS-CoV-2
Infections, ICU Admissions and Deaths in Greece.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 21</td>
<td align="left">The available coronavirus disease 2019 (COVID-19)
vaccines have shown their effectiveness in clinical trials. We aimed to
assess the real-world effects of SARS-CoV-2 vaccinations in Greece. We
combined national data on vaccinations, SARS-CoV-2 cases,
COVID-19-related ICU admissions and COVID-19-related deaths. We observed
3,367,673 vaccinations (30.68% of the Greek population), 278,821
SARS-CoV-2 infections and 7401 COVID-19-related deaths. The vaccination
rate significantly increased from week 2 to week 6 by 85.70%, and from
week 7 to 25 by 15.65%. The weekly mean of SARS-CoV-2 cases, COVID-19
ICU patients and COVID-19 deaths markedly declined as vaccination
coverage accumulated. The rate of SARS-CoV-2 cases increased
significantly from week 2 to week 13 by 16.15%, while from weeks 14-25
the rate decreased significantly by 13.50%. The rate of COVID-19-related
ICU admissions decreased significantly by 7.41% from week 2 to week 4,
increased significantly by 17.22% from weeks 5-11, then decreased
significantly from weeks 17-20, by 11.99%, and from weeks 21-25, by
16.77%. The rate of COVID-19-related deaths increased significantly from
week 2 to week 15 by 12.08% and decreased significantly by 16.58% from
weeks 16-25. The data from this nationwide observational study underline
the beneficial impact of the national vaccination campaign in Greece,
which may offer control of the SARS-CoV-2 pandemic.</td>
</tr>
<tr class="odd">
<td align="left">35214794</td>
<td align="left">Intentions Regarding COVID-19 Vaccination in Females
Aged 15-49 Years.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 20</td>
<td align="left">To control the coronavirus disease 2019 (COVID-19)
pandemic, the Japanese government is promoting vaccination, which many
people are willing to accept; however, some are reluctant to receive
vaccinations. The purpose of this study was to analyze the intentions of
women aged 15-49 years regarding the COVID-19 vaccination and to
identify methods of promoting vaccination. We used secondary data from a
web research company of approximately 1020 participants. The data
contained the following variables: vaccination status, reasons for not
getting vaccinated, and the intentions and reasons related to the third
vaccination. We categorized the reasons using text data and evaluated
the age-related differences. The proportion of women aged 15-49 years
who refused COVID-19 vaccination in Japan was 17.0%, and the rate was
not significantly different by age group. The most common reasons were
safety and side effect concerns. Of those who received the second
vaccination, 32.7% hesitated or refused the third vaccination, and the
rate was not significantly different by age group. The reasons were
side-effect concerns, a lack of information, and the influence of their
surroundings. Addressing the side effects and providing adequate
information may help promote vaccination among women aged 15-49
years.</td>
</tr>
<tr class="even">
<td align="left">35214792</td>
<td align="left">Systemic COVID-19 Vaccination Enhances the Humoral
Immune Response after SARS-CoV-2 Infection: A Population Study from a
Hospital in Poland Criteria for COVID-19 Reimmunization Are Needed.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 19</td>
<td align="left">Systemic vaccination with the BNT162b2 mRNA vaccine
stimulates the humoral response. Our study aimed to compare the
intensity of the humoral immune response, measured by SARS-CoV-2 IgG,
SARS-CoV-2 IgM, and S-RBD-neutralizing IgG antibody levels after
COVID-19 vaccination versus after SARS-CoV-2 infection. We analyzed 1060
people in the following groups: convalescents; healthy unvaccinated
individuals; individuals vaccinated with Comirnaty, AstraZeneca,
Moderna, or Johnson &amp; Johnson; and vaccinated SARS-CoV-2
convalescents. The concentrations of SARS-CoV-2 IgG, SARS-CoV-2 IgM, and
S-RBD-neutralizing antibodies were estimated in an oncology hospital
laboratory by chemiluminescent immunoassay (CLIA; MAGLUMI). Results: (1)
We observed a rise in antibody response in both the SARS-CoV-2
convalescent and COVID-19-vaccinated groups. (2) The levels of all
antibody concentrations in vaccinated COVID-19 convalescents were
significantly higher. (3) We differentiated asymptomatic SARS-CoV-2
convalescents from the control group. Our analysis suggests that
monitoring SARS-CoV-2 IgG antibody concentrations is essential as an
indicator of asymptomatic COVID-19 and as a measure of the effectiveness
of the humoral response in convalescents and vaccinated people.
Considering the time-limited effects of post-SARS-CoV-2 infection
recovery or vaccination and the physiological half-life, among other
factors, we suggest monitoring IgG antibody levels as a criterion for
future vaccination.</td>
</tr>
<tr class="odd">
<td align="left">35214791</td>
<td align="left">Humoral and Cellular Responses to COVID-19 Vaccines in
SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">In the face of a global COVID-19 vaccine shortage, an
efficient vaccination strategy is required. Therefore, the
immunogenicity of single or double COVID-19 vaccination doses (ChAdOX1,
BNT162b2, or mRNA-1273) of SARS-CoV-2-recovered individuals was compared
to that of unvaccinated individuals with SARS-CoV-2 infection at least
one year post-convalescence. Moreover, the immunogenicity of
SARS-CoV-2-naïve individuals vaccinated with a complete schedule of
Ad26.CoV2.S, ChAdOX1, BNT162b2, mRNA-1273, or ChAdOX1/BNT162b2 vaccines
was evaluated. Anti-SARS-CoV-2 S1 IgG antibody (S1-IgG), pseudotyped
virus-neutralizing antibody titer (pVNT50), and IFN-&lt;U+03B3&gt;
ELISpot counts were measured. Humoral immune responses were
significantly higher in vaccinated than in unvaccinated recovered
individuals, with a 43-fold increase in the mean pVNT50 values. However,
there was no significant difference in the pVNT50 and IFN-&lt;U+03B3&gt;
ELISpot values between the single- and double-dose regimens. In
SARS-CoV-2-naïve individuals, antibody responses varied according to the
vaccine type: BNT162b2 and mRNA-1273 induced similar levels of S1-IgG to
those observed in vaccinated, convalescent individuals; in contrast,
pVNT50 was much lower in SARS-CoV-2-naïve vaccinees than in vaccinated
recovered individuals. Therefore, a single dose of ChAdOX1, BNT162b2, or
mRNA-1273 vaccines would be a good alternative for recovered individuals
instead of a double-dose regimen.</td>
</tr>
<tr class="even">
<td align="left">35214789</td>
<td align="left">SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90
Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in
Singapore.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We
evaluated the post-booster (BNT162b2) antibody responses in Singapore.
<AbstractText Label="METHODS" NlmCategory="METHODS">Participants (n =
43) were tested pre-booster and 20/30/60/90 days post-booster.
Participants were boosted 120-240 days (mean 214 days) after their
second dose and had no history or serologic evidence of prior COVID-19
infection; all participants had undetectable SARS-CoV-2 nucleocapsid
antibodies throughout the study. Total nucleocapsid and spike antibodies
(S-Ab) were assessed on the Roche Elecsys e802 and neutralizing antibody
(N-Ab) on the Snibe quantitative N-Ab assay.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Pre-booster median
S-Ab/N-Ab titers were 829 BAU/mL/0.83 µg/mL; 2 participants were below
manufacturer’s N-Ab cut-offs of 0.3 µg/mL (0.192 and 0.229). Both S-Ab
and N-Ab titers peaked at 30 days post-booster (median S-Ab 25,220
BAU/mL and N-Ab 30.3 µg/mL) at 30-37× pre-booster median levels. These
peak post-booster S-Ab/N-Ab titers were 11× (25,220 vs. 2235 BAU/mL) and
9× (30.3 vs. 3.52 µg/mL) higher than the previously reported peak
post-second dose levels. Antibody titers declined to 12,315 BAU/mL (51%
decrease) and 14.3 µg/mL (53% decrease) 90 days post-booster. Non-linear
regression estimates for S-Ab/N-Ab half-lives were 44/58 days. At 180
days post-booster, S-Ab/N-Ab are estimated to be 2671 BAU/mL/4.83 µg/mL.
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both S-Ab
and N-Ab show a good response following post-booster vaccination, with
half-lives that may provide a prolonged antibody response.</td>
</tr>
<tr class="odd">
<td align="left">35214788</td>
<td align="left">Is Mandatory Vaccination in Population over 60 Adequate
to Control the COVID-19 Pandemic in E.U.?</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">Vaccine hesitancy, which potentially leads to the
refusal or delayed acceptance of COVID-19 vaccines, is considered a key
driver of the increasing death toll from the pandemic in the EU. The
European Commission and several member states’ governments are either
planning or have already directly or indirectly announced mandatory
vaccination for individuals aged over 60, the group which has repeatedly
proved to be the most vulnerable. In this paper, an assessment of this
strategy’s benefits is attempted by deriving a metric for the potential
gains of vaccination mandates that can be used to compare EU member
states. This is completed by examining the reduction in Standard
Expected Years of Life Lost (SEYLL) per person for the EU population
over 60 as a function of the member states’ vaccination percentage in
these ages. The publicly available data and results of the second
iteration of the SHARE COVID-19 survey on the acceptance of COVID-19
vaccines, conducted during the summer of 2021, are used as inputs.</td>
</tr>
<tr class="even">
<td align="left">35214787</td>
<td align="left">Humoral Responses and Chronic GVHD Exacerbation after
COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">The COVID-19 pandemic threatens patients with a
compromised immune and endothelial system, including patients who
underwent allogeneic stem cell transplantation (alloSCT). Thus, there is
an unmet need for optimizing vaccination management in this high-risk
cohort. Here, we monitored antibodies against SARS-CoV-2 spike protein
(anti-S1) in 167 vaccinated alloSCT patients. Humoral immune responses
were detectable in 81% of patients after two vaccinations with either
mRNA-, vector-based, or heterologous regimens. Age, B-cell counts, time
interval from vaccination, and the type of vaccine determined antibody
titres in patients without systemic immunosuppression (sIS). Similar to
a healthy control cohort, mRNA vaccine-based regimens induced higher
titres than vector-based vaccines. Patients on two or more
immunosuppressants rarely developed immunity. In contrast, 62% and 45%
of patients without or on only one immunosuppressant, respectively,
showed a strong humoral vaccination response (titre &gt; 100).
Exacerbation of cGVHD upon vaccination was observed in 6% of all
patients and in 22% of patients receiving immunosuppression for cGVHD.
cGVHD exacerbation and low antibody titres were both associated with
higher angiopoietin-2 (ANG2) serum levels. In conclusion, mRNA-based
vaccines elicit strong humoral responses in alloSCT patients in the
absence of double sIS. Biomarkers such as ANG2 might help with weighing
cGVHD risk versus beneficial responses.</td>
</tr>
<tr class="odd">
<td align="left">35214785</td>
<td align="left">Decline of Humoral Responses 6 Months after Vaccination
with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">This study analyzed binding and neutralizing antibody
titers up to 6 months after standard vaccination with BNT162b2 (two
doses of 30 µg each) in SARS-CoV-2 naïve patients (n = 59) on
hemodialysis. Humoral vaccine responses were measured before and 6, 12,
and 24 weeks after the first vaccination. A chemiluminescent immunoassay
(CLIA) was used to quantify SARS-CoV-2 IgG against the spike
glycoprotein. SARS-CoV-2 neutralizing activity was tested against the
wild-type virus. A multivariable binary regression model was used to
identify risk factors for the absence of humoral immune responses at 6
months. At week 6, vaccine-specific seroconversion was detected in 96.6%
of all patients with median anti-SARS-CoV-2 IgGs of 918 BAU/mL. At weeks
12 and 24, seroconversion rates decreased to 91.5% and 79.7%, and
corresponding median binding antibody titers declined to 298 BAU/mL and
89 BAU/mL, respectively. Neutralizing antibodies showed a decay from
79.6% at week 6 to 32.8% at week 24. The risk factor with the strongest
association for vanishing immune responses was low serum albumin (p =
0.018). Regarding vaccine-specific humoral responses 6 months after the
standard BNT162b2 vaccination schedule, SARS-CoV-2 naïve patients
receiving hemodialysis must be considered at risk of becoming infected
with SARS-CoV-2 and being infectious.</td>
</tr>
<tr class="even">
<td align="left">35214784</td>
<td align="left">COVID-19 in China and the US: Differences in Hospital
Admission Co-Variates and Outcomes.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">(1) Background: Although there are extensive data on
admission co-variates and outcomes of persons with coronavirus
infectious disease-2019 (COVID-19) at diverse geographic sites, there
are few, if any, subject-level comparisons between sites in regions and
countries. We investigated differences in hospital admission co-variates
and outcomes of hospitalized people with COVID-19 between Wuhan City,
China and the New York City region, USA. (2) Methods: We retrospectively
analyzed clinical data on 1859 hospitalized subjects with COVID-19 in
Wuhan City, China, from 20 January to 4 April 2020. Data on 5700
hospitalized subjects with COVID-19 in the New York City region, USA,
from 1 March to 4 April 2020 were extracted from an article by
Richardson et al. Hospital admission co-variates (epidemiological,
demographic, and laboratory co-variates) and outcomes (rate of intensive
care unit [ICU] admission, invasive mechanical ventilation [IMV], major
organ failure and death, and length of hospital stay) were compared
between the cohorts. (3) Results: Wuhan subjects were younger, more
likely female, less likely to have co-morbidities and fever, more likely
to have a blood lymphocyte concentration &gt; 1 × 109/L, and less likely
to have abnormal liver and cardiac function tests compared with New York
subjects. There were outcomes data on all Wuhan subjects and 2634 New
York subjects. Wuhan subjects had higher blood nadir median lymphocyte
concentrations and longer hospitalizations, and were less likely to
receive IMV, ICU hospitalization, and interventions for kidney failure.
Amongst subjects not receiving IMV, those in Wuhan were less likely to
die compared with New York subjects. In contrast, risk of death was
similar in subjects receiving IMV at both sites. (4) Conclusions: We
found different hospital admission co-variates and outcomes between
hospitalized persons with COVID-19 between Wuhan City and the New York
region, which should be useful developing a comprehensive global
understanding of the SARS-CoV-2 pandemic and COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">35214783</td>
<td align="left">Aseptic Meningitis, Mucocutaneous Lesions and Arthritis
after COVID-19 Vaccination in a 15-Year-Old Boy.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">We report a 15-year-old boy who developed aseptic
meningitis 10 days after administration of the second dose of the
COVID-19 vaccine BNT162b2. Although accompanying aphthous mouth ulcers
resembling herpetic stomatitis initially led us to suspect an underlying
viral infection, broad virological and microbiological screening did not
identify any causative pathogen. Gonarthritis and skin lesions, which
both developed within three days after admission, extended the clinical
presentation eventually resembling an acute Behçet’s disease episode.
This is the first description of a juvenile patient with aseptic and
pathogen-negative meningitis occurring in close temporal association
with vaccination against COVID-19, along with a few previously reported
adult patients with isolated meningitis and a further case with
meningitis and an accompanying Behçet’s disease-like multisystem
inflammation episode as seen in our patient. With billions of
individuals being vaccinated worldwide so far and only a few cases of
aseptic pathogen-negative meningitis reported in close temporal
relation, causality is unclear. However, aseptic meningitis should be
kept in mind in the differential diagnosis of patients with persistent
or delayed onset of headache and fever following COVID-19
vaccination.</td>
</tr>
<tr class="even">
<td align="left">35214782</td>
<td align="left">Comparative Immunogenicity of COVID-19 Vaccines in a
Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected
Participants.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left">To assess vaccine immunogenicity in non-infected and
previously infected individuals in a real-world scenario, SARS-CoV-2
antibody responses were determined during follow-up 2 (April 2021) of
the population-based Tirschenreuth COVID-19 cohort study comprising 3378
inhabitants of the Tirschenreuth county aged 14 years or older.
Seronegative participants vaccinated once with Vaxzevria, Comirnaty, or
Spikevax had median neutralizing antibody titers ranging from ID50 = 25
to 75. Individuals with two immunizations with Comirnaty or Spikevax had
higher median ID50s (of 253 and 554, respectively). Regression analysis
indicated that both increased age and increased time since vaccination
independently decreased RBD binding and neutralizing antibody levels.
Unvaccinated participants with detectable N-antibodies at baseline (June
2020) revealed a median ID50 of 72 at the April 2021 follow-up.
Previously infected participants that received one dose of Vaxzevria or
Comirnaty had median ID50 to 929 and 2502, respectively. Individuals
with a second dose of Comirnaty given in a three-week interval after the
first dose did not have higher median antibody levels than individuals
with one dose. Prior infection also primed for high systemic IgA levels
in response to one dose of Comirnaty that exceeded IgA levels observed
after two doses of Comirnaty in previously uninfected participants.
Neutralizing antibody levels targeting the spike protein of Beta and
Delta variants were diminished compared to the wild type in vaccinated
and infected participants.</td>
</tr>
<tr class="odd">
<td align="left">35214781</td>
<td align="left">Demographic Characteristics and Status of Vaccinated
Individuals with a History of COVID-19 Infection Pre- or
Post-Vaccination: A Descriptive Study of a Nationally Representative
Sample in Saudi Arabia.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 18</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Saudi
Arabia expedited the approval of some COVID-19 vaccines and launched
mass vaccination campaigns. The aim of this study was to describe the
demographics of vaccinated COVID-19 cases and compare the mortality
rates of COVID-19 cases who were infected post-vaccination in Saudi
Arabia. <AbstractText Label="METHODS" NlmCategory="METHODS">This was a
retrospective cohort study. We retrieved data for COVID-19 cases who
were infected pre- or post-vaccination and had received at least one
injection of the Oxford-AstraZeneca or Pfizer-BioNTech vaccine from 4
December 2020 to 15 October 2021.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of
patients who were infected and had received at least one dose of a
COVID-19 vaccine was 281,744. Approximately 45% of subjects were
infected post-vaccination, and 75% of subjects had received the
Pfizer-BioNTech vaccine. Only 0.342% of the patients who were infected
post-vaccination died, and 447 patients were admitted to ICUs. Most of
the patients who were infected with COVID-19 post-vaccination and were
admitted to ICUs (69.84%) had received only one dose of the vaccine (p
&lt; 0.0001). The mean time to infection for patients who had received
one and two doses of the Oxford-AstraZeneca vaccine were 27 and 8 days
longer than their counterparts who had received one and two doses of
Pfizer-BioNTech vaccine, respectively. No difference in the odds of
mortality between the Pfizer-BioNTech and Oxford-AstraZeneca vaccines
was found (OR = 1.121, 95% CI = [0.907-1.386], p-value = 0.291).
Patients who had received two doses of the vaccine had significantly
lower odds of mortality compared to those who had received one dose (p
&lt; 0.0001).
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vaccines are
vital in combating the COVID-19 pandemic. The results of this study show
no difference between the Pfizer-BioNTech and Oxford-AstraZeneca
vaccines in the rate of mortality. However, the number of vaccine doses
was significantly associated with a lower risk of mortality. Future
studies should examine the effectiveness of different COVID-19 vaccines
using real-world data and more robust designs.</td>
</tr>
<tr class="even">
<td align="left">35214779</td>
<td align="left">The Safety of mRNA-1273, BNT162b2 and JNJ-78436735
COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World
Data.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 17</td>
<td align="left">Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and
BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735,
Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19
infections. We analyzed severe and common adverse events in response to
COVID-19 vaccines using real-world, Vaccine Adverse Effect Reporting
System (VAERS) data. From 14 December 2020 to 30 September 2021, 481,172
(50.7 ± 17.5 years, males 27.89%, 12.35 per 100,000 people) individuals
reported adverse events (AEs). The median time to severe AEs was 2 days
after injection. The risk of severe AEs following the one viral vector
vaccine (OR = 1.044, 95% CI = 1.005-1.086) was significantly higher than
that after the two mRNA vaccines, and the risk among males (OR = 1.374,
95% CI = 1.342-1.406) was higher than among females, except for
anaphylaxis. For common AEs, however, the risk to males (OR = 0.621, 95%
CI = 0.612-0.63) was lower than to females. In conclusion, we provided
medical insight and clinical guidance about vaccine types by
characterizing AEs using real-world data. In particular, COVID-19 mRNA
vaccines are safer than viral vector vaccines with regard to coagulation
disorders, whereas inflammation-related AEs are lower in the viral
vaccine. The risk-benefit ratio of vaccines should be carefully
considered, and close monitoring and management of severe AEs is
needed.</td>
</tr>
<tr class="odd">
<td align="left">35214774</td>
<td align="left">Intensity and Dynamics of Anti-SARS-CoV-2 Immune
Responses after BNT162b2 mRNA Vaccination: Implications for Public
Health Vaccination Strategies.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 17</td>
<td align="left">The aim of our study was to investigate the
immunogenicity of the BNT162b2 vaccination according to the age and
medical status of vaccinated individuals. A total of 511 individuals
were enrolled (median age: 54.0 years, range: 19-105); 509 of these
individuals (99.6%) received two doses of BNT162b2 at an interval of 21
days. IgG and IgA responses were evaluated on days 21, 42, 90, and 180
after the first dose with chemiluminescent microparticle and ELISA
assays. The cell-mediated immune responses were assessed by an automated
interferon-gamma release assay. We demonstrated positive antibody
responses after vaccination for the majority of enrolled participants,
although waning of IgG and IgA titers was also observed over time. We
further observed that the intensity of humoral responses was positively
correlated with increased age and prior COVID-19 infection (either
before or after the first vaccination). Moreover, we found that only a
medical history of autoimmune disease could affect the intensity of IgA
and IgG responses (3 weeks after the primary and secondary immunization,
respectively), while development of systemic adverse reactions after the
second vaccination dose was significantly associated with the height of
IgG responses. Finally, we identified a clear correlation between
humoral and cellular responses, suggesting that the study of cellular
responses is not required as a routine laboratory test after
vaccination. Our results provide useful information about the
immunogenicity of COVID-19 vaccination with significant implications for
public health vaccination strategies.</td>
</tr>
<tr class="even">
<td align="left">35214773</td>
<td align="left">Adverse Events Reporting Quality of Randomized
Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for
Reporting Harms: A Systematic Review.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 17</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Assessing
the quality of evidence from vaccine clinical trials is essential to
ensure the safety and efficacy of the vaccine and further enhance public
acceptance. This study aims to summarize and critically evaluate the
quality of harm reporting on randomized controlled trials for the
COVID-19 vaccine and determine the factors associated with reporting
quality. <AbstractText Label="METHODS" NlmCategory="METHODS">We
systematically searched the literature using PRISMA guidelines for
randomized controlled trials (RCT) on COVID-19 Vaccine until 30 December
2021. Published articles were searched from electronic databases such as
PubMed, Science Direct, Google Scholar, and Bibliovid. Bias analysis was
performed using RoB-2 tools. The quality of reporting was assessed by
the Consolidated Standards of Reporting Trials (CONSORT) harm extension
modified into 21 items.
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 61 RCT
studies (402,014 patients) were analyzed. Over half the studies
demonstrated adequate reporting (59.02%), and 21 studies (34.4%)
reported a low risk of bias. All studies reported death and serious
adverse events (AEs), but only six studies mentioned how to handle the
recurrent AEs. Reporting of AEs in subgroup analysis was also poor
(25%). <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The
RCTs on the COVID-19 vaccine were less biased with good quality on
reporting harm based on the modified CONSORT harm extension. However,
study quality must be considered, especially for a balance of
information between effectivity and safety.</td>
</tr>
<tr class="odd">
<td align="left">35214772</td>
<td align="left">A Multi-Center, Randomised, Double-Blind,
Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG
Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections
among Symptomatic Healthcare Professionals during the COVID-19 Pandemic
in Poland-First Results.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 17</td>
<td align="left">Tuberculosis vaccines (Bacillus Calmette-Guérin, BCG)
were introduced 100 years ago and are still recommended by the World
Health Organization to prevent the disease. Studies have shown that BCG
vaccination can stimulate non-specific immune responses and reduce the
incidence of certain diseases. At the beginning of the coronavirus
disease 2019 (COVID-19) pandemic, it was hypothesised that the incidence
of COVID-19 was lower in countries with BCG prevention. In an attempt to
verify this thesis, we conducted a multicenter, randomised,
double-blind, placebo-controlled study on a group of 695 health care
workers aged 25 years and over in Poland. All participants in the study
had a tuberculin test, after which those who were negative were
randomised (1:1) and received either the BCG- or placebo vaccine. From
then on, these people were subjected to three months of observation for
the occurrence of COVID-19 symptoms. The statistical analysis did not
reveal any significant correlation between the frequency of incidents
suspected of COVID-19 and BCG-10 vaccination, the result of the
tuberculin test and the number of scars. The only statistically
significant feature was the type of medical profession-nurses became
infected more often than doctors or other medical workers (p = 0.02).
The results differ from similar trials in other countries. Perhaps this
is due to the lack of an unvaccinated control group. The impact of BCG
vaccination on the course of COVID-19 requires further research.</td>
</tr>
<tr class="even">
<td align="left">35214769</td>
<td align="left">Prevalence of COVID-19 Infection among Patients with
Diabetes and Their Vaccination Coverage Status in Saudi Arabia: A
Cross-Sectional Analysis from a Hospital-Based Diabetes Registry.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">Patients with diabetes have a higher risk of severe
infection and mortality due to COVID-19. Considering the current limited
effective pharmacological treatments, vaccination remains one of the
most effective means to control the pandemic. The current study aimed to
determine the prevalence of COVID-19 infection and the rate of COVID-19
vaccination coverage among patients with type 2 diabetes mellitus. The
patients were identified from a diabetes hospital registry at Prince
Sultan Military Medical City, Riyadh, Saudi Arabia in July 2021. The
history of COVID-19 infection and the vaccination status were retrieved
from the National Health Electronic Surveillance Network (HESN) program
and the Seha platform, respectively. A total of 11,573 patients were
included in this study (representing 99.5% of all patients in the
registry). A total of 1981 patients (17.1%) had a history of confirmed
COVID-19 infection. The rate of vaccination with a 1st dose was 84.8% (n
= 9811), while the rate of full vaccination with the 2nd dose was 55.5%
(n = 6422). The analysis showed that a higher proportion of male
patients were fully vaccinated than female patients (61.0% versus 51.2%,
p &lt; 0.001). There were statistically significant differences among
the age groups, with the full vaccination rate ranging from 59.0% for
the 61-70-year-old age group to 49.0% for the &gt; 80-year-old age group
(p &lt; 0.001). The patients with no previous history of COVID-19
infection were more likely to get fully vaccinated than those with a
previous history of the infection (63.9% versus 14.6%, respectively, p
&lt; 0.001). The factors associated with a higher likelihood of
unvaccinated status included the female gender (adjusted odds ratio
(aOR) = 1.705 (95% confidence interval (CI): 1.528-1.902)), elderly
patients in the age group of 61-70 (aOR (95% CI) = 1.390 (1.102-1.753)),
the age group of 71-80 (aOR (95% CI) = 1.924 (1.499-2.470)) and the age
group of &gt;80 (aOR (95% CI) = 3.081 (2.252-4.214), and prior history
of COVID-19 infection (aOR (95% CI) = 2.501 (2.223-2.813)). In
conclusion, a considerable proportion of patients with type 2 diabetes
had confirmed COVID-19 infection. Continued targeted efforts are needed
to accelerate vaccination coverage rates among patients with diabetes in
general and the particular subgroups identified in this study.</td>
</tr>
<tr class="odd">
<td align="left">35214765</td>
<td align="left">Death after the Administration of COVID-19 Vaccines
Approved by EMA: Has a Causal Relationship Been Demonstrated?</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">More than eight billion doses of COVID-19 vaccines have
been administered globally so far and 44.29% of people are fully
vaccinated. Pre-authorization clinical trials were carried out and the
safety of vaccines is still continuously monitored through
post-commercialization surveillance. However, some people are afraid of
vaccine side effects, claiming they could lead to death, and hesitate to
get vaccinated. Herein, a literature review of COVID-19-vaccine-related
deaths has been carried out according to the PRISMA standards to
understand if there is a causal relationship between vaccination and
death and to highlight the real extent of such events. There have been
55 cases of death after COVID-19 vaccination reported and a causal
relationship has been excluded in 17 cases. In the remaining cases, the
causal link between the vaccine and the death was not specified (8) or
considered possible (15), probable (1), or very probable/demonstrated
(14). The causes of deaths among these cases were: vaccine-induced
immune thrombotic thrombocytopenia (VITT) (32), myocarditis (3), ADEM
(1), myocardial infarction (1), and rhabdomyolysis (1). In such cases,
the demonstration of a causal relationship is not obvious, and more
studies, especially with post-mortem investigations, are needed to
deepen understanding of the possible pathophysiological mechanisms of
fatal vaccine side effects. In any event, given the scarcity of fatal
cases, the benefits of vaccination outweigh the risks and the scientific
community needs to be cohesive in asserting that vaccination is
fundamental to containing the spread of SARS-CoV-2.</td>
</tr>
<tr class="even">
<td align="left">35214764</td>
<td align="left">Induction of Broadly Cross-Reactive Antibodies by
Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like
Particles.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">The impact of the COVID-19 pandemic has been reduced
since the application of vaccination programs, mostly shown in the
reduction of hospitalized patients. However, the emerging variants, in
particular Omicron, have caused a steep increase in the number of
infections; this increase is, nevertheless, not matched by an increase
in hospitalization. Therefore, a vaccine that induces cross-reactive
antibodies against most or all variants is a potential solution for the
issue of emerging new variants. Here, we present a vaccine candidate
which displays receptor-binding domain (RBD) of SARS-CoV-2 on virus-like
particles (VLP) that, in mice, not only induce strong antibody responses
against RBD but also bind RBDs from other variants of concern (VOCs).
The antibodies induced by wild-type (wt) RBD displayed on
immunologically optimized Cucumber mosaic virus incorporated tetanus
toxin (CuMVTT) VLPs bind to wt as well as RBDs of VOCs with high
avidities, indicating induction of strongly cross-reactive IgG
antibodies. Interestingly, similar cross-reactive IgA antibodies were
induced in immunized mice. Furthermore, these cross-reactive antibodies
demonstrated efficacy in neutralizing wt (Wuhan) as well as SARS-CoV-2
VOCs (Beta, Delta, and Gamma). In summary, RBDs displayed on VLPs are
capable of inducing protective cross-reactive IgG and IgA antibodies in
mice, indicating that it may be possible to cover emerging VOCs with a
single vaccine based on wt RBD.</td>
</tr>
<tr class="odd">
<td align="left">35214761</td>
<td align="left">The Effect of Smoking on Humoral Response to COVID-19
Vaccines: A Systematic Review of Epidemiological Studies.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">While the role of active smoking on response to
vaccines is yet to be fully understood, some real-world studies have
outlined a possible link between smoking and humoral response to
COVID-19 vaccines. Thus, the present rapid systematic review aimed at
summarizing the current epidemiological evidence on this association.
Following PRISMA and WHO guidelines on rapid systematic reviews, we
systematically reviewed published literature on this topic and discussed
the findings according to the aim of analysing smoking and its impact on
humoral response to COVID-19 postvaccination antibody titres. The search
strategy yielded a total of 23 articles. The sample size amongst the
studies ranged between 74 and 3475 participants (median, 360), with the
proportion of smokers being between 4.2% and 40.8% (median, 26.0%). The
studies included in this review analysis investigated the dynamics of
antibody response to different type of COVID-19 vaccines. In 17 out of
23 studies, current smokers showed much lower antibody titres or more
rapid lowering of the vaccine-induced IgG compared with nonsmokers. This
rapid systematic review indicates that active smoking negatively impacts
humoral response to COVID-19 vaccines, although the pathophysiologic
mechanisms for this association have not been entirely suggested. The
results advocate targeted policies to promote tailored health promotion
initiatives, which can increase risk perception and ensure appropriate
protection measures to be taken to avoid the health consequences of
COVID-19 in smokers.</td>
</tr>
<tr class="even">
<td align="left">35214759</td>
<td align="left">Capturing a Crucial ‘Disorder-to-Order Transition’ at
the Heart of the Coronavirus Molecular Pathology-Triggered by Highly
Persistent, Interchangeable Salt-Bridges.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">The COVID-19 origin debate has greatly been influenced
by genome comparison studies of late, revealing the emergence of the
Furin-like cleavage site at the S1/S2 junction of the SARS-CoV-2 Spike
(FLCSSpike) containing its 681PRRAR685 motif, absent in other related
respiratory viruses. Being the rate-limiting (i.e., the slowest) step,
the host Furin cleavage is instrumental in the abrupt increase in
transmissibility in COVID-19, compared to earlier onsets of respiratory
viral diseases. In such a context, the current paper entraps a
‘disorder-to-order transition’ of the FLCSSpike (concomitant to an
entropy arrest) upon binding to Furin. The interaction clearly seems to
be optimized for a more efficient proteolytic cleavage in SARS-CoV-2.
The study further shows the formation of dynamically interchangeable and
persistent networks of salt-bridges at the Spike-Furin interface in
SARS-CoV-2 involving the three arginines (R682, R683, R685) of the
FLCSSpike with several anionic residues (E230, E236, D259, D264, D306)
coming from Furin, strategically distributed around its catalytic triad.
Multiplicity and structural degeneracy of plausible salt-bridge network
archetypes seem to be the other key characteristic features of the
Spike-Furin binding in SARS-CoV-2, allowing the system to breathe-a
trademark of protein disorder transitions. Interestingly, with respect
to the homologous interaction in SARS-CoV (2002/2003) taken as a
baseline, the Spike-Furin binding events, generally, in the coronavirus
lineage, seems to have preference for ionic bond formation, even with a
lesser number of cationic residues at their potentially polybasic
FLCSSpike patches. The interaction energies are suggestive of
characteristic metastabilities attributed to Spike-Furin interactions,
generally to the coronavirus lineage, which appears to be favorable for
proteolytic cleavages targeted at flexible protein loops. The current
findings not only offer novel mechanistic insights into the coronavirus
molecular pathology and evolution, but also add substantially to the
existing theories of proteolytic cleavages.</td>
</tr>
<tr class="odd">
<td align="left">35214757</td>
<td align="left">COVID-19 Vaccination Improved Psychological Distress
(Anxiety and Depression Scores) in Chronic Kidney Disease Patients: A
Prospective Study.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 16</td>
<td align="left">The purpose of the study is to analyze the impact of
vaccination against SARS-CoV-2 on anxiety and depression scores in
patients with different modalities of chronic kidney disease. One
hundred and seventeen renal patients (50 hemodialysis patients, 13
peritoneal dialysis patients, 32 kidney transplants, and 22 advanced
chronic kidney disease patients at pre-dialysis care) were evaluated for
depression, anxiety, health-related quality of life (HRQOL), and
perceived fears and resources with standardized (Hospital Anxiety and
Depression Scale (HADS)) and self-reported questionnaires. The measure
points were before vaccination and 15 days after vaccination. The main
finding of the study was that there was a decrease in the global mean of
normal scores for anxiety and depression symptoms in chronic kidney
disease patients post-vaccination. We did not find statistically
significant differences in depression or anxiety scores, nor any HRQOL
differences between the treatment groups. The three main fears reported
by the participants at baseline were those of adverse effects, not
getting the vaccine, and lack of information. These findings highlight
the potential interest of assessing psychological variables related to
the impact of vaccination against SARS-CoV-2. New studies will be
required to assess the impact of comprehensive vaccine coverage and its
psychological impact.</td>
</tr>
<tr class="even">
<td align="left">35214756</td>
<td align="left">Different Clinical Outcomes of COVID-19 in Two
Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the
Same Viral Variant but with Different Predisposing Conditions for the
Progression of the Disease.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 15</td>
<td align="left">Safe and effective vaccines are available to face the
global threat of the COVID-19 pandemic. In this article, we report on
the clinical cases of two healthcare workers vaccinated with two doses
of BNT162b2 vaccine who were infected by the same viral clade but had
different clinical outcomes.</td>
</tr>
<tr class="odd">
<td align="left">35214751</td>
<td align="left">Influenza Vaccination Uptake in the General Italian
Population during the 2020-2021 Flu Season: Data from the EPICOVID-19
Online Web-Based Survey.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 15</td>
<td align="left">To assess influenza vaccine uptake during the 2020/2021
flu season and compare it with that of the 2019/2020 flu season among
respondents to the second phase of the web-based EPICOVID-19 survey, we
performed an observational web-based nationwide online survey
(January-February 2021) in which respondents to the first survey
(April-June 2020) were contacted and asked to complete a second
questionnaire. Factors associated with vaccine uptake in the 2020/2021
flu season were assessed by applying a multivariable multinomial
logistic regression model. Out of the 198,822 respondents to the first
survey, 41,473 (20.9%) agreed to fill out the follow-up questionnaire;
of these, 8339 (20.1%) were vaccinated only during the 2020/2021 season,
8828 (21.3%) were vaccinated during both seasons and 22,710 (54.8%) were
vaccinated in neither season. Educational level (medium (aOR 1.33 95%CI
1.13-1.56) and high (aOR 1.69 95%CI 1.44-1.97) vs. low) and
socio-economic deprivation according to SES scoring (1 point aOR 0.83
(95%CI 0.78-0.89), 2 aOR 0.68 (95%CI 0.60-0.77) points or =3 points aOR
0.42 (95%CI 0.28-0.45) vs. 0 points) were found to be associated with
flu vaccine uptake. Our study shows that social determinants seemed to
affect flu vaccination uptake and identifies specific categories of the
population to target during future influenza vaccination campaigns.</td>
</tr>
<tr class="even">
<td align="left">35214749</td>
<td align="left">Neutralization of SARS-CoV-2 Variants by
rVSV-&lt;U+0394&gt;G-Spike-Elicited Human Sera.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 14</td>
<td align="left">The emergence of rapidly spreading variants of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major
challenge to the ability of vaccines and therapeutic antibodies to
provide immunity. These variants contain mutations of specific amino
acids that might impede vaccine efficacy. BriLife®
(rVSV-&lt;U+0394&gt;G-spike) is a newly developed SARS-CoV-2 vaccine
candidate currently in phase II clinical trials. It is based on a
replication-competent vesicular stomatitis virus (VSV) platform. The
rVSV-&lt;U+0394&gt;G-spike contains several spontaneously acquired spike
mutations that correspond to SARS-CoV-2 variants’ mutations. We show
that human sera from BriLife® vaccinees preserve comparable
neutralization titers towards alpha, gamma, and delta variants and show
less than a three-fold reduction in the neutralization capacity of beta
and omicron compared to the original virus. Taken together, we show that
human sera from BriLife® vaccinees overall maintain a neutralizing
antibody response against all tested variants. We suggest that
BriLife®-acquired mutations may prove advantageous against future
SARS-CoV-2 VOCs.</td>
</tr>
<tr class="odd">
<td align="left">35214748</td>
<td align="left">Racial and Ethnic Diversity in SARS-CoV-2 Vaccine
Clinical Trials Conducted in the United States.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 14</td>
<td align="left">Evidence shows that White and non-Hispanic individuals
are overrepresented in clinical trials. The development of new vaccines
and drugs, however, necessitates that clinical research trials include
representative participants, particularly in light of evidence showing
that underrepresented minorities may have a different response to
certain medications and vaccines. Racial and ethnic disparities among
clinical trials are multilayered and complex, and this requires action.
The results of this study indicate that significant racial and ethnic
disparities consistently exist among the most recent early SARS-CoV-2
vaccine clinical trials as compared to the pandemic H1N1 vaccine
clinical trials of 2009. New strategies, policies, training programs,
and reforms are required to address these disparities among clinical
trials.</td>
</tr>
<tr class="even">
<td align="left">35214746</td>
<td align="left">COVID-19 Vaccine Hesitancy Prevalence and Predictors
among the Students of Jazan University, Saudi Arabia Using the Health
Belief Model: A Cross-Sectional Study.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 14</td>
<td align="left">Vaccination has a major role in the control of the
COVID-19 pandemic. The behavior toward accepting the COVID-19 vaccine is
complex and multifactorial, while the level of acceptance and hesitancy
depends on many factors. This study aims to measure the level of vaccine
acceptance among Jazan University students and identify its predictors.
In this cross-sectional study, an online questionnaire based on the
health belief model (HBM) was sent through social media “WhatsApp” to
two strata of students selected by convenient sampling. The overall
desire to get vaccinated was noted in 83.6% of participants, and 16.4%
reported no desire to be vaccinated. The constructs of the HBM were
shown to significantly predict vaccine acceptance with the exception of
“perceived susceptibility”. In conclusion, the level of acceptance of
the COVID-19 vaccine among Jazan University students was relatively
high. The HBM constructs are important predictors of the vaccination
behavior with the exception of the construct “perceived
susceptibility”.</td>
</tr>
<tr class="odd">
<td align="left">35214744</td>
<td align="left">COVID-19 Vaccination Safety and Tolerability in
Patients Allegedly at High Risk for Immediate Hypersensitivity
Reactions.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 14</td>
<td align="left">The reported incidence of immediate hypersensitivity
reactions (IHR) including anaphylaxis after COVID-19 vaccination is
10-fold higher than for other vaccines. Several patient groups are
theorized to be at particular risk. Since specific vaccination
guidelines for these patients are based on expert opinion, we performed
a retrospective monocentric analysis of the tolerability of adenoviral
vector and mRNA-based COVID-19 vaccines in a cohort of patients
allegedly at high risk of IHR. Reactions were assessed immediately
on-site by allergists during a monitored vaccination protocol and after
3-7 days through telephone interviews. The cohort included 196 patients
(aged 12-84 years) with primary mast cell disease (pMCD, 50.5%),
idiopathic anaphylaxis (IA, 19.9%), hereditary angioedema (HAE, 5.1%) or
miscellaneous indications (24.5%). Twenty-five immediate reactions were
observed in 221 vaccine doses (11.3%). Most occurred in IA or
miscellaneous patients. None fulfilled anaphylaxis criteria and most
were mild and self-limiting. Reaction occurrence was significantly
associated with female sex. In total, 13.5% of pMCD patients reported
mast cell activation-like symptoms within 72 h post-vaccination. All
pediatric pMCD patients (n = 9, 12-18 years) tolerated both mRNA-based
vaccine doses. In summary, adenoviral vector and mRNA-based COVID-19
vaccines were safe and well-tolerated in patients with pMCD, HAE, and
IA. No anaphylaxis was observed. The mild and subjective nature of most
reactions suggests a nocebo effect associated with vaccination in a
medicalized setting. Patients with pMCD could experience mild flare-ups
of mast cell activation-like symptoms, supporting antihistamine
premedication.</td>
</tr>
<tr class="even">
<td align="left">35214743</td>
<td align="left">Modelling SARS-CoV-2 Binding Antibody Waning 8 Months
after BNT162b2 Vaccination.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 13</td>
<td align="left">Several lines of evidence suggest that binding
SARS-CoV-2 antibodies such as anti-SARS-CoV-2 RBD IgG (anti-RBD) and
neutralising antibodies (NA) are correlates of protection against
SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The
effectiveness (VE) of BNT162b2 in preventing SARS-CoV-2 infection wanes
over time, and this reduction is mainly associated with waning immunity,
suggesting that the kinetics of antibodies reduction might be of
interest to predict VE. In a study of 97 health care workers (HCWs)
vaccinated with the BNT162b2 vaccine, we assessed the kinetics of
anti-RBD 30-250 days after vaccination using 388 individually matched
plasma samples. Anti-RBD levels declined by 85%, 92%, and 95% at the
4th, 6th, and 8th month from the peak, respectively. The kinetics were
estimated using the trajectories of anti-RBD by various models. The
restricted cubic splines model had a better fit to the observed data.
The trajectories of anti-RBD declines were statistically significantly
lower for risk factors of severe COVID-19 and the absence of vaccination
side effects. Moreover, previous SARS-CoV-2 infection was associated
with divergent trajectories consistent with a slower anti-RBD decline
over time. These results suggest that anti-RBD may serve as a harbinger
for vaccine effectiveness (VE), and it should be explored as a predictor
of breakthrough infections and VE.</td>
</tr>
<tr class="odd">
<td align="left">35214742</td>
<td align="left">Propensity-Score-Matched Evaluation of Adverse Events
Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA
Vaccines.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 13</td>
<td align="left">This study aimed to observe adverse events following
immunisation (AEFIs) that affected recovery within two weeks after
COVID-19 vaccination and investigate their risks in
propensity-score-matched populations. Data were collected from 447,346
reports from the VAERS between 1 January 2021 and 31 July 2021.
Propensity-score-matched populations were constructed by adjusting for
demographic characteristics and 11 underlying diseases in eligible
subjects who received 1 of 3 COVID-19 vaccines: 19,462 Ad26.COV2.S,
120,580 mRNA-1273, and 100,752 BNT162b2. We observed that 88 suspected
AEFIs (22 in Ad26.COV2.S, 62 in mRNA-1273, and 54 in BNT162b2) were
associated with an increased risk of delayed recovery within 2 weeks
after COVID-19 vaccinations. Nervous system, musculoskeletal and
connective tissue, gastrointestinal, skin, and subcutaneous tissue
disorders were the most common AEFIs after COVID-19 vaccination.
Interestingly, four local and systemic reactions affected recovery in
different vaccine recipients during our study period: asthenic
conditions and febrile disorders in Ad26.COV2.S and mRNA-1273; general
signs and symptoms in mRNA-1273 and BNT162b2; injection site reactions
in Ad26.COV2.S and BNT162b2. Although it is necessary to confirm a
causal relationship with COVID-19 vaccinations, some symptoms, including
paralysis, allergic disorders, breathing abnormalities, and visual
impairment, may hinder the recovery of these recipients.</td>
</tr>
<tr class="even">
<td align="left">35214741</td>
<td align="left">Autochthonous Outbreak of SARS-CoV-2 Omicron Variant in
Booster-Vaccinated (3 Doses) Healthcare Workers in Southern Italy: Just
the Tip of the Iceberg?</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 13</td>
<td align="left">The Omicron variant of concern (VOC), first detected in
Italy at the end of November 2021, has since spread rapidly, despite
high vaccine coverage in the Italian population, especially in
healthcare workers (HCWs). This study describes an outbreak of
SARS-CoV-2 Omicron infection in 15 booster-vaccinated HCWs. On 16
December 2021, two HCWs working in the same ward were infected with
SARS-CoV-2. The Omicron VOC was suspected due to S gene target failure
on molecular testing. Further investigation revealed that 15 (65%) of 23
HCWs attending a social gathering on 13 December were infected with
Omicron, as shown by whole-genome sequencing, with a phylogenetic tree
suggesting a common source of exposure. Five of these HCWs experienced
mild symptoms. A patient with multiple chronic conditions hospitalized
in the same ward was also infected by one of the HCWs involved in the
outbreak. Despite being booster vaccinated, this patient required ICU
treatment. Ten subjects achieved negativity in 10-19 days. The outbreak
in booster-vaccinated subjects confirms the high transmissibility and
immune evasion of the Omicron VOC. More stringent non-pharmaceutical
interventions, administration of booster doses, and genomic surveillance
are crucial long-term strategies to mitigate the consequences of the
spread of the Omicron VOC.</td>
</tr>
<tr class="odd">
<td align="left">35214739</td>
<td align="left">Factors Associated with COVID-19 Vaccine Hesitancy
after Implementation of a Mass Vaccination Campaign.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 12</td>
<td align="left">An online cross-sectional study on COVID-19 vaccination
adhesion was conducted in Portugal nine months after vaccination rollout
(September-November 2021). Logistic regression was used to identify
factors associated with hesitancy to take the COVID-19 vaccine in the
community-based survey, “COVID-19 Barometer: Social Opinion”. Hesitancy
was 11%; however, of those, 60.5% stated that they intended to take the
vaccine. Hesitancy was associated with factors such as lower monthly
household income; no intention of taking the flu vaccine this year;
perceived reasonable health status; having two or more diseases; low
confidence in the health service response; worse perception of the
adequacy of anti-COVID-19 government measures; low or no perceived risk
of getting COVID-19; feeling agitated, anxious or sad some days; and
lack of trust in the safety and efficacy of the vaccines. Confidence in
vaccines, namely against COVID-19, is paramount for public health and
should be monitored during vaccination rollout. Clear communication of
the risks and benefits of vaccination needs improvement to increase
adherence and public confidence.</td>
</tr>
<tr class="even">
<td align="left">35214738</td>
<td align="left">Significance of HLA Haplotypes in Two Patients with
Subacute Thyroiditis Triggered by mRNA-Based COVID-19 Vaccine.</td>
<td align="left">Vaccines</td>
<td align="left">2022 Feb 11</td>
<td align="left">Subacute thyroiditis (SAT) can be triggered by several
viral factors in genetically predisposed individuals. In the case of
COVID-19, SAT can be induced by SARS-CoV-2 infection as well as COVID-19
vaccination. The aim of this study was to present two cases of SAT
triggered by mRNA-based COVID-19 vaccines, with special attention paid
to the possible significance of HLA-related SAT susceptibility. In our
patients, a strong similarity of HLA profiles with regard not only to
SAT high-risk alleles but also to other SAT-unrelated ones was observed.
The rare phenomenon of SAT occurrence after COVID-19 vaccination can be
HLA-dependent and related to a co-presence of HLA-B<em>35:03 and
-C</em>04:01. Taking into account the similarity of HLA profiles in both
our patients, the co-presence of other alleles, such as HLA-A<em>03:01,
-DQA1:01, DQB1</em>05:01 as well as some of HLA-DRB1, can also play a
role. This hypothesis is strongly consistent with
autoimmune/inflammatory syndrome induced by adjuvants (ASIA) being the
postulated mechanism of this post-vaccine reaction, as ASIA-related
immune reactions are directly associated with HLA-based genetic
susceptibility. Further research is necessary to confirm these
findings.</td>
</tr>
</tbody>
</table>
<p>There are 250 rows and 5 columns in the database.</p>
<pre><code>## [1] 250   5</code></pre>
</div>
</div>
<div id="text-mining" class="section level2">
<h2>Text Mining</h2>
<p>First take a look at the most frequent tokens appear in
abstracts:</p>
<p><img src="data:image/png;base64,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" width="672" /><img src="data:image/png;base64,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" width="672" /></p>
<p>We can see that some stopwords appear to be the most frequent ones in
abstracts of papers. For example, words such as “the”, “of”, “and”,
“to”, and “in” are the five most frequent ones. Meanwhile, words such as
“covid”, “patients”, and “cancer” also appear in the top 20 frequent
words list. These words did tell us some information about what these
papers are about.</p>
<p>Then we are going to take a look at the most frequent tokens in
abstracts after removing all stopwords:</p>
<p><img src="data:image/png;base64,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" width="672" /><img src="data:image/png;base64,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" width="672" /></p>
<p>We see that words such as “covid”, “19”, “patients”, “cancer”, and
“prostate” become the top 5 most frequent words in abstracts. It’s also
interesting to see that the word “covid” and “19” have close
frequencies, and the word “cancer” and “prostate” have close
frequencies. This may suggest that these words tend to appear in pairs.
We can explore more about these bi-grams by tokenizing the abstract into
bi-grams and count them. We can also see some of our search terms such
as “covid”, “prostate cancer”, and “preeclampsia” appear in the top 20
frequent words list. Generally speaking, after we removing stopwords,
the list of frequent words appear to contain more information about the
papers, we can infer what these papers are about by looking at these
frequent tokens.</p>
<div id="we-will-present-five-most-common-tokens-for-each-search-term-after-removing-stop-words." class="section level4">
<h4>We will present five most common tokens for each search term after
removing stop-words.</h4>
<pre><code>##              term
## 1           covid
## 2      meningitis
## 3 prostate cancer
## 4 cystic fibrosis
## 5    preeclampsia</code></pre>
<pre><code>## Selecting by n</code></pre>
<pre><code>##            word            term    n
## 1         covid           covid 7271
## 2            19           covid 7035
## 3      patients           covid 2293
## 4       disease           covid  943
## 5      pandemic           covid  800
## 6      fibrosis cystic fibrosis  867
## 7        cystic cystic fibrosis  862
## 8            cf cystic fibrosis  625
## 9      patients cystic fibrosis  586
## 10      disease cystic fibrosis  400
## 11     patients      meningitis  446
## 12   meningitis      meningitis  429
## 13    meningeal      meningitis  219
## 14          csf      meningitis  206
## 15     clinical      meningitis  187
## 16          pre    preeclampsia 2038
## 17    eclampsia    preeclampsia 1998
## 18 preeclampsia    preeclampsia 1863
## 19        women    preeclampsia 1196
## 20    pregnancy    preeclampsia  969
## 21       cancer prostate cancer 3840
## 22     prostate prostate cancer 3832
## 23     patients prostate cancer  934
## 24    treatment prostate cancer  926
## 25      disease prostate cancer  652</code></pre>
<pre class="r"><code>tokens &lt;- df %&gt;% filter(term==&quot;covid&quot;) %&gt;% unnest_tokens(word, abstract) %&gt;% anti_join(stop_words, by=&quot;word&quot;) %&gt;% group_by(word) %&gt;% summarize(word_frequency = n()) %&gt;% arrange(across(word_frequency, desc)) %&gt;% head(5)

tokens %&gt;% ggplot(aes(x=reorder(word, word_frequency), y=word_frequency)) + geom_bar(stat=&#39;identity&#39;) + coord_flip()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>tokens &lt;- df %&gt;% filter(term==&quot;meningitis&quot;) %&gt;% unnest_tokens(word, abstract) %&gt;% anti_join(stop_words, by=&quot;word&quot;) %&gt;% group_by(word) %&gt;% summarize(word_frequency = n()) %&gt;% arrange(across(word_frequency, desc)) %&gt;% head(5)

tokens %&gt;% ggplot(aes(x=reorder(word, word_frequency), y=word_frequency)) + geom_bar(stat=&#39;identity&#39;) + coord_flip()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>tokens &lt;- df %&gt;% filter(term==&quot;prostate cancer&quot;) %&gt;% unnest_tokens(word, abstract) %&gt;% anti_join(stop_words, by=&quot;word&quot;) %&gt;% group_by(word) %&gt;% summarize(word_frequency = n()) %&gt;% arrange(across(word_frequency, desc)) %&gt;% head(5)

tokens %&gt;% ggplot(aes(x=reorder(word, word_frequency), y=word_frequency)) + geom_bar(stat=&#39;identity&#39;) + coord_flip()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>tokens &lt;- df %&gt;% filter(term==&quot;cystic fibrosis&quot;) %&gt;% unnest_tokens(word, abstract) %&gt;% anti_join(stop_words, by=&quot;word&quot;) %&gt;% group_by(word) %&gt;% summarize(word_frequency = n()) %&gt;% arrange(across(word_frequency, desc)) %&gt;% head(5)

tokens %&gt;% ggplot(aes(x=reorder(word, word_frequency), y=word_frequency)) + geom_bar(stat=&#39;identity&#39;) + coord_flip()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>tokens &lt;- df %&gt;% filter(term==&quot;preeclampsia&quot;) %&gt;% unnest_tokens(word, abstract) %&gt;% anti_join(stop_words, by=&quot;word&quot;) %&gt;% group_by(word) %&gt;% summarize(word_frequency = n()) %&gt;% arrange(across(word_frequency, desc)) %&gt;% head(5)

tokens %&gt;% ggplot(aes(x=reorder(word, word_frequency), y=word_frequency)) + geom_bar(stat=&#39;identity&#39;) + coord_flip()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
</div>
<div id="next-we-are-going-to-tokenize-the-abstracts-into-bigrams.-here-are-10-most-common-bigram-and-their-visualization." class="section level4">
<h4>Next, we are going to tokenize the abstracts into bigrams. Here are
10 most common bigram and their visualization.</h4>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>From the visualization, we can see that the bigram “covid 19” appears
over 6500 times, which is the most frequently appeared bigram in papers.
We can also see that “sars cov” and “cov 2” are close in their
frequencies, this may indicates that they usually comes in the form of
tri-grams. Moreover, “prostate cancer” did appear as a frequent bi-gram.
These conclusions match up with our previous prediction on bigrams.
Lastly, we can see that our search term “cystic fibrosis” also appears
on the list.</p>
</div>
<div id="lastly-we-will-calculate-the-tf-idf-value-for-each-word-search-term-combination." class="section level4">
<h4>Lastly, we will calculate the TF-IDF value for each word-search term
combination.</h4>
<pre><code>## Selecting by tf_idf</code></pre>
<pre><code>##               word            term    n          tf       idf      tf_idf
## 1            covid           covid 7271 0.064487805 1.6094379 0.103789118
## 2         pandemic           covid  800 0.007095344 1.6094379 0.011419515
## 3      coronavirus           covid  647 0.005738359 1.6094379 0.009235533
## 4             sars           covid  372 0.003299335 1.6094379 0.005310075
## 5              cov           covid  333 0.002953437 1.6094379 0.004753373
## 6               cf cystic fibrosis  625 0.023400352 0.9162907 0.021441526
## 7         fibrosis cystic fibrosis  867 0.032460968 0.5108256 0.016581894
## 8           cystic cystic fibrosis  862 0.032273765 0.5108256 0.016486266
## 9             cftr cystic fibrosis   86 0.003219888 1.6094379 0.005182211
## 10           sweat cystic fibrosis   83 0.003107567 1.6094379 0.005001436
## 11      meningitis      meningitis  429 0.016373421 1.6094379 0.026352004
## 12       meningeal      meningitis  219 0.008358460 1.6094379 0.013452422
## 13 pachymeningitis      meningitis  149 0.005686806 1.6094379 0.009152561
## 14             csf      meningitis  206 0.007862295 0.9162907 0.007204148
## 15        meninges      meningitis  106 0.004045647 1.6094379 0.006511218
## 16       eclampsia    preeclampsia 1998 0.025388515 1.6094379 0.040861239
## 17    preeclampsia    preeclampsia 1863 0.023673075 1.6094379 0.038100345
## 18       pregnancy    preeclampsia  969 0.012313049 0.5108256 0.006289821
## 19        maternal    preeclampsia  797 0.010127451 0.5108256 0.005173361
## 20     gestational    preeclampsia  191 0.002427030 1.6094379 0.003906155
## 21        prostate prostate cancer 3832 0.056244588 1.6094379 0.090522172
## 22        androgen prostate cancer  305 0.004476670 1.6094379 0.007204922
## 23             psa prostate cancer  282 0.004139085 1.6094379 0.006661600
## 24   prostatectomy prostate cancer  215 0.003155685 1.6094379 0.005078880
## 25      castration prostate cancer  148 0.002172286 1.6094379 0.003496159</code></pre>
<p>The result are different from question 1. For term “covid”, tokens
“coronavirus”, “sars”, and “cov” have replaced “19”, “patient”,
“disease”. For term “cystic fibrosis”, tokens “cftr”, “sweat” have
replaced “patient”, “disease”. For term “meningitis”, tokens
“pachymeningitis”, “meninges” have replaced “patient”, “clinical”. For
term “preeclampsia”, tokens “maternal”, “gestational” have replaced
“women”, “pre”. For term “prostate cancer”, tokens “androgen”, “psa”,
“prostatectomy”, and “castration” have replaced “cancer”, “patient”,
“disease”, “treatment”. This is reasonable, since we can see that the
word “patient” appears in all papers from different search term, this
makes it less representative under each search term and has a smaller
ti-idf value in each search term. Similar reason applies to other words
that are replaced. The 5 tokens from each search term with the highest
TF-IDF value are now the most representative ones under each search
term.</p>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
